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Abstract 
 
Gout is the most prevalent inflammatory arthritis, predominantly managed in 
primary care.  Both hyperuricaemia (the biochemical precursor to gout) and other 
inflammatory arthritides, e.g. rheumatoid arthritis, have been shown to increase 
risk of vascular disease.  This thesis aims to investigate the risk of incident 
cardiovascular, cerebrovascular and peripheral vascular disease in primary care 
gout patients. 
A systematic review identified 17 studies investigating gout and vascular diseases. 
Meta-analysis showed increased mortality from all cardiovascular and coronary 
heart disease.  Increased incidence of, but not mortality from myocardial infarction 
was found.   Few studies investigated the association between gout and 
cerebrovascular or peripheral vascular disease.  
A retrospective cohort study used data from the Clinical Practice Research 
Datalink to examine the risk of incident cardiovascular, cerebrovascular and 
peripheral vascular disease in 8386 gout patients and 39766 age-, gender- and 
practice-matched controls, in the ten years following diagnosis of gout (or matched 
date) using Cox proportional hazards and multilevel discrete-time event history 
analysis.  Risk was also investigated by gender and with follow-up limited to one, 
two and five years.  The effect of exposure to drugs used to treat both gout and 
vascular risk factors on the magnitude of risk was examined using a cohort and 
nested case-control study design. 
The strongest association identified was between gout and peripheral vascular 
disease.  Women with gout had the greatest excess vascular risk and experienced 
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a wider range of vascular events.  Exposure to drugs used to manage vascular 
risk factors was associated with increased likelihood of a vascular event, but use 
of gout treatments such as allopurinol did not influence incident vascular risk.  
This suggests that gout patients, particularly women, should have screening for 
and aggressive management of vascular risk factors, although as conventional 
approaches may be insufficient, further research is required to establish the 
optimum risk reduction strategy.  
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Chapter 1: Background 
1.1 Overview 
This chapter summarises the important features of gout considering historical, 
epidemiological and clinical features.  
1.2 History 
The clinical condition of gouty arthritis was first described by Hippocrates in the 5th 
century BC, however, archaeologists have identified evidence of deposits of uric 
acid in the joints of mummified Egyptians dating from approximately 4000 years 
ago.   
Hippocrates referred to gout as the “unwalkable disease” and observed it was the 
“arthritis of the rich” in contrast to rheumatism which he considered the “arthritis of 
the poor”.  The writings of Hippocrates provided the earliest epidemiological 
observations on gout: 
‘eunuchs do not take the gout, nor become bald, a woman does not take 
the gout, unless her menses be stopped, a youth does not get gout before 
sexual intercourse, in gouty affections, inflammation subsides within 40 
days, gouty affections become active in spring and in autumn,’ (Adams, 
1849) 
Much of the historical terminology and context surrounding gout may be explained 
by Greek legends known to Hippocrates and his contemporaries, such as the story 
that the goddess Podagre was the product of the seduction of Aphrodite by 
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Dionysus, the Greek god of wine.  (Rodnan, 1965) The Roman physician Galen 
was of Greek descent and was also thought to have expressed the view that “gout 
is the daughter of Bacchus,” Bacchus being the Roman name for Dionysus, god of 
wine.  (Gaebel, 1983) Although gout is described relatively frequently in Roman 
writing, particularly by Seneca, advisor to Nero in 1 AD, gout in women was 
particularly frowned upon as a sign of deeply flawed moral virtue, (Porter & 
Rousseau, 2000) perhaps because the male preponderance for the condition was 
considered to mark out any woman afflicted with it as unusual. 
It now seems more likely that the link between gout and the “intemperate lifestyle” 
was due to the process by which the Romans made wine, rather than the quantity 
of it consumed.  The particular technique by which the Romans preserved wine 
involved mixing it with grape syrup which had been simmered in lead-lined 
vessels, resulting in high levels of lead within the wine consumed, which in 
combination with lead from water which ran through lead-lined pipes resulted in 
excessive levels of ingested lead.  (Nriagu, 1983)  Lead poisoning has latterly 
been linked with gout via a mechanism of chronic kidney disease and an impaired 
renin-angiotensin-aldosterone system.  (Nolan & Shaikh, 1992) Emperors 
Claudius, Nero, Caligula and Tiberius were known to suffer gout, but were also 
known for their unusual speech and unpredictable behaviours, perhaps 
representing the neuro-psychiatric sequelae of excessive lead consumption.  
(Nriagu, 1983) Industrial and occupational exposure to lead, as well as the 
presence of lead in household paints has also been linked with high prevalence of 
gout in the 19th century.  (Newcombe, 2012)  
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Perhaps the most famous description of gout is attributed to the physician and 
gout sufferer Thomas Sydenham. 
 “The patient goes to bed and sleeps quietly until about two in the morning 
when he is awakened by a pain which usually seizes the great toe, but 
sometimes the heel, the calf of the leg or the ankle. The pain resembles 
that of a dislocated bone ... and this is immediately succeeded by a 
chillness, shivering and a slight fever ... the pain ..., which is mild in the 
beginning ..., grows gradually more violent every hour ... so exquisitely 
painful as not to endure the weight of the clothes nor the shaking of the 
room from a person walking briskly therein," (Sydenham & Wallis, 1788)  
Gout was considered a condition of the higher social classes and was therefore 
desirable.  It was written in the London Times in the 1900’s that,  
“The common cold is well named- but the gout seems to instantly raise the 
patient’s social status.” (Copeman, 1964)  
The term gout, from the Latin “gutta”, meaning drop, originated from the belief that 
health and disease arose from the balance between the four bodily humors (black 
bile, yellow bile, blood and phlegm), gout being caused by humors falling to the 
affected body part causing inflammation and swelling.  (Copeman, 1964)  The 
Greek word podagra or “foot-grabber” refers to the predilection of gout for the foot, 
in particular the first metatarsophalangeal joint, and dates back to the second 
century AD.  (Porter & Rousseau, 2000)  
Antoni van Leeuwenhoek was the first to describe crystals from a gouty tophus 
seen under a microscope in the late 17th century.  Although their chemical 
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composition was not understood until much later, he described them to be, “long, 
transparent little particles, many pointed at both ends and about 4 'axes' of the 
globules in length.” (Porter & Rousseau, 2000) Karl Scheele was the first to isolate 
uric acid from a renal calculus in the 1700’s, and Wollaston the first to show the 
presence of urate in aspirate from a gouty tophus from his own ear. (Scheele, 
1776; Wollaston, 1797)  The work of Sir Alfred Garrod in the 1850’s made perhaps 
the seminal discovery in the pathogenesis of gout, differentiating those with gouty 
arthritis from those with rheumatism using the presence of serum hyperuricaemia. 
(Garrod, 1848) He also developed the “thread test”, the first clinical chemical test 
undertaken, which used microscopy to view urate crystals in desiccated, acetate-
impregnated serum and finally allowed both a diagnostic test and a clear 
differentiation between gout and rheumatoid arthritis. (Garrod, 1848)  
Treatment for acute gout, such as colchicine extracted from autumn crocus, was 
thought to have been in use as early as the 6th century AD.   However, in keeping 
with its alternative use as a purgative, its use was limited by the associated gastro-
intestinal side effects.  Sydenham condemned the gastrointestinal side effects of 
medicines, particularly colchicine, as evidence that it was too poisonous for use.  
(Copeman, 1964) It was not until a century later that high-dose salicylates were 
shown to be an effective treatment for acute gout, and despite their limited use 
due to side effects, paving the way for the modern day use of non-steroidal anti-
inflammatory drugs as an alternative to colchicine in acute gout. (Nuki & Simkin, 
2006)  
Despite the long assumed association between gout and lifestyle, little evidence 
exists to support this.  It was not until 1876 that Sir Alfred Garrod published the 
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first work suggesting that hyperuricaemia could be controlled by limiting dietary 
intake of purines.  (Garrod, 1876) The first clinical experiments in support of this 
theory were undertaken between 1894 and 1897, by Haig.  (Haig, 1897) Large 
epidemiological studies examining the impact of various dietary constituents 
including purines, alcohol, fructose-flavoured soft drinks amongst others, on the 
incidence of gout, did not begin until the beginning of the 21st century.  (Choi et al, 
2004a; Choi et al, 2004b; Choi et al, 2007b; Choi & Curhan, 2008; Choi et al, 
2009; Choi & Curhan, 2010; Choi et al, 2010)  
Prophylactic treatments for gout emerged much later.  The important milestones in 
the treatment of gout are shown in Figure 1.1.
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Figure 1.1:  Key milestones in the treatment of gout
 
Colchine (from 
autumn crocus) first 
used to treat acute 
gout  
 
Use of uricosuric drugs such as 
probenecid, sulfinpyrazone and 
benzbromarone introduced as a more 
tolerable treatment of chronic gout 
 
Elion & Hitchings discovered 
allopurinol, the first & most 
commonly used xanthine 
oxidase inhibitor.  Awarded 
the Nobel Prize for Medicine 
1988 
Febuxostat licensed as an alternative  
xanthine oxidase inhibitor for those unable to 
tolerate allopurinol, or failed to respond to 
allopurinol  
 
Salicylates used as uricosurics 
but the high doses required (4 
and 6 grams per day), made this 
treatment impractical  
 
Absence of the xanthine oxidase enzyme 
identified as reason for the ineffective 
excretion of uric acid in humans  
 
Suppression of SUA to <6mg/dL 
shown to control symptoms of gout 
and crystal burden could be reversed, 
making gout a “curable” condition 
 
Following the identification of 
IL-1β as an important part of 
the inflammatory pathway 
stimulated by MSU crystals, 
interleukin receptor antagonists 
such as anakinra offer new 
treatments for acute flares of 
gout  
Pegloticase, a synthesised 
substitute for xanthine 
oxidase was licensed for 
use in Europe  
6AD        1897    1950     1988  2001      2005 2007    2013
   
Figure 1.1: Key mileston s in th  treatm nt of gout 
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1.3 Epidemiology 
This section will describe the epidemiology of gout including both prevalence and 
incidence in the UK and worldwide. 
1.3.1 Prevalence of gout  
1.3.1.1 Prevalence of gout in the UK 
Gout is the most prevalent inflammatory arthropathy at 2.5% in the UK, (Kuo et al, 
2014) compared to  rheumatoid arthritis 0.8%, (Symmons et al, 2002) psoriatic 
arthritis 0.3%, (Taylor, 2002) and ankylosing spondylitis 40/100,000.  (McCormick 
et al., 1995) Kuo also highlighted the increasing prevalence, estimating this had 
increased by 63.9% since 1997.  (Kuo et al, 2014) Prior to the publication of this 
most recent study, the prevalence of gout was estimated to be 1.4% in 2005 by 
two studies using two different databases of primary care electronic patient 
records (CPRD and the IMS Disease Analyser). (Annemans et al, 2008; Mikuls et 
al, 2005b) In contrast, a study using the Royal College of General Practitioners 
(RCGP) Weekly Returns Service, a database of reasons for consultation collected 
by the RCGP from a network of 100 practices in England and Wales, between 
2001 and 2007 estimated the mean prevalence of gout during this period to be 
much lower at 0.46%. (Elliot et al, 2009)  This lower estimate is likely to result from 
the RCGP Weekly returns service being based on reason for consultation, which 
since gout is episodic in nature and not all patients consult with every flare, is 
more representative of the prevalence of consultation for gout rather than that of 
the disease itself.   
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1.3.1.2 Prevalence of gout worldwide 
The worldwide prevalence of gout is summarised below, grouped by continent, in 
table 1.1.  Within Europe, only Greece has a higher prevalence of gout than the 
UK, and outside Europe only large developed nations such as Australia and New 
Zealand and the USA have a higher prevalence of gout than the UK.
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Table 1.1: Reported prevalence of gout by continent 
 
Study Year of 
publication 
Country Study design Study population Definition of gout Prevalence  
(%) 
Europe 
(Annemans et al, 
2008) 
2008 Germany Retrospective cross-
sectional  primary care 
electronic medical 
record database study  
4006 At least 2 entries of 
a gout Read code in 
primary care record 
Period prevalence 
2000-2005 
1.4 
(Anagnostopoulos et 
al, 2010) 
2010 Greece Prospective cross-
sectional population 
survey 
1705 Self report 
Physician 
confirmation using 
ACR criteria 
Period prevalence 
2007-2008 
4.75 
(Trifiro et al, 2013) 2013 Italy Retrospective cross-
sectional primary care 
electronic medical 
records database study 
Not stated Physician recorded 
diagnosis of gout 
Point prevalence 
0.67 in 2005 
0.91 in 2009 
North and South America 
(Wallace et al, 2004) 2004 USA Retrospective cross-
sectional managed-care 
administrative database 
study 
Not stated Physician recorded 
diagnosis of gout 
Point prevalence 
0.29 in 1990 
0.52 in 1999 
(Zhu et al, 2011) 2011 USA Nationwide population 
survey (National Health 
and Nutrition 
Examination Survey) 
5707 Self-report of health 
professional or 
physician 
diagnosed gout 
Period prevalence 
3.9 in 2007/8 
(Pelaez-Ballestas et 
al, 2011) 
2011 Mexico (5 
regions) 
Cross-sectional survey 19,213 Self-report verified 
by clinician 
assessment 
Point prevalence 
0.3 
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Study Year of 
publication 
Country Study design Study population Definition of gout Prevalence  
(%) 
Asia 
(Nan et al, 2006) 2006 China 
(Quingdao) 
Cross-sectional 
population based survey 
2438 Self-report Point prevalence 
0.36 
(Miao et al, 2008) 2008 China 
(Eastern 
coastal 
cities 
Cross-sectional 
population based survey 
5003 Self-report 
validated by ACR 
criteria 
Point prevalence 
1.14 
(Çakır et al, 2012) 2011 Western 
Turkey 
Cross-sectional 
population based survey 
17,835 Self-report 
validated by clinical 
examination 
Point prevalence 
0.02 
(Li et al, 2012) 2012 China Cross-sectional 
population-based 
survey 
10,556 Self-report 
validated by ACR 
criteria 
Point prevalence 
0.09 
Australasia 
(Klemp et al, 1997) 1997 New 
Zealand 
Cross-sectional 
population-based 
survey 
657 Clinical examination 
and ARA survey 
criteria  
Point prevalence 
4.7 
(Winnard et al, 2012) 2012 New 
Zealand 
(Aotearoa) 
Cross-sectional study 
using national 
administrative health 
dataset   
4,295,296 ICD code for gout in 
clinical record or 
record of 
prescription for 
allopurinol or 
colchicine  
Point prevalence 
2.69 in 2009 
(Robinson et al, 
2012) 
2012 Australia Systematic review Not stated, but 
<28,000 from those 
where study 
population is 
reported  
Various Point prevalence 
1.7 in 1995/6 
(Smith et al, 2014) 2014 Global Systematic review Not stated and 
cannot be 
estimated from the 
paper 
ACR survey criteria Point prevalence 
0.08 in 2010 
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Thus large differences in the prevalence of gout can be seen, even across 
geographically similar areas.  The highest reported prevalence can be seen in 
New Zealand, Greece and the USA. (Anagnostopoulos et al, 2010; Klemp et al, 
1997; Zhu et al, 2011)   This may represent differences in genetic or dietary 
factors, or may simply be the result of using differing definitions of gout (such as 
self-report versus coded diagnoses in medical records) to estimate prevalence. 
Seasonal variation in the prevalence of gout has also been suggested, with peak 
incidence of both acute attacks and new diagnosis of gout reported during the 
summer, although the physiological reasons for this trend remain unclear.  (Alter et 
al, 1994; Elliot et al, 2009; Gallerani et al, 1999; McLeod, 1972; Williamson, 1920)  
1.3.2  Incidence of Gout  
1.3.2.1 Incidence of gout in the UK 
The incidence of gout, or the proportion of newly occurring cases of gout within a 
specified period, had been thought to have remained relatively stable in recent 
years.  (Roddy & Doherty, 2010) However, more recent evidence has suggested 
that incidence is increasing.  (Kuo et al, 2014)  
The most recent estimate of incidence examines the period between 1997 and 
2012, in the CPRD, the world’s largest database of electronic primary care records 
and reports an overall incidence of gout of 1.8 cases per 1,000 patient years with 
an average increase in incidence of 1.5% per year.  Men had a higher incidence of 
gout (2.58 cases per 1000 person-years) compared to women (0.99 per 1000 
person-years).  (Kuo et al, 2014) The CPRD was also used to investigate the 
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period 1990 to 1999 and reported gout incidence to be at its lowest in 1991, with 
an incidence of 11.9 cases per 10,000 patient years, and at its highest in 1994, 
with an incidence of 18.0 cases per 10,000 patient years.  The incidence declined 
to 13.1 cases per 10,000 patient years in 1999. (Mikuls et al, 2005b) The same 
study also report a higher incidence of gout in males compared with females, with 
the highest incidence reported in males between the ages of 65-84 years.  (Mikuls 
et al, 2005b) A further study used the RCGP Weekly Returns Service, and 
investigated the period 1994 to 2007.  (Elliot et al, 2009)  They reported the mean 
annual incidence of new gout cases during that period to be 12.4 per 10,000 
population, with no evidence of a changing trend.  They reported the annual 
incidence in men to be three times that in women, and increasing incidence with 
increasing age.  (Elliot et al, 2009)  
The Health Improvement Network (THIN) database, an alternative database of 
anonymised electronic primary care records, has also been used to investigate the 
period between 2000 and 2007.  (Cea Soriano et al, 2011)  This study estimated 
the incidence of gout to be 2.68 per 1,000 person years.  The incidence of gout 
was 4.42 (95% CI 4.36 to 4.48) in men and 1.32 (95% CI 1.29 to 1.35) in women 
per 1,000 person-years and was found to increase with increasing age. (Cea 
Soriano et al, 2011) 
1.3.2.2  Incidence of Gout Worldwide 
The studies reporting incidence of gout worldwide are described in Table 1.2 
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Table 1.2 Incidence of gout worldwide 
 
Study Year of 
publication 
Country Study design Study 
population 
Ascertainment of 
gout 
Incidence 
(Roubenoff et al, 
1991) 
1991 USA Longitudinal cohort 
study 
1271 Medical record 
review 
1.73 per 1000 PY  
(Arromdee et al, 
2002) 
2002 USA Retrospective 
cross-sectional 
study using 
electronic medical 
records  
Not stated ACR survey 
criteria for gout 
based on medical 
record review 
AIR 45.0/100,000 1977/8 
AIR 62.3/100,000 1995/6 
(Bhole et al, 
2010)  
2010 USA Prospective cohort 
study 
4427 Self-report of pre-
specified criteria 
strongly 
suggestive of 
clinical gout  
1.4/1000 PY in women  
4.0/1000 PY in men 
(Trifiro et al, 
2013) 
2013 Italy Retrospective 
cross-sectional 
primary care 
electronic medical 
records database 
study 
Not stated Physician 
recorded diagnosis 
of gout 
0.93/1000 PY in 2005 
0.95/1000 PY in 2009  
(Maynard et al, 
2014) 
2013 USA Longitudinal cohort 
study 
11,963 Self-report Overall; 0.84/1000 PY 
(1.5/1000 PY black men;  
1.2/1000 in black women; 
0.94/1000 PY white men; 
0.50/1000 PY  in white 
women 
AIR = annual incidence rate; PY= Patient years 
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1.4  Gout pathophysiology 
Gout is the clinical manifestation of deposition of monosodium urate (MSU) 
crystals in joints and soft tissues.   As serum uric acid (SUA) levels rise, eventually 
the blood becomes saturated with urate, and precipitation of MSU crystals results.  
These MSU crystals are deposited in the joints and soft tissues, triggering 
inflammation and painful synovitis.   
Uric acid is produced as purines that are both ingested in the diet, and synthesised 
through tissue degradation, are broken down.  This process is illustrated in figure 
1.2 
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Figure 1.2 Uric acid metabolism   
 
Source: (Pacher et al, 2006) 
 
Solubility of uric acid in water is low, and in humans, the evolutionary loss of urate 
oxidase means that uric acid cannot be converted to the more soluble allantoin, as 
in other mammals. (Wu et al, 1989) Uric acid homeostasis occurs as production is 
balanced against its excretion via the renal and gastrointestinal tracts.  If this 
balance is disturbed, levels of serum uric acid begin to rise.  In approximately 90% 
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of cases, this hyperuricaemia is due to impaired renal excretion of urate, with the 
remaining 10% the result of endogenous overproduction, although some patients 
are likely to experience both phenomena.  (Choi et al, 2005b)  
 
The mechanism underlying urate homeostasis was only recently reported by 
Enomoto (2002).  Since urate exists primarily as a weak acid within the body, it 
was thought likely that the structure of any urate transporter would be similar to 
that of other organic anion transporters (OATs).  Enomoto et al, 2002, identified a 
gene, and associated Deoxyribonucleic Acid (DNA), which they named URAT1, in 
the proximal epithelial cells of the human kidney, which they suggested as the 
mechanism by which extracellular urate is reabsorbed from the tubular lumen to 
the intracellular cytosol at the proximal tubules.  (Enomoto et al, 2002) A range of 
other genetic associations with renal urate homeostasis have been described, 
(Anzai et al, 2012) but as they are not related to the main subject of interest, will 
not be considered further in this thesis.  
 In most, this period of hyperuricaemia is asymptomatic, and whilst evidence 
suggests that higher levels of serum urate lead to an increased risk of MSU crystal 
deposition, even in patients with the highest levels of serum urate (>9mg/dL), only 
a minority of patients (22%) go on to develop gout. (Campion et al, 1987) 
However, in some, for reasons which are poorly understood, at a concentration of 
approximately 6.8mg/dL, when super-saturation of uric acid in the extracellular 
fluid is reached, precipitation and deposition of monosodium urate crystals in joints 
and soft tissues occurs. (Kippen et al, 1974; Loeb, 1972)  How these sites of 
deposition are determined remains unclear. 
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Deposition of MSU crystals and cell-crystal contact results in intra-articular 
initiation of inflammation through a mechanism which remains unclear, but is 
thought to involve: 
 phagocytosis of the synovial fibroblasts  
 degranulation resulting in cell activation  
 influx of leucocytes  
 expression of pro-inflammatory and chemotactic molecules  
 Martinon et al, 2006, were the first to propose a stepwise underlying mechanism 
involving a multi-protein complex known as the “inflammasome” and resulting in 
increased production of the inflammatory cytokine Interleukin-1β (IL-1β).  
(Martinon et al, 2006)  This mechanism is summarised in Figure 1.3 below. 
 
 
 
 
 
 
 
 
 
 
 
  
18 
     
 
Figure 1.3 Mechanisms underlying MSU crystal-induced inflammation 
 
Adapted from (Dalbeth & Merriman, 2009) 
Step 2 is considered the most relevant to crystal induced inflammation, since it is 
this step which involves activation of the “inflammasome”, a multiprotein complex 
linking the identification of an intracellular danger signals by NOD-like receptors 
(NLR’s), to the activation of pro-inflammatory cytokines.   
Once activated, the inflammasome is formed by a member of the NACHT, LRR 
and pyrin domain-containing protein family (NALP 1, 2 or 3) and the adaptor 
protein ASC. The ASC protein connects the NALPs with, and activates a further 
protein Caspase-1, allowing cleavage of the pro-IL-1β into active IL-1β.  
Step 1 
MSU crystals stimulate intracellular 
danger signals detected by NOD-
like receptors 
Pro IL-1β released 
 
Step 2 
NALP and ASC proteins connect 
with and activate caspase-1 
forming the “inflammasome” 
The inflammasome mediates 
cleavage of Pro-IL-1β into active 
IL-1β 
Step 3 
Active IL-1β is released into the extracellular 
environment resulting in an acute inflammatory 
response 
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Martinon et al, 2006, reported this mechanism to be extremely sensitive with 
secretion of IL-1β after stimulation of monocytes by only very small amounts of 
MSU or calcium pyrophosphate dihydrate (CPPD) crystals and extremely specific 
since there was no secretion of IL-1β in response to presence of non-pathogenic 
crystals or particulate elements tested.  Furthermore they reported that presence 
of a caspase-1 inhibitor was able to completely block MSU-induced IL-1β 
cleavage, confirming the role of caspase-1 in cleavage of the pro-IL-1β. (Martinon 
et al, 2006)  
The resulting MSU crystal-induced inflammatory synovitis results in an acutely 
painful arthritis, most commonly of the first metatarsal joint, associated with 
swelling and overlying redness. These attacks are self-limiting, although the 
severe pain associated with acute attacks warrants prompt treatment.  Studies 
have also identified evidence of subclinical inflammation persisting between acute 
attacks of gout, in the so called “intercritical” period. (Pascual et al, 1999; Roddy et 
al, 2013) This persistent inflammation implies a chronicity to the disease course of 
gout that was previously unrecognised by clinicians, and suggests that the disease 
remains active physiologically, even in the absence of clinical symptoms.   
 
However, this raises an important question about why, in the ongoing presence of 
MSU crystals and sub-clinical inflammation, acute attacks are episodic suggesting 
additional factors influencing their onset.  Similarly the reasons for, and 
mechanisms underlying, the self-limiting nature of acute attacks of gout are also 
likely to be multifactorial, but remain poorly understood.   
  
20 
     
 
1.4.1 The relationship between gout and age and gender 
Increasing age and male gender are both recognised as risk factors for gout.  
(Choi et al, 2005b)  This is demonstrated graphically in figure 1.4, taken from Kuo 
et al, 2014, describing the epidemiology of gout in the UK from 1990-1999.  (Kuo 
et al, 2014) 
Figure 1.4: Incidence & prevalence of gout in the UK by age and gender in 2012 
Findings are shown by the solid lines with 95% confidence intervals by the dashed lines either side 
 
Men 
Women 
Overall 
Men 
Overall 
Women 
Source: (Kuo et al, 2014) 
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The increased prevalence of gout in men was first described by Hippocrates: 
“A woman does not take the gout, unless her menses be stopped,” (Adams, 
1849)  
This gender difference continues to be reported. (Choi et al, 2005b)  Mechanisms 
for this include a higher baseline serum urate level, and higher prevalence of 
hyperuricaemia in men which may be caused by the uricosuric effect of oestrogen 
on the renal tubules leading to increased uric acid excretion in women. (Chen et 
al, 2012)  This may also explain the increased incidence of gout in post-
menopausal women.  (Dirken-Heukensfeldt et al, 2010) Studies have shown that 
higher levels of uric acid increase the risk of gout in women, but that the strength 
of this association is considerably less among women than men, meaning that 
even with similar levels of blood urate, women have a lesser chance of developing 
gout than men. (Bhole et al, 2010)  This is supported by findings of significantly 
higher blood urate concentrations in female gout patients, compared with male 
equivalents.  (Puig et al, 1991) However, the physiological basis for these findings 
remain relatively poorly understood. 
It is interesting to note that prevalence of gout in women peaks between ages 84-
89 years, whereas in men it peaks between ages 80-84.  This may be a 
manifestation of the healthy-survivor effect, since the life expectancy of men is 
shorter than that of women.  It has been observed by other studies that mean age 
at onset of gout can be as much as 10 years older in women compared with men.  
(Chen et al, 2012) It has been suggest that this may be due to increased 
sensitivity of the kidneys to insulin in women, since insulin is known to reduce the 
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renal excretion of urate, and that higher prevalence of abdominal obesity with 
associated insulin-resistance, increased production and impaired excretion of uric 
in post-menopausal women may be a contributory factor. (Bhole et al, 2010)  
However, to date, women remain a relatively understudied group in the 
epidemiology and clinical course of gout, and further research is required to gain 
understanding of the gender-specifics of gout.    
1.4.2 The relationship between gout and genetic factors 
Basal serum uric acid levels in humans are uniquely high, owing to three separate 
mutations resulting in a non-functioning uricase gene. (Riches et al, 2009) 
Hyperuricaemia is the strongest risk factor for incidence of gout, (Zhang et al, 
2006b) and the heritability of hyperuricaemia has been shown in twin studies. 
(Emmerson et al, 1992; Krishnan et al, 2012)  Links between common variants of 
several genes and hyperuricaemia have been demonstrated in recent studies,  
(Kolz et al, 2009; van der Harst et al, 2010; Yang et al, 2010) and  these genes are 
thought to increase serum urate levels by contributing to either uric acid over 
production, or uric acid under-secretion.   Known contributors to these 
mechanisms underlying hyperuricaemia are shown in Figure 1.5 
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Figure 1.5 Contributors to mechanisms underlying hyperuricaemia and gout 
 
 
Source: (Reginato et al, 2012) 
 
Most of the genes found to contribute to urate under-excretion encode transporter 
proteins found in the apical membrane of the human proximal renal tubule.  
(Reginato et al, 2012) These are summarised in Table 1.3. 
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Table 1.3a Variants at genetic loci SLC2A9 reported to associate with hyperuricaemia and gout
Location of mutation Phenotype Populations References 
SLC2A9 (chromosome 4) encoding glucose transporter type 9 (GLUT-9) 
Intron 3 SUA, FeUA, gout European Vitart et al, 2008 
Intron 4 SUA, FeUA, gout White 
 
 
 
African-American 
Vitart et al, 2008;Doring et al, 
2008; Wallace et al, 2008; 
Dehghan et al, 2008; 
Brandstatter et al, 2008 
Charles et al, 2011; Tin et al, 
2011 
Exon 6 SUA, gout White 
 
 
African-American 
Amish 
Dehghan et al, 2008; Hollis-
Moffatt et al, 2009;Karns et 
al, 2012 
Tin et al, 2011 
McArdle et al, 2008 
Intron 6 SUA, gout White 
 
 
Icelandic 
African-American 
Doring et al, 2008; Kolz et al, 
2009; Li et al, 2007; Stark et 
al, 2008; Karns et al, 2012 
Sulem et al, 2011 
Tin et al, 2011 
Intron 7 SUA, FeUA, gout European 
White 
 
 
 
African-American 
Vitart et al, 2008; Karns et al, 
2012 
Doring et al, 2008; Li et al, 
2007; Stark et al, 2008; Karns 
et al, 2012; Yang et al, 2010;  
Tin et al, 2011 
Intron 8 SUA, gout European Tin et al, 2011 
Intron 9 SUA, gout African-American 
 
Croatian 
Charles et al, 2011;Tin et al, 
2011 
Karns et al, 2012 
Intergenic SUA, gout White 
Amish 
Croatian 
Pacific Islander 
New Zealand 
Dehghan et al 2008 
McArdle et al, 2008 
Karns et al, 2012 
Hollis-Moffatt et al, 2009 
Hollis-Moffatt et al, 2009 
Intergenic SUA Croatian 
African-American 
Karns et al, 2012 
Charles et al, 2011 
Intergenic  Gout Amish McArdle et al, 2008 
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Table 1.3b Variants at genetic loci ABCG2 reported to associate with hyperuricaemia and gout 
 
 
 
 
 
 
 
 
 
 
 
Location of mutation Phenotype Populations References 
ABCG2 (chromosome 4) encoding ATP-binding cassette subfamily G member 2 (ABCG2) an ATP 
dependent transporter protein 
Exon 2 SUA Japanese Matsuo et al, 2009 
Exon 4 SUA, gout Japanese Matsuo et al, 2009 
Exon 5 FeUA, SUA, gout White 
 
 
 
African 
Chinese 
Icelandic 
Japanese 
 
Pacific Islander 
New Zealander 
Kolz et al, 2009; Dehghan et 
al, 2008; Stark et al, 2008; 
Karns et al, 2012; Woodward 
et al, 2009 
Dehghan et al, 2008; Tin et 
al, 2011 
Wang et al, 2010 
Sulem et al, 2011 
Yamagishi et al, 2010; 
Matsuo et al, 2009 
Phipps-Green et al, 2010 
Caulfield et al, 2008; Phipps-
Green et al, 2010  
Intergenic SUA White Kolz et al, 2009; Yang et al, 
2010; Karns et al, 2012 
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Table 1.3c Variants at genetic loci SLC22A12 reported to associate with hyperuricaemia and gout  
  
Location of mutation Phenotype Populations References 
SLC22A12 (chromosome 11) encoding urate anion transporter 1 (URAT1) 
Exon 1 FeUA, SUA Chinese 
White 
 
African-American 
Tu et al, 2010 
Kolz et al, 2009; Graessler et 
al, 2006 
Tin et al, 2011 
Exon 2 FeUA German Graessler et al, 2006 
Exon 2 SUA African-American Tin et al, 2011 
Intron 3 SUA Chinese Li et al, 2010 
Intron 4 SUA European 
 
Japanese 
Chinese 
Kolz et al, 2009; van der 
Harst et al, 2010;  
Shima et al, 2006 
Guan et al, 2009 
Intron 4 FeUA, SUA Korean Jang et al, 2008 
Intron 4 Gout Chinese 
Solomon Islander 
Tu et al, 2010 
Tu et al, 2010 
Exon 8 SUA, FeUA, gout German 
Chinese 
Solomon Islander 
Graessler et al, 2006 
Tu et al, 2010; Li et al, 2010 
Tu et al, 2010 
Intergenic SUA European 
 
Africa-American 
Kolz et al, 2009; Karns et al, 
2012 
Tin et al, 2011 
Intergenic FeUA, SUA German 
Chinese 
Graessler et al, 2006 
Li et al, 2010 
FeUA = Fractional excretion of uric acid, SUA = serum uric acid 
Adapted from Reginato et al, 2012 (Reginato et al, 2012) 
These genetic loci have been identified to encode transporter proteins within the 
proximal renal tubule which influence renal urate excretion, and their actions are 
represented in Figure 1.6.   
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Figure 1.6 Contribution of known genetic variants to renal under excretion of urate  
 
 
Source: (Reginato et al, 2012) 
Twin and familial studies have shown a polygenic mode of inheritance for 
hyperuricaemia and renal excretion of urate, and the heritable component of 
hyperuricaemia has been estimated at between 40 and 60%. (Emmerson et al, 
1992; Wilk et al, 2000) However, in contrast, relatively fewer of the loci identified 
influence the phenotypic expression of gout, with only 6% of variance in serum 
urate levels in patients with gout being explained by common genetic associations, 
and 67% being explained by non genetic factors. (Reginato et al, 2012) This would 
suggest that there are other important influences on the pathogenesis of gout 
beyond genetic predisposition to hyperuricaemia, in keeping with the evidence that 
only a minority of those with hyperuricaemia go on to develop clinical gout.  (Choi 
et al, 2005b)  
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Single gene mutations predisposing to rare clinical syndromes associated with 
hyperuricaemia and gout, including Lesch-Nyhan Syndrome, (Ea et al, 2009) 
glycogen storage diseases, (Reginato & Olsen, 2007) and uromodulin defects, 
(Bleyer et al, 2003; Scolari et al, 2004) have also been identified.  These 
monogenic mutations influence purine pathways, usually present at a young age 
and are often associated with additions non-gout clinical features.  (Reginato et al, 
2012)  These are summarised in table 1.4 below. 
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Table 1.4:  Rare Mendelian syndromes associated with hyperuricaemia and gout 
 
Source: (Riches et al, 2009) 
Disease Inheritance Gene Phenotype 
Syndromes of altered purine metabolism 
HPRT related XD 
Hypoxanthine guanine phosphoribosyl 
transferase (HPRT 1) 
Hyperuricaemia, gout, neurological 
dysfunction 
PRPS related XD 
Phosphoribosyl pyrophosphate synthetase 
1 (PRPS 1) 
Hyperuricaemia, gout 
Syndromes of excessive cell death and urate generation 
Glycogen storage disease type 
Ia 
AR Glucose 6 phosphatase 
Growth retardation, hypoglycaemia, 
hepatomegaly, hyperuricaemia, gout, lactic 
acidosis 
Glycogen storage disease type 
Ib 
AR Glucose six phosphate transporter 
Growth retardation, hypoglycaemia, 
hepatomegaly, hyperuricaemia, gout, lactic 
acidosis 
Glycogen storage disease type 
III 
AR Glycogen debranching enzyme Early onset hyperuricaemia, gout 
Glycogen storage disease type V AR Muscle glycogen phosphorylase Early onset hyperuricaemia, gout 
Glycogen storage disease type 
VII 
AR Muscle phosphofructokinase Early onset hyperuricaemia, gout 
Syndromes of reduced renal excretion of uric acid 
Medullary cystic kidney disease, 
type 1 
AD Unknown 
Variable penetrance: renal dysfunction, 
hypertension, gout 
Medullary cystic kidney disease, 
type 2 
AD/AR Uromodulin 
Progressive renal dysfunction, variable 
hyperuricaemia, early onset gout 
Familial juvenile hyperuricemic 
nephropathy 
AD Uromodulin 
Progressive renal dysfunction, variable 
hyperuricaemia, early onset gout 
AD= autosomal dominant; AR= autosomal recessive; XD=x-linked dominant; HPRT= Hypoxanthine guanine phosphoribosyl transferase; 
PRPS= Phosphoribosyl pyrophosphate synthetase  
  
30 
 
However, aside from these rare syndromes, the heritability of gout remains largely 
unproven. (Riches et al, 2009) Whilst mutations in genetic loci have been shown to 
play an important role in renal excretion of urate, thought to be a significant 
contributor to risk of gout, genetic factors have not yet been implicated in other 
mechanisms underlying gout pathogenesis, such as MSU-crystal formation and 
inflammatory response to MSU-crystals. (Merriman & Dalbeth, 2011)  It may be 
that the genetic variations which influence these factors are yet to be identified, or 
that environmental factors are more important in the phenotypic expression of 
gout. (Krishnan et al, 2012) Comparison of clinical and genetic scoring systems to 
predict risk of gout also supports this latter suggestion,  since whilst a scoring 
system based on differing combinations of genetic mutations thought to influence 
urate levels predicted a 41-fold increase in risk of gout compared to patients 
without such mutations, (Yang et al, 2010) a clinical score combining easily 
measureable risk factors including BMI, alcohol consumption, diuretic use and 
hypertension predicted an increased risk of gout of up to 79 times.  (Choi et al, 
2005a) It has therefore been suggested that the clinical utility of identification of 
genetic risk factors for gout is limited. (Reginato et al, 2012)  
1.4.3 The relationship between gout and dietary factors 
Diets that are rich in meat and alcohol have historically been blamed for the 
development of gout.  The link between diet and gout was first observed by 
Hippocrates who dubbed it the “disease of kings”. (Adams, 1849) The influence of 
dietary components on hyperuricaemia has been reported by a number of studies, 
an unsurprising association given the mechanism by which urate is produced in 
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the human body is from the degradation of purines which derive mainly from the 
diet. (Choi et al, 2005; Choi et al, 2004a; Choi et al, 2007b; Choi & Curhan, 2008; 
Choi et al, 2009; Choi et al, 2010)  As hyperuricaemia is the major risk factor for 
gout, it could reasonably expected that increased purine intake and resultant 
increased levels of uric acid should also increase likelihood of gout, however whilst 
consumption of some purine-rich foodstuffs, such as red meat and seafood, has 
been linked with an increased likelihood of gout, (Choi et al, 2004a) other dietary 
constituents such as purine-rich vegetables, which for the same reasons might 
reasonably be expected to increase the risk of gout, have not, although the 
reasons for this remain unclear.  (Choi et al, 2004a) A summary of these 
relationships, adapted from the review by Dalbeth & So, 2010, is presented in 
table 1.5.  
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Table 1.5: Dietary constituents and risk of gout 
 
Dietary constituent Risk of 
incident 
gout 
RR for risk 
of gout* 
(95%CI) 
References 
Foods 
    Meat 
Increased 
1.41 
(1.07-1.86) 
(Choi et al, 2004a)1 
    Seafood 
Increased 
1.51 
 
(1.17-1.95) 
(Choi et al, 2004a)1 
    Purine-rich vegetables 
 No effect 
0.96 
(0.74-1.24) 
(Choi et al, 2004a) 1 
    High fat dairy products 
 No effect 
1.0 
(0.77-1.29) 
(Choi et al, 2004a) 1 
    Low fat dairy products 
Reduced 
0.58 
(0.45-0.76) 
(Choi et al, 2004a) 1 
    Fructose rich fruits 
Increased 
1.64 
(1.05-2.56) 
(Choi & Curhan, 2008) 
1 
    Vitamin C 
Reduced 
0.55 
(0.38-0.80) 
(Choi et al, 2009) 1 
 
RR = Relative Risk; CI = Confidence interval 
* multivariate relative risk, typically comparing highest quintile of ingestion with 
referent group (no ingestion or lowest quintile of ingestion) 
 
1  Reports results from the Health Professionals Follow-up study which followed  
47,150 men prospectively for up to 12 years  
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Dietary constituent Risk of 
incident 
gout 
RR for risk 
of gout* 
(95%CI) 
References 
Drinks 
    Sugar sweetened soft 
drinks 
Increased 
M 1.85 
(1.08-3.16) 
F 2.39 
(1.34-4.26) 
(Choi & Curhan, 2008) 
1 
(Choi et al, 2010) 2 
 
    Diet soft drinks 
No effect 
M 1.12 
(0.82-1.52) 
F 1.18 
(0.87-1.58) 
(Choi & Curhan, 2008) 
1 
(Choi et al, 2010) 2 
 
    Fruit juice  
 
 
Increased 
 
 
 
No effect 
M 1.81 
(1.12-2.93) 
F (orange 
juice) 2.42 
(1.27-4.63) 
F (other 
juices) 
1.14  
(0.57-2.27) 
(Choi & Curhan, 2008) 
1 
 
 
 
 
 
(Choi et al, 2010)2 
 
    Free fructose 
Increased 
M 2.02 
(1.49-2.75) 
F 1.62 
(1.20-2.19) 
(Choi & Curhan, 2008) 
1  
(Choi et al, 2010)2 
    Coffee 
Reduced 
M 0.41 
F 0.43 
(Choi et al, 2007b) 1 
(Choi & Curhan, 2010) 
2 
 
    Decaffeinated coffee 
Reduced 
M 0.73 
F 0.77 
(Choi et al, 2007b) 1 
(Choi & Curhan, 2010) 
2 
 
    Tea 
No effect 
M 0.82 
F 1.55 
(Choi et al, 2007b) 1 
(Choi & Curhan, 2010) 
2 
 
RR= Relative risk; CI = Confidence interval 
* multivariate relative risk, typically comparing highest quintile of ingestion with referent group (no 
ingestion or lowest quintile of ingestion) 
1
  Reports results from the Health Professionals Follow-up study which followed  47,150 men 
prospectively for up to 12 years  
2  
Reports results from the Nurses’ Health Study which prospectively followed 78,9.6 women for up 
to 22 years 
 
Source: Adapted from Dalbeth & So, 2010 (Dalbeth & So, 2010) 
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The examination of the association between the incident phenotypic expression of 
gout, as opposed to asymptomatic hyperuricaemia, in the Health Professionals 
Follow-up Study has been not been reproduced.  However, Zhang et al, 2012, 
have gone on to report an increased odds of recurrence of gouty attacks in those 
with existing gout in those with high consumption of plant based purines.  (Zhang 
et al, 2012) 
 
Current research has focused on investigating the interaction of genetic variants 
with dietary factors, since many of them encode anion transporters exchanging 
uric acid for the breakdown products of these dietary constituents.  It has been 
suggested that the genetic mutations which predispose to gout exaggerate the 
hyperuricaemic response to other predisposing factors, and research is ongoing to 
establish interactions between particular genetic variants and dietary constituents 
which have been linked to increased risk of gout.  (Dalbeth et al, 2014) 
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1.4.4 The relationship between gout and alcohol consumption 
Alcohol intake, particularly port, has historically been linked with gout but it has 
shown that it was likely to be lead contaminants within port that were responsible 
for its precipitation of gout.  (Ball, 1971) However existing literature supports the 
consumption of alcohol as a continuing risk factor in the development of gout.  
(Gibson et al, 1983; Sharpe, 1984) The Health Professionals follow up study 
demonstrated an association between alcohol and gout reporting differing levels of 
risk depending on the type of alcohol consumed, with beer conferring the greatest 
risk, and no increased risk reported between men who consumed 2 glasses of 
wine per day, compared to those who consumed one per month.  (Choi et al, 
2004b) Their findings are summarised in table 1.6 below. 
Table 1.6: Summary of the association between alcohol consumption and risk of gout 
 
Dietary factor Risk of developing gout RR for 
developing gout* 
(95%CI) 
References 
All alcohol Increased 2.53 
(1.73-3.70) 
Choi et al, 2004 (b)1
 
(Choi et al, 2004b) 
Beer Increased 2.51 
(1.77-3.55) 
Choi et al, 2004 (b)1
 
(Choi et al, 2004b) 
Spirits Increased 1.60 
(1.19-2.16) 
Choi et al, 2004 (b)1 
(Choi et al, 2004b) 
Wine No effect 1.05 
(0.64-1.72) 
Choi et al, 2004 (b)1 
(Choi et al, 2004b) 
RR = relative risk CI= confidence interval 
* multivariate relative risk, typically comparing highest quintile of ingestion with referent 
group (no ingestion or lowest quintile of ingestion) 
1  Reports results from the Health Professionals Follow-up study which followed  47,150 
men prospectively for up to 12 years  
Adapted from: (Dalbeth & So, 2010) 
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This may be explained by the fact that beer contains purines in addition to alcohol. 
Standard beers have an alcohol content of about 1 gram per 100 mL, but also 
contain approximately 8 mg purines per 100 mL, with some, particularly low 
alcohol varieties containing more purines. (Gibson et al, 1983)  
 
In addition to the direct intake of purines from beer, alcohol predisposes to gout 
through a mechanism of hyperuricaemia caused by accelerated synthesis of uric 
acid from adenosine, produced during alcohol metabolism, or via the reduced 
urinary excretion of uric acid due to the elevation of blood lactate produced by the 
oxidation of ethanol.  (Nakamura et al, 2012) Lin et al, 2000, reported that 
excessive alcohol consumption, particularly binge drinking, was the most important 
factor in the development of gout, even when the serum urate level was less than 
8mg/dL. (Lin et al, 2000) It is likely that this results from dehydration, and the 
relative increase in SUA levels resulting from a decrease in circulating volume. 
 
 
1.4.5 The relationship between gout and diuretic use 
Several drugs are known to increase serum uric acid levels with the strongest 
association being with diuretic drugs.  Diuretics are thought to contribute to 
hyperuricaemia through renal mechanisms including reduced uric acid excretion, 
increased urate reabsorption and direct effects on urate transporters at the renal 
proximal tubule, (Hueskes et al., 2012) and the use of both loop and thiazide 
diuretics are thought to be one of the most common modifiable risk factors for 
gout.  This is especially the case in the elderly and women, where the renal effects 
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of diuretics are likely to compound the effects of reduced post-menopausal 
oestrogen levels in further reducing renal urate excretion. (Doherty, 2009) A recent 
systematic review found that risk of gouty arthritis is increased in patients using 
diuretics, but noted only moderate quality of the included studies (n= 2 RCTs, 6 
cohort and 5 case-control studies) and significant heterogeneity in study size, 
population and adjustment for potential confounders.  (Hueskes et al., 2012) A 
major factor to be considered in this relationship is confounding by indication, 
since the indications for diuretics such as heart failure or hypertension, may be the 
true risk factors for developing gout. 
 
1.5. Diagnosis of gout 
Despite being the most common inflammatory arthropathy in the UK, there is 
evidence that gout is under-diagnosed. (Sturrock, 2000)  This may relate to its 
natural disease course with two distinct modes of presentation, painful acute gout 
and “asymptomatic” chronic gout.  Clearly, in the absence of the typical features of 
a gouty attack making a definitive clinical diagnosis is challenging. 
Following the identification of MSU crystals in the synovial fluid of patients with 
gout by McCarthy and Hollander in the 1960’s, demonstrating the presence of 
these crystals within joints by aspiration of joint fluid for microscopic examination 
has become the “gold standard” for the diagnosis of gout. (McCarty & Hollander, 
1961)  Crystals can be identified during both the acute and chronic phases of the 
disease, from joints that are inflamed or not, and even joints previously unaffected 
by gouty attacks.  (Pascual et al, 1999; Roddy et al, 2013) However, evidence 
suggests that this “gold standard” test is applied in only the minority of cases. 
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(Janssens et al, 2010a) Reasons for this are likely to be twofold: firstly joint 
aspiration is an invasive and painful procedure and patients, particularly those 
presenting with an acute flare, may be reluctant to undergo it.  Secondly, is that 
the majority of gout patients are diagnosed and managed in primary care, (Pal et 
al, 2000; Rott & Agudelo, 2003; Zhang et al, 2006b) and primary care physicians 
may be less willing or skilled to undertake joint aspiration.  
Thus, primary care physicians in particular have come to rely on clinical criteria for 
guidance in the diagnosis of gout.  The first of these was proposed by Wallace et 
al, 1977, (summarised in Table 1.7) although not validated. (Wallace et al, 1977) 
Two recent publications have assessed the validity of the Wallace criteria in both 
primary, (Janssens et al, 2010b) and secondary care, (Malik et al, 2009) and found 
them lacking sensitivity and specificity. 
 
The European League Against Rheumatism (EULAR) undertook a systematic 
literature review and expert consensus Delphi exercise in 2006 to establish 10 
diagnostic statements to assist with the diagnosis of gout.  Each statement was 
assessed for sensitivity, specificity and likelihood ratio (LR) of predicting diagnosis 
of gout. (Zhang et al, 2006b) In 2011, a group in the U.S.A. reviewed these 
recommendations, along with new evidence and issued 10 revised diagnostic 
recommendations.   (Hamburger et al, 2011) The three sets of recommendations 
are presented side by side in table 1.7 below, to demonstrate their similarities in 
diagnostic clinical features and crystal identification.   The differences relating to 
presence of hyperuricaemia, presence of MSU crystals in asymptomatic joints and 
screening for co-morbidities largely reflect the growth in understanding of the 
pathogenesis and epidemiology of gout since the Wallace criteria were published.  
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Wallace, 1977 (Wallace et al, 1977) EULAR 2006 (Zhang et al, 2006b) Hamburger et al, 2011 (Hamburger et al, 2011) 
Features suggestive of acute gout include   
 monoarthritis attack,  
 particularly a unilateral first MTP joint, or 
tarsal joint attack,  
 redness over the joint 
 maximal inflammation reached within one 
day 
Features highly suggestive of acute crystal 
inflammation, though not specific for gout are:  
Rapid development of  
 severe pain, swelling, and tenderness  
 with overlying erythema 
 reaching its maximum within 6–12 hours  
 
Features highly suggestive of acute crystal 
inflammation, though not specific for gout are: 
Rapid development of  
 acute monoarticular attacks of the lower limbs 
 severe pain, swelling, and tenderness, maximal 
within 6-12 hours  
 with overlying erythema 
Diagnosis of gout also suggested by 
 Recurrent attacks of acute arthritis 
 Tophi 
Clinical diagnosis reasonably accurate in typical 
presentations of gout, e.g. recurrent podagra with 
hyperuricaemia, but not definitive without crystal 
confirmation  
Clinical diagnosis reasonably accurate in typical 
presentations of gout 
 
 
MSU crystals in joint fluid aspirate:  
 Required for definitive diagnosis of gout 
 During an acute attack 
Presence of MSU crystals in synovial fluid or 
tophus aspirates: 
 Required for definitive diagnosis of gout 
 Reliable even in the intercritical period  
Presence of MSU crystals in synovial fluid or tophus 
aspirates: 
 Required for definitive diagnosis of gout 
 Reliable even in the intercritical period 
Septic arthritis must be excluded 
 Joint fluid culture should be negative for 
organisms during an attack 
Septic arthritis must be excluded using  
 Gram staining and culture of synovial fluid, 
even in presence of MSU crystals as gout and 
sepsis may coexist 
Septic arthritis must be excluded using 
 Gram staining and culture of synovial fluid, 
even in presence of MSU crystals as gout and 
sepsis may coexist 
Hyperuricaemia should be present SUA levels neither confirm nor exclude gout 
 During an acute attack SUA levels may be 
normal 
SUA levels neither confirm nor exclude gout 
 During an acute attack SUA levels may be 
normal  
 Renal UA excretion should be determined in 
selected gout patients, especially 
 those with onset of gout <25 years or a family 
history of young onset gout 
 renal calculi 
Assessment of renal UA excretion rarely necessary 
but should be considered in selected gout patients, 
 those with onset of gout <25 years or a family 
history of young onset gout 
 lithogenic workup in those with renal stones 
X-ray findings suggestive of gout 
 Asymmetric swelling within a joint  
 Subcortical cysts without erosions  
 X-rays may be useful in assessing chronic gout  
Not useful in diagnosis of early or acute gout 
 X-rays may be useful in assessing chronic gout 
 Not useful in diagnosis of early or acute gout  
 Only necessary if a fracture is suspected 
 Risk factors for gout and associated co‐morbidity 
should be assessed, including  
 features of the metabolic syndrome 
(obesity, hyperglycaemia, hyperlipidaemia, 
hypertension) 
Risk factors for gout should be assessed, including  
 features of metabolic syndrome (obesity, 
hyperglycaemia, hyperlipidaemia, and 
hypertension), CKD,  medications, family 
history and lifestyle  
Table 1.7:  Comparison between published diagnostic criteria for gout 
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Pelaez-Ballestas et al, 2010, undertook a cross-sectional study of MSU-crystal 
confirmed gout patients in Mexico, obtaining demographic and clinical features 
prospectively. (Pelaez-Ballestas et al, 2010) These clinical features were then 
compared to criteria recommended by Wallace et al, 1977 and Zhang et al, 2006 
to determine what easily obtained clinical data might make a diagnosis of chronic 
gout highly likely, if joint aspiration were not possible.  Janssens et al, 2010 using 
similar methodology, developed the Neijimegen scoring tool to determine which 
clinical features strongly predicted a diagnosis of acute gout.  (Janssens et al, 
2010a) The findings of these two studies are presented in Table 1.8 below for 
comparison. 
Table 1.8: Comparison of clinical criteria for diagnosis of acute gout  
 
Pelaez-Ballestas et al, 2010  Neijmegen Clinical Scoring Tool 
Criteria Criteria Clinical 
Score 
Gout diagnosed by presence of ≥4/8 
of: 
Gout confirmed in over 
80% with score of 8 or 
more: 
 
≥ 1 attack of acute arthritis Male sex 2.0 
Mono or oligoarthritis attacks Previous patient-reported 
arthritis attack 
2.0 
Rapid pain and swelling (<24 hours) Onset within 1 day 0.5 
Erythema Joint redness 1.0 
Podagra 
Unilateral tarsiitis 
MTP1 involvement 2.5 
Possible tophi Hypertension or ≥1 
cardiovascular diseases a 
1.5 
Hyperuricaemia Serum uric acid level 
>5.88mg/dL 
3.5 
Maximum Score 8.0 Maximum Score 13.0 
 MTP1= first metatarsophalangeal joint; a 
angina pectoris, myocardial infarction, 
heart failure, cerebrovascular accident, 
transient ischaemic attack or peripheral 
vascular disease 
Source: (Janssens et al, 2010a); (Pelaez-Ballestas et al, 2010) 
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1.6 Clinical features of gout 
1.6.1 Acute gout 
Acute attacks of gout present with a rapid onset of symptoms resulting from 
synovitis triggered by MSU crystal deposition within joints.  These attacks have a 
characteristic presentation in that they are excruciatingly painful, with maximal 
pain and inflammation often reached within 12 hours, and are self-limiting, lasting 
on average between 7 and 10 days.  Recurrence is common, with approximately 
two thirds of patients with at least one gout attack in the previous year 
experiencing a recurrent attack.  (Neogi et al, 2006)  
The first acute attack affects the first MTP joint in 56-78% of patients, with 90% 
having acute gout of the great toe at some point in their disease course.  (Roddy, 
2011) Several theories exist as to the reason for acute attacks of gout favouring 
the first MTP joint.  These include cooler temperature of peripheral joints, 
susceptibility of the foot to trauma which contributes to crystal formation, and a 
preference for crystal deposition at joints also affected by osteoarthritis (OA), 
common in the first MTP joint as a result of the aforementioned factors combined 
with extraordinary biomechanical stress on that particular joint.  (Roddy, 2011) 
Other commonly affected joints include joints of the foot, ankle, knee, wrist, finger 
and elbow but mechanisms behind this joint distribution are unclear.   
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1.6.2 Chronic gout 
Chronic uncontrolled hyperuricaemia can lead to tophi, which result from 
deposition of urate crystals in the soft tissues, tendon sheaths, and bony 
prominences.  These tophi can cause joint deformity and destruction, but can also 
cause localised pressure effects, and form the site for inflammation, ulceration and 
infection.   (Kumar & Gow, 2002)  Within the joint itself, chronic hyperuricaemia 
and gout may lead to joint damage and the typical “punched out” erosions seen 
(represented in Figure 1.7).  
Figure 1.7: The effect of chronic gout on synovial joints 
 
 
Source:  (Choi et al, 2005b)  
Tophi are thought to develop within 5 years of the onset of gout in 30% of 
untreated patients, (Schumacher et al, 2005) with this figure rising to 75% of 
patients with untreated gout for 20 years or more.  (Gutman, 1973) Many years of 
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sustained normouricaemia are required before tophi can be seen to recede.  
(Kumar & Gow, 2002)  
Chronic gout also predisposes to co-morbidities such as hypertension, diabetes 
and renal disease, and these associations will be discussed in more detail in 
Chapter 2. 
1.7 Management of gout  
The majority of patients with gout are diagnosed and managed in primary care, 
with less than 10% being referred to a rheumatologist.  (Pal et al, 2000)  Having 
discussed diagnostic tools for use in primary care, this section will briefly discuss 
the primary care management of both acute and chronic gout.  
Effective treatments are available for both acute and chronic gout, with evidence to 
suggest that with optimal drug management gout can be considered a curable 
disease.  (Li-Yu et al, 2001)  
1.7.1 Management of acute gout 
Since patients presenting with acute gout are experiencing severe pain, 
treatments must be targeted at rapidly reducing inflammation and pain.  Several 
options exist including non-steroidal anti-inflammatory drugs (NSAIDs), cyclo-
oxygenase II (COX II) inhibitors, colchicine, and oral or parenteral corticosteroids. 
UK national guidance from the British Society of Rheumatology (BSR), (Jordan et 
al, 2007) European guidance from the European League Against Rheumatism 
(EULAR), (Zhang et al, 2006a) and US guidance from the American College of 
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Rheumatology (ACR), (Khanna et al, 2012b) on the management of acute gout 
are summarised in Table 1.9.  The BSR and EULAR guidance are very similar in 
recommending monotherapy with NSAIDs as a first line treatment for all acute 
gout (in the absence of contraindications).  The ACR guidelines take much more of 
an individual approach,  recommending that treatment decisions should be based 
upon the severity of pain and number of joints affected, endorsing combination 
therapy as a first line for severe or polyarticular attacks, and endorsing use of 
newer interleukin (IL)-receptor antagonists that are not yet part of the BSR or 
EULAR recommendations. 
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Table 1.9: Comparison of the BSR, EULAR and ACR guidelines for the management of acute gout. 
 
 BSR (Jordan et al, 2007) EULAR (Zhang et al, 2006a) ACR (Khanna et al, 2012b) 
General advice  Rest affected joints  
 Start treatment with an anti-inflammatory 
drug immediately and continue for 1-2 
weeks 
None given  Treatment should be initiated with 24 hours of 
onset 
 Severity should be assessed and inform choice 
of therapy 
Medication of 
choice 
 Fast acting oral NSAIDs at maximum 
doses if there are no contraindications 
 NSAID if no 
contraindications 
 Mild/moderate pain (≤6 on VAS) or 1-3 small or 
1-2 large joints affected monotherapy with any 
of NSAID, colchicine (1.8g over first hour then 
0.6mg bd-tds) or systemic corticosteroids 
(prednisolone 0.5mg/kg/day for 5-10 days) 
 
 Severe pain/polyarticular use combination 
therapy  
 NSAID + colchicine  
 Colchicine + oral steroid 
 NSAID + colchicine + IA steroid 
 Colchicine 0.5mg bd – qds as an 
alternative  
 Slower to work than NSAIDs  
 Colchicine (at  low dose e.g. 
0.5mg bd-tds to avoid side 
effects) as an alternative 
 
Gastroprotection  Co-prescription of gastro-protective agents 
should follow standard guidelines for the 
use of NSAIDs and Coxibs 
Not stated  Do not combine oral corticosteroid and NSAID 
due to risk of serious GI side effects 
Allopurinol in 
acute attacks 
 Allopurinol should not be commenced 
during an acute attack  
 Continue established allopurinol and treat 
the acute attack conventionally 
Not stated  Can be initiated during an attack provided 
appropriate anti-inflammatory medication has 
already be initiated 
 Continue urate lowering therapy during an 
acute attack 
Adjunctive 
medication 
 Opiate analgesics can be used as 
adjuncts 
 Intra-articular aspiration and 
injection of a long acting 
steroid can be used as an 
adjunct 
 Inadequate response to mono-therapy -  use or 
add an appropriate alternative agent 
 
 Intra-articular, oral, IM or IV corticosteroids 
can be used as an adjunct 
 Inadequate response to combination therapy -  
use anakinra 100mg s/c daily or canakinumab 
150mg s/c daily for 3 days  Diuretics used to treat  
 hypertension should be stopped  
 heart failure should be continued 
 If gout associated with 
diuretic therapy, stop the 
diuretic if possible.   
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1.7.2 Management of chronic gout 
The primary goal in the management of chronic gout is suppression of serum 
urate.  Li-Yu et al, 2001, demonstrated that maintenance of a serum urate level of 
<6mg/dL reduced acute gout flares. (Li-Yu et al, 2001) To this end urate lowering 
therapy (ULT) is paramount in preventing long term sequelae and recurrent 
attacks.  The most frequently used ULT is allopurinol (a xanthine oxidase 
inhibitor), as although an alternative xanthine oxidase inhibitor, febuxostat, is 
available usage is limited by its high cost relative to allopurinol.  UK national 
guidance from the BSR, (Jordan et al, 2007) European guidance from EULAR, 
(Zhang et al, 2006b) and US guidance from the ACR, (Khanna et al, 2012b) on the 
management of chronic gout are presented in Table 1.10 below. Both the BSR 
and EULAR guidelines emphasise the key role of allopurinol as first line treatment, 
with other uricosurics such as sulphinpyrazone or benzbromarone, used as 
second line agents in those unable to tolerate them.  However, whilst the ACR 
guidelines recommend xanthine oxidase (XO) inhibitors as first line ULT, they do 
not specify whether allopurinol or febuxostat should be used preferentially.  The 
ACR also endorse initiation of ULT during an acute attack provided that 
appropriate anti-inflammatory treatment has been started, whilst the BSR and 
EULAR guidance explicitly advise against this.
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 BSR (Jordan et al, 2007) EULAR (Zhang et al, 2006b) ACR (Khanna et al, 2012b) 
Criteria for 
initiation of 
ULT 
A second or further attacks  within 1 year OR  
Presence of any of  
 tophi  
 renal insufficiency 
 uric acid stones   
 ongoing treatment with diuretics 
 Recurrent acute attack  
 Arthropathy 
 Tophi 
 Radiographic changes of gout 
 ≥2 acute attacks per year 
 Tophi  
 CKD Stage 2 or worse 
 Past urolithiasis 
Timing of 
initiation 
No sooner than 1-2 weeks after resolution of 
acute attack 
Not stated Can be started during acute attack provided 
anti-inflammatory medication already 
initiated 
Choice of 
ULT 
Allopurinol (dose adjusted for renal function) Allopurinol (dose adjusted in renal 
impairment) 
XO inhibitor - either allopurinol (dose 
adjusted in renal impairment) or febuxostat 
Co-
prescription 
of 
prophylaxis 
 Colchicine 0.5mg bd, continued for up to 6 
months or 
 NSAID or coxib for no more than 6 weeks 
 Colchicine (0.5-1mg daily) and/or  
 NSAID (with gastro-protection if 
indicated) 
 Colchicine (0.6-1.2mg daily) or 
 NSAID (with gastro-protection if 
indicated) 
 Prednisolone ≤10mg OD if NSAID and 
colchicine not tolerated 
 Continued for greater of 6 months or 3 
months after achieving SUA target if no 
tophi present/ 6 months if tophi present  
Titration  Start at 50-100mg per day  
 Increase by 50-100mg every few weeks if 
required 
 Start at low dose (100mg OD)  
 Increase by 100mg every 2-4 weeks if 
required 
 Start at ≤100mg OD (50mg in CKD 
Stage 4 or above) 
 Titrate every 2-5 weeks 
Target urate 
level 
< 300micromol/l ≤360 micromol/L (6mg/dL) Individual to each patient :  
minimum target ≤360 micromol/L (6mg/dL) 
but lower target may be required 
Duration of 
treatment 
Not stated Not stated Indefinite 
Second 
choice of 
medication 
Uricosuric agents can be used  second line in 
 Patients who under-excrete uric acid  
 Resistance to, or intolerance of allopurinol   
 Sulphinpyrazone (200-800mg/day)  
preferred where renal function normal 
 Benzbromarone (50-200mg/day) if 
mild/moderate renal insufficiency 
If allopurinol toxicity occurs consider 
 Other xanthine oxidase inhibitor 
(febuxostat)  
 Uricosuric agent if normal renal 
function (benzbromarone in renal 
insufficiency but hepatotoxicity risk) 
 Allopurinol desensitisation (only in 
cases of mild rash) 
Uricosurics if intolerant or resistant to one 
XO inhibitor 
 Probenecid preferred in those with 
normal renal function 
 Measurement of urinary uric acid should 
precede initiation of uricosurics 
Table 1.10: Comparison of the BSR,EULAR and ACR guidelines on the management of chronic gout 
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Newer targeted therapies are becoming available.  Immunomodulatory therapies 
with interleukin receptor antagonists such as anakinra, canakinumab and 
rilonacept, have been developed to combat the release of IL-1β on stimulation of 
the NALP3 inflammasome by MSU crystals. (So et al, 2009; So et al, 2007; 
Terkeltaub et al, 2009)  
Since the absence of the uricase enzyme in humans was discovered, synthetic 
uricase has been suggested as a potential therapy for hyperuricaemia and gout.  
Rasburicase was the first of these, showing promising reduction in SUA and size 
of tophi, but adverse reactions were experienced by 80% of experimental subjects.  
(Richette et al, 2007) Pegloticase is a porcine-like recombinant uricase, but 
despite significant reductions in SUA and size of tophi, it was also associated with 
high incidence of serious adverse reactions, and as such is not in common usage 
at present. (Sherman et al, 2008)  
1.7.3. Guidelines for holistic management of gout patients 
Both UK national guidance from the BSR, (Jordan et al, 2007) European guidance 
from EULAR, (Zhang et al, 2006b) and US guidance from the ACR, (Khanna et al, 
2012a) emphasise that advice on dietary and lifestyle modification should always 
be offered to all patients with gout as an adjunct to whatever form of 
pharmacological treatment they receive, and that a holistic view of the 
management of gout should be considered.  These recommendations are 
summarised in table 1.11 below. 
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Table 1.11: Comparison of the BSR, EULAR and ACR advice on the holistic management of gout 
 
BSR (Jordan et al, 2007) EULAR (Zhang et al, 2006b) ACR (Khanna et al, 2012a) 
Lifestyle factors 
 Optimise weight 
 Increase exercise 
 Modify diet 
 Reduce alcohol intake 
 Maintain fluid intake 
 Weight loss if obese 
 Modify diet 
 Reduce alcohol intake 
 
 Weight loss if obese 
 Modify diet 
 Limit alcohol intake 
 
Co-morbidity 
Treat underlying cardiovascular risk  
 
The effect of aspirin on SUA is 
bimodal: 
 Aspirin in analgesic doses 
(600-2400 mg/day should be 
avoided  
 Aspirin for cardiovascular 
prophylaxis (75-150mg) 
should be used appropriately  
 Associated comorbidity and risk factors 
should be addressed, such as 
o Hyperlipidaemia 
o Hypertension 
o Hyperglycaemia 
o Obesity 
o Smoking  
 For hypertension consider losartan 
 For hyperlipidaemia consider fenofibrate  
 Both have modest uricosuric effects 
 Address comorbidity checklist  
o Metabolic syndrome 
o Type 2 Diabetes 
o Hypertension 
o Hyperlipidaemia/other modifiable risk 
factors for cardio or cerebrovascular 
disease 
o History of urolithiasis 
o CKD, glomerular or interstitial renal 
disease 
 Consider PCR testing for HLA-B*5801 in 
selected patients at high risk of severe 
allopurinol sensitivity reactions (Koreans with 
Stage 3 CKD or worse; Han Chinese and Thai 
irrespective of renal function) 
 Eliminate non-essential drugs which may 
contribute to hyperuricaemia 
 Consider use of losartan and fenofibrate as part 
of ULT  
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From table 1.11, it is clear that these general recommendations are very similar, 
and reflect the reduction, or management of, some of the major modifiable risk 
factors for gout, and common co-morbidities associated with gout.  The ACR 
guidelines suggest testing for genetic variants that may predispose to a serious 
adverse reaction to allopurinol in patients of particular ethnicities, which the BSR 
and EULAR guidelines do not, but this may reflect wider access to this relatively 
costly test, a greater proportion of the ethnicities at risk within the US population, 
or simply that this test was not available when the BSR and EULAR guidelines 
were written.  
1.8 Impact of Gout 
Chronic gout impacts on long-term health in a number of ways.  This is supported 
by a systematic review which concludes that gout is associated with reduced 
health-related quality of life, particularly in the physical function domains.  
(Chandratre et al, 2013)  
There have been no recent studies of the economic burden of gout in the UK, 
although in 2007 approximately 26,119 in-patient bed days were attributable to 
gout, and in 2008 3.3 million prescriptions for allopurinol were issued at a cost of 
over £4.2 million. (Parsons et al, 2011)   
Studies in the USA have reported that the annual cost to employers for employees 
with gout is nearly twice that of those without gout, with higher costs for medical 
claims, prescription claims, sick leave, short-term disability and workers 
compensation benefits.  (Brook et al, 2006) Workers with gout were likely to have 
5 more sick days than those without gout, which translates to an annual loss of in 
the region of 2.6 billion dollars.  (Wertheimer et al, 2013) It is estimated that gout-
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related health care costs are in the region of 4 billion dollars, resulting in an 
estimated total cost of gout to the US economy of in excess of 6 million dollars.  
(Wertheimer et al, 2013)  
Smith et al, 2014, examined the global burden of gout and placed it 138th out of 
291 conditions ranked in terms of years lived with disability, and that this has 
significantly increased over the last 10 years, and ranked gout 173rd of 291 in 
terms of overall disability burden.  (Smith et al, 2014)  
1.9 Summary 
This section has introduced gout, the condition of interest for discussion in this 
thesis, and the important epidemiological, pathophysiological and clinical features 
of this condition.  
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Chapter 2: The relationship between inflammatory and 
vascular disease 
2.1 Overview 
This chapter will discuss existing evidence examining associations between 
inflammatory conditions and subsequent vascular disease, and the mechanisms 
which underlie these relationships.  The evidence examining an association 
between gout and vascular disease will then be discussed as it relates to the aims 
and objectives of this thesis. 
2.2 Background 
Inflammatory disorders may affect a number of body systems including the skin, 
respiratory, gastrointestinal, and rheumatological systems.  Clinical manifestations 
may differ but the mechanism underlying these diseases is similar and results from 
the triggering of inflammatory pathways and the subsequent release of pro-
inflammatory cytokines. A number of inflammatory conditions, both 
rheumatological and otherwise, have already been linked with increased risk of 
vascular disease, suggesting that as a chronic inflammatory disease, gout may 
also confer such an additional risk. 
2.3. Inflammatory conditions associated with vascular disease 
Current evidence examining the relationship between inflammatory 
rheumatological conditions such as rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE) and polymyalgia rheumatic (PMR), and non rheumatological 
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inflammatory conditions such as psoriasis and inflammatory bowel disease is 
discussed in this section.  
2.3.1 Inflammatory rheumatological conditions and risk of vascular disease 
2.3.1.1 Prevalence of vascular diseases  
An increased prevalence of vascular diseases has been reported in patients with 
RA, ankylosing spondylitis (AS), and SLE. (Roman et al, 2003; Szabo et al, 2011; 
Wolfe et al, 2003) RA has been reported to be associated with a 30-60% increase 
in prevalence of cardiovascular disease, (Naranjo et al, 2008; Wolfe et al, 2003) 
although studies reporting prevalence of cerebrovascular disease in RA are 
conflicting.  (Naranjo et al, 2008)  AS has been associated with a 30% increase in 
prevalence of ischaemic heart diseases (IHD) and a 25% increase in prevalence 
of cerebrovascular disease, (Szabo et al, 2011) whilst SLE, in addition to 
cardiovascular and cerebrovascular risks has also been associated with an 
increased prevalence of peripheral vascular disease.  (June & Scalzi, 2013)  
2.3.1.2 Incidence of vascular diseases 
Recent meta-analyses confirmed an increased incidence of vascular disease in 
patients with rheumatoid arthritis, (Avina-Zubieta et al, 2012; Zoller et al, 2012) of 
a similar magnitude to that found in patients with diabetes.  (Peters et al, 2009)  A 
meta-analysis of observational studies examining the association between 
rheumatoid arthritis and incident vascular disease reported risk of incident stroke 
to be increased by 40%, incident CVD to be increased by almost 50%, risk of 
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incident MI by almost 70%, and risk of incident heart failure by almost 90%. 
(Avina-Zubieta et al, 2012)  A further meta-analysis also reported a 60% increase 
in incidence of ischaemic stroke and more than double the risk of incident 
haemorrhagic stroke. (Zoller et al, 2012)  
Several cohort studies report on incidence of vascular diseases associated with 
SLE. (Hak et al, 2009; Magder & Petri, 2012; Zoller et al, 2012) A recent 
systematic review summarised the findings from relevant observational studies 
examining incident vascular disease in patients with SLE, reporting a two-three 
fold increase in incident cardiovascular disease, a 2-10 fold increase in incident 
MI, and a 2-8 fold increase in incident cerebrovascular disease. (Schoenfeld et al., 
2013) The incidence of vascular disease in patients with spondyloarthropathies 
has been reported by a number of recent cohort studies, but this data is yet to be 
meta-analysed. (Bremander et al, 2011; Huang et al, 2013; Keller et al, 2014; 
Zoller et al, 2012)  A one-and-a-half-fold increased risk of incident IHD was 
reported in patients with ankylosing spondylitis, (Huang et al, 2013) and a doubling 
of risk of morbidity from IHD also reported. (Bremander et al, 2011) A two-fold 
increased incidence of cerebrovascular disease is reported elsewhere, (Keller et 
al, 2014) with a further study suggesting that this overall risk is predominantly due 
to an increased risk of haemorrhagic stroke (SIR 2.72 (1.96-3.67)) compared to 
ischaemic stroke (SIR 1.23 (1.01-1.48)).  (Zoller et al, 2012)  
A recent systematic review reported PMR to be associated with an increased 
incidence of cerebrovascular events, MI and PVD, (Hancock et al, 2012) with a 
subsequent study demonstrating ischaemic and haemorrhagic stroke to be 
increased by a similar 50% in patients with PMR. (Zoller et al, 2012)  The same 
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study reports an increase incidence of haemorrhagic stroke but not ischaemic 
stroke in patients with systemic sclerosis.  (Zoller et al, 2012) 
2.3.1.3 Mortality from vascular diseases 
Rheumatoid arthritis has been shown to increase risk of mortality from vascular 
causes in a recent meta-analysis of observational studies. (Aviña‐Zubieta et al, 
2008) This study reported a 50% increase in mortality from CVD, a 60% increase 
in mortality from IHD, and a 60% increase in mortality from stroke in patients with 
rheumatoid arthritis compared to those without.  (Aviña‐Zubieta et al, 2008)  
Three meta-analyses report on mortality from vascular disease associated with 
SLE.  Pooled risk of all vascular mortality was reported to be approximately two 
and a half times that of those without SLE (SMR 2.59 (1.95-3.44)).  (Toledano et 
al, 2012) They reported the risk to be highest in women (SMR 2.50 (2.31-2.70)) 
compared to men (SMR 1.90 (1.64-2.20)). (Toledano et al, 2012)  Two further 
meta-analyses reported a similar two to four-fold risk of mortality from 
cardiovascular causes.   (Schoenfeld et al., 2013; Yurkovich et al, 2014) However, 
the greatest risk was found in patients diagnosed at a younger age, with those 
aged 20-39 at the time of diagnosis at sixteen times the risk of death from 
cardiovascular cause compared to controls. (Schoenfeld et al., 2013)  
Spondyloarthropathies have also been linked with increased risk of cardiovascular 
mortality.  Two retrospective cohort studies report a 60-80% increased 
cardiovascular mortality associated with AS,   (Bakland et al, 2011; Mok et al, 
2011) whilst a recent meta-analysis reported a 36% increase in risk of 
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cardiovascular mortality associated with psoriatic arthropathy.  (Toledano et al, 
2012)  
A recent meta-analysis has also reported a 3-fold increase in cardiovascular 
mortality associated with systemic sclerosis and 5 fold-increase in cardiovascular 
mortality associated with vasculitis, (Toledano et al, 2012) and a systematic review 
reported an association between PMR and increased risk of vascular mortality, 
although there was significant heterogeneity between studies which precluded 
formal meta-analysis.  (Hancock et al, 2012)  
2.3.2 Other inflammatory conditions and risk of vascular disease 
2.3.2.1 Incidence of vascular diseases 
Two recent meta-analyses of cohort studies reported an increased incidence of 
vascular diseases in patients with the inflammatory skin condition psoriasis.  
(Horreau et al, 2013; Miller et al, 2013)  In the first, mild psoriasis was associated 
with a 20% increased risk of any vascular event, including cardiovascular and 
cerebrovascular events, and this excess risk increased to 60% in patients with 
severe psoriasis.  (Horreau et al, 2013) They also reported a 25% increased 
incidence of MI, 20% increased incidence of coronary artery disease, but no 
increased incidence of cerebrovascular disease associated with psoriasis.  The 
same systematic review identified four studies which examined risk of incident 
peripheral vascular disease associated with psoriasis. (Horreau et al, 2013) Three 
of the four reported this risk to be increased by between 25% and 98%, with the 
highest increase in risk estimated by the only one of the three studies to adjust for 
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potential confounders. (Prodanovich et al, 2009)  The second meta-analysis 
reported similar associations with incident vascular disease of an increased 
magnitude.  (Miller et al, 2013) Psoriasis was associated with a 40% increased risk 
of any incident cardiovascular disease and a 50% increase in incident ischaemic 
heart disease.  A 50% increased risk of incident PVD, and no increased risk of 
cerebrovascular disease associated with psoriasis was also reported, similar to 
that found by Horreau et al, 2013. (Horreau et al, 2013; Miller et al, 2013)  
Dermatomyositis, an inflammatory skin and muscle condition, has also been linked 
with increased risk of incident vascular diseases.  The risk of MI in patients with 
this condition has been reported to be three-times that of those without the 
condition, and risk of ischaemic stroke reported to be increased to by two-thirds. 
(Lai et al, 2013)  
The inflammatory bowel diseases ulcerative colitis (UC) and Crohn’s disease are 
both associated with increased incidence both ischaemic and haemorrhagic 
stroke.  (Zoller et al, 2012) Excess risk of ischaemic stroke was similar (between 
20% and 30%), but risk of haemorrhagic stroke was higher in Crohn’s disease 
(80%) than in UC (37%).  (Zoller et al, 2012)  A similar trend was also seen in risk 
of stroke associated with sarcoidosis, where excess risk of ischaemic stroke was 
reported to be approximately 20% and risk of haemorrhagic stroke higher at 60%.  
(Zoller et al, 2012)  
2.3.2.2 Mortality from vascular diseases 
Studies examining the relationship between inflammatory bowel disease and 
vascular mortality report conflicting results.  One meta-analysis reported excess 
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mortality from all vascular causes to be 50% higher in patients with Crohn’s 
compared to those without, (Toledano et al, 2012) and yet two others found no 
statistically significant relationship between either Crohn’s disease or UC and 
cardiovascular mortality.  (Bewtra et al, 2013; Dorn & Sandler, 2007)  
No statistically significant risk of cardiovascular mortality has been reported in 
association with psoriasis. (Miller et al, 2013)  
No studies were identified which reported mortality in inflammatory muscle 
conditions. 
2.4 Mechanisms underlying the association between inflammatory disorders and 
vascular disease 
This section will discuss vascular disease, including the anatomical sites at which 
it is commonly found, the clinical presentations and pathogenesis responsible, and 
the mechanisms by which inflammatory conditions are thought to predispose to it. 
2.4.1 Pathogenesis of vascular disease 
The onset of vascular disease is triggered by damage to arterial walls resulting 
from stressors such as hypertension, which results in impaired arterial elasticity 
and narrowing of the vessel lumen by atherosclerotic plaques.  Plaque deposition 
predisposes to vascular disease by narrowing of the arterial lumen compromising 
blood flow, but also by the release of thrombi as a result of plaque erosion or 
rupture. (Legein et al, 2013) The endothelial cells lining the artery regulate 
vascular tone, where nitric oxide promotes endothelium-dependent vasodilation 
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through vascular smooth muscle cells, and inhibition of platelet aggregation and 
expression of adhesion molecules. (Pennathur & Heinecke, 2007)   
Stary, 2003, classified atherogenic lesions by type according to their stage of 
development. (Stary, 2003)  These types of lesion and the corresponding stages 
of development of vascular disease are illustrated in figure 2.1.  
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Figure 2.1 Pathogenesis of vascular disease 
  
Type I lesion: endothelium 
expresses surface adhesion 
molecules E selectin and P selectin, 
attracting more polymorphonuclear 
cells and monocytes in the 
subendothelial space 
Type II lesion: macrophages begin to 
take up large amounts of LDL (fatty 
streak)) 
Type III: as the process 
continues, macrophages 
become foam cells 
Type IV: lipid exudes into the 
extracellular space and begins to 
coalesce to form the lipid core 
Type V: SMCs and fibroblasts move 
in, forming fibroatheromas with soft 
inner lipid cores and outer fibrous 
caps 
Type VI: rupture of the fibrous 
cap with resultant thrombosis 
causes ACS 
As lesions stabilise, they become 
fibrocalcific (type VII lesion) and, 
ultimately, fibrotic with extensive 
collagen content (type VIII lesion) 
 
Activated platelets, macrophages and dysfunctional 
endothelial cells produce platelet derived growth 
factor, insulin like growth factor, thrombin, 
angiotensin II impair bioavailability of nitric oxide, 
increasing oxidative stress and endothelial 
dysmotility 
 
Fatty streaks (have been observed in the aorta and 
coronary arteries of 20 year olds) 
 Results from focal accumulation of serum 
lipoproteins within the intima of the vessel 
wall 
 Contains lipid-laden macrophages, T 
lymphocytes and SMC 
 May progress to fibrous plaque following 
progressive accumulation of lipids, and 
migration and proliferation of SMCs 
 
As endothelial injury and inflammation progress 
fibro-atheroma’s grow and form a plaque 
 SMC proliferation results in extracellular 
connective tissue matrix and forms a fibrous 
cap that overlies a core of lipid-laden foam 
cells, extracellular lipid and necrotic cellular 
debris  
 The developing plaque acquires its own 
microvascular network which is prone to 
haemorrhage and contributes to the 
progression of atherosclerosis 
 As the plaque grows two types of vascular 
remodelling take place: 
o Positive remodelling – outward 
bulging of arterial wall whilst the  
lumen remains uncompromised  
o Negative remodelling – no vascular 
dilatation and atheroma grows 
inward, causing luminal narrowing.   
Plaque rupture occurs due to weakening of fibrous 
cap by inflammatory cells:  
 T lymphocytes and macrophages produce 
cytokines (e.g.IL-1, TNF, TNF-α) that 
localise to plaques which have a soft lipid 
core and thinner fibrous caps 
 These cytokines stimulate proteolytic 
enzymes which degrade collagen 
 T cells that accumulate at sites of plaque 
rupture and thrombosis also  inhibit collagen 
synthesis 
 Denudation of overlying endothelium or 
rupture of protective fibrous cap results in 
exposure of  blood to the thrombogenic 
contents of the core of the plaque   
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Clinically the early stages of this process are asymptomatic, with significant arterial 
stenosis required prior to onset of symptomatic diseases.  Vascular disease can 
manifest at different sites (e.g. coronary arteries, carotid arteries or peripheral 
arteries) with differing clinical presentations of vascular disease at the same site 
depending on the underlying pathology.   
As an atherosclerotic plaque grows there is progressive luminal narrowing, blood-
flow abnormalities and compromised oxygen supply to the target organ. 
Disruption of the fibrous cap covering the plaque allows contact between the 
thrombogenic lipid core and the blood, and may result in thrombus formation, 
partial or complete occlusion of the vessel, or progression of the lesion by 
organisation of the thrombus and incorporation into the plaque.  Plaque rupture is 
the main event that causes acute clinical presentations of myocardial infarction 
(MI)  or acute coronary syndrome (ACS), also known as unstable angina, however 
severely obstructive plaques do not usually cause MI or ACS and are more 
strongly associated with stable angina.  The reason for this is related to the way 
that arteries adapt to the presence of a plaque, a process known as vascular 
remodelling.   
As shown in figure 2.1, arteries can enlarge in response to the plaque formation, 
and arteries which are positively remodelled (expand outwards to avoid stenosis of 
the lumen) are more prone to plaque rupture and clinical manifestations 
associated with thrombus formation, since plaque must occupy 50-70% to cause 
flow limitation, and the outward expansion prevents this from occurring.  Those 
arteries which are negatively remodelled in response to atheroma formation (no 
outward expansion of the artery therefore allowing plaque to encroach into the 
      
62 
        
  
lumen) are more likely to achieve the required degree of stenosis to limit flow 
through the vessel and are thus more commonly associated with clinical 
manifestations resulting from flow limitation (e.g. stable angina) but can also be 
prone to plaque rupture.  The relationships of these underlying processes with the 
clinical manifestations of vascular diseases that result are shown in figure 2.2 
below.
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Figure 2.2 Clinical manifestations of vascular disease according to underlying pathology 
 
 
Atheroma in arterial wall  
Coronary arteries = cardiovascular 
disease  
Carotid or Cerebral arteries = 
cerebrovascular disease 
Iliac, Popliteal or other leg arteries = 
peripheral vascular disease 
Fibrous cap ruptures: 
thrombus formation 
Rough surface of fibrous 
cap and thrombogenic 
lipid core are exposed to 
blood activating local 
coagulation pathways 
Thrombus at site of 
plaque rupture  
OR  
Embolism of thrombus 
Cardiovascular  
ACS (occlusion causes 
no myocyte death)  
MI (occlusion causes 
myocyte death) 
Cerebrovascular  
TIA (incomplete or 
transient occlusion)  
CVA (complete 
occlusion resulting in 
cell death) 
Peripheral vascular  
Limb Ischaemia 
Fibrous cap remains 
intact 
Plaque causes stenosis 
of lumen resulting in 
impaired blood supply 
to target organ 
Mismatch in demand for 
oxygen and supply, 
particularly during 
exertion 
Cardiovascular 
Stable Angina 
Peripheral vascular  
Intermittent 
claudication 
ACS = Acute Coronary Syndrome; MI = Myocardial Infarction; TIA = Transient Ischaemic Attack; CVA = Cerebrovascular Accident (“Stroke”); 
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2.4.2 Risk factors for vascular disease 
Vascular disease is known to be multi-factorial in origin and new predisposing risk 
factors continue to emerge.  Some risk factors, such as those contributed by 
lifestyle choices (e.g. smoking) are considered modifiable, whilst others resulting 
from factors such as age or gender remain unmodifiable.  Known vascular risk 
factors are summarised in table 2.1 below.  
Table 2.1 Traditional and non-traditional cardiovascular risk factors 
 
Traditional Non-traditional 
Hypertension Albuminuria 
Diabetes Homocysteinuria 
Kidney disease Lipoprotein (a) and apolipoprotein (a) 
Higher LDL cholesterol Anaemia 
Lower HDL cholesterol Abnormal calcium/phosphate 
metabolism 
Smoking Extracellular fluid overload 
Physical activity Electrolyte imbalance 
Menopause Oxidative stress 
Family history of cardiovascular disease Inflammation 
Left ventricular hypertrophy Malnutrition 
Older age Thrombogenic factors 
Male gender Sleep disturbances 
 Altered nitric oxide/endothelin balance 
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Adapted from: (Sarnak et al, 2003) Whilst many of these relationships, such as 
those between hypertension and hyperlipidaemia and cardiovascular risk have 
been recognised for decades, (Gordon & Kannel, 1982) as shown in table 2.1 
novel risk factors continue to emerge, and although the precise interactions 
between these non-traditional risk factors and both traditional risk factors and the 
mechanisms underlying vascular disease remain unclear, some potential 
relationships and influences are suggested in figure 2.3 below. 
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Figure 2.3 Suggested interactions between traditional and non-traditional vascular risk factors and atherosclerosis 
 
 
 
 
 
 
 
 
 
 
 
 
ATHEROSCLEROSIS 
Endothelial 
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load 
Sleep 
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(increased 
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demand 
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Whilst the majority of these are outside of the scope of this thesis and will not be 
considered further, inflammation as a novel risk factor for vascular disease will be 
discussed below. 
2.4.3 Role of inflammation in vascular disease 
Atherosclerosis is acknowledged to be an inflammatory condition.  (Hansson, 
2009) It has been demonstrated that vascular endothelial cells and smooth muscle 
cells not only respond to pro-inflammatory cytokines, in particular IL-1 and TNF, 
but also produce these and others as part of their response to inflammation.  
(Hansson, 2009) It is thought that immune activation of the artery wall may hamper 
plaque stability, predisposing to plaque rupture and consequent thrombi resulting 
in acute coronary events. (Libby & Hansson, 1991) This shared inflammatory 
aetiology is thought to underlie at least part of the association between systemic 
inflammatory conditions and atherosclerosis, although the mechanism by which 
the conditions are related is likely to be multifactorial and far more complex. 
For reasons discussed in section 2.4.1 any reduction in endothelial bioavailability 
of nitric oxide will result in a proatherogenic state.  (Landmesser et al, 2006) 
Oxidative stress, a mechanism by which bioavailability of nitric oxide is thought to 
be reduced by the action of oxidants, also known as free radicals or reactive 
oxygen species (ROS) at the vascular endothelium, (Sies & Cadenas, 1985) also 
plays an important role in endothelial dysfunction. 
The resulting endothelial dysfunction is also known to play an important role in 
plaque formation and rupture by predisposing to subendothelial retention of lipids 
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from plasma which are oxidised by free radicals, triggering the inflammatory 
process.  The endothelium secretes chemokines and adhesion molecules resulting 
in the adhesion of activated platelets and white blood cells.  The activated platelets 
and white blood cells trigger further infiltration by monocytes, which are then 
differentiated within the intima to become macrophages which ingest lipids to 
become foam cells.  (Legein et al, 2013) Foam cells accumulate in the intima 
becoming fatty streaks which can be reversed if the inflammatory stimuli which 
initiated the process are reversed.  However, where lipids continue to accumulate, 
invasion by macrophages, apoptosis and secondary necrosis of foam cells result 
in the development of a necrotic core and disruption to the architecture of the 
intima.  Leaky neovascularisation can result in intraplaque haemorrhage 
increasing size and triggering further inflammation, and presence of collagen-rich 
fibrous tissue and calcification further enlarge the plaque.  (Bentzon et al, 2014)  
Plaque rupture occurs when the highly thrombogenic core of the plaque is 
exposed to the blood by a gap in its fibrous surroundings.  The complete occlusion 
of coronary arteries by resulting thrombus can result in MI or sudden death, and 
incomplete or transient occlusion combined with vaso-spasm more often results in 
unstable angina or acute coronary syndromes.   (Bentzon et al, 2014)  
It has been suggested that a result of the metabolic syndrome may be the 
expression of adipokines by adipocytes and immune cells, and which form an 
important link between inflammation and metabolism.  It is thought that their 
immunomodulatory role underpins insulin resistance, which further impairs 
endothelial function.   (Deng & Scherer, 2010)  
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Potential mechanisms behind the association between inflammatory disorders are 
summarised in figure 2.4 below. 
Figure 2.4:  Mechanisms by which systemic inflammatory diseases may 
predispose to vascular disease 
 
 
 
  
Systemic inflammatory condition 
e.g. Rheumatoid Arthritis 
Resulting systemic inflammation 
results in increased:  
 Homocysteine 
 TNF-α, IL-1, IL-6 
 Adhesion molecules 
 Modified lipids 
 Acute phase 
reactants e.g. CRP 
 Tissue Factor 
 Insulin resistance 
The effect of this at the level of 
the endothelium is: 
 Endothelial cell 
damage 
 ↓NO, ↑ Free 
radicals 
 ↑ platelet 
aggregation 
 ↑ collagen 
breakdown 
 Smooth muscle cell 
proliferation 
Resulting in: 
 Endothelial 
dysfunction 
 Endothelial lipid 
deposits 
 Proliferation of 
smooth muscle cells 
 
Plaque formation and 
progressive stenosis 
of vascular lumen 
Action of cytokines on 
fibrous cap of plaque 
results in plaque rupture 
and thrombus 
Occlusive 
stable 
vascular 
disease  
e.g. angina 
Unstable acute 
vascular events 
e.g. MI or stroke 
Occlusive 
stable 
vascular 
disease  
e.g. angina 
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2.5 The relationship between gout and vascular diseases  
There are a number of reasons why there may be an association between gout 
and vascular disease.  These include the presence of asymptomatic 
hyperuricaemia prior to onset of clinical gout, the common co-existence of co-
morbidities which predispose to both gout and vascular disease, such as 
hypertension, and finally the presence of chronic inflammation resulting in 
accelerated atherosclerosis.  These potential mechanisms will be discussed 
below. 
2.5.1 Hyperuricaemia and risk of vascular disease 
Hyperuricaemia is known to be an independent risk factor for both cardiovascular 
and cerebrovascular disease.  (Kim et al, 2009; Kim et al, 2010) This occurs 
through a mechanism of amplified oxidation of lipids and induction of cellular 
oxidative stress which contributes to endothelial dysfunction, resulting in 
decreased arterial compliance, impaired blood flow and pro-atherogenic state.  
(Ceriello & Motz, 2004) Studies have also demonstrated renovascular disease, 
renal injury and hypertension can result from this hyperuricaemic-mediated 
endothelial dysfunction, (Jin et al, 2012) which further contributes to vascular risk. 
Uric acid is also thought to have direct pro-inflammatory effects on vascular cells.  
(Kanellis et al, 2003; Kang et al, 2005) Studies of losartan (an angiotensin-II 
receptor antagonist used in hypertension) and atorvastatin (a cholesterol lowering 
medication) have demonstrated that a reduction of uric acid levels reduces 
cardiovascular risk,  (Athyros et al, 2007; Høieggen et al, 2004) whilst allopurinol, 
the most commonly used urate lowering therapy, has been shown to improve 
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endothelial dysfunction,  (Kanbay et al, 2011; Meléndez-Ramírez et al, 2012) 
blood pressure, (Kanbay et al, 2007; Kanbay et al, 2011) all-cause mortality in 
hyperuricaemic patients, (Luk et al, 2009) and exercise tolerance in patients with 
chronic stable angina. (Noman et al, 2010)   
2.5.2 Co-morbidities in gout and risk of vascular disease 
Many conditions known to predispose to vascular disease also predispose to gout.  
These include features of the metabolic syndrome, a collection of cardiovascular 
risk factors, defined as the presentation of three or more of: 
 abdominal obesity (waist circumference >102cm for men and >88cm for 
women)  
 triglyceride level ≥150mg/dl   
 high density lipoprotein (HDL) cholesterol level < 40mg/dl for men or 
<50mg/dl for women  
 blood pressure ≥130/85 mmHg  
 fasting glycaemia ≥100 mg/dl (Grundy et al, 2004)  
Increased prevalence of metabolic syndrome has been demonstrated in gout 
patients (44-63% in patients with gout compared to 5-25% in those without).  
(Choi et al, 2007a; Rho et al, 2005)  Individual components of metabolic 
syndrome, have also been shown to predispose to gout, particularly obesity, 
(Bhole et al, 2010; Choi et al, 2005a; Juraschek et al, 2013b; Maynard et al, 
2012) and hypertension.  (Bhole et al, 2010; Choi et al, 2005a; Zhu et al, 2012)  
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Although diabetes appears to be protective against risk of gout, (Rodriguez et al, 
2010) gout itself has been reported to increase the risk of incident type II diabetes 
mellitus. (Choi et al, 2008) Gout has been shown to be a risk factor for chronic 
kidney disease (CKD), (Teng et al, 2012; Yang et al, 2010) and similarly CKD has 
also been shown to be a common co-morbidity and risk factor for gout.  (Soriano 
et al, 2011)  
It is likely that these traditional vascular risk factors which commonly co-exist with 
gout contribute to any association between gout and vascular disease.  However, 
the magnitude of this contribution and whether any association between gout and 
vascular disease persists after adjustment for these risk factors remains unclear.  
2.5.3 Chronic inflammation in gout and risk of vascular disease  
Since other inflammatory arthritides, such as rheumatoid arthritis, ankylosing 
spondylitis and other spondyloarthropathies (SpA), which do not result from 
hyperuricaemia, have also been associated with increased cardiovascular risk,  
(Avina-Zubieta et al, 2012; Gladman et al, 2009; Szabo et al, 2011) it would seem 
likely that inflammation plays a role in the development of vascular disease.    
Mechanisms whereby inflammatory conditions lead to increased cardiovascular 
risk include the release of pro-inflammatory cytokines such as TNF-alpha, IL-1 and 
IL-6 leading to endothelial dysfunction and impaired arterial compliance. (Soltész 
et al, 2011)  
A recent meta-analysis examining the association between individual inflammatory 
cytokines and vascular risk reported that a 1- standard deviation (SD) higher 
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baseline level for each of IL-6, IL-18, and TNF-α is associated with ∼10–25% 
higher risk of non-fatal MI or CHD death. (Kaptoge et al, 2014) IL-6 has also been 
reported to be independently associated with endothelial activation in patients with 
RA, (Dessein et al, 2013) and systemic arterial stiffness in patients with SLE,  
(Barbulescu et al, 2012) and use of immunosuppressive therapies including TNF-α 
inhibitors, and traditional disease modifying anti-rheumatic drugs (DMARDs) such 
as methotrexate and cyclosporine has been shown to reduce endothelial 
dysfunction and reduce cardiovascular risk in patients with RA, psoriatic 
arthropathy and SLE.  (Murdaca et al, 2012)  
Monosodium urate (MSU) crystals deposited in gout have been shown to strongly 
induce inflammation, through direct neutrophil activation and activation of the 
NALP3 inflammasome resulting in the release of similar pro-inflammatory 
cytokines, particularly IL-1, IL-6 and TNF-α, (Jin et al, 2012) during an acute 
attack.  There is evidence that this inflammation persists between attacks, 
(Pascual et al, 1999; Roddy et al, 2013) and it seems likely that similar 
inflammatory mechanisms are at play in both RA and gout patients to result in an 
increased burden of vascular disease.   
The idea that inflammatory activity is the major risk factor for development of 
subsequent cardiovascular disease has prompted the European League Against 
Rheumatism (EULAR) to publish recommendations for cardiovascular screening 
and management in inflammatory arthritis patients, (Peters et al, 2010) including 
an aggressive approach to managing both risk factors and inflammation. However 
at present, these recommendations are limited to patients with rheumatoid 
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arthritis, ankylosing spondylitis and psoriatic arthropathy, and do not extend to 
patients with gout.   
2.6 Summary  
This chapter has reviewed the evidence linking other inflammatory conditions with 
vascular disease.  Common inflammatory risk factors specifically found in gout 
patients have also been described.  In chapter 3 a systematic literature review 
examining the relationship between gout and vascular disease will be synthesised. 
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Chapter 3:  Systematic Literature Review 
3.1 Chapter Overview 
This chapter will describe the rationale for, methods and results of a systematic 
review synthesising the current literature examining the relationship between gout 
and vascular disease. 
3.2 Aims 
Previous chapters have highlighted that gout is a chronic inflammatory condition, 
with inflammation that persists even in the asymptomatic intercritical period, 
(Pascual et al, 1999; Roddy et al, 2013) and that other inflammatory conditions 
such as RA are associated with an increased risk of vascular disease. This 
chapter describes the identification and synthesis of the current medical literature 
examining the potential association between gout and vascular disease. 
3.2.1 Literature review aims 
Existing systematic reviews, meta-analyses and individual studies which examine 
the relationship of interest will be identified.  Outcomes of interest will include 
incidence and prevalence of, or mortality from cardiovascular, cerebrovascular or 
peripheral vascular disease in patients with gout.   
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3.2.2 Literature review objectives 
The main objectives of the literature review are to establish whether there is an 
increased risk of cardiovascular, cerebrovascular or peripheral vascular disease in 
patients with gout.   
Gaps in existing literature will be identified and used to inform the design of an 
observational study examining this relationship in more detail. 
3.3 Methods 
3.3.1 Medical Literature Databases 
Four online bibliographic databases (MEDLINE, EMBASE, CINAHL and The 
Cochrane Library) were searched for relevant articles, from their creation to June 
2014.  These databases are described in more detail below. 
3.3.1.1 MEDLINE 
MEDLINE (Medical literature analysis and retrieval system Online) is compiled by 
the United States National Library of Medicine.  It contains more than 21 million 
records, mainly English language journals, covering medicine and medical 
sciences from 1946 to the present.   It uses an indexing system known as Medical 
Subject Heading (MeSH) terms to index entries allowing focused as well as free 
text searching. 
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3.3.1.2 EMBASE 
EMBASE (Excerpta Medical Database) is compiled by the publisher Elsevier and 
contains over 25 million records dating from 1947 to the present. It includes 
biomedical and pharmaceutical content and uses an indexing system known as 
EMTREE to allow focused searching. 
3.3.1.3 CINAHL 
CINAHL (Cumulative Index to Nursing and Allied Health Literature) is compiled by 
EBSCO publishing and contains over 2.6 million records from 1981 to the present.  
Its content includes nursing, biomedical and allied health disciplines.  CINAHL 
uses a thesaurus for focused searching adapted from the MeSH terms used by 
MEDLINE. 
3.3.1.4 The Cochrane Library 
The Cochrane Library is a collection of six databases, including the Cochrane 
Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, 
Cochrane Methodology Register, Database of Abstracts of Reviews of Effects, 
Health Technology Assessment Database and the NHS Economic Evaluation 
Database.  Its aim is to make the results of well-designed controlled trials and 
systematic reviews easily available in order to inform healthcare decisions.   It is 
published by Wiley Online, and is free to all UK residents. 
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3.3.2 Search strategy 
MEDLINE, EMBASE, CINAHL and the Cochrane Library were each searched 
using a combination of free-text and MeSH (or database-specific equivalent) 
headings.  The search terms used are described in more detail below. 
3.3.3 Search Terminology 
The search strategy aim was to create a literature search broad enough to include 
all papers on the association of interest, but narrow enough to exclude the majority 
of irrelevant results.  The selection of search terms is described in this section. 
3.3.3.1 Condition of Interest – Gout 
“Gout” was searched separately in both free-text and MeSH (or database-specific 
equivalent) terms.  MeSH headings were “exploded” to broaden their definition.  
This would result in the inclusion of similar terms such as “gouty arthritis” in the 
search.  These separate searches were then combined by use of the Boolean 
operator “or”.   
3.3.3.2 Outcome of Interest – Vascular Disease 
MeSH, CINAHL and EMTREE terms were identified for various forms of vascular 
disease.  The most common vascular diseases including “angina pectoris”, 
“myocardial infarction” (MI), “cerebrovascular accident” (CVA) and “transient 
ischaemic attack” (TIA ) as well as the lay terms commonly used for these 
conditions such as “heart attack” and “stroke” were initially used to interrogate the 
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database-specific indexing trees to identify search terms related to those diseases.  
From this, more general organ-system based terms, “cardiovascular disease”, 
“cerebrovascular disease” and peripheral vascular disease” were used to identify 
other less specific but important descriptors that may broaden the search.   These 
terms were also “exploded” in order to broaden their definition.  Free text 
searching was also performed, using complete and truncated versions of the 
search terms identified, allowing similar terms such as ischaemic and ischaemia to 
be returned by the same search term. These searches were combined with the 
MeSH searches using the Boolean operator “or”. 
3.3.3.3 Study design – Observational 
Observational studies were selected as the most appropriate design by which to 
compare vascular outcomes between groups of gout and non-gout patients, since 
there may be a considerable time between incidence of the exposure (gout) and 
development of the outcome of interest (vascular disease).  MeSH, EMTREE and 
CINAHL terms were identified and exploded in order to broaden their search 
definition.  Free text searching was also performed and the searches finally 
combined using the Boolean operator “or”.   
3.3.4 Search Term Combination and Search Limits 
Searches were performed for the exposure (gout), outcome (vascular disease) 
and design terms as detailed in section 3.3.3 above, and then combined using the 
Boolean operator “and”.  This process was undertaken three times with the 
outcome included being a different type of vascular disease each time, 
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cardiovascular the first, cerebrovascular the second and peripheral vascular 
disease the final time. Searches were limited to human studies only.  No other 
limits were applied. 
The detailed search strategies can be found in Appendix 1. 
3.3.5 Inclusion and exclusion criteria 
Potential title/abstracts, and/or full text articles were independently assessed to 
determine inclusion or exclusion by the author and another reviewer, Dr Priyanka 
Chandratre (Clinical Research Training Fellow & Honorary Specialist Registrar in 
Rheumatology).   
To be eligible for inclusion, studies must have met all of the following criteria;  
1. Exposure of interest: studies must report on patients with gout, or a subset of 
patients with gout. 
2. Outcome of interest: studies must report the incidence or prevalence of vascular 
disease, or mortality from vascular disease. 
3. Study design: studies must compare the outcomes of interest between gout 
patients and a control group, or statistics based upon the general population.   
Studies were excluded from the review if they met any of the following criteria; 
1. Exposure of interest – studies reporting other diseases, or studies examining 
patients with hyperuricaemia, without a subgroup of patients with gout. 
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2. Outcome of interest – studies with outcomes other than those specified by the 
inclusion criteria. 
3. Article type – papers other than those reporting on observational studies, for 
example case studies, editorials or clinical guidelines. 
4. Full text not available - every effort was made to obtain the full text of all 
relevant articles identified, including applications to the British Library for papers 
that could not be accessed elsewhere, those that could not be obtained through 
the British Library were excluded 
5.  Foreign language translation – where English translations were not available, 
translators working within the Research Institute for Primary Care & Health 
Sciences, Keele University were utilised, and foreign language papers where a 
translator was not available within the department were excluded. 
Full text review was undertaken for any title/abstract that did not clearly meet 
either the inclusion or exclusion criteria.  
In addition, full text review was undertaken for;  
Any title/abstract which met all inclusion criteria except for specifically 
identifying gout (but that did identify hyperuricaemia) to ascertain any 
subgroups of gout patients. 
 Any title/abstract which appeared to report all-cause mortality to ascertain 
any report of vascular mortality. 
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When multiple articles were published from a single study, reports that contained 
the most complete and relevant data on the association between gout and 
vascular disease were selected.  
Disagreement was resolved by consultation with a third reviewer (Dr Samantha 
Hider, PhD supervisor, Senior Lecturer in Rheumatology and Honorary Consultant 
Rheumatologist).     
3.3.6 Reference Search 
The reference sections of each paper identified as meeting the inclusion criteria 
detailed in section 3.3.5 were screened to ensure no relevant references were 
missed.  This screening was performed by the same process as that for the 
studies identified from the medical database search. 
3.4 Quality assessment 
All included articles were assessed for quality by the author and second reviewer 
Priyanka Chandratre (Clinical Research Training Fellow & Honorary Specialist 
Registrar in Rheumatology) using an adaptation of a previously validated quality 
assessment tool. (Wells et al, 2000)  
3.4.1 Quality assessment tool design 
Prior to full review of the included papers, established quality assessment tools 
were reviewed and adapted to include questions specific to the study of gout.   
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The final version combines quality assessment points from the Newcastle-Ottawa 
Scale (NOS), (Wells et al, 2000) recommended for use in systematic reviews of 
observational studies by the Cochrane Collaboration, with one supplementary 
point from a tool by Altman, (Altman, 2001) and one developed by the author.  The 
supplementary points added assess whether the appropriate statistical methods 
were used, (Altman, 2001) and how the study accounts for patients with 
asymptomatic hyperuricaemia (author-defined).  The latter was included as it was 
considered important to treat patients with asymptomatic hyperuricaemia 
separately to those with clinical gout because although asymptomatic 
hyperuricaemia is the biochemical precursor to gout, only a minority of 
hyperuricaemic patients go on to develop clinical gout, and by definition 
asymptomatic hyperuricaemic patients lack the inflammatory response triggered 
by deposition of MSU crystals thought to contribute to risk of vascular disease. 
The quality assessment tool used, along with a detailed description of the origins 
of the individual quality assessment points is given in table 3.1
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Table 3.1 Quality Assessment criteria 
   
Criteria 
Number 
Review criteria Awarded Not awarded Origin 
Selection 
1. Are the gout patients in the study likely to be representative of 
the total gout population? 
Yes Unlikely or not 
described 
NOS 
2. Are the non-gout patients (or mortality statistics) from the same 
population as the gout patients? 
Yes No or not described NOS 
3. How was gout/non-gout status ascertained? Secure record or standardised 
interview/clinical assessment 
Self-report or not 
described 
NOS 
4. Does the study demonstrate that the outcomes of interest (to 
this review) were not present at the start of the study? 
Yes No or not described NOS 
 Comparability 
5. Study controls for age and sex? Yes No or not described NOS 
6. Study controls for other predictors of CVD or mortality? 
(diabetes, hypertension, BMI, hyperlipidaemia, smoking status) 
Yes No or not described NOS 
 Outcomes 
7. How was outcome assessed? Independent blind assessment or record 
linkage 
Self report or not 
described 
NOS 
8. Was follow up long enough for outcomes to occur? Greater than 2 years Less than 2 years or 
not described 
NOS 
9. How adequate was follow-up of cohorts? (<30% loss to follow 
up) 
Yes (can be assumed for retrospective 
studies) 
No or not described NOS 
 Analysis 
10. Was the analysis of data appropriate? Appropriate methods used Appropriate methods 
not used or methods 
not described 
Altman* 
11. How well does the study account for patients with 
hyperuricaemia? 
Excludes hyperuricaemia patients, 
analyses pure gout as a separate group 
or analyses data with development of 
hyperuricaemia as a possible predictive 
variable 
Does not exclude 
hyperuricaemia 
patients or does not 
account for them in the 
analysis 
Author- 
specified 
NOS = Newcastle Ottawa Scale (Wells et al, 2000) 
*(Altman, 2001) 
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3.4.2 Quality Assessment of Studies 
Quality assessment was performed independently, and agreement reached with a 
second reviewer, Dr Priyanka Chandratre (Clinical Research Training Fellow & 
Honorary Specialist Registrar in Rheumatology). Disagreements were discussed 
and if necessary decided by a third reviewer, Dr Samantha Hider, PhD supervisor, 
Senior Lecturer in Rheumatology & Honorary Consultant Rheumatologist. 
Agreement was reached on quality assessment score in 100% of cases. 
 
3.5 Data extraction 
Included articles were also read by another reviewer, Dr Priyanka Chandratre 
(Clinical Research Training Fellow & Honorary Specialist Registrar in 
Rheumatology) and data tabulated into a purpose-designed form.  Data was 
collected on gout and control population number and source, duration of follow-up, 
loss to follow-up, definition of gout used, average age and gender distribution of 
the study population, information on previous vascular disease or vascular risk 
factors and outcomes. 
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3.6 Data analysis 
 
Pooled estimates of hazard ratios (HRs) were calculated using the DerSimonian 
and Laird random effects model, (DerSimonian & Laird, 1986) for mortality from 
any cardiovascular disease and coronary heart disease, and incidence of coronary 
heart disease.  This technique weights individual studies according to the precision 
of each study estimate, giving a pooled estimate and 95% confidence interval.  A 
random effects model was chosen due to the likelihood of heterogeneity between 
studies.  Measuring the inconsistency of studies’ results was considered using 
Cochran’s Q test and the I2 statistic.  The former is the classical measure of 
heterogeneity which is calculated as the weighted sum of squared differences 
between individual study effects and the pooled effect across studies, with the 
weights being those used in the pooling method.  The latter I2 statistic describes 
the percentage of variation across studies that is due to heterogeneity rather than 
chance.  (Higgins & Thompson, 2002)  
 
Data for the prevalence of cardiovascular diseases, mortality from myocardial 
infarction, and incidence of any cardiovascular disease and MI were unsuitable for 
meta-analysis due to heterogeneity in study design and outcomes measured, and 
are thus narratively described. 
 
Differences between the studies and their characteristics, including having met or 
not met the quality assessment criteria and the geographical location, population 
size and gender distributions of the study populations were compared using 
Fisher’s Exact Test, a statistical test used to compare categorical data, particularly 
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where sample sizes are small. (Fisher, 1922) Statistical analysis was performed 
using Stata statistical software release 12 (StataCorp: College Station, TX, 2011) 
 
3.7 Assessment of Publication Bias  
Publication bias refers to the suggestion that studies with statistically significant 
findings are more likely to be published than those with negative findings, 
particularly in large English language journals and those indexed in online 
electronic databases such as Medline and Embase. (Juni et al, 2002) Presence of 
publication bias was assessed using funnel plot, Begg’s and Egger’s tests, (Begg 
& Mazumdar, 1994; Egger et al, 1997) described below. 
3.7.1 Use of funnel plots in detection of publication bias 
Plots of sample size against effect size, called funnel plots because they are 
commonly of the appearance of a symmetrical inverted funnel, can be used to 
detect publication bias. (Egger & Smith, 1995; Light & Pillemer, 1984) The funnel 
shaped appearance is created since, if precision of the effect estimate is increased 
as sample size of the included studies increases, results from smaller studies 
scatter widely at the bottom of the graph, with larger studies plotting closer 
together towards the top of the graph.  Therefore presence of bias will result in an 
asymmetrical or skewed plot to visual inspection.  (Sterne & Egger, 2001) 
However, numerical methods of detecting asymmetry in funnel plots have also 
been proposed, such as the eponymous Egger’s and Begg’s tests. (Begg & 
Mazumdar, 1994; Egger et al, 1997) In this thesis I present assessment of 
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publication bias using both Begg’s and Egger’s test and these are described in 
more detail below. 
 
3.7.2 Begg’s Test 
Begg’s test is used to identify evidence of publication bias in meta-analyses by 
looking for correlation between the individual study estimates and meta-analysis 
weight, i.e. whether the study estimate is related to the study size. (Begg & 
Mazumdar, 1994)  However, the variance is not the same at all points, and in 
order to account for this, the pooled estimate is subtracted from each individual 
study estimate, and the result divided by the standard error.  This results in 
estimates with a similar variance, and Kendall’s rank correlation coefficient is used 
to test a correlation between deviation divided by standard error and the study 
weight (equivalent to study size).  However, where there are few studies included 
in a meta-analysis Begg’s test has little power to detect publication bias.  (Sterne 
et al, 2002) Although Begg’s test makes fewer assumptions than Egger’s test, it is 
insensitive to many types of bias that Egger’s test will detect. 
 
3.7.3 Egger’s Test  
Egger’s test approaches the problem of publication bias slightly differently, using 
linear regression to estimate the relationship between the effect size divided by its 
standard error, (also called the standard normal deviate), and the inverse standard 
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error.  The inverse standard error for small samples should be close to zero (since 
standard error is dependent on sample size), and so even where small studies 
estimate large effect sizes, the standard normal deviate will be small since the 
standard error with be large, with the reverse being true for larger studies. (Egger 
et al, 1997) In the absence of funnel plot asymmetry indicating publication bias, 
then the intercept from the unweighted logistic regression should be zero.  Thus 
the further from zero the intercept, the greater the asymmetry and therefore the 
greater the indicator of publication bias. 
3.8 Results 
Following the systematic literature searches summarised in Figure 3.1-3.3 14 
papers examining the association between gout and cardiovascular disease were 
included, 2 papers examining gout and cerebrovascular disease, and 2 papers 
examining gout and peripheral vascular disease. 
3.8.1 Summary of Search Results 
A flowchart showing the number of articles identified by the search strategy and 
their subsequent inclusion or exclusion in the final review can be found in Figures 
3.1- 3.3 with the results for cardiovascular, cerebrovascular and peripheral 
vascular disease displayed separately.  
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Figure 3.1 Summary of systematic review article search process for gout and 
cardiovascular Disease 
 
  
1501 articles found 
by systematic 
literature search 
116 articles either 
meeting the 
inclusion/exclusion 
criteria or unable to 
be excluded on 
title/abstract review 
1255 articles 
excluded on 
title/abstract 
102 articles 
excluded on full 
text review  
Reasons: 
 Not the relationship 
of interest (n=63) 
 Editorial or 
discursive (n=15) 
 English translation 
not possible  (n=9) 
 No comparator 
groups (n=9) 
 Inadequate 
description of  study 
design (n=4) 
 Full text could not be 
obtained (n=2) 
14 articles included 
5 articles either 
meeting 
inclusion/exclusion 
criteria or unable 
to be excluded on 
title/abstract 
review during 
reference list 
search  
5 articles 
excluded on full 
text review 
0 articles included 
14 articles included 
in total 
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Figure 3.2 Summary of systematic review article search process for gout and 
cerebrovascular disease 
  
349 articles found 
by systematic 
literature search 
30 articles either 
meeting the 
inclusion/exclusion 
criteria or unable to 
be excluded on 
title/abstract review 
319 articles 
excluded on 
title/abstract 
28 articles 
excluded on full 
text review 
Reasons: 
 Not the relationship 
of  interest (n=15) 
 Editorial or 
discursive (n=13)  
 
2 articles included 
2 articles either 
meeting 
inclusion/exclusion 
criteria or unable 
to be excluded on 
title/abstract 
review during 
reference list 
search  
2 articles 
excluded on full 
text review 
0 articles included 
2 articles included in 
total 
      
92 
         
   
Figure 3.3 Summary of systematic review article search process for gout and 
peripheral vascular disease 
 
 
 
  
576 articles found 
by systematic 
literature search 
23 articles either 
meeting the 
inclusion/exclusion 
criteria or unable to 
be excluded on 
title/abstract review 
553 articles 
excluded on 
title/abstract 
21 articles 
excluded on full 
text review 
Reasons: 
 Not examine 
the relationship 
of interest 
(n=12) 
 Editorial or 
discursive 
articles (n=3) 
 Full text could 
not be obtained 
(n=6) 
2 articles included 
1 articles 
excluded on full 
text review 
0 articles included 
2 articles included in 
total 
1 articles either 
meeting 
inclusion/exclusion 
criteria or unable 
to be excluded on 
title/abstract 
review during 
reference list 
search  
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Two studies report the relationship between gout and cerebrovascular disease, 
one reports mortality from cerebrovascular disease, (Teng et al, 2012) and the 
other incidence of stroke. (Seminog & Goldacre, 2013)  
Of 2 articles identified to report on gout and peripheral vascular disease (PVD), 1 
reported on incidence of PVD, (Baker et al, 2007) and 1 on prevalence of PVD. 
(De Muckadell & Gyntelberg, 1976)  
Table 3.2 shows the quality assessment of the included studies.
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Author Type of vascular 
disease 
investigated  
Quality Assessment Criteria 
                                                                 
Total 
Score 
1 2 3 4 5 6 7 8 9 10 11 
Abbott Cardiovascular 1 1 1 1 0 1 1 1 0 1 1 9 
Baker PVD 0 1 0 1 1 1 1 1 1 1 1 9 
Choi & 
Curhan (b) 
Cardiovascular 0 1 0 1 1 1 1 1 1 1 1 9 
De Vera Cardiovascular 1 1 1 1 0 1 1 1 1 1 1 10 
Gelber Cardiovascular 0 1 0 1 0 1 1 1 1 1 1 8 
Janssens Cardiovascular 1 1 1 1 1 1 1 1 1 1 1 11 
Kok Cardiovascular 1 1 1 1 1 1 1 1 N/A 1 1 10 
Krishnan 
2006 
Cardiovascular 0 1 1 1 1 1 1 1 1 1 1 10 
Krishnan 
2008 
Cardiovascular 0 1 1 1 1 1 1 1 0 1 1 9 
Kuo 2010 Cardiovascular 1 1 0 1 1 1 1 0 0 1 1 8 
Kuo 2013 Cardiovascular 1 1 1 1 1 1 1 1 N/A 1 1 10 
Mikuls Cardiovascular 1 1 1 0 1 0 1 N/A N/A 1 1 7 
Novak Cardiovascular 1 1 1 0 1 0 1 N/A N/A 1 1 7 
Schaffalitzky 
de 
Muckadell 
Cardiovascular 
PVD 
1 1 0 0 1 0 1 N/A N/A 1 1 6 
Seminog & 
Goldacre 
Cardiovascular 
Cerebrovascular 
0 1 1 1 1 1 1 1 N/A 1 1 9 
Stack Cardiovascular 1 1 1 0 1 1 1 1 0 1 1 9 
Teng Cardiovascular 
Cerebrovascular 
1 1 1 1 1 1 1 1 1 1 1 11 
 
Table 3.2 Quality assessment of included studies 
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Author Year Type of vascular 
disease 
investigated 
Location Gout Population 
(number and source) 
Control Population Average 
Follow-up 
Length (years) 
Loss to 
Follow up 
Abbott et al 1988 Cardiovascular USA n=113 community n=4188 community With gout 
M=7.3, F=8.0 
Without gout 
M=7.6, W=8.4 
Not 
described 
Baker et al 2007 PVD USA n=1485 community n=11343 community 10.5 Less than 
10% 
Choi & Curhan 2007 Cardiovascular USA n=2280 community n=44978 community 12 6% per 2y 
cycle 
Devera 2010 Cardiovascular Canada n=9642 community n=48210 community 7 Not 
described 
Gelber et al 1997 Cardiovascular USA n=106 community n=1518 community MH cohort 30 
JH cohort 33 
5% 
Janssens et al 2003 Cardiovascular Holland  prevalence study 
n=261 
case-control n=170 
community 
first part 522 
2nd n=340 community, 
age-, sex-, practice-
matched 
11.1 Not 
described 
Kok 2012 Cardiovascular Taiwan n=164436 
community 
n=3694377 
community 
Not stated N/A 
Krishnan et al  2006 Cardiovascular USA n=1123 community n=11743 community 6.5 Not 
described 
Krishnan et al 
(Uses sample of 
population used 
by Krishan et al, 
2006) 
2008 Cardiovascular USA n=655 community n=8450 community 17 Not 
described 
Kuo et al 2010 Cardiovascular Taiwan n=1311 community n=48021 community 4.75 Not 
described 
Kuo et al 2013 Cardiovascular Taiwan n= 704503 
community 
n=677947 community 8 N/A 
Mikuls et al 2005 Cardiovascular UK n=56483 community n=150867 OA 
community patients – 
10 Not 
applicable 
Table 3.3:  Included Articles study population and follow-up information 
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Author Year Type of vascular 
disease 
investigated 
Location Gout Population 
(number and source) 
Control Population Average 
Follow-up 
Length (years) 
Loss to 
Follow up 
not matched 
Novak et al 2007 Cardiovascular US n=1171 community n=58550 
“matched” age, 
gender, race 
community 
N/A: 
Prevalence at 
index date 
Not 
applicable 
Schaffalitzky de 
Muckadell & 
Gyntelberg 
1976 Cardiovascular 
PVD 
Denmark n=104 community n=208 community, 
age-matched 
1 9.5% 
Seminog & 
Goldacre  
2013 Cardiovascular 
Cerebrovascular 
England n=205207 hospital n=7673635 hospital 3.8 HES 
dataset 
5.7 ORLS 
dataset 
N/A 
Stack 2014 Cardiovascular USA n=468 community n=15304 community 10 N/A 
Teng et al 2012 Cardiovascular 
Cerebrovascular 
Singapore Sub-population with 
no prior history of 
vascular disease 
n=1736 community 
n= 45299 community 8.1 17.3% 
CPRD = Clinical Practice Research Datalink; F= female; HES= Hospital Episode Statistics; JH=Johns Hopkins Hospital; M=male; MH= 
Meharry Hopkins Hospital; N/A= not applicable; OA = osteoarthritis; ORLS= Oxford Record Linkage Study; PVD=peripheral vascular 
disease; y=year 
 
  
Table 3.3:  Included Articles study population and follow-up information 
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3.8.2 Gout and cardiovascular disease 
3.8.2.1 Gout and prevalence of cardiovascular disease 
Four studies were identified reporting prevalence of cardiovascular disease in 
patients with gout compared to those without (with a combined population of 58019 
gout patients and 210151 non-gout patients).  Two were retrospective cohort studies 
using electronic medical records, one from Europe and one from the US; one was a 
cross-sectional survey from Denmark, and one a case-control study from Holland. 
(De Muckadell & Gyntelberg, 1976; Janssens et al, 2003; Mikuls et al, 2005b; Novak 
et al, 2007)  
 The two cohort studies and cross-sectional survey reported a statistically significant 
increased prevalence of cardiovascular disease, (De Muckadell & Gyntelberg, 1976; 
Mikuls et al, 2005b; Novak et al, 2007) whilst the case-control study did not. 
(Janssens et al, 2003) The studies differ not only by design but also by the types of 
cardiovascular disease used as events of interest, with one reporting prevalence of 
any cardiovascular disease, (Janssens et al, 2003) two reporting prevalence of 
coronary artery disease, (Mikuls et al, 2005b; Novak et al, 2007) two prevalence of 
MI, (De Muckadell & Gyntelberg, 1976; Novak et al, 2007) and one prevalence of 
angina. (De Muckadell & Gyntelberg, 1976) The findings reported are summarised in 
table 3.4. 
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Table 3.4 Studies reporting prevalence of cardiovascular disease 
Author Gout definition Average age % male Previous vascular disease or risk 
factor data 
Outcomes 
Prevalence of any cardiovascular disease 
Janssens et al, 
2003 
ICHPPC-2 codes Not described Gout=91 
Not gout=68 
2 parts – prevalence of CV 
diseases and then those without 
were followed up 
 
% prevalence 
 Gout group =26% 
 Controls = 21%   
 Difference not 
statistically significant 
Prevalence of coronary heart disease 
Mikuls et al, 2005 CPRD coded (OXMIS 
codes) 
Gout=60.5 
Not gout=66.8 
Gout=79.6 
Not gout=33.8 
Not collected and therefore not 
excluded – adjusted for age and 
sex  
 COR 1.34 (1.31-1.37) 
 AOR 1.75 (1.70-1.79) 
Novak et al, 2007 ICD code-physician 
recorded 
Gout group 45.9 
No gout group 
40.4 
Gout group  
85.0% 
No gout  
54.3% 
Preindex data not collected – not 
adjusted 
% prevalence 
 Gout group = 7.26%  
 No gout = 3.53%  
 p≤0.05 for difference 
 
Schaffalitzky de 
Muckadell & 
Gyntelberg, 1976 
Patient recall of 
physician diagnosed 
gout 
Not described – all 
between 40 and 59 
100 Not described % prevalence Angina   
 Gout group = 11.5%  
 No gout = 2.4%  
 p=<0.001 for difference 
Prevalence of MI 
Novak et al, 2007 ICD code-physician 
recorded 
Gout group 45.9 
No gout group 
40.4 
Gout group  
85.0% 
No gout  
54.3% 
Preindex data not collected – not 
adjusted 
% prevalence AMI   
 Gout group 0.51% 
 No gout = 0.35%  
 No significance levels 
are reported 
Schaffalitzky de 
Muckadell & 
Gyntelberg, 1976 
Patient recall of 
physician diagnosed 
gout 
Not described – all 
between 40 and 59 
100 Not described % prevalence 
 Gout = 2.9%  
 No gout = 1.4%  
 Difference not 
statistically significant 
AMI = acute myocardial infarction; AOR = adjusted odds ratio; CHD = coronary heart disease; COR = crude odds ratio; CPRD = clinical practice research datalink; CV= cardiovascular; ICD = 
International Classification of Diseases; ICHPPC= International Classification of Health Problems in Primary Care, OXMIS = Oxford Medical Information Systems 
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3.8.2.2 Gout and incidence of cardiovascular disease 
Eight studies were identified reporting incidence of cardiovascular disease in 
patients with gout compared to those without (923,235 gout patients and 
8,462,741 non-gout patients).  Four were prospective cohort studies from the US, 
(Abbott et al, 1988; Choi & Curhan, 2007; Gelber et al, 1997; Krishnan et al, 2006) 
three were retrospective cohort studies using healthcare records from Canada, 
Taiwan and the UK,  (De Vera et al, 2010; Kuo et al, 2013; Seminog & Goldacre, 
2013) and one a case-control study from Holland. (Janssens et al, 2003)  
These studies also differed in the types of incident cardiovascular disease 
investigated and reported conflicting results.  One study was identified which 
reported incidence of any cardiovascular disease, (Janssens et al, 2003) two 
which reported incidence of coronary heart disease, (Abbott et al, 1988; Gelber et 
al, 1997) one reporting incidence of angina, (Abbott et al, 1988) and six incidence 
of MI. (Abbott et al, 1988; Choi & Curhan, 2007; De Vera et al, 2010; Krishnan et 
al, 2006; Kuo et al, 2013; Seminog & Goldacre, 2013) The results will be 
presented grouped according to the types of incident cardiovascular disease 
investigated. 
Janssens et al, 2003 did not find an increased risk of any type of cardiovascular 
disease (which included stroke), and  Gelber et al, 1997 did not find any increased 
risk of incident coronary heart disease in their population of male healthcare 
professionals with gout compared to those without.  (Gelber et al, 1997; Janssens 
et al, 2003) In contrast, Abbott et al, 1987, did report a statistically significant 
increased risk of both coronary heart disease and angina in their male participants 
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with gout compared to those without, but not their female participants (although 
the number of female participants was extremely small n=19). (Abbott et al, 1988) 
The details reported in these studies are presented in table 3.5 
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Table 3.5 Studies investigating gout and incidence of cardiovascular disease 
 
Author Gout definition Average age % male Previous vascular 
disease or risk 
factor information 
Outcomes 
Incidence of any cardiovascular disease 
Janssens et 
al, 2003 
ICHPPC-2 codes Not described Gout=91 
Not gout=68 
2 parts – 
prevalence of CV 
diseases and then 
those without were 
followed up 
Risk ratio 0.98 (N.S) 
Incidence of coronary heart disease 
Abbott et al, 
1988 
Self report Gout  
M=53.3/F=58.7 
Not gout  
M=54.6/F=55.3 
Gout =83% 
Not gout = 
42% 
Total = 43% 
Excluded if prior 
HTN and CVD:  
adjusted for age, 
BP, total 
cholesterol level, 
alcohol 
consumption, BMI, 
DM 
Men – Coronary Heart Disease 
 CHR 1.6 (1.1-2.2)  
 AHR 1.6 (1.1-2.5) 
Men - Angina  
 CHR 1.9 (1.2-3.1)  
 AHR1.8 (1.1-3.2) 
Women 
No statistically significant 
relationships 
Gelber et al, 
1997 
Self report – ACR 
survey gout 
criteria 
Meharry 
Hopkins Cohort 
=29 
Johns Hopkins 
Cohort =26 
100 Excluded if prior 
CHD:  adjusted for 
serum cholesterol, 
BMI, smoking, 
alcohol, DM, HTN 
 CHR 0.85 (0.40-1.81) 
 AHR 0.59 (0.24-1.46) 
ACR = American College of Rheumatology; AHR =  adjusted hazard ratio; BMI = body mass index; BP = blood pressure; CHD = coronary 
heart disease; CHR = crude hazard ratio; CV = cardiovascular ; CVD = cardiovascular disease; DM = diabetes mellitus; HR= hazard ratio; 
HTN = hypertension; ICHPPC= International Classification of Health Problems in Primary Care; NS = non-significant;  
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Thus only the studies investigating incident coronary heart disease were appropriate 
for meta-analysis and this was undertaken using both the fixed and random effects 
model. (Abbott et al, 1988; Gelber et al, 1997)  
The results of this meta-analysis are shown below in Tables 3.6 and 3.7 presented 
as the crude results (table 3.6) followed by the adjusted results (table 3.7) and 
Figures 3.4 and 3.5. Due to the likelihood of heterogeneity between studies, the 
DerSimonian and Laird random effects model was more appropriate. The pooled 
estimate of the HR was 1.28 (95%CI[0.71-2.31]) for the crude results, and for the 
adjusted results was 1.08 (95%CI[0.09-2.07]).  No statistically significant excess risk 
of incidence of coronary heart disease was demonstrated.  
Table 3.6:   Study effect sizes and weights in meta-analysis of crude results of studies examining the 
relationship between gout and incidence of coronary heart disease 
 
Authors Hazard Ratio 95% CI % Weight 
Abbott et al, 1987 1.60 1.10-2.20 64.6% 
Gelber et al, 1997 0.85 0.40-1.81 35.4% 
D&L Pooled Effect 
Size 
1.28 0.71-2.31 100.0% 
CI= confidence interval; D&L = DerSimonian & Laird 
 
I2 = 55.1% which reflects moderate heterogeneity, but Cochran’s Q test yielded 
p=0.14, suggesting no significant heterogeneity.  
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Table 3.7:   Study effect sizes and weights in meta-analysis of adjusted results of studies examining 
the relationship between gout and incident coronary heart disease 
 
 
I2 = 74.3% which reflects significant heterogeneity, but Cochran’s Q test yielded 
p=0.05 suggesting no significant heterogeneity. 
  
Author Hazard Ratio 95% CI % Weight 
Abbott et al, 1987 1.60 1.10-2.50 58.4 
Gelber et al, 1997 0.59 0.24-1.46 41.6 
D&L Pooled Effect Size 1.06 0.40-2.77 100% 
CI= confidence interval; D&L = DerSimonian & Laird 
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Figure 3.4: Meta-analysis of crude findings of studies examining the relationship between gout and incidence of coronary heart 
disease 
 
NOTE: Weights are from random effects analysis 
Overall  (I-squared = 55.1%, p = 0.136) 
Abbott et al, 1988 
Gelber et al, 1997 
Study  
1.28 (0.71, 2.31) 
1.60 (1.10, 2.20) 
Hazard 
0.85 (0.40, 1.81) 
Ratio (95% CI) 
100.00 
64.63 
% 
35.37 
Weight 
1.28 (0.71, 2.31) 
1.60 (1.10, 2.20) 
Hazard 
0.85 (0.40, 1.81) 
Ratio (95% CI) 
100.00 
64.63 
% 
35.37 
Weight 
    1 .4  2.5 
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Figure 3.5: Meta-analysis of adjusted findings of studies examining the relationship between gout and incidence of coronary heart 
disease 
NOTE: Weights are from random effects analysis 
Overall  (I-squared = 74.3%, p = 0.049) 
Gelber et al, 1997 
Study 
Abbott et al, 1988 
1.06 (0.40, 2.77) 
0.59 (0.24, 1.46) 
Ratio (95% CI) 
1.60 (1.10, 2.50) 
100.00 
41.56 
Weight 
58.44 
1.06 (0.40, 2.77) 
0.59 (0.24, 1.46) 
Hazard 
Ratio (95% CI) 
1.60 (1.10, 2.50) 
100.00 
41.56 
% 
Weight 
58.44 
  1 .24 4.17 
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Thus, after adjustment for potential confounders, no statistically significant 
increase in incident coronary heart disease in patients with gout was found, and no 
significant between study differences were identified.   
 
3.8.2.2.1 Gout and incidence of myocardial infarction 
The six studies which examined risk of incident MI in patients with gout also report 
conflicting findings.  An increased incidence of all MI (fatal and non-fatal) was 
reported in a solely male population by Krishnan et al, 2006, in a mixed population 
by Kuo et al, 2013, in women but not men by DeVera et al, 2010, but not in either 
gender by Abbott et al, 1988.  (Abbott et al, 1988; De Vera et al, 2010; Krishnan et 
al, 2006; Kuo et al, 2013)  Increased incidence of non-fatal MI was reported in 
exclusively male populations by two studies, (Choi & Curhan, 2007; Krishnan et al, 
2006) in a mixed population by two studies, (De Vera et al, 2010; Seminog & 
Goldacre, 2013) although one of these found increased risk in women but not 
men. (De Vera et al, 2010) Two studies examined the incidence of fatal MI, one 
using an exclusively male population reporting an increased incidence, (Choi & 
Curhan, 2007) and the other in a mixed gender population where no increased 
incidence of MI was found after adjustment for other cardiovascular risk factors. 
(Kuo et al, 2013) The details of these findings are summarised in table 3.8 
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Table 3.8 Studies investigating gout and the risk of incident MI 
Author Gout definition Average age % male Previous vascular disease or risk factor 
information 
Outcomes 
Abbott et 
al, 1987 
Self report Gout  
M=53.3/F=58.7 
Not gout  
M=54.6/F=55.3 
Gout =83% 
Not gout = 
42% 
Total = 43% 
Excluded if prior HTN and CVD:  adjusted for 
age, BP, total cholesterol, alcohol 
consumption, BMI, DM 
Men  
 Adjusted age only HR 1.4 (0.9-
2.3) 
 Multivariate HR 1.5 (0.9-2.6) 
Women-No significant relationships 
Choi & 
Curhan, 
2007 
Self-report of 
physician 
diagnosis of gout 
at baseline, 
incident cases 
using ACR 
survey criteria 
Gout= 
59 
Not gout=54 
100 Those with and without CHD at baseline 
analysed separately: Adjusted for age, HTN, 
HLD, DM, use of aspirin/diuretics, smoking, 
BMI, physical activity, alcohol intake, FH MI, 
total energy intake, dietary intake of trans fat/ 
cholesterol/ protein/  linoleic fatty acid and ratio 
of polyunsaturated fat to saturated fat 
Non-fatal MI 
AHR 1.59 (1.04-2.41) 
Devera et 
al, 2010 
ICD-9 codes Gout 
M=73.9/F=75 
Not gout 
M=73.3/F=75.0 
Gout=59.7% 
Not 
gout=59.7% 
Total 59.7% 
 
Excluded if prior IHD:  adjusted for age, HTN, 
HLD, DM, COPD, Charlson score, monthly 
prescription drug use – NSAID, diuretic, statin, 
anticoagulants, aspirin, HRT, steroid. 
All MI   
 CHR M= 1.19(1.07-1.32)  
   F= 1.67 (1.45-1.93) 
 AHR M= 1.11 (0.99-1.23) 
   F=  1.39 (1.20-1.61) 
Non- fatal MI  
 CHR M= 1.18 (1.05-1.33) 
   F=1.71 (1.44-2.02) 
 AHR M= 1.11 (0.98-1.25)   
   F= 1.41 (1.19-1.67) 
Fatal MI 
 CHR M= 1.19 (0.96-1.49) 
   F=1.57 (1.18-2.09) 
 AHR M= 1.10 (0.88-1.38)   
   F= 1.33 (0.99-1.78) 
Krishnan et 
al, 2006  
Self-report 
physician 
diagnosed+ 
documented 
sustained 
hyperuricaemia 
Total=46 
Gout=47 
Not gout=46 
100 Excluded if previous MI/raised cholesterol/DM 
or on treatment for or raised BP:  adjusted for 
age, BP, serum cholesterol, creatinine, DM, 
smoking, FH MI, aspirin, diuretic,  alcohol 
consumption, BMI  
AMI non-fatal  
 OR 1.31(1.24-1.38) 
All (fatal +non-fatal)  
 OR 1.26 (1.14-1.40) 
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Table 3.8 Studies investigating gout and the risk of incident MI (cont’d) 
 
 
 
 
 
Author Gout definition Average age % male Previous vascular disease or risk factor 
information 
Outcomes 
Kuo et al, 
2013 
ICD code – 
physician recorded 
Gout group = 
55.4 
No gout group 
= 42.0 
Gout=70.3 
Not 
gout=50.4 
Age, sex, history of DM, HTN, stroke, ESRD All MI 
 Age & sex  adjusted HR 
1.75(1.59-1.94) 
 AHR= 1.23(1.11-1.36) 
Fatal MI 
 Age & sex adj HR 1.46 (1.02-
2.08) 
 AHR 0.97 (0.68-1.39) 
Non-fatal MI 
- Age and sex adj HR 1.78 
(1.61-1.98) 
- AHR=1.26(1.14-1.40) 
Seminog & 
Goldacre, 
2013 
ICD code- 
physician recorded 
Overall: 
HES=70.3 
ORLS=68.8 
Overall: 
HES=74% 
ORLS=73% 
Age, sex, calendar years in the database, 
region of residence and deprivation score 
All MI 
 AHR HES1.82(1.78-1.85)/ORLS 
1.95(1.57-2.40) 
ACR = American College of Rheumatology; AHR = adjusted hazard ratio; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; 
CHR = crude hazard ratio; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; DM = diabetes mellitus; FH MI = family history 
of myocardial infarction; HES= Hospital Episode Statistics; HLD = Hyperlipidaemia; HR= hazard ratio; HRT = hormone replacement therapy; HTN = 
hypertension; ICD = International Classification of Diseases; IHD = ischaemic heart disease; MI = myocardial infarction; NSAID = non-steroidal anti-
inflammatory drug; OR=odds ratio; ORLS= Oxford Record Linkage Study  
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3.8.2.3 Gout and cardiovascular disease mortality 
Eight publications were identified which reported mortality from cardiovascular 
causes in participants with gout compared to those without (with a combined 
population of 181,651 gout patients and 3,916,3821 non-gout patients).  Six 
published studies report mortality from any cardiovascular disease as an outcome,  
(Choi & Curhan, 2007; Kok et al, 2012; Krishnan et al, 2008; Kuo et al, 2010; 
Stack et al, 2013; Teng et al, 2012) three reported mortality from coronary heart 
disease, (Choi & Curhan, 2007; Krishnan et al, 2008; Teng et al, 2012) and three 
reported mortality from MI. (De Vera et al, 2010; Krishnan et al, 2006; Krishnan et 
al, 2008) The results of these studies will be presented grouped according to the 
type of cardiovascular disease being investigated in association with mortality in 
patients with gout. 
3.8.2.3.1  Gout and mortality from any cardiovascular disease 
The six studies reporting mortality from any cardiovascular cause in participants 
with gout, compared to those without were all of the cohort design, three from the 
US, (Choi & Curhan, 2007; Krishnan et al, 2008; Stack et al, 2013) and three from 
Taiwan.  (Kok et al, 2012; Kuo et al, 2010; Teng et al, 2012) Details of the studies 
reporting mortality from any cardiovascular disease in patients with gout are 
shown in table 3.9 below. 
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Table 3.9: Studies examining gout and mortality from any cardiovascular disease   
Author Gout definition Average age % male Previous vascular disease or risk factor 
information 
Outcomes 
Choi & 
Curhan, 
2007 
Self report of physician diagnosis 
of gout at baseline, incident 
cases using ACR survey criteria 
Gout= 
59 
Not gout=54 
100 Analysis split into those with CHD at 
baseline and not – adjusted for age, 
HTN, HLD, DM, aspirin, diuretic use, 
smoking, BMI, physical activity, alcohol 
use, FH MI, dietary constituents 
 Age adjusted HR 1.76 
(1.47-2.10) 
 AHR 1.38 (1.15-1.66) 
 
Krishnan et 
al, 2008 
1.Self report physician 
diagnosed +documented 
sustained hyperuricaemia 
2. use of gout medication in 5y 
preceding 
3.self report of gout without urate 
level 
Gout=52.9 
Not 
gout=52.1 
100 Excluded if pre-existing CVD - adjusted 
for age, BP, serum cholesterol, plasma 
triglycerides, serum creatinine, glucose, 
smoking, FH MI, aspirin use, diuretic 
use, alcohol use, BMI 
 CHR 1.30 (1.07-1.58) 
 AHR 1.21 (0.99-1.49) 
Kuo et al, 
2010 
Physician recorded (record of 
crystals in fluid or ICD-9 coded 
as gout) or self report 
Gout=52 
Not gout=50 
Gout=90.4 
Not gout=52.4 
Excluded those with prior MI or stroke 
adjusted for features of metabolic 
syndrome 
 CHR 3.59 (1.98-6.47) 
 AHR 1.97 (1.08-3.59) 
Teng et al, 
2012 
Self report of physician diagnosis 
+ self report of elevated serum 
urate + self report of dietary 
advice for gout given 
Gout=61.5 
Not 
gout=61.6 
Gout=65.7 
Not gout=41.5 
 
Model 3 
(subgroup with 
no prior history 
of vascular 
disease) 
=43.3% male 
No exclusions in original study – 
subgroup analysis excludes those with 
prior vascular disease: adjusted for age, 
BMI, gender, education, alcohol 
consumption, smoking, activity, serum 
cholesterol, fats, HTN, DM 
 Men AHR 1.10 (0.82-
1.46)  
 Women AHR 1.51 
(1.00-2.30) 
 All AHR 1.23 (0.97-
1.56) 
 
Kok et al, 
2012 
ICD code-physician recorded Not stated, all 
aged over 50 
Gout=76.2% 
Not gout=47.0% 
Age, sex, smoking-related diagnosis, 
alcoholism-related diagnosis, HTN, 
HLD, Charlson co-morbidity index 
 CHR 1.69 (1.65-1.74) 
 AHR  1.10 (1.07-
1.13) 
Stack et al, 
2013 
Self-report of physician diagnosis Gout = 60 
Not gout = 
44.3 
Gout=68.3% 
Not gout=47.3 
Age, sex, race, coronary disease, 
congestive heart failure, stroke, 
diabetes, HTN, physical activity, 
smoking behaviour, BMI  
 CHR 5.25 (3.83-7.19) 
 AHR 1.58 (1.13-2.19) 
ACR= American college of Rheumatologists; AHR=adjusted hazard ratio; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; 
CHR=crude hazard ratio; CV= cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; HLD= hyperlipidaemia; HTN = hypertension; ICD= 
International Classification of Diseases; FH MI; family history of myocardiaI infarction; MI = myocardial infarction 
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The results of this meta-analysis are shown below in Tables 3.10 and 3.11 
presented as the crude results (table 3.10) followed by the adjusted results (table 
3.11) and Figures 3.6 and 3.7. The pooled estimate of the HR was 2.01 (95%CI 
1.54-2.63) for the crude results, and for the adjusted results was 1.27 (95%CI 
1.11-1.46).   A statistically significant excess risk of mortality from cardiovascular 
causes was demonstrated. 
Table 3.10:   Study effect sizes and weights in meta-analysis of crude results of studies examining 
the relationship between gout and mortality from any cardiovascular disease   
 
Authors Hazard Ratio 95% CI % Weight 
Kuo et al, 2010 3.59 1.98-6.47 10.15 
Krishnan et al, 2008 1.30 1.07-1.58 18.15 
Teng et al, 2012 1.34 1.07-1.69 17.52 
Choi & Curhan, 2007 1.76 1.47-2.10 18.43 
Kok et al, 2012 1.69 1.65-1.74 20.03 
Stack et al, 2014 5.25 3.83-7.19 15.72 
D & L Pooled Effect 
Size 
2.01 1.54-2.63 100.00 
CI= confidence interval; D&L = DerSimonian & Laird 
 
I2= 92.5% which reflects significant heterogeneity, and Cochran’s Q test yielded 
p<0.01. 
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Table 3.11:   Study effect sizes and weights in meta-analysis of adjusted results for studies 
examining the relationship between gout and any cardiovascular disease 
 
Authors Hazard Ratio 95% CI % Weight 
Kuo et al, 2010 1.97 1.08-3.59 4.53 
Krishnan et al, 2008 1.21 0.99-1.49 18.31 
Teng et al, 2012 1.23 0.97-1.56 16.06 
Choi & Curhan, 2007 1.38 1.15-1.66 19.85 
Kok et al, 2012 1.10 1.07-1.13 30.12 
Stack et al, 2014 1.58 1.13-2.19 11.12 
D & L Pooled Effect Size 1.27 1.11-1.46 100.00 
CI= confidence interval; D&L = DerSimonian & Laird 
 
I2= 66.9% which reflects significant heterogeneity, and Cochran’s Q test yielded 
p<0.01
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Figure 3.6: Meta-analysis of crude findings of studies examining the relationship between gout and mortality from any cardiovascular disease 
 
NOTE: Weights are from random effects analysis 
Overall  (I-squared = 92.5%, p = 0.000) 
Choi & Curhan, 2007 
Kok et al, 2012 
Study 
Stack et al, 2014 
Krishnan et al, 2008 
Teng et al, 2012 
Kuo et al, 2010 
2.01 (1.54, 2.63) 
1.76 (1.47, 2.10) 
1.69 (1.65, 1.74) 
Hazard 
Ratio (95% CI) 
5.25 (3.83, 7.19) 
1.30 (1.07, 1.58) 
1.34 (1.07, 1.69) 
3.59 (1.98, 6.47) 
100.00 
18.43 
20.03 
% Weight 
15.72 
18.15 
17.52 
10.15 
2.01 (1.54, 2.63) 
1.76 (1.47, 2.10) 
1.69 (1.65, 1.74) 
Hazard Ratio  
(95% CI) 
5.25 (3.83, 7.19) 
1.30 (1.07, 1.58) 
1.34 (1.07, 1.69) 
3.59 (1.98, 6.47) 
100.00 
18.43 
20.03 
% 
15.72 
18.15 
17.52 
10.15 
    1 .139 7.19 
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Figure 3.7: Meta-analysis of adjusted findings of studies examining the relationship between gout and mortality from any 
cardiovascular disease 
 
NOTE: Weights are from random effects analysis 
Overall  (I-squared = 66.9%, p = 0.010) 
Krishnan et al, 2008 
Stack et al, 2014 
Kok et al, 2012 
Kuo et al, 2010 
Choi&Curhan, 2007 
Study 
Teng et al, 2012 
1.27 (1.11, 1.46) 
1.21 (0.99, 1.49) 
1.58 (1.13, 2.19) 
1.10 (1.07, 1.13) 
1.97 (1.08, 3.59) 
1.38 (1.15, 1.66) 
Ratio (95% CI) 
1.23 (0.97, 1.56) 
Hazard 
100.00 
18.31 
11.12 
30.12 
4.53 
19.85 
Weight 
16.06 
% 
1.27 (1.11, 1.46) 
1.21 (0.99, 1.49) 
1.58 (1.13, 2.19) 
1.10 (1.07, 1.13) 
1.97 (1.08, 3.59) 
1.38 (1.15, 1.66) 
1.23 (0.97, 1.56) 
zard Ratio 
(95% CI) 
100.00 
18.31 
11.12 
30.12 
4.53 
19.85 
16.06 
% 
Weight
    1 .279 3.59 
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Thus, even after adjustment for potential confounders, a statistically significant 
increase in mortality from any cardiovascular disease has been identified in 
patients with gout, although this may result from between study differences. 
 
3.8.2.3.2 Gout and coronary heart disease mortality 
Three cohort studies examine the association between gout and mortality from 
coronary heart disease, (Choi & Curhan, 2007; Krishnan et al, 2008; Teng et al, 
2012) two from the US, (Choi & Curhan, 2007; Krishnan et al, 2008) and one from 
Taiwan. (Teng et al, 2012) The results of these studies are presented in table 3.12 
below 
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Table 3.12: Studies examining gout and coronary heart disease mortality 
Author Gout definition Average age % male Previous vascular disease or 
risk factor information 
Outcomes 
Choi & Curhan, 
2007 
Self report of physician 
diagnosis of gout at 
baseline, incident cases 
using ACR survey criteria 
Gout= 
59 
Not gout=54 
100 Analysis split into those with 
CHD at baseline and not – 
adjusted  for age, HTN, 
Serum cholesterol, DM, 
aspirin, diuretic use, 
smoking, BMI, physical 
activity, alcohol consumption, 
FHMI, Dietary constituents 
 CHR 1.95 (1.57-2.44) 
 AHR 1.55 (1.24-1.93) 
Krishnan et al, 2008 1.Self report physician 
diagnosed +documented 
sustained hyperuricaemia 
2. use of gout medication 
in 5y preceding 
3.self report of gout 
without urate level 
Gout=52.9 
Not gout=52.1 
100 Excluded if pre-existing CVD 
- adjusted for age, BP, serum 
cholesterol, plasma 
triglycerides, serum 
creatinine, plasma glucose, 
smoking, FH, aspirin use, 
diuretic use, alcohol 
consumption, BMI 
 CHR 1.37 (1.09-1.74) 
 AHR 1.35 (1.06-1.72) 
 
Teng et al, 2012 Self report of physician 
diagnosis + self report of 
elevated serum urate + 
self report of dietary 
advice for gout given 
Gout=61.5 
Not gout=61.6 
Gout=65.7 
Not 
gout=41.5 
 
Model 3* 
=43.3%  
No exclusions in original 
study – subgroup analysis 
excludes those with prior 
vascular disease: adjusted 
for age, BMI, gender, 
education, alcohol 
consumption, smoking, 
activity levels, serum 
cholesterol, fats, HTN, DM 
 Men AHR 1.16 (0.81-
1.67) 
 Women AHR 1.81 
(1.07-3.05) 
 Combined  AHR 1.35 
(1.00-1.82) 
 
*subgroup with no prior history of vascular disease 
ACR = American College of Rheumatology; AHR = adjusted hazard ratio; BMI = body mass index; BP = blood pressure; CHD = coronary 
heart disease; CHR = crude hazard ratio; CVD = cardiovascular disease; DM = diabetes mellitus; FH = family history; FH MI = family history 
of myocardial infarction; HR= hazard ratio; HTN = hypertension;  
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The results of this meta-analysis are shown below in Tables 3.13 and 3.14 
presented as the crude results (table 3.13) followed by the adjusted results (table 
3.14) and Figures 3.8 and 3.9. The pooled estimate of the HR was 1.60 (95%CI 
1.28-2.00) for the crude results, and for the adjusted results was 1.43 (95%CI 
1.24-1.65).  A statistically significant excess risk of mortality from coronary heart 
disease was demonstrated. 
Table 3.13:   Study effect sizes and weights in meta-analysis of crude results of studies examining 
the relationship between gout and coronary heart disease mortality 
 
I2 = 59.3% which reflects moderate heterogeneity, but Cochran’s Q test yielded 
p=0.09.   
 
 
 
 
 
 
 
Table 3.14:   Study effect sizes and weights in meta-analysis of adjusted results of studies 
examining gout and coronary heart disease mortality 
Author Effect Size 95% CI % Weight 
Krishnan et al, 
2008 
1.37 1.09-1.74 34.89 
Teng et al, 2012 1.51 1.13-2.03 28.67 
Choi & Curhan, 
2007 
1.95 1.57-2.44 36.44 
D&L Pooled Effect 
Size 
1.60 1.28-2.00 100.00 
CI= confidence interval; D&L = DerSimonian & Laird 
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I2 = 0.0% and Cochran’s Q test yielded p=0.65, suggesting no statistically 
significant heterogeneity. 
 
 
 
 
 
 
Author Effect Size 95% CI % Weight 
Krishnan et al, 2008 1.35 1.06-1.72 35.13 
Teng et al, 2012 1.35 1.00-1.82 22.94 
Choi & Curhan, 2007 1.55 1.24-1.93 41.93 
D&L Pooled Effect Size 1.43 1.24-1.65 100.00 
CI= confidence interval; D&L = DerSimonian & Laird 
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Figure 3.8: Meta-analysis of crude findings of studies examining the relationship between gout and mortality from coronary heart 
disease 
NOTE: Weights are from random effects analysis 
Overall  (I-squared = 59.3%, p = 0.086) 
Study 
Krishnan et al, 2008 
Teng et al, 2012 
Choi & Curhan, 2007 
1.60 (1.28, 2.00) 
Ratio (95% CI) 
1.37 (1.09, 1.74) 
1.51 (1.13, 2.03) 
1.95 (1.57, 2.44) 
Hazard 
100.00 
Weight 
34.89 
28.67 
36.44 
% 
1.60 (1.28, 2.00) 
1.37 (1.09, 1.74) 
1.51 (1.13, 2.03) 
1.95 (1.57, 2.44) 
Hazard 
Ratio 
(95%CI) 
100.00 
34.89 
28.67 
36.44 
% 
Weight 
    1 .41 2.44 
      
 
         
   
1
2
0
 
Figure 3.9: Meta-analysis of adjusted findings of studies examining the relationship between gout and mortality from coronary heart disease 
 
NOTE: Weights are from random effects analysis 
Overall  (I-squared = 0.0%, p = 0.649) 
Choi & Curhan, 2007 
Teng et al, 2012 
Krishnan et al, 2008 
Study 
1.43 (1.24, 1.65) 
1.55 (1.24, 1.93) 
1.35 (1.00, 1.82) 
Hazard 
1.35 (1.06, 1.72) 
Ratio (95% CI) 
100.00 
41.93 
22.94 
% 
35.13 
t 
1.43 (1.24, 1.65) 
1.55 (1.24, 1.93) 
1.35 (1.00, 1.82) 
Hazard  Ratio 
 (95% CI) 
1.35 (1.06, 1.72) 
 
100.00 
41.93 
22.94 
% 
 Weight 
35.13 
 
    1 .518 1.93 
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Thus, even after adjustment for potential confounders, a statistically significant 
increase in mortality from coronary heart disease has been identified in patients 
with gout, which cannot be attributed to between study differences. 
3.8.2.3.3 Gout and mortality from myocardial infarction 
Two publications were identified which report on the association between gout and 
mortality from myocardial infarction.  (De Vera et al, 2010; Krishnan et al, 2008) 
Both report the results of cohort studies, one prospective from the US, (Krishnan 
et al, 2008) and one retrospective from Canada. (De Vera et al, 2010) Krishnan et 
al, 2008, report an increased risk of fatal acute myocardial infarction in male gout 
patients in crude analysis, whereas DeVera et al, 2010, report an increased risk of 
fatal myocardial infarction in female but not male gout patients in crude analysis.  
(De Vera et al, 2010; Krishnan et al, 2008)  However, neither of these studies 
reported a significant excess risk of mortality from MI in patients with gout, after 
adjustment for traditional vascular risk factors in either gender. Due to significant 
differences in the reporting of outcomes, this data is not suitable for meta-analysis 
and is therefore reported narratively.  The details of the studies examining this 
relationship are shown in table 3.15  
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Table 3.15 Studies examining the association between gout and mortality from MI 
 
Author Gout definition Average age % male Previous vascular disease or risk 
factor information 
Outcomes 
Devera et al, 
2010 
ICD-9 codes Gout 
M=73.9 
F=75 
Not gout 
M=73.3 
F=75.0 
Gout=59.7% 
Not 
gout=59.7% 
Total 59.7% 
 
Excluded if prior IHD:  adjusted 
for age, HTN, HLD, DM, COPD, 
charlson score, monthly 
prescription drug use – NSAID, 
diuretics, statins, anticoagulants, 
aspirin, HRT, steroids. 
Women  
 CHR 1.57 (1.18-2.09) 
 AHR 1.33 (0.99-1.78) 
Men  
 CHR 1.19 (0.96-1.49) 
 AHR 1.10 (0.88-1.38) 
N.S for gender interaction  
Krishnan et al, 
2008 
1.Self report physician 
diagnosed +documented 
sustained hyperuricaemia 
2. use of gout medication 
in 5y preceding 
3.self report of gout 
without urate level 
Gout=52.9 
Not 
gout=52.1 
100 Excluded if pre-existing CVD - 
adjusted for age, BP, serum 
cholesterol, plasma triglycerides, 
serum creatinine, glucose, 
smoking, FH, aspirin use, diuretic 
use, alcohol consumption, BMI 
 CHR 1.46 (1.03-2.06) 
 AHR 1.35 (0.94-1.93) 
 
AHR = adjusted hazard ratio; AMI = acute myocardial infarction;  BMI = body mass index; BP = blood pressure; CHD = coronary heart 
disease; CHR = crude hazard ratio; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease; DM = diabetes mellitus; 
FH = family history; HLD = Hyperlipidaemia; HR= hazard ratio; HRT = hormone replacement therapy; HTN = hypertension; ICD = 
International Classification of Diseases; IHD = ischaemic heart disease; MI = myocardial infarction; NS = non-significant; NSAID = non-
steroidal anti-inflammatory drug; 
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3.8.3 Gout and cerebrovascular disease 
Two studies which investigated the relationship between gout and cerebrovascular 
disease were identified.   
Teng et al, 2012, reports no increased risk of mortality from cerebrovascular 
disease in patients with gout compared to those without in a Taiwanese 
retrospective cohort study (HR 1.06 [0.63-1.78]). (Teng et al, 2012) In contrast, a 
retrospective cohort study using two databases of electronic patient records from 
the UK to investigate the association between gout and incidence of 
cerebrovascular disease reported an increased risk of all strokes, ischaemic 
stroke, haemorrhagic stroke and stroke of unspecified aetiology. (Seminog & 
Goldacre, 2013)  
Six other studies report cardiovascular disease including stroke as outcomes.  
(Choi & Curhan, 2007; Janssens et al, 2003; Kok et al, 2012; Krishnan et al, 2008; 
Kuo et al, 2010; Stack et al, 2013) Authors were contacted to establish whether 
any disaggregated outcomes for stroke or cerebrovascular disease could be 
provided.  Two of the authors responded that they were unable to provide this, 
(Janssens et al, 2003; Kuo et al, 2010) whilst the remainder did not respond.  The 
details of the studies examining this relationship are shown in table 3.16. 
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Table 3.16 Studies examining the association between gout and cerebrovascular disease 
 
Author Gout definition Average age % male Previous vascular disease or risk 
factor information 
Outcomes 
Mortality from cerebrovascular disease 
Teng et al, 2012 Self report of physician 
diagnosis + self report of 
elevated serum urate + self 
report of dietary advice for 
gout given 
Gout=61.5 
Not gout=61.6 
Gout=65.7 
Not gout=41.5 
 
Model 3 
(subgroup with 
no prior history 
of vascular 
disease) 
=43.3% male 
No exclusions in original study – 
subgroup analysis excludes those 
with prior vascular disease: adjusted 
for age, BMI, gender, education, 
alcohol consumption, smoking, 
activity levels, serum cholesterol, 
fats, HTN, DM 
 Fatal stroke AHR 1.06 
(0.63-1.78) 
 Men 0.85 (0.43-1.68) 
 Women 1.45 (0.64-3.29) 
Incidence of cerebrovascular disease 
Seminog & 
Goldacre, 2013 
ICD code- physician 
recorded 
Overall: 
HES=70.3 
ORLS=68.8 
Overall: 
HES=74% 
ORLS=73% 
Age, sex, calendar years in the 
database, region of residence and 
deprivation score 
 All stroke AHR HES 1.71 
(1.68-1.75)/ORLS 1.91 
(1.70-2.14) 
 Ischaemic stroke AHR 
HES 1.68 (1.64-
1.73)/ORLS 2.10 (1.61-
2.70) 
 Haemorrhagic stroke 
AHR HES 1.69 (1.61-
1.77)/ORLS 1.95 (1.30-
2.81) 
 Stroke unspecified AHR  
HES 2.00 (1.95-
2.06)/ORLS 1.90 (1.67-
2.15) 
AHR = adjusted hazard ratio; BMI = body mass index; DM = diabetes mellitus; HES= hospital episode statistics; HTN = hypertension; ICD = International 
Classification of Diseases; ORLS= oxford record linkage study 
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3.8.4 Gout and peripheral vascular disease 
Two studies were identified which examined the relationship between gout and 
peripheral vascular disease (PVD), with one reporting prevalence, and one 
reporting incidence of PVD in patients with gout compared to those without. (Baker 
et al, 2007; De Muckadell & Gyntelberg, 1976)  
The only study reporting prevalence of PVD in patients with gout was a cross-
sectional survey from Denmark. (De Muckadell & Gyntelberg, 1976) They 
estimated prevalence of PVD in 104 patients with gout and 208 participants 
without gout and reported an approximately three-fold increase in prevalence of 
PVD in patients with gout (4.8%) compared to those without (1.4%). However, this 
difference was not statistically significant.   
The only study in which incidence of PVD in patients with gout was investigated 
was a cohort study from the US, which used participants at increased risk of 
coronary heart disease initially recruited to a randomised controlled trial 
investigating the effectiveness of an intervention aimed at reducing their 
cardiovascular risk. They report an increased risk of incident PVD in patients with 
gout (n=1485) compared to those without gout (n=11343).  However, examining 
this association was not the purpose of this study and it is likely to have been 
underpowered to detect any significant difference.  (Baker et al, 2007) 
The details of these studies are shown in table 3.17 below. 
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Table 3.17 Studies investigating gout and peripheral vascular disease 
 
Author Gout definition Average age % 
male 
Previous vascular 
disease or risk factor 
information 
Outcomes 
Prevalence of PVD 
Schaffalitzky de 
Muckadell & 
Gyntelberg, 1976 
Patient recall of 
physician 
diagnosed gout 
Not described – 
all between 40 
and 59 
100 Pt recall data % prevalence of intermittent 
claudication  
 Gout = 4.8%  
 Non-gout = 1.4% 
 Difference N.S 
Incidence of PVD 
Baker et al, 2007 Self report 46 100 Excluded if prior MI, 
angina, DM, body 
weight>150% desirable, 
HLD, HTN: adj for age, 
FH cardiovascular 
disease, DM, HLD, 
Smoking, HTN, BMI  
 OR 1.33 (1.07-1.66) 
BMI=body mass index; DM=diabetes mellitus; FH= family history; HLD= hyperlipidaemia; HTN= hypertension; MI = myocardial 
infarction; NS = non-significant; OR = odds ratio 
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3.9 Assessment of heterogeneity  
This section will examine possible explanations for the heterogeneity of the 
included studies.   
Due to the wide range of outcomes reported in the included studies, and the fact 
that some studies report more than one outcome measure, for the purposes of this 
analysis, publications are split into those reporting any significant increased risk of 
vascular disease in patients with gout, and those that do not. 
The first section will assess heterogeneity in the context having achieved or not 
achieved the quality criteria set out earlier in this chapter. 
The second section will assess heterogeneity in the context of other study criteria, 
such as study population size, gender distribution and geographical location. 
3.9.1 Assessment of heterogeneity and quality assessment criteria 
Fisher’s exact test was used to test differences in having met (or not met) the 
individual quality criteria between those studies which showed any increased risk 
of vascular disease in gout patients, and those that did not find any such 
association.  The small number of articles meant that non-parametric testing was 
required and so the Fisher’s Exact Test, rather than the chi squared test was 
applied.  (Fisher, 1922) Table 3.18 shows the results of this statistical testing.  
Taking a p value of less than 0.05 to determine statistical significance, Table 3.18 
can be clearly seen to show no statistically significant differences between 
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achievement of quality criteria between those studies which demonstrate an 
increased risk of vascular disease in gout, and those that do not.  
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Table 3.18: Table presenting the numbers of studies reporting an increased risk of vascular disease in gout (significant) compared with those that did not, 
and which met/did not meet the set quality criteria, with the statistical significance of this difference  
 
 Quality Criteria 
1 2 3 4 5 6 7 8 9 10 11 
Significant  Met 8 13 9 9 12 10 13 12 5 13 13 
 Unmet 5 0 4 4 1 3 0 1 8 0 0 
Non-
significant 
Met 3 4 3 4 2 4 4 4 4 4 4 
 Unmet 1 0 1 0 2 0 0 0 0 0 0 
2 Tailed Significance 
level using Fisher’s 
Exact Test 
1.0  1.0 0.50 0.20 0.50  1.0 0.07   
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3.9.2 Assessment of heterogeneity and study characteristics 
In this section, the heterogeneity of the results of the included studies which report 
an association between gout and risk of vascular disease compared with those 
that do not will be discussed with reference to certain study characteristics.  These 
were; 
1) Geographical location of the study: the two groups were compared 
according to whether the studies were conducted in the United States and 
Canada or elsewhere. 
2) Size of the total study population:  studies were divided into those that had 
>10,000 participants and those that did not. 
3) Gender distribution of study population:  studies were divided into those 
with all male participants and those with some female participants. 
Fisher’s exact test (for reasons explained in section 3.6 and 3.9.1) was used to 
test differences in presence or absence of these study characteristics described 
between those studies which showed any increased risk of vascular disease in 
gout patients, and those that did not find any such association.  Table 3.19 shows 
the results of this statistical testing.  Taking a p value of less than 0.05 to 
determine statistical significance, Table 3.19 can be clearly seen to show no 
statistically significant differences in presence or absence of these study 
characteristics between those studies which demonstrate an increased risk of 
vascular disease in gout, and those that do not.  
      
 
         
   
1
3
1
 
Table 3.19:  Table presenting the numbers of studies reporting an increased risk of vascular disease in gout (significant) compared with those that did not, 
and which met/did not certain population characteristics, with the statistical significance of this difference 
 
 Study Characteristics 
Study based in the US or 
Canada 
Study population >10,000 All male population 
Significant  Met 7 9 5 
 Unmet 6 4 8 
Non-significant Met 2 2 1 
 Unmet 2 2 3 
2 Tailed Significance level 
using Fisher’s Exact Test 
1.00 1.00 0.56 
 
 
      
132 
         
   
3.10 Assessment of publication bias  
Evidence of publication bias was assessed using funnel plots and Begg’s and 
Egger’s tests. These are presented below, however the results should be 
interpreted with caution since the small number of papers included in each 
analysis significantly limits the power of Begg’s or Egger’s test.   
Mortality: Any cardiovascular disease 
Figure 3.10 Funnel plot of publications examining the relationship between gout 
and mortality from any cardiovascular disease (adjusted results) 
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Table 3.20 Results of Begg’s and Egger’s tests in assessing publication bias in studies examining 
the relationship between gout and mortality from any cardiovascular disease 
 
 Test value p for significance 
Begg’s test 0.61 0.66 
Egger’s test 1.13 0.26 
 
There is evidence of some publication bias in the relationship between gout and 
any cardiovascular mortality, seen in the funnel plot where there is an obviously 
skewed distribution of markers, but the statistical tests applied do not show any 
evidence of publication bias.  This discrepancy demonstrates the low power of 
Begg’s and Egger’s tests to detect publication bias where the number of included 
studies is small. 
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Mortality: Coronary heart disease  
Figure 3.11 Funnel plot of publications examining the relationship between gout 
and mortality from coronary heart disease (adjusted results) 
 
Table 3.21 Results of Begg’s and Egger’s tests in assessing publication bias in studies examining 
the relationship between gout and mortality from coronary heart disease 
 
 Test value p for significance 
Begg’s test -0.52 0.602 
Egger’s test -0.27 0.723 
 
There is no evidence of publication bias shown in either the funnel plot where the 
markers are all clustered around the null value, or the statistical tests applied 
which are both non-significant. 
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Incidence:  Coronary heart disease  
Figure 3.12 Funnel plot of publications examining the relationship between gout 
and incidence of coronary heart disease (adjusted results) 
  
Table 3.22 Results of Begg’s and Egger’s tests in assessing publication bias in studies examining 
the relationship between gout and incidence of coronary heart disease 
 
 Test value p for significance 
Begg’s test 1.00 0.317 
Egger’s test 7.23 not given 
 
There is no evidence of publication bias, since distribution across the funnel plot is 
symmetrical, and Begg’s test is non-significant, although there are only two studies 
included. 
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3.11 Discussion 
This section will discuss both the results of the studies identified by this review, 
and their design and methodological quality. 
3.11.1 Discussion of the relationship between gout and vascular disease 
The results of this review demonstrate an increased risk of mortality from any 
cardiovascular cause and coronary heart disease, but not MI, whereas these 
relationships are reversed when incidence of disease is measured, with increased 
incidence of MI reported, but not increased incidence of any cardiovascular 
disease or coronary heart disease.   
These results are consistent with the only previous systematic review of 4 studies, 
which concluded that gout is an independent risk factor for cardiovascular 
mortality. (Lottmann et al, 2012) 3 of the studies included in that review were 
included in this meta-analysis, (Choi & Curhan, 2007; Krishnan et al, 2008; Kuo et 
al, 2010) however one was excluded, (Cohen et al, 2008) since the study 
population consisted of renal dialysis and transplantation patients, and was not felt 
to be broadly representative of the wider gout population.  Five additional newer 
studies were included in this review. (Kok et al, 2012; Kuo et al, 2013; Seminog & 
Goldacre, 2013; Stack et al, 2013; Teng et al, 2012)  
There are a number of possible explanations for the disparity in association 
between gout and incidence and mortality from different types of vascular disease.   
In the case of an association between gout and risk of any cardiovascular and 
CHD mortality, but not MI mortality the most obvious reason is ascertainment bias, 
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where deaths are attributed to a cardiovascular or CHD cause when in fact this is 
not the true cause of death, This is less likely to be the case with MI where a 
reliable combination of electrocardiogram findings and biochemical test results are 
required to make the diagnosis.  Linked to this is the concept of spectrum bias, 
whereby any cardiovascular disease and CHD cover a broader range of 
conditions, and in fact in some of the studies include cerebrovascular disease, 
(Choi & Curhan, 2007; Janssens et al, 2003; Kok et al, 2012; Krishnan et al, 2008; 
Kuo et al, 2010; Stack et al, 2013) resulting in the more frequent recording of 
codes relating to any cardiovascular disease and CHD than MI.   Thus 
comparatively less MI’s are likely to be detected in both gout and non-gout groups 
in studies using retrospective record review, and even fewer fatal MI’s, thus the 
studies may not be large enough to detect sufficient events to detect an 
association.    
It may genuinely be the case that there is not an increased mortality from MI 
associated with gout, and that gout only increases risk of non-fatal MI.  
Alternatively this finding may represent the effect of surveillance bias, with 
screening for and management of vascular risk factors in patients with gout, or 
lifestyle advice given following diagnosis of gout, preventing otherwise fatal MI.  
However, there is evidence to suggest that only the minority of patients with gout 
have screening for cardiovascular risk factors within a month following diagnosis. 
(Roddy et al, 2010) It is more likely to represent misclassification with poor 
identification and/or coding of MI compared with other forms of vascular disease, 
perhaps using more general cardiovascular or CHD codes and thus attributing the 
death to these causes.  
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Competing risks must also be considered in associations with mortality, whereby 
when a study is interested in cause-specific mortality and there is a significant and 
competing risk, such as mortality from another cause, for example end-stage renal 
disease (ESRD) or cancer, then patients who die from the competing risk can no 
longer remain at risk of mortality from the cause of interest.  Thus, the estimate of 
risk of mortality from the cause of interest will be attenuated by patients who can 
no longer remain “at risk” of mortality from MI since they have already died of 
something else.  Therefore, it is possible that gout is associated with an increased 
risk of non-fatal MI, but then patients die of an alternative cause such as heart 
failure, recorded as CHD or CVD, or a different system disorder such as ESRD. 
The lack of association with incidence of cardiovascular disease and CHD may be 
the result of only two studies investigating this particular association.  Perhaps 
future studies examining incidence of disease will alter this finding, or simply 
confirm the lack of association.  Assuming, however, that these findings are not 
the result of bias, inadequate study size to detect events, or neglect of incidence 
as an outcome, there may be other factors influencing these relationships resulting 
in the differences between associations of incidence and mortality from 
cardiovascular disease, CHD and MI. 
The increased mortality from, but not incidence of CVD and CHD, and increased 
incidence of, but not mortality from MI may be explained by relative difference in 
risk factors for the onset of different manifestations of cardiovascular disease.  
There is evidence to suggest that the risk factors for stable angina are different 
from those for unheralded MI or acute coronary syndrome (ACS) at first 
presentation. (Canoui-Poitrine et al, 2009; Dunder et al, 2004)  Rheumatoid 
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arthritis patients have been reported to be less likely to report symptoms of angina, 
but more likely to experience unrecognised MI and sudden death. (Maradit‐
Kremers et al, 2005)   This may be explained by the evidence to suggest 
circulating plasma levels of proinflammatory cytokines differ in stable and unstable 
angina, with raised IL-1β levels significantly higher in those with unstable than 
stable angina, or controls. (Simon et al, 2000) Inflammation has been implicated in 
all phases of athero-thrombosis, including rupture of atherosclerotic plaques 
responsible for acute cardiac and cerebrovascular circulations.  Interleukins 1 and 
6 are particularly implicated, with evidence that IL-1 can induce a procoagulant 
state, as well as monocyte and leucocyte adhesion in human vascular endothelial 
cells, and increased levels of IL-1β in atherosclerotic compared with normal 
coronary arteries.  (Ridker et al, 2011)  IL-6 has been shown to be an independent 
risk factor for cardiovascular disease mortality, (Lee et al, 2012; Su et al, 2013) 
and a strong independent relationship between circulating IL-6 levels and 
endothelial activation in patients with rheumatoid arthritis.  (Dessein et al, 2013)  
There is evidence that the NALP3 inflammasome, triggered to produce active IL-1 
by the presence of MSU crystals, is also activated by cholesterol crystals and LDL 
cholesterol.  (Duewell et al, 2010) There is also evidence that management of 
disease burden in rheumatoid arthritis has been shown to reduce dyslipidaemia. 
(Steiner & Urowitz, 2009)  Although there is a paucity of evidence examining how 
the management of gout affects long-term outcomes, it would seem that in a 
condition known to caused increased circulating levels of IL-1 and IL-6 
predisposing to atherosclerosis, and where co-morbid vascular risk factors such as 
dyslipidaemias are common, it would seem that further investigation of ways to 
reduce these risks is warranted.  Of particular interest is the evidence that only 
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40% of patients with gout receive urate lowering therapy (ULT), (Annemans et al, 
2008; Kuo et al, 2014) and that persistence with such ULT is poor, (De Vera et al, 
2014; Kuo et al, 2014) which when considered alongside the presence of sub-
clinical inflammation even in the asymptomatic intercritical period, suggests the 
majority of gout patients remain at increased risk. 
Two of the studies included in this review were cohort studies which followed 
randomised controlled trials, where patients from all arms of the trial who did not 
develop the original outcome of interest within the trial follow-up were then 
observed as part of a cohort study.  One of the two studies examining incidence of 
CVD in patients with gout was one of these cohort studies originating from a trial 
population.  Recruitment to trials can often have very specific inclusion criteria, 
often resulting in a very niche population remaining to be included in any 
subsequent cohort study, potentially influencing the strength of the association, 
however as a large prospective cohort study, where the inclusion criteria applied to 
all participants with and without gout, it was felt appropriate to include this study.  
Two studies examine the relationship between gout and cerebrovascular disease, 
one reporting no increased risk of fatal stroke in patients with gout after adjustment 
for vascular risk factors, (Teng et al, 2012) but the other reporting increased 
incidence of all types of stroke in patient with gout. (Seminog & Goldacre, 2013) 
These findings are not in complete agreement with a previous systematic review 
which linked hyperuricaemia with increased risk of both stroke incidence and 
mortality. (Kim et al, 2009) This may reflect the inclusion of cerebrovascular 
outcomes as part of cardiovascular disease outcomes, (Choi & Curhan, 2007; 
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Janssens et al, 2003; Kok et al, 2012; Krishnan et al, 2008; Kuo et al, 2010; Stack 
et al, 2013) and a relative paucity of literature on this particular relationship.   
Literature examining the relationship between gout and peripheral vascular 
disease is also limited.  Although the one published study reporting on this 
association reports an increased risk of incident  peripheral vascular disease in 
patients with gout, compared to those without gout, OR 1.33 95%CI[1.07-1.66], 
(Baker et al, 2007) this was not the purpose of this study and it is likely to have 
been underpowered to detect any difference.  This in keeping with literature linking 
hyperuricaemia with peripheral vascular disease, (Langlois et al, 2003; Shankar et 
al, 2008; Tseng, 2004; Vigna et al, 1992) which is unsurprising given the many 
common risk factors such as  hypertension, diabetes, metabolic syndrome, chronic 
kidney disease (CKD) and smoking, (Shammas, 2007) that the two conditions 
share.   
3.12 Strengths and Limitations of the Review 
The strengths of our review include our inclusion criteria, with initially only case-
control study designs excluded, and finally only large cohort studies included.  This 
eliminated the recall bias associated with the case-control study design.  
Participants were all required to be disease free at baseline and thus, cases of 
vascular diseases identified were truly incident.  Whilst some cohorts originated in 
controlled trials, participants who continued in these observational studies were 
observed for up to 17 years following the end of the trial perhaps compensating for 
more stringent enrolment criteria in the original trials.   
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Rigorous data extraction was also a strength of this review.  All papers were 
independently assessed for inclusion or exclusion by two reviewers, with a third 
reviewer identified in the case of disagreement. Authors were contacted for 
additional information where necessary.   A validated tool appropriate for cohort 
studies, the Newcastle-Ottawa Scale, was used to quality assess papers, with the 
addition of criteria considered to be important to this particular study.  These 
additions quality assessed areas of the study papers not included in the NOS tool, 
appropriateness of statistical methods, and the separation of asymptomatic 
hyperuricaemia from clinical gout, since this distinction is important in accurately 
estimating any association between gout and vascular disease.  
Crude and multivariate data were pooled separately and examined for potential 
sources of heterogeneity (geographical location of study, year of publication, 
gender distribution), and studies which did and did not report associations were 
compared by met and unmet quality assessment criteria to establish statistically 
significant trends. Where studies were considered too heterogeneous for meta-
analysis data was described narratively.  Finally no evidence of publication bias 
was found in our review. 
Limitations of our review include the small number of papers available for inclusion 
in the review, particularly about the association between gout and cerebrovascular 
and peripheral vascular disease (cardiovascular n=14; cerebrovascular n=2; 
peripheral vascular disease n=1).  Despite a thorough and comprehensive search 
strategy the possibility remains that some relevant articles may not have been 
identified.  Similarly, studies with negative findings are less likely to be published, 
and publication bias may be introduced, and this was difficult to assess for the 
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majority of the outcomes due to the small number of papers identified.   The 
paucity of evidence investigating the association between cerebrovascular and 
peripheral vascular disease in particular limits the reliability with which this review 
can conclude that an association with gout is indeed present, although it may be 
that some publications reporting investigation of this relationship were excluded 
since it was not possible to translate them into English language. 
There was some degree of heterogeneity in the definitions of gout used in the 
studies, from self-report to those including medical record review.  Clearly the 
reliability of case definition of gout will affect the magnitude of the association, and 
thus had more stringent definitions been used throughout then a different pattern 
of association may have been seen.  Similarly, the potential confounders adjusted 
for in the multivariate analyses also differed between studies.  If some studies fail 
to adjust for important cofounders and therefore report a spurious association this 
will be reflected in the review.  Despite the size of many of the studies, serum 
urate levels and disease severity were not included in many of the studies which 
may have influenced the associations observed.  As previously discussed, 
misclassification (ascertainment) bias must be considered in both the recording of 
gout and the vascular outcomes of interest, and competing risks could not be 
accounted for in the estimation of association with mortality from vascular causes.   
3.13 Summary 
This review finds that gout is an independent risk factor for mortality from all 
cardiovascular disease and coronary heart disease but not myocardial infarction, 
and is an independent risk factor for incidence of myocardial infarction but not all 
cardiovascular disease or coronary heart disease.  It was noted that incidence of 
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cardiovascular disease was neglected as an outcome in current literature in 
comparison with mortality. 
The literature is inadequate to determine whether any association exists between 
gout and cerebrovascular or peripheral vascular disease, and incidence of 
cardiovascular disease and further research on these particular relationships is 
required. 
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Chapter 4: Retrospective Cohort Study Methodology 
4.1 Overview 
This chapter will describe the choice of methodology used to investigate the 
association between gout and vascular disease, including study design, study 
population, potential sources of bias and statistical analysis.   
4.2 Background   
The evidence reviewed in chapters two and three has identified gaps in the 
existing literature examining the relationship between gout and vascular disease, 
particularly the relationship between gout and the incidence of all types of vascular 
disease (cardiovascular, peripheral vascular and cerebrovascular).  Appropriate 
examination of these potential associations will require a study design which will 
allow the determination of the incidence of vascular diseases in patients with and 
without exposure to gout, taking into account other potential confounding 
exposures (e.g. smoking or hypertension) which may also influence the risk of 
vascular disease.  Two study designs lend themselves to an investigation of this 
kind.  These are the cohort study design and the case-control study design.   
4.3 Choice of study design 
A cohort study design was chosen as the primary aim of the study was to 
investigate the association between gout and incident vascular disease in a 
primary care population, taking account of other vascular risk factors, in order to 
better inform clinicians and patients in managing both their gout and its 
comorbidity.  A cohort study design compares groups of people, based upon an 
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exposure or disease of interest (e.g. gout), and follows them to determine whether 
that exposure makes that group more or less likely to develop an outcome of 
interest (e.g. first vascular event).  Several of the studies identified in chapter 3 
have utilised this design to investigate associations between gout and vascular 
disease, including the Framingham Study, (Abbott et al, 1988) the Multiple Risk 
Factor Intervention (MR-FIT) Study, (Krishnan et al, 2008) and the Health 
Professionals Follow-up Study.  (Choi & Curhan, 2007) Cohort studies can be 
described as either prospective or retrospective, and the relative merits of each of 
these will be discussed below. 
4.3.1 Prospective Cohort Studies 
Prospective cohort studies are conceived, designed and patients enrolled prior to 
them having developed the outcome of interest.  A pictoral representation of the 
prospective cohort study design is shown in Figure 4.1. 
Figure 4.1: Pictoral representation of the prospective cohort study design 
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4.3.2 Retrospective Cohort Studies 
Retrospective studies are conceived and designed after some of the outcomes of 
interest have already developed.  For this reason, the data used has usually been 
collected for another purpose, for example, primary care healthcare records, or 
death registries.   
The retrospective cohort study design is represented in Figure 4.2 below 
 
Figure 4.2: Pictoral representation of the retrospective cohort study design 
 
 
 
 
 
 
 
The retrospective cohort study is often confused with the case-control study since 
both use patients in whom outcomes of interest may already have developed, 
however they can be distinguished by the way in which “cases” and “controls” are 
matched.  Figure 4.3 gives a pictoral representation of the case-control study 
design.   
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Figure 4.3:  Pictoral representation of the case-control study design  
 
 
 
 
 
 
 
 
Figures 4.2 and 4.3 illustrate the differences between the retrospective cohort 
study design and the case-control design.  The retrospective cohort study, despite 
the data and outcomes already having been recorded, investigates associations 
between exposures and outcomes by matching cases and controls on their 
exposure status (gout or no-gout).   In a case-control study, participants are 
matched on whether or not they have the outcome of interest (vascular disease) 
and their records then examined for evidence of exposures of interest (gout).   
4.3.3 Relative advantages and disadvantages 
The advantages and disadvantages are shown for comparison on Table 4.1 
below.
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Table 4.1 Advantages and disadvantages of cohort and case-control study designs 
 
 Prospective cohort study Retrospective cohort study Case-control study 
Advantages  Can be designed to answer 
specific questions  
 Can collect data at pre-
determined points in time   
 Can validate exposures and 
diseases in real time  
 Loss to follow up can be 
minimised since participants can 
be contacted 
 Less time consuming 
 Less expensive 
 Can utilise pre-existing sources of 
data e.g. electronic medical 
records 
 Can be used to examine rare 
exposures 
 Can examine multiple outcomes 
for a particular exposure 
 Quicker 
 Cheaper 
 No loss to follow-up 
 Can utilise existing records, e.g. 
electronic medical records 
 Can be used to examine rare 
outcomes 
 Multiple risk factors can be 
investigated simultaneously  
Disadvantages  Often long follow-up required 
 Expensive 
 Labour intensive 
 Data cannot be pre-specified as 
usually collected for alternative 
purpose 
 May be incomplete data on 
variables of interest, introducing 
information or recall bias 
 Loss to follow up cannot be 
influenced 
 Risk of recall bias since patients 
who have the condition of interest 
more clearly recall particular 
exposures than those who do not   
 Accuracy of diagnoses or 
exposures cannot be validated 
since data is pre-recorded   
 Not suitable for investigation of 
rates of disease in exposed and 
unexposed individuals  
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4.3.4 Advantages specific to the association of interest 
The main advantage of using a cohort study design to investigate the association 
between gout and vascular disease is the ability to calculate rates of vascular 
disease in exposed (patients with gout) compared to unexposed (patients without 
gout) patients over time.  This would generate a measure of risk that is both 
clinically meaningful, and easy for patients to understand and discuss when 
making health choices, since it is easy for patients to understand the risk of an 
outcome (e.g. vascular disease) in an exposed group (e.g. patients with gout) 
compared to the risk in an unexposed group, for example that a hazard ratio of 1.2 
suggests that those with gout have a 20% greater chance of developing vascular 
disease than those without gout given similar risk factors and follow-up time.   
This study design can also investigate multiple risk factors associated with an 
outcome, and thus other traditional vascular risk factors such as hypertension and 
smoking can also be considered.   
The cohort design would also allow the choice of either a prospective design, or a 
retrospective design using existing records, such as a database of primary care 
electronic health records (EHR). 
A retrospective study design was chosen for this investigation because 
considerable follow-up time may be required to detect incident vascular disease, 
making a prospective study potentially very lengthy and costly.  Further 
investigating this relationship in a primary care population could be achieved using 
large existing databases of EHR, which routinely collect data on the majority of 
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vascular risk factors of interest and lend themselves to the retrospective cohort 
design.   
4.4 Study population 
Having chosen the retrospective study design, this section will describe the 
selection of the study population.    
4.4.1 Use of electronic medical records for research 
The use of data from routinely collected from EHR has been found to be a cost-
effective way to undertake epidemiological studies of large patient populations.  
(Jordan et al, 2006) Furthermore, in excess of 98% of the UK population are 
registered with a GP, (Agarwal & Crooks, 2008) making the use of electronic EHR 
a convenient way to sample the general population.  Important insights into the 
epidemiology of diseases presenting in primary care can be gained, as well as 
information about consultation behaviour of patients, and management of 
conditions offered by GPs.   
All consultations and healthcare transactions are recorded within this record, from 
a diagnostic Read code labelling each encounter with the main reason for 
consultation, to results of investigations, prescription and referral data.  
Furthermore, in addition to the consultations initiated by the patient, additional data 
is collected routinely through primary care, such as blood pressure readings, 
weight monitoring, smoking status and levels of alcohol consumption, often on an 
annual basis, making some of the information which may have been collected in a 
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prospective cohort study available to those using EHR to undertake retrospective 
studies.   
Comparable data from secondary care in the UK is less accessible as paper 
based records are largely used in hospital settings, rather than electronic ones.  
This is in contrast to the USA, where the privatised nature of their healthcare 
system allows for the interrogation of databases of administrative claims for 
episodes of care which can be used to obtain similar data.   
In the UK, there are three predominant databases used for epidemiological 
research using primary care data.  These are the Clinical Practice Research 
Datalink (CPRD) (formerly known as the General Practice Research Database 
(GPRD)), The Health Improvement Network (THIN), and QResearch.  QResearch 
has not been used to investigate the epidemiology of gout, however both CPRD 
and THIN have been used for both case-control and cohort studies on these 
subjects.  The existing studies are shown in table 4.2 below.  
 
 
 
 
 
 
 
 
 
 
Table 4.2 Existing cohort studies relating to gout in primary care databases 
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Author Year of 
Publication 
Number of 
Participants 
Subject 
CPRD 
(Mikuls et al, 
2005a) 
2005 63,105 Suboptimal physician 
adherence to quality 
indicators for the 
management of gout and 
asymptomatic 
hyperuricaemia 
(Mikuls et al, 
2005b)  
2005 1,716,276 Gout epidemiology 
(Kuo et al, 2014) 2014 4,634,974 Trends in the epidemiology 
of gout and patterns of use 
of ULT 
THIN 
(Soriano et al, 
2011) 
2011 1,775,505 Epidemiology of gout in the 
UK 
(Rothenbacher et 
al, 2011) 
2011 23,857 Frequency and risk factors of 
gout flares in a large 
population-based cohort of 
incident gout 
CPRD=clinical practice research datalink; THIN=the health improvement network; 
UK=United Kingdom; ULT=urate lowering therapy 
4.4.2 Matching  
In any study comparing groups, similarities and differences between groups must 
be considered.  Matching aims to ensure selection of a comparator group that is 
similar to another group with respect to the distribution of one or more confounding 
factors, and is one way reduce the risk of spurious findings resulting from these 
differences.  (Bland & Altman, 1994)  
In a cohort study such as this, matching is done based upon exposure status (gout 
vs non-gout), to ensure that within the study sample, exposed and unexposed 
patient cohorts are similar in ways which may affect the direction or magnitude of 
any association found.  For example, if samples were not similarly distributed 
across age ranges, then as vascular disease becomes more likely with increasing 
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age, any association identified may simply reflect one cohort being older than the 
other, and not excess risk due to gout.   
Matched sampling leads to a balanced number of exposed and unexposed 
subjects across the selected matching variables. This balance can reduce the 
variance in the parameters of interest, which improves statistical efficiency.  Using 
age as an example again,  when comparing groups by age band, unmatched 
cohorts may result in a Type II error, since an effect may not be detected if the 
number of cases or controls in each age group are too small, rather than because 
there is in fact no association. Matching ensures that there is at least one or more 
matched controls present in the same age band as the case, removing the 
resulting risk of spurious acceptance of the null-hypothesis. This may also 
increase the efficiency of a study, and control for factors not easily measured, by 
optimising the amount of information gathered from each subject rather than 
increasing the number of subjects.  (Rothman & Greenland, 1998)  
There are disadvantages to matching.  Firstly, matching on causal variables may 
introduce selection bias, which is a bias resulting from a systematic difference 
between groups being compared due to non-random or flawed selection of 
participants.  (Rothman & Greenland, 1998) Secondly, the contribution of the 
matching variable to the association of interest cannot be examined because 
matching creates a sample of controls that is not representative of the population 
as a whole, since the frequency of exposure in the control sample will be shifted 
towards that of the cases. (Rothman & Greenland, 1998)   
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4.4.2.1 Choice of matching criteria 
In this study cases and controls were matched on the basis of age, gender and 
registered general practice.  These criteria for matching were chosen since both 
gout and vascular disease become more common with age, have different gender 
biases, and may be influenced by socio-economic factors. Furthermore, although 
these factors are likely to influence the occurrence of vascular disease in patients 
with gout, they are not causal, and therefore matching on these factors removes 
their ability to influence any association detected. 
4.4.2.2 Matching technique 
Having chosen the criteria on which participants will be matched, the technique by 
which participants will be matched must be chosen.  Matching can either be 
performed subject-by-subject (individual matching) or for groups of participants 
(frequency matching).   
Individual matching allows each participant to be matched exactly based upon 
either continuous variables, such as exact age, or categorical variables such as 
age bands.  Whilst this may appear preferable, individual matching may reduce 
the population of the study since cases cannot be included if there are no suitable 
controls available.  Each exposed case is matched to a set number of unexposed 
controls, or the number of controls can be allowed to vary between cases.  In an 
ideal situation, the statistical power of the study is increased by increasing the 
number of controls per case up to four controls per case, but beyond this the 
additional gain is small. (Miettinen, 1969)  
      
156 
         
   
Frequency matching involves matching an entire stratum of control subjects with 
an entire stratum of cases based on the matching factors.  For example, if cases 
and controls are to be matched by age and gender then the case group might be 
divided into four groups; women <45 years old, women ≥45 years old, men <45 
years old and men ≥45 years old.  The proportion of cases in each of these groups 
could then be determined and a similar proportion of controls sampled from each 
strata. (Szklo & Nieto, 2014) Since the cohorts of cases and their controls are only 
required to have a similar distribution of strata defined by matching factors across 
the whole group e.g. similar proportion of males and females, rather than the 
individual characteristics of each case being required to exactly match those of 
their controls, exclusion of participants at the matching stage is minimised.   
Using either technique for matching, residual confounding cannot be eliminated, 
with risk particularly high where the matching variable is a confounder, 
necessitating careful thought when choosing matching criteria.   
In this study, frequency matching would increase inclusion of cases and controls, 
as the matching criteria chosen (year of birth, gender and registered general 
practice) must all be met exactly.  Matching by registered general practice (each of 
which has a geographically defined region within which patients must reside in 
order to register with that practice) is likely to be the most limiting factor, reducing 
the pool from which each control can be chosen to the size of the registered 
patient list of the general practice at which the case is patient.  Matching 
individually would require there to be four or more patients on that practice list of 
the same gender, and having been born in the same year, who did not have gout.  
Matching by registered general practice is intended to minimise the impact of the 
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socio-demographic factors on the association of interest, however there can be 
considerable differences within one practice area.   In the case of individual 
matching this may simply mean that an extremely restrictive matching criteria has 
been applied with little benefit, however where these differences are magnified 
across strata during frequency matching, even this crude measure of socio-
demographics may become unreliable. 
Since no additional socio-demographic information was available on the individual 
participants, matching by registered general practice was the only method 
available of accounting for socio-demographic status.  Thus, to avoid the 
magnification of intra-practice boundary differences in socio-economic 
characteristics, individual matching by age (year of birth), gender and registered 
general practice at a ratio of four participants without gout, to each participant with 
gout, was selected as the method for this study. 
4.5 Sources of error in cohort studies 
There are two major sources of error that a cohort study may be susceptible to; 
random error and systematic error (also known as bias).  Both may contribute to 
erroneous findings and will be discussed below. 
4.5.1 Random Error 
Random error results in imprecise study findings resulting from variation within the 
study population due to chance alone.   There are a number of sources of random 
error which include random variation in the sampling of study subjects, genuine 
unexplained biological variation in occurrence measures between subjects, and 
mismeasurement of study variables.  These chance deviations may result in less 
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precise results and therefore reduce the power of the study to detect a true 
association, causing the null hypothesis to be falsely rejected (Type I error) or 
accepted (Type II error).  
Since random error affects precision by contributing to variance of measurements 
or estimates, measures to reduce the effect of random error must mitigate against 
this variance.  Since variance can be reduced by increasing the size of the study, 
sample size must be adequate and take into account the required level of 
statistical significance of the expected result, the acceptable chance of missing the 
real effect, the magnitude of the effect under investigation, the amount of disease 
in the population and the relative sizes of the groups being compared in order to 
achieve the desired precision of the study.   
4.5.2  Bias 
Bias has been defined as “deviation of results or inferences from the truth, or 
processes leading to such deviation.  Any trend in the collection, analysis, 
interpretation, publication, or review of the data that can lead to conclusions that 
are systematically different from the truth.” (Last, 2001)  
There are many forms of bias that a cohort study may be susceptible to, but all 
represent a systematic error leading to a consistent over or underestimation of 
results.  Random error may also contribute to erroneous results, but these errors 
are caused by factors that may vary from one error to the next, and may be due to 
chance, rather than a deficiency in the study design or conduct itself.  Random 
error may produce less precise results and therefore reduce the power of the 
study to detect a true association, but it does not produce a consistent systematic 
inaccuracy in the results. 
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Many forms of bias have been described.  The major classifications relevant to the 
investigation of this association are selection bias and information bias.   
4.5.2.1 Selection Bias 
Selection bias is defined as error due to systematic differences in characteristics 
between those who take part in the study and those who do not. (Last, 2001)  In 
this study which uses EHR, only those who consult with gout are eligible for 
inclusion as cases.  At the milder end of the disease spectrum, there may be 
patients who do not consult their GP with their symptoms, or manage their gouty 
symptoms with over-the-counter medications; therefore presence of those 
symptoms would not be recorded in the EHR, resulting in these patients not being 
eligible for inclusion.   Furthermore, since the definitive diagnosis of gout requires 
aspiration and examination of synovial fluid to determine the presence of MSU 
crystals, (Zhang et al, 2006b) a procedure not readily accessible to general 
practitioners who make the diagnosis on clinical grounds, there is the possibility of 
diagnostic inaccuracy and therefore ascertainment bias. Ascertainment bias is a 
bias which results in unequal representation of different classes of cases or 
participants within a sample.  It can be caused by selection of participants from 
specialised populations, such as secondary care gout clinics, or by the diagnostic 
techniques used to identify the condition.  Thus it may be that patients who 
present with the most severe or typical symptoms rendering diagnosis of gout 
obvious are over-represented, whilst those who present with atypical or rarer 
symptoms of the condition are under-represented since the clinical diagnosis is 
more difficult.  Whilst clinical diagnosis of gout in primary care has been shown to 
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be reliable, (Roddy et al, 2007; Roddy et al, 2010) the possibility of ascertainment 
bias cannot be excluded. 
The technique used to retrieve data from EHR within large databases can also 
predispose to selection bias, since identification of diagnoses relies upon the use 
of a library of codes which correspond to those diagnoses.  Correct identification of 
these codes in searching for patients with gout is crucial in ensuring that all 
potentially eligible patients are identified, for example if a commonly used code for 
gout is omitted from the list of codes used to identify gouty patients then there may 
be a large proportion of patients with gout who are eligible for inclusion in the 
study but are not identified as such.  Similarly, such an omission may result in 
participants appearing eligible for inclusion in the non-gout group, when in fact 
they do have gout that has been recorded using a code omitted from the list.  This 
also extends to the identification of co-morbidities since, for reasons discussed in 
Chapter 5, all participants were required to be free of vascular disease at entry into 
the study. If the codes used to identify these vascular diseases within the patients 
electronic medical record were incorrect, this could result in the inclusion of 
patients with prior vascular disease that has not been identified, potentially 
increasing any association detected, or the exclusion of patients without a history 
of vascular disease who should have been eligible for inclusion rendering the 
sample unrepresentative. 
4.5.2.2 Information bias 
Information bias is defined as “a flaw in measuring the exposure or outcome data 
that results in different quality (accuracy) of information between comparison 
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groups”. (Last, 2001)  The form of information bias most relevant to this study is 
misclassification bias.   
Misclassification bias is a systematic error whereby participants are attributed a 
value or category other than that to which they should have been assigned, (Last, 
2001) for example if inaccurate codes are used to identify incident vascular 
events, participants may be identified to have the outcome of interest when in fact 
they do not, perhaps leading to the detection of a spurious association.  Similarly, 
the use of EHR relies on the accurate coding of events by clinicians.  If coding is 
inaccurate, inconsistent, or too vague using symptom-based rather than diagnostic 
codes (e.g. coding onset of angina as “chest pain”, for which there are multiple 
non-vascular causes) then events of interest may not be identified and thus the 
magnitude of an association systematically underestimated. 
4.5.2.3 Techniques used to minimise bias 
Although bias can never be completely eliminated in any study, it must be 
considered in the study design with the aim of minimising the impact on the study 
findings.   
As described above, accurate identification of cases for inclusion as gout 
participants, those participants with prior history of vascular disease, and 
participants who experienced the vascular outcomes of interest was of the utmost 
importance to the accuracy and generalisability of the study findings.  For this 
reason it was initially hoped to use previously validated lists of codes to identify 
gout and vascular disease within the CPRD, however these were not available.  A 
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rigorous process of identifying diagnostic codes for gout, vascular disease, and all 
of the potentially explanatory covariates of interest was undertaken.   
Our lists of codes for outcomes were created in a systematic way, based upon the 
Read coding system which underpins all EHR database coding in the UK.  Read 
codes are divided into chapters relating to the relevant organ systems, and codes 
are hierarchical in their specificity.  All relevant chapters of Read codes were 
collected and each code individually considered for inclusion by Dr Lorna Clarson 
(GP), Dr Samantha Hider (PhD lead supervisor, Senior Clinical Lecturer in 
Rheumatology and Honorary Consultant Rheumatologist) and Professor Christian 
Mallen (PhD co-supervisor, Professor of General Practice Research and GP).  
Consensus was then reached on final codes to be included and records 
individually checked by Dr Lorna Clarson to ensure that in those where an event 
was identified it was the incident event, and other codes had not previously been 
used that were not on the list.  Records for 50 of those patients in whom an event 
was not identified were also checked by Dr Lorna Clarson to ensure that no 
vascular events of interest had been recorded using codes not in the list and 
therefore missed. This exercise was repeated for each type of vascular event until 
all were satisfied that the lists were complete.    
Although a formal chart validation study would have been helpful, this was not 
possible due to the nature of the primary care data, and had already been 
performed to evaluate validity of coding of cardiovascular outcomes in CPRD, 
reporting a positive predictive value of diagnosis of MI coded in CPRD of over 
80%, and comparable reliability of coding for ischaemic heart disease to other 
primary care databases. (Khan et al, 2010a) The data did not contain data from 
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secondary care records in order to verify that the Read code corresponded to a 
correct diagnosis made in hospital. 
4.6 Analysis of Cohort Studies 
In cohort studies participants exposed to specific risk factors (e.g. gout) are 
compared to those who are unexposed.  The aim of the analysis undertaken must 
therefore be to best estimate risk of the outcome (dependent variable) based upon 
a set of exposures (independent or explanatory variables), in a clinically 
interpretable model.  (Hosmer et al, 2013)  
Regression techniques are used to fit a model predicting the outcome as a 
function of the explanatory variables.  This regression can take many forms; linear 
where the outcome variable is assumed to be continuous, logistic regression 
where the outcome variable is binary, Poisson regression where the outcome 
variable is a count (e.g. number of events) and proportional hazards regression 
where time to event is the outcome of interest.  Since in this study the outcome of 
interest is risk of vascular event, including the time to event, the most appropriate 
technique to use is survival analysis using Cox proportional hazards regression.   
4.6.1 Proportional Hazards Regression 
Proportional hazards regression is a technique used when the outcome of interest 
is time to a particular event of interest, calling this “survival time”, and thus this 
type of analysis is often referred to as survival analysis.  Survival time may 
describe time until death, although use of the technique has been extended to 
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include other outcomes such as healthy time survived from diagnosis of a 
condition until incidence of a particular event, e.g. complication or exacerbation. 
This study aims to estimate the excess risk of vascular disease in patients with 
gout, compared to those without gout.  This risk can be calculated either with or 
without taking into account the time that individuals remain in the study.  For this 
study (detecting incident vascular events) it was decided that not only was the 
number of events of importance, but that time to vascular event from diagnosis of 
gout (or equivalent “index date” for controls) was also a relevant outcome 
measure.    
Survival analysis is a specific approach which allows study participants who do not 
experience the event of interest, or are lost to follow up during the study, perhaps 
by transferring out of the area, to be taken account of in the analysis.   
Furthermore, survival data are rarely normally distributed and so simple analysis 
such as taking the mean of survival time is not appropriate.      
In analysing survival data, two functions that are dependent on time are of 
particular interest: the survival function and the hazard function.  The survival 
function S(t) is defined as the probability of surviving to at least time t.  The hazard 
function h(t) is the conditional probability of dying at time t having survived to that 
time.   
Patients are classified at each time point as: 
 having experienced the event of interest 
 being at risk of the event   
 censored (e.g. having died or lost to follow up)   
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This model uses the assumption that the prognosis for censored and surviving 
patients is the same, and that events happen contemporaneously with their 
recording. 
The graph of S(t) against t is called the survival curve.  The Kaplan-Meier method 
can be used to estimate this curve from the observed survival times without the 
assumption of an underlying probability distribution.  This method is based on the 
basic idea that the probability of surviving k or more periods from entering the 
study is a product of the k observed survival rates for each period (i.e. the 
cumulative proportion surviving).  (Kaplan & Meier, 1958) The limitation of the 
Kaplan-Meier method is that it is limited to univariate analysis and cannot take 
account of multiple contributory factors or confounding influences. 
The Cox Proportional Hazards (CPH) model can be used to model response in the 
event hazard function to potential explanatory covariates, and assess the influence 
of that particular variable on the likelihood of developing an incident event over 
time.  (Cox, 1972)  The CPH model estimates the baseline hazard 
nonparametrically, meaning that no inappropriate statistical distribution (e.g. 
normal distribution) is attributed to survival data, and several key assumptions 
underpin this model.   
 There is a baseline hazard function which is constant and common to all the 
subjects in all of the groups for comparison.  Each group has a hazard 
function that is a positive multiple of this baseline hazard and covariates act 
only on this group-specific hazard function and not the baseline hazard.   
 The assumption of proportional hazards whereby, although there is no 
assumption made about the probability distribution of the hazard, it is 
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assumed that if the risk for dying at a particular point in time in one group is, 
for example, twice that in the other group, then it will also be twice that of 
the other group at any other time point, i.e. the hazard ratio does not 
depend on time. 
 Censoring is non-informative, meaning that censoring is independent of the 
outcome of interest and, for example, if the outcome of interest is mortality, 
patients are not removed from the study just prior to death.   
 
4.6.2.1 Assumption of proportional hazards 
Schoenfeld residuals were first proposed in 1982, and are used to assess 
goodness-of fit of the proportional hazards regression model. (Schoenfeld, 1982) 
Rather than a single residual for each individual, there is a separate residual for 
each individual for each covariate, and these residuals are independent of time.  
Thus regressing residuals against time should show a random pattern, confirming 
this independence from time, and thus satisfaction of the proportional hazards 
assumption. 
Where the assumption of proportional hazards is not satisfied it suggests that in 
that particular statistical model the hazard ratio changes over time and this 
technique allows assessment of which of the covariates within the model may vary 
over time resulting in the overall change in difference in risk between groups.  
These covariates can then be re-entered as time-varying covariates in order that 
the model as a whole can satisfy the assumption of proportionality. 
 
      
167 
         
   
4.6.2  Multilevel Discrete-time Event History Analysis 
An alternative way to analyse data where covariates are likely to vary with time is 
to analyse the data using time windows of a specified length and to record a value 
of the covariate in each time window.   Whereas using the CPH regression model 
time is essentially treated as a continuous variable, Multilevel Discrete-time Event 
History Analysis (MDtEHA) is a form of regression allowing follow-up time to be 
divided into discrete intervals (e.g. years following diagnosis of gout) until the 
occurrence of an event of interest, or the patient is censored.  Each time interval 
contains a binary indicator of whether an event of interest has occurred during that 
window of time.  This method of analysis allows a discrete time hazard function to 
be generated for each time window, that is, the probability of having an event 
during that interval, given no previous occurrence.  (Allison, 1984)  
Having these individual windows of follow up also allows a more realistic 
examination of the effect of covariates of interest, since these can be allowed to 
vary in each discrete time window, and change in these covariates throughout the 
follow-up can be used to estimate the contemporaneous association between the 
change in that covariate and probability of experiencing the outcome of interest.  
Thus if a patient is to develop a new risk factor or incident comorbidity 
predisposing to the event of interest, or receive a new prescription for a medication 
potentially protecting against the event of interest, then the effect of this new 
covariate within that time window can be taken into account in the overall estimate 
of risk.  
The resulting odds ratio reflects the risk of experiencing an event of interest 
associated with each individual covariate across all participants, and are 
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interpreted in the usual way regarding continuous or categorical predictors.  This 
form of analysis therefore also differs from CPH regression in that it estimates the 
odds ratio of occurrence of the event of interest associated with each particular 
covariate, across all participants, as opposed to a hazard ratio. 
Advantages of MDtEHA include: 
 Assumption of proportional hazards does not need to be satisfied  
 Can take account of covariates which change during follow-up 
Disadvantages of MDtEHA include: 
 Manipulation of data is required in order to be able to fit such models   
- Each patient must have at least a binary indicator of 
presence/absence of the event of interest for each discrete interval 
of time until they either experience the event of interest or are 
censored.   
- This requires manipulation of a dataset from the format in which 
continuous-time survival analysis is applied, from one row of data per 
participant, to a row of data for each time window for each patient 
until the event of interest occurs or they are censored    
- If there are many covariates of interest, or multiple short time 
windows a large dataset can result, resulting in slow, difficult 
computation of the data 
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4.6.3 Important differences between CPH regression and MDtEHA 
There are several important differences between CPH regression and MDtEHA.  
Understanding these differences is key to understanding the estimates of risk 
produced using the two different techniques, and the reasons behind the 
application of both.  The most important of these differences are listed below: 
 
1. CPH regression estimates the difference in risk between two groups (e.g. 
exposed to gout compared with unexposed), whereas MDtEHA does not 
compare groups but rather estimates the probability of any participant 
(exposed or unexposed) experiencing an event of interest associated with 
each covariate in the model. Thus proportional hazards regression 
estimates hazard ratios whilst MDtEHA estimates odds ratios  
2. Covariates in a CPH regression are measured at baseline (the diagnosis of 
the condition of interest, or matched date for controls), whereas MDtEHA 
allows use of the data on covariates in post-baseline follow-up to be used to 
estimate overall risk, therefore accommodating changes in co-morbidities, 
prescriptions or lifestyle choices (e.g. giving up smoking). 
3. Presence of covariates recorded at baseline is presumed to be a constant 
contribution to risk of event of interest using CPH regression, in contrast to 
MDtEHA where covariates can only contribute to the overall estimate of risk 
in time windows where a value is recorded. 
4. Cox regression depends on the proportional hazards assumption being 
satisfied. There are discrete time models that do not invoke the 
proportionality assumption, but we can still ask whether a predictor’s effect 
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is constant or if it varies over time.For a binary time varying covariate such 
as statin use, the  regression estimate contrasts the population logit hazard 
for people who have taken statins with those who have not.  
4.7 Summary 
This chapter has discussed the choice of a retrospective cohort study design 
utilising pre-existing data from a large database of primary care EHR to examine 
the association between gout and vascular disease.  It has also identified selection 
and information bias as important considerations in the study methods, and 
describes the techniques of Cox Proportional Hazards Regression and Multilevel 
Discrete Time Event History Analysis which will be used in the analysis of the 
data.
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Chapter 5:  Study Methods 
5.1 Overview 
Chapter 4 introduced the retrospective cohort study, its advantages and 
disadvantages, and previous uses in this context.  This chapter will discuss the 
application of this methodology to the investigation of the association between 
gout and vascular disease.  The final study design, study population and its 
source, data handling and statistical analysis are described in detail. 
5.2 Overview of study design 
This study uses a retrospective cohort design, comparing the risk of developing 
vascular disease between a cohort of gout cases and a cohort of age, sex and 
practice matched controls.  Data from the UK Clinical Practice Research Datalink 
(CPRD) were examined for 8386 patients diagnosed with gout between 1987 and 
1999, matched with 39,869 age-, gender and GP practice matched controls.  All 
had no previous history of vascular disease in order to investigate the relationship 
between gout and incident vascular disease.  This was important for two reasons, 
firstly that a prior vascular event itself can be considered a risk factor for a further 
event, and secondly that the ongoing routine monitoring associated a pre-existing 
diagnosis of vascular disease would introduce surveillance bias.   
Incident cardiovascular, cerebrovascular and peripheral vascular disease was 
identified in the following ten years from the baseline consultation for gout, or a 
matched “index date” equivalent to the date of the baseline consultation for 
controls.  Figure 5.1 shows a pictoral representation of the study. 
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Figure 5.1: A pictoral representation of the study 
 
 
 
 
 
 
 
 
5.3   Study population 
5.3.1  Clinical Practice Research Datalink  
The CPRD is the largest database of primary care EHR in the world, containing 
anonymised data for approximately 8% of the population of England and Wales 
(over 12 million patients, 5 million of whom are active patients. This data set was 
established in 1987 and was formally known as the General Practice Research 
Datalink (GPRD).  (Tate et al, 2014)  Currently over 650 general practices 
contribute nationally representative data. (www.cprd.com/intro.asp last accessed 
14/06/2014)  The high validity of diagnosis in the CPRD has been reported by two 
Diagnosis 
of gout 
Matched 
“index 
date” 
Age 
>50 
Measured covariates 
Pre-index presence of:  
Hypertension 
Hyperlipidaemia 
Chronic Kidney Disease 
Charlson co-morbidity 
score 
Smoking exposure 
Alcohol exposure 
BMI >25 
 
First 
vascular 
event e.g. 
stroke 
Death, transfer 
away from 
practice, last 
collection of data 
from practice, 10 
years from index 
date 
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systematic reviews, with correct diagnosis confirmed in a median of 89% of cases 
for 183 diseases. (Herrett et al, 2010; Khan et al, 2010a)  
A typical patient record might contain demographic information as well as 
information on each episode of care, including a diagnostic Read code describing 
the main reason for the contact, results of examinations and investigations, 
prescriptions and onward referrals.  Read codes are a coded thesaurus of clinical 
terms, used to record each contact in general practice records. Entries are 
numerically coded allowing for easier identification. 
5.3.2 Previous use of the CPRD 
Between 1995 and 2009, the CPRD has been used in over 700 published studies.  
Validity of CVD diagnoses in CPRD, or the extent to which diagnosis of CVD in 
CPRD is likely to represent an accurate diagnosis of CVD, or be similarly recorded 
in an alternative similar database, was assessed by a recent systematic review.  A 
positive predictive value of diagnosis of myocardial infarction and cerebrovascular 
disease coded in CPRD of over 90%, and comparable reliability of coding for 
ischaemic heart disease to other primary care databases such as the Doctors’ 
Independent Network (DIN), a separate UK primary care database which collects 
data from over 300 non-CPRD practices, was reported. (Herrett et al, 2013; Khan 
et al, 2010a)  
The CPRD has been used to study the risk of vascular disease associated with 
numerous conditions.  Table 5.1 summarises a selection of the most recent. 
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Table 5.1:  Summary of studies using the CPRD to examine relationships between vascular 
disease and other medical conditions 
 
Authors Year of Publication Association examined 
(Mehta et al, 2010) 2009 Psoriasis and cardiovascular mortality 
(García Rodríguez 
et al, 2010) 
2010 Chronic obstructive pulmonary 
disease, heart failure, myocardial 
infarction, lung cancer and death 
(Schneider et al, 
2010)  
2010 Chronic obstructive pulmonary disease 
and cardiovascular disease 
(Solaymani-
Dodaran et al, 
2008) 
2008 Primary biliary cirrhosis and 
cardiovascular and cerebrovascular 
events 
(Soedamah-Muthu 
et al, 2006) 
2006 Type 1 Diabetes and cardiovascular 
disease 
(Smeeth et al, 
2004) 
2004 Inflammatory states and myocardial 
infarction and stroke 
(Watson et al, 
2003) 
2003 All-cause mortality and vascular events 
among patients with rheumatoid 
arthritis, osteoarthritis, or no arthritis 
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5.3.3 Identification of Participants 
In order to search CPRD data, numerical codes must be identified relating to the 
condition of interest.  In this study these codes were identified using a browser 
supplied by the CPRD.  The browser could be searched with free text, or wildcard 
entries.  Wild card entries allowed entries to be identified that contained words of 
interest within them, for example, a wildcard entry for “vascular” would return 
entries for cardiovascular, cerebrovascular etc. 
Gout case identification 
The CPRD identified gout cases using codes returned by the CPRD browser and 
listed in appendix 2. Only patients aged over 50 at time of first diagnosis for gout 
were included to prevent the inclusion of patients with rare genetic causes of gout 
(e.g. Lesch Nyhan syndrome) that may further predispose them to vascular 
disease.  Lists of codes identifying vascular disease were used to identify and 
exclude any patients with a pre-index history of vascular disease (listed in 
Appendix 2).  The date of first ever consultation for gout was taken as the “index 
date”, and records examined for vascular outcomes of interest over the next 10 
years. 
Control (non-gout) identification  
Controls were matched by year of birth, gender and registered general practice, 
with an average minimum of 4:1 control to case ratio, this ratio having been 
selected for reasons stated in Chapter 4.4.2 previously.  Matching of five controls 
to one case was undertaken in order to maintain statistical power, despite the 
likelihood that some patients may need to be excluded for a variety of reasons, 
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such as evidence of pre-existing vascular disease or large amounts of missing 
data.  Lists of codes for gout, hyperuricaemia, and vascular disease were used to 
identify and exclude controls with any pre-index history of those conditions (see 
Appendix 2).  The control patients were assigned an index date equivalent to the 
date of first consultation for gout of the gout patient to which they were matched, 
records were then examined for outcomes of interest over the next 10 years. 
 
5.3.4 Matching procedure 
The process of matching control subjects with gout patients was undertaken by the 
CPRD using their standard procedure for matching, but using our specified 
matching criteria. The potential control subjects were stratified by primary care 
practice, year of birth and gender, and up to five control subjects were randomly 
selected from the appropriate stratum for each gout patient. 
 
5.4 Known vascular disease risk factors 
Vascular disease has many contributory factors, including medical conditions such 
as diabetes and hypertension, and lifestyle factors such as smoking and alcohol 
consumption.   
Vascular risk factors of interest were chosen a priori by discussion between GPs 
and rheumatologists on the basis of being considered clinically relevant and 
measurable, and representative of traditional risk factors for vascular diseases 
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described in the literature.  They included gender, presence of hypertension, 
hyperlipidaemia and chronic kidney disease, and measures of age, body mass 
index (BMI), ever/never exposure to smoking/alcohol, and ever/never exposure to 
prescribed statins or aspirin at baseline (date of diagnosis of gout or matched 
index date for controls).  Use of anti-hypertensive medication was not used as an 
indication of history of hypertension since many anti-hypertensives are also used 
for alternative clinical indications, for example both beta-blockers and calcium 
channel blockers can also be used for cardiac arrhythmias and prophylaxis of 
chronic headaches.   
Charlson Co-morbidity Index at baseline was also calculated using a technique 
described by Khan et al. (Charlson et al, 1987; Khan et al, 2010b) The Charlson 
co-morbidity index is a weighted index taking account of the number and 
seriousness of co-morbid conditions to predict one year mortality.  (Charlson et al, 
1987) The presence of relevant conditions was identified by searching pre-index 
patient records using lists of codes (listed in Appendix 2). A list of CPRD codes 
which allowed identification of relevant conditions and their weights within the EHR 
had been previously prepared by Kahn et al, 2010, (Khan et al, 2010b) the weights 
of these conditions were then added together to create an overall co-morbidity 
score for each participant, and this was entered as a continuous variable.  Lifestyle 
factors were recorded in a separate coded file and this was searched for relevant 
information on smoking, alcohol consumption and BMI.   
The matching variables were also entered into the analysis as explanatory 
covariates, in order to remove variability due to the matching variable and ensure 
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a more accurate estimation of the strength of the association. (Bland & Altman, 
1994)  
Data was recorded on smoking status for 70% of participants, alcohol 
consumption for 80%, and BMI for 76% of all participants.  In order to minimise the 
effect that the missing data would have on the size of the dataset available for 
analysis, these variables were categorised into ever/never exposure to smoking 
and alcohol, and overweight yes/no (BMI >25) with a “missing” category for each.  
The decision was made not to undertake imputation, a technique by which missing 
data is replaced to avoid deletion of cases which have missing values.  This 
deletion reduces the power of the study, and imputation can be considered if the 
data is missing at random.  However, since a database of primary care EHR is 
being used as the data source, and the data held within these records is collected 
by healthcare professionals, it is entirely possible that missing data is not missing 
at random but in fact there are underlying reasons why it has not been collected, 
for example, lack of BMI recording in those who are obese due to difficulty in 
broaching this issue with the patient. In this case imputation would introduce bias 
and was therefore not used. (Taylor et al, 2013) 
Physical activity and family history of cardiovascular disease were not included in 
the model despite being recognised vascular risk factors, since these 
characteristics were only recorded for the minority of patients. Level of physical 
activity was recorded in 41.8% and family history of cardiovascular disease in 
12.3%. 
Further discussion of how these potential explanatory variables were entered into 
the statistical model can be found in section 5.6.4. 
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5.5 Vascular outcomes of interest 
Vascular events of interest were identified by searching post-index records using 
lists of codes designed to identify particular outcomes (see Appendix 2).  The 
outcomes of interest are shown in table 5.2 below 
Table 5.2: Outcomes of interest 
 
Cardiovascular Disease Cerebrovascular disease Peripheral Vascular 
Disease 
All cardiovascular events 
(codes which indicated 
incident ischaemic 
cardiac events, but were 
not sufficiently specific to 
allocate to either angina 
or MI) 
All cerebrovascular 
events (codes which 
indicated incident 
cerebrovascular events, 
but were not sufficiently 
specific to allocate to 
either TIA or CVA) 
Any peripheral vascular 
disease 
Angina TIA  
Myocardial infarction CVA  
CVA = cerebrovascular accident; MI = myocardial infarction; TIA = transient 
ischaemic attack; 
 
The date of the first vascular event was recorded and time to event from baseline 
was calculated.  It was decided to use the first vascular event only, as having had 
one vascular event increases risk of subsequent events which may exaggerate 
risks attributable to gout.  
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5.6 Statistical methods 
This section describes the statistical analysis performed in the study. 
Data were analysed using SPSS Statistics version 20.0 (SPSS Inc, IBM Corp; 
2012 )  and Stata statistical software release 12 (StataCorp: College Station, TX, 
2011) 
5.6.1 Descriptive statistics 
Descriptive statistics were used to explore similarities and differences in gout and 
non-gout groups at baseline.  Age and gender distribution, and frequency and 
percentage of co-morbid conditions allowed validation against the wider gout 
population to establish the generalisability of the study results. 
5.6.2 Cox Proportional Hazards Modelling    
Proportional Hazards Regression as described in section 4.6.1, was used to thus 
estimate the risk of vascular disease in those exposed to gout, compared to those 
who were not, taking into account time in the study.   
5.6.3 Censored events 
The principles underlying survival analysis were developed to take account of 
subjects within populations who do not go on to develop the event of interest 
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during the follow up period, or who are lost to follow up, and consequently, for 
whom, survival times cannot be known.  This is termed “censoring”.   
Within this study, in the absence of a vascular event, patients were censored at 
the earliest of the following time points: 
- 10 years from their index consultation for gout 
- Transfer out of the practice contributing their records to the CPRD 
- Death (not due to a vascular cause) 
- Last collection of data from the practice contributing their records  
 
This constitutes “right censoring” and, in the case of those who reach 10 years 
post diagnosis of gout without a vascular event, assumes that events in these 
individuals (if they were to occur) were beyond the end of the study follow-up 
period.  In the event of death from a non-vascular cause, the individual is no 
longer at risk of a vascular event and their contribution to the study ends at the 
point at which they are censored.  In those participants who transfer out of the 
practice contributing their records to the CPRD, or whose last record is prior to 10 
years from their diagnosis of gout, survival time cannot be known and so they are 
censored at that point. Follow-up was censored to 10 years as fewer participants 
had records longer than this which would skew the estimate of risk. 
It was decided not to allow participants who had experienced cardiovascular 
events to remain “at risk” of cerebrovascular events where this was the outcome of 
interest, for the same reason that we excluded participants with a prior history of 
vascular disease, that is a prior vascular event predisposes to further vascular 
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events, and in the example above it would not be possible to ascertain that the risk 
estimated was that of truly incident cerebrovascular disease in gout. 
5.6.4 Explanatory Covariates 
There are many factors which contribute to the risk of developing vascular 
disease.  These can include medical conditions such as hypertension or 
hyperlipidaemia, or lifestyle factors such as smoking and alcohol consumption.  In 
order to establish the role that various factors play in the risk of developing 
vascular disease after a diagnosis of gout, two models were designed.   
Model 1 was designed to minimise surveillance bias (i.e. detection of vascular 
disease resulting from routine monitoring for another condition) and assess the 
risk of vascular disease in gout patients presenting to the GP for the first time, i.e. 
only introducing covariates into the model that might be known prior to further 
examination or investigation by the GP.  Potential confounders introduced in 
Model 1 included age at baseline, gender, categorical variables for ever/never 
exposure to smoking and alcohol, and yes/no for overweight (BMI >25), and 
continuous Charlson Co-morbidity Index score.  Model 2 was designed to assess 
risk of vascular disease taking into account all potential confounders.  Covariates 
introduced into Model 2 included all of those in Model 1, with the addition of 
presence at baseline of hypertension, renal disease and hyperlipidaemia, and 
dichotomised values for statin and aspirin consumption (categorised as ever/never 
prescribed).  Presence of diabetes was not included separately since this forms 
part of the Charlson score. 
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Potential explanatory covariates of interest had been identified a priori, and thus all 
were included into the statistical model to determine the adjusted effect of each 
risk factor on the outcome. If, after adjustment, gout as a risk factor maintains a 
statistically significant association with the outcome, it can be considered an 
independent risk factor for the vascular event in question. (Brotman et al, 2005)  
5.6.5  Assumption of proportional hazards 
Since proportional hazards regression requires the assumption of proportionality 
(that any increased or decreased risk found in one group compared with another 
remains proportionally similar over time), this assumption was tested for each 
covariate. 
The validity of the assumption of proportional hazards was assessed using 
Schoenfeld residuals and Stata’s own diagnostic test.  Where this assumption of 
proportionality was violated (suggesting the risk associated with potential 
explanatory covariates may vary over time) the relevant variables were re-
introduced into the model as time-varying covariates, thus allowing the 
proportional hazards assumption for the association between gout and the 
vascular outcome in that particular model, to be satisfied. (Bellera et al, 2010)  
Robust standard errors (also known as heteroskedasticity-consistent standard 
errors) were used to try to improve the precision of the estimate of risk since this 
study was of a matched design.   Where variance within a sample population is not 
equal (heteroskedasticity), standard errors are liable to be unduly influenced by 
outliers, and thus reduce precision of the estimate.  In matched studies, where 
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there may be clustering i.e. observations within groups of exposed gout patients 
and their unexposed matched controls may be correlated in some unknown way, it 
is likely that standard errors may not be independently and identically distributed.  
In this situation it is recommended that a robust estimator, such as the White-
Huber estimator, is used, since this technique is considered more resistant to the 
effect of outliers.  (Huber, 1972) 
5.7 Subgroup analysis and Interactions 
The risk of vascular events was investigated by gender subset (since both gout 
and vascular disease are more common in men), (Roddy & Doherty, 2010; 
Rossouw, 2002) and over different time periods following the diagnosis of gout, by 
limiting follow-up to 1 year, 2 years and 5 years post index date. Risk over different 
time periods was investigated to add clinical utility to the findings of the study, 
allowing trends or peaks in risk to be identified and thus identify optimum points at 
which screening for or management of vascular risk factors should be 
implemented. Time points were chosen to reflect potentially clinically relevant 
points in the time-course of gout; within one year of diagnosis to estimate initial 
risk of vascular disease associated with transition from asymptomatic 
hyperuricaemia to gouty arthropathy, within two years since initiation of urate-
lowering therapy (ULT) requires at least two attacks per year, and so any impact of 
ULT would not be seen until two years following diagnosis of gout, and five years 
estimates risk at the study mid-point.   
      
185 
         
   
5.7.1 Interactions 
When investigating the relationship by subset, interactions must be considered.  
An interaction describes a situation where the effect of one variable on the 
dependent variable is influenced by the value of another variable in the model; for 
example, whether risk of vascular event in participants with gout is influenced by 
gender.  In the absence of significant interactions it is appropriate to present an 
overall estimate of the effect of gout on the risk of vascular disease (the main 
effects).  Where an interaction is significant the main effects cannot be interpreted 
in the usual way since this effect is different in men and women.  In this situation 
the results must be presented by gender (the simple effects), since the effect of 
gout varies by gender.   
Where there are two variables to be considered, as here with the effect of gout 
and gender on risk of vascular disease, the product of the two variables is 
introduced into the model in order to assess the significance of any interaction.  
Where there are more than two explanatory variables, several interaction terms 
are created.   
The influence of follow-up time on the gout effect was found to be non-significant 
using Stata’s own test of proportional hazards (χ2(1) =0.82 p=0.05).  The only 
significant interaction was that between gout and gender.  
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5.7.2 Significance of Interactions 
In order to test the significance of the interaction terms the Wald test was chosen, 
since where there is potential for clustering (such as that induced by matching) the 
likelihood used for estimation does not reflect the true distribution of the sample 
since observations are no longer independent.  For this reason the likelihood ratio 
test cannot be used.  The Wald test compares the result of the parameter estimate 
divided by the estimated standard error of the parameter at this value, all squared, 
with the chi-squared critical value at one degree of freedom, with 95% confidence, 
which equals 3.84. If the Wald statistic value is greater than 3.84, then the 
interaction term was considered significant in the model. (Gould et al., 2006)  
Where interaction terms were found to be significant, stratified effect sizes were 
calculated in order to clarify differences, using the STATA LINCOM command, a 
post-estimation command that can be used to calculate the appropriate linear 
combinations from the model containing the interaction.  This has the added 
advantage of using all the data rather than fitting separate models for gender. 
(Collett, 1994)  
5.7.3  Multilevel Discrete Time Event History Analysis  
In order to estimate the overall risk of vascular events, but also accommodate 
changes in presence or absence of co-morbidities, medications or lifestyle related 
risk factors (e.g. giving up smoking, or losing weight) during follow-up, MDtEHA 
was used.  Time following diagnosis of gout was divided into discrete windows of 
one year, and EHR from that period examined for data on covariates of interest, 
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since many of the covariates of interest in this model were subject to variation over 
time.  Some, such as gender, do not vary, whilst age will inevitably vary with time 
elapsed since diagnosis.  Others, such as BMI, blood pressure, incidence of 
comorbidities and prescription for aspirin and statins not present at baseline may 
vary during follow-up and this variation may influence risk of vascular event.  Data 
collected during follow-up is not used in this way in the Cox Regression analysis 
since all covariates of interest are measured at baseline, and not subsequently.  
Thus gout/non-gout status was entered into the model, alongside values 
(present/absent or categorised) for covariates of interest in each year-long time 
window, into an MDtEHA logistic regression model (since the outcome of interest 
is a binary one).  This model is used to estimate the odds of experiencing an 
incident vascular event associated with each covariate.   
The covariates used were slightly different to those used in the continuous model.  
They included age, gender, presence of hyperlipidaemia or renal disease, 
continuous Charlson co-morbidity score, measure of blood pressure (categorised 
into normal ≤150/90; high > 150/90 or missing), measure of BMI (categorised into 
normal ≤25; high > 25kg/m2 or missing) and prescription of aspirin or statins.  
Since individual blood pressure measurements could be identified and included as 
covariates in each time window, diagnosis of hypertension was removed from the 
model to avoid overadjustment.   
An interaction between gout and gender was tested as this was found to be 
significant in the continuous model.  An interaction term for this gout*gender 
interaction was also included and the STATA lincom post-estimation command 
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was used as described in 5.7.2 to estimate the effects of gout exposure within 
gender. 
5.8 Summary  
This chapter has described the application of the retrospective matched-cohort 
study methodology to the investigation of the association between gout and 
vascular disease used.   
It has described the derivation and validation of a dataset of EHR from the CPRD 
used for the study, and discussed the statistical methods of CPH regression and 
MDtEHA applied in analysing these data.  This chapter has also described the 
methods used to investigate the effect of gout-specific characteristics, such as 
medication use (using defined daily dosage to compare the effect between 
groups), consulting behaviour and compliance with urate lowering therapy, on risk 
of incident vascular disease.   
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Chapter 6: Results 
6.1 Overview 
This chapter will present the results of the cohort study.   
The baseline demographics and pre-existing comorbidity of the cohort are 
described, followed by the results of both the continuous and discrete-time survival 
analysis comparing risk of incident vascular disease in patients with gout to those 
without.   
6.2 Baseline data 
This section will describe the characteristics of the study population, including 
gender distribution and age at date of diagnosis of gout (inclusion criteria required 
patients to be aged 50 years or over at the time of diagnosis of gout).  These data 
are shown in table 6.1.   
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Table 6.1: Participant demographics at baseline 
 
 Gout Non-gout p for 
significance 
Participants, n 8386 39766  
Age at diagnosis 
(S.D), y 
66.3 (+/- 10.8) 66.2 (+/- 10.7) 0.99 
Male, % 69.4 69.2 0.70 
Ever smoker 
(missing), % 
28.3 (23.1) 26.2 (31.2) <0.01 
Ever drinker (missing), 
% 
73.5 (13.8) 64.4 (21.2) <0.01 
BMI >25kg/m2 
(missing),% 
59.7 (18.3) 43.6 (25.0) <0.01 
Hypertension, % 36.0 17.3 <0.01 
Hyperlipidaemia, % 5.7 3.2 <0.01 
Diabetes, % 4.2 4.4 0.33 
Chronic kidney 
disease, % 
1.4 0.2 <0.01 
Ever statin use, % 34.3 25.6 <0.01 
Ever aspirin use, % 42.7 33.4 <0.01 
S.D.= standard deviation 
6.3 Frequency of vascular outcomes 
This section reports the frequency, percentage and median time to first vascular 
event outcomes within the gout and control groups, subdivided into particular 
vascular outcomes.   
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6.3.1 Number of vascular events  
There were a total of 11,266 vascular events during follow up.  The number of 
events by outcome is summarised in table 6.2 below, presented as median time to 
event and interquartile range (IQR). 
Table 6.2: Frequency, percentage and median time to first vascular event outcomes within each 
group 
 
Vascular Event Gout 
(n=8386) 
Median 
Time to 
event* 
(months) 
IQR Not gout 
(n=39766) 
Median 
Time to 
event* 
(months) 
IQR 
All vascular 
events 
(n=11266) 
 2447(29%) 40 17-73 8819(22%) 42 18-75 
All 
cardiovascular 
events 
(n=6734) 
 1520(18%) 44 19-78 5214(13%) 46 20-79 
Angina 
(n=2848) 
634(8%) 42 18-74  2214(6%) 44 19-77 
MI 
(n=2121) 
 445(5%) 42 18-75 1676(4%) 44 19-77 
All 
cerebrovascular 
events 
(n=4007) 
812(10%) 42 18-74 3195(8%) 43 19-77 
Stroke 
(n=2368) 
490(6%) 43 19-76  1878(5%) 44 19-77 
TIA 
(n=1725) 
 367(4%) 42 18-74 1358(3%) 44 19-77 
PVD 
(n=1291) 
318(4%) 42 18-74  973(2%) 43 18-76 
* median time to event is the median only for those who experience an event of interest 
and ignores censoring 
IQR=inter-quartile range; MI= myocardial infarction; TIA= transient ischaemic attack; 
PVD= peripheral vascular disease 
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The frequency of development of all vascular events was higher in the gout group 
than in the control group for all types of vascular events. 
The median time to event was also shorter in the gout group than the non-gout 
group for all vascular outcomes.  
6.4 Survival Analysis  
This section reports the results of the survival analysis.  The results are presented 
by gender since there were statistically significant interactions between gout and 
gender in the models for many of the outcomes.   
6.4.1 Unadjusted Analysis 
Table 6.3 shows the results of the unadjusted Cox Proportional Hazards 
Regression.  Absolute risk per 1000 person years for each outcome of interest is 
reported, alongside the hazard ratios (HRs) comparing the likelihood of having a 
first vascular event in patients with gout, compared to those without, before 
adjustment for known cardiovascular risk factors.  The proportional hazards 
assumption for gout exposure was met for all types of vascular events.  The 
results are presented by gender as there was a statistically significant interaction 
between gout and gender. The influence of follow-up time on the gout effect was 
found to be non-significant using Stata’s own test of proportional hazards (χ2(1) 
=0.82 p=0.05).
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Table 6.3: Unadjusted risk of a first vascular event between the gout and non-gout groups 
Outcome 
 
Number 
of Events 
Men Women P for gender 
interaction 
Gout No Gout Gout vs No 
Gout 
Gout No Gout Gout vs No 
Gout 
Absolute Risk 
per 1,000 
person-years 
(95% CI) 
Absolute Risk 
per 1,000 
person-years 
(95% CI) 
HR 
(95% CI) 
Absolute Risk 
per 1,000 
person-years 
(95% CI) 
Absolute Risk 
per 1,000 
person-years 
(95% CI 
HR 
(95% CI) 
All vascular 
events 
 
11,266 43.63 
(41.55-45.77) 
33.70 
(32.86-34.55) 
1.29  
(1.22-1.36) 
51.89 
(48.32-55.64) 
33.41 
(32.15-34.71) 
1.56 
(1.44-1.69) 
<0.01 
All CHD 
 
6734 28.46 
(26.80-30.20) 
21.06 
(20.41-21.74) 
1.36 
(1.27-1.45) 
29.11 
(26.47-31.94) 
17.72 
(16.81-18.67) 
1.64 
(1.48-1.82) 
<0.01 
Angina 
 
2848 11.80 
(10.73-12.97) 
8.95 
(8.52-9.39) 
1.31 
(1.18-1.46) 
12.32  
(10.63-14.22) 
7.23 
(6.65-7.84) 
1.70 
(1.45-2.00) 
<0.01 
MI 
 
2121 9.27 
(8.34-10.29) 
6.92 
(6.55-7.31) 
1.33 
(1.18-1.50) 
6.11 
(4.93-7.48) 
5.19 
(4.70-5.72) 
1.19 
(0.95-1.49) 
0.39 
All CVD 
 
4007 13.09 
(11.98-14.28) 
11.13 
(10.66-11.63) 
1.11 
(0.97-1.26) 
20.78 
(18.55-23.19) 
14.54 
(13.72-15.41) 
1.39 
(1.18-1.65) 
0.04 
TIA 
 
1725 6.04 
(5.27-6.87) 
4.77 
(4.46-5.10) 
1.25 
(1.09-1.45) 
9.34 
(7.87-11.00) 
6.06 
(5.53-6.62) 
1.57 
(1.30-1.89) 
0.07 
CVA 
 
2368 7.45 
(6.62-8.38) 
6.63 
(6.26-7.02) 
1.12 
(0.98-1.27) 
13.71 
(11.92-15.09) 
8.39 
(7.77-9.05) 
1.67 
(1.43-1.95) 
 
<0.01 
PVD 1291 5.60 
(4.88-6.41) 
4.01 
(3.72-4.31) 
1.39 
(1.19-1.62) 
7.09 
(5.81-8.55) 
3.05 
(2.68-3.46) 
2.35 
(1.87-2.94) 
 
<0.01 
HR=Hazard Ratio, CI=Confidence Interval, CHD= coronary heart disease, MI=Myocardial Infarction, CVD= Cerebrovascular Disease, TIA=Transient 
Ischaemic Attack, CVA=Cerebrovascular Attack, PVD=Peripheral Vascular Disease 
Covariates include age at baseline, gender, gout*gender interaction 
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Table 6.3 shows there were statistically significant positive associations between 
gout and all the vascular outcomes with the exception of MI in the unadjusted 
analysis in women, and all outcomes except all cerebrovascular disease and CVA 
in men. 
Figure 6.1 shows a Kaplan-Meier plot of the unadjusted results, which compared 
the likelihood of surviving without a vascular event between the gout and non-gout 
groups. 
Figure 6.1: Kaplan-Meier plot of the likelihood of vascular event free survival 
between gout and non-gout participants. 
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the index date, with this difference increasing over time from gout diagnosis or 
index date.   
6.4.2 Adjusted Hazard Ratios 
Table 6.4 presents the HRs comparing the risk of having a first vascular event 
after adjustment using Model 1(age at diagnosis of gout, or matched index date for 
controls, gender, gout*gender interaction, pre-index smoking, alcohol 
consumption, BMI, and Charlson Co-morbidity Index), and Model 2 (model 1 plus 
pre-index vascular risk factors hypertension, hyperlipidaemia, renal disease, 
aspirin and statin use) calculated using a Cox proportional hazard model.  The 
results are presented by gender as there were statistically significant interactions 
between gout and gender in the models for many of the outcomes. The 
significance of the interaction in the gout effect between men and women, and the 
size of the difference are shown in Table 6.5.  
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Table 6.4: HRs comparing risk of vascular events between gout and non- gout groups after adjustment for confounders  
Outcome 
 
Model 1 Model 2 
  HR Men 
(95% CI) 
 HR Women 
(95% CI) 
P for gender 
interaction 
 
HR Men 
(95% CI) 
HR Women 
(95% CI) 
P for gender 
interaction 
 
All vascular events 
 
1.22 
(1.16-1.29) 
1.45 
(1.34-1.57) 
<0.001 1.06 
(1.01-1.12) 
1.25 
(1.15-1.35) 
<0.001 
All CHD 1.26 
(1.18-1.35) 
1.50 
(1.35-1.67) 
0.005 1.08 
(1.01-1.15) 
1.25 
(1.12-1.39) 
0.024 
Angina 
 
1.20 
(1.08-1.34) 
1.55 
(1.32-1.82) 
0.010 1.02 
(0.92-1.13) 
1.28 
(1.09-1.51) 
0.003 
MI 
 
1.30 
(1.15-1.46) 
1.12 
(0.89-1.40) 
0.254 1.12 
(1.00-1.27) 
0.97 
(0.77-1.22) 
0.263 
All CVD 1.11 
(0.97-1.26) 
1.35 
(1.14-1.60) 
0.068 0.95 
(0.83-1.09) 
1.17 
(0.99-1.38) 
0.058 
TIA 
 
1.22 
(1.05-1.41) 
1.50 
(1.24-1.81) 
0.085 1.02 
(0.88-1.18) 
1.26 
(1.05-1.53) 
0.796 
CVA 
 
1.08 
(0.95-1.23) 
1.58 
(1.35-1.84) 
<0.001 0.93 
(0.81-1.06) 
1.34 
(1.15-1.57) 
<0.001 
PVD 1.35 
(1.16-1.58) 
2.17 
(1.73-2.73) 
<0.001 1.18 
(1.01-1.38) 
1.89 
(1.50-2.38) 
0.040 
HR=Hazard Ratio, CI=Confidence Interval, CHD= coronary heart disease, MI=Myocardial Infarction, TIA=Transient Ischaemic Attack, 
CVA=Cerebrovascular Attack, CVD= cerebrovascular disease, PVD= peripheral vascular disease 
Model 1 covariates:  gender, gender*gout interaction, baseline age, body mass index >25kg/m2, ever/never smoking, ever/never alcohol 
consumption, Charlson Co-morbidity Score 
Model 2 covariates include Model 1 and baseline history of hypertension, hyperlipidaemia, chronic kidney disease, ever/never statin use, 
ever/never aspirin use  
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As reported in table 6.4, results for the male participants showed gout to be a risk 
factor for all forms of vascular events, with the exception of all cerebrovascular 
event and CVA.  After adjustment in model 2, a statistically significant excess risk 
of all vascular events, all CHD, and PVD remained.  
Results for the female participants found gout to be a risk factor for all forms of 
vascular events with the exception of MI after adjustment in model 1.  After 
adjustment in model 2, risks remained significant but attenuated for all vascular 
events except MI and all cerebrovascular events. 
Excess risk of all types of vascular events is greater in female than male 
participants.  In model 1 the excess risk in women is approximately double that in 
men (with the exception of MI where there is significant risk in men but not 
women).  After adjustment for the wider range of risk factors in model 2 this 
difference in risk increases to between three and four times the risk in women 
compared to men.   
The magnitude and significance of the gout*gender interaction terms are shown in 
table 6.5 below. 
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Table 6.5: The significance and magnitude of the interaction in the gout effect between men and women  
Outcome 
 
Model 1 Model 2 
  Gender 
Interaction HR  
95% CI  P for gender 
interaction 
Gender 
Interaction HR  
95% CI P for gender 
interaction 
All vascular events 
 
1.19 1.08-1.30 <0.001 1.17 1.07-1.29 0.001 
All cardiovascular 
events 
 
1.19 1.05-1.35 0.005 1.15 1.02-1.31 0.024 
Angina 
 
1.29 1.06-1.56 0.010 1.26 1.04-1.53 0.003 
MI 
 
0.86 0.67-1.11 0.254 0.86 0.67-1.12 0.263 
All cerebrovascular 
events 
 
1.22 0.99-1.51 0.068 1.23 0.99-1.52 0.058 
TIA 
 
1.23 0.97-1.56 0.085 1.24 0.98-1.57 0.796 
CVA 
 
1.45 1.19-1.78 <0.001 1.44 1.18-1.77 <0.001 
Peripheral vascular 
 
1.60 1.22-2.11 <0.001 1.60 1.22-2.12 0.040 
HR=Hazard Ratio, CI=Confidence Interval, MI=Myocardial Infarction, TIA=Transient Ischaemic Attack, CVA=Cerebrovascular Attack 
Model 1 covariates age at diagnosis of gout/matched index date, gender, gout*interaction, body mass index >25kg/m2, ever/never smoking, 
ever/never alcohol consumption, Charlson Co-morbidity Score 
Model 2 covariates include Model 1 and history of hypertension, hyperlipidaemia, renal disease, ever/never statin use, ever/never aspirin use 
      
199 
         
   
The assumption of proportional hazards was tested for each model using 
Schoenfeld residuals.  The covariates which did not satisfy proportional hazards 
assumptions and which were therefore entered as time-varying covariates were 
different for each vascular disease of interest.  These are shown in table 6.6 
below. 
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Table 6.6: Time-varying covariates entered into each Cox Regression model 
 
 All vascular events All CHD Angina MI All CVD TIA CVA PVD 
 M1 M2 M1 M2 M1 M2 M1 M2 M1 M2 M1 M2 M1 M2 M1 M2 
Age at gout diagnosis √        √        
Gender                 
BMI >25      √        √   
Ever drinker √ √ √  √  √  √  √ √ √    
Ever smoker       √ √     √   √ 
Charlson score              √   
Pre-index HTN  √  √  √  √        √ 
Pre-index HLD              √   
Pre-index renal disease                 
Ever aspirin  √  √  √  √  √    √  √ 
Ever statin  √  √  √  √  √  √  √  √ 
BMI = body mass index; CHD =  coronary heart disease; CVD = cerebrovascular disease; CVA = cerebrovascular disease; HLD = hyperlipidaemia; HTN = hypertension; PVD = peripheral 
vascular disease; TIA = transient ischaemic attack;  
Model 1 (M1) = gender gout*gender interaction, baseline age, BMI, ever/never smoking, ever/never alcohol consumption, Charlson co-morbidity score 
Model 2 (M2) = Model 1 plus baseline history of hypertension, hyperlipidaemia, renal disease, prescription of aspirin or statins 
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6.4.3 Results of Cox regression with follow-up censored at 1, 2 and 5 years 
The relationship of time following diagnosis of gout with risk of vascular events 
was investigated by limiting follow-up to one, two and five years following 
diagnosis of gout (or matched index date), and risk of vascular events estimated 
during these time periods.  As described in section 5.7 this was done to add 
clinical utility to the estimate of risk, to highlight trends or peaks in risk at different 
times following diagnosis of gout in order to inform decisions about optimum time 
for screening for and management of vascular risk.    
The influence of follow-up time on the gout effect was examined by stratification 
within mutually exclusive time-intervals (first year, second year, years 2-5, and 
years 6-10) and testing for an interaction with time using the likelihood ratio test.  
The STATA LINCOM post-estimation command was then used to calculate the 
stratified effect size.  These results are shown in Table 6.7 
Table 6.7 The significance and magnitude of the interaction in the gout effect and follow-up time 
 
Follow-up time 
(mutually exclusive) 
HR CI p for Gout*Time 
interaction 
Up to 1 year 1.29 0.90-1.85 0.55 
1-2 years 1.26 1.02-1.56 0.40 
2-5 years 1.42 1.20-1.67 0.75 
5-10 years 1.36 1.30-1.43 0.58 
HR = Hazard Ratio; CI=Confidence Interval 
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There was no significant interaction between the gout effect and follow-up time as 
demonstrated by the likelihood ratio test (LR χ2(4) =1.12 p=0.89).  The stability of 
the gout effect size over time was reinforced by the estat phtest (test of 
proportional hazards) which confirmed no effect of time (χ2(1) =0.82 p=0.05).  
Table 6.8 shows the results comparing gout and non-gout participants risk of 
developing all vascular events limited to one year, two years, five years and ten 
years after index date, with and without adjusting for potential confounders. 
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Table 6.8: HRs comparing risk of developing all vascular events within a specified time following index date 
 
Follow up time 
(Total person-
years of follow-
up) 
Total 
number of 
events 
Unadjusted Model 1 Model 2  
Men Women Men Women Men Women 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
Up to 1yr 
(27,394) 
1953 1.21 
1.08-1.37 
1.31 
1.10-1.54 
1.16 
1.02-1.31 
1.25 
1.06-1.49 
1.02 
0.90-1.16 
1.12 
0.94-1.32 
Up to 2yrs 
(69,500) 
3548 1.13 
1.03-1.24 
1.38 
1.21-1.57 
1.06 
0.97-1.17 
1.33 
1.16-1.51 
0.97 
0.88-1.07 
1.21 
1.07-1.38 
Up to 5yrs 
(387,638) 
7308 1.26 
1.18-1.34 
1.28 
1.17-1.41 
1.12 
1.01-1.26 
1.16 
1.02-1.32 
0.97 
0.87-1.08 
1.04 
0.91-1.18 
Up to 10yrs 
(3,302,692) 
11266 1.29 
1.22-1.36 
1.56 
1.44-1.69 
1.22 
1.16-1.29 
1.45 
1.34-1.57 
1.06 
1.01-1.12 
1.25 
1.15-1.35 
HR = hazard ratio; CI = confidence interval 
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All vascular events  
Excess risk of all vascular events was found in gout patients of both genders at 1, 
2, 5 and 10 years post-diagnosis of gout in unadjusted analyses.  As a general 
trend, excess risk rose with increasing duration of follow-up, although the 
magnitude of the increase between one and ten years post-diagnosis was greater 
in women with gout (25%) compared with men with gout (10%).   
Risk of all vascular events is greater in women at one, two, five and 10 years 
following diagnosis of gout than in men. At one year post-diagnosis, in unadjusted 
analysis risk in women with gout is approximately 10% greater than that in men 
with gout and 30% higher than women without gout.  The magnitude of this risk is 
attenuated after adjustment for the covariates in model 1, but remains significant in 
women at all time points, however significance is lost for men at two years of 
follow-up in men.  After adjustment for the covariates in model 2 risk is further 
attenuated and only remains significant in women at 2 and 10 years of follow-up, 
and after 10 years of follow-up in men.   
Both genders show an increase in risk with increasing duration of follow up, 
although the magnitude of this increase is much smaller in men (8% in unadjusted 
analysis, 6% after adjustment in model 1 and 4% in model 2) than women (25% in 
unadjusted analysis, 20% after adjustments in model 1 and 13% after adjustment 
in model 2) 
Tables 6.9 and 6.10 show the unadjusted and adjusted results comparing gout 
and non-gout participants risk of all incident cardiovascular events, angina or MI 
with follow-up limited to one, two and five years. 
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Table 6.9: Unadjusted HRs comparing gout and non-gout participants risk of developing all CHD, angina or MI within a specified time following index date 
 
Follow up 
time 
All CHD Angina MI 
No of 
events 
Men Women No of 
events 
Men Women No of 
events 
Men Women 
HR 
95%CI 
HR 
95%CI 
HR 
95% CI 
HR 
95% CI 
HR 
95% CI 
HR 
95% CI 
Up to 1yr 1084 1.27 
1.08-1.49 
1.43 
1.13-1.82 
493 1.43 
1.12-1.83 
1.43 
1.00-2.04 
299 1.25 
0.90-1.73 
0.73 
0.41-1.30 
Up to 2yrs 2019 1.18 
1.04-1.33 
1.44 
1.20-1.72 
911 1.12 
0.93-1.35 
1.46 
1.11-1.91 
543 1.16 
0.92-1.47 
0.92 
0.59-1.42 
Up to 5yrs 4183 1.34 
1.24-1.45 
1.36 
1.20-1.55 
1865 1.21 
1.07-1.38 
1.51 
1.25-1.83 
1234 1.33 
1.14-1.54 
0.98 
0.73-1.31 
Up to 10yrs 6734 1.36 
1.27-1.45 
1.64 
1.48-1.82 
2848 1.31 
1.18-1.46 
1.70 
1.45-2.00 
2121 1.33 
1.18-1.50 
1.19 
0.95-1.49 
All CHD includes incident angina, MI and all other codes relating to incident coronary heart disease 
CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; MI = myocardial infarction 
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Table 6.10 Adjusted HRs comparing risk of incident cardiovascular events, angina or MI within a specified time following index date 
Follow 
up 
time 
 
All CHD Angina MI 
Men  Women Men Women Men Women  
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR  
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
Up to 
1yr 
 
1.19 
1.01-1.40 
1.00 
0.85-1.19 
1.32 
1.04-1.68 
1.13 
0.88-1.45 
1.30 
1.02-1.67 
1.10 
0.85-1.42 
1.28 
0.90-1.83 
1.08 
0.74-1.56 
1.21 
0.87-1.68 
1.10 
0.78-1.55 
0.70 
0.39-1.26 
0.66 
0.36-1.22 
Up to 
2yrs 
 
1.08 
0.95-1.22 
0.96 
0.85-1.09 
1.37 
1.14-1.64 
1.23 
1.03-1.48 
1.01 
0.83-1.22 
0.91 
0.75-1.11 
1.36 
1.03-1.79 
1.23 
0.93-1.62 
1.10 
0.87-1.40 
1.07 
0.84-1.36 
0.88 
0.57-1.37 
0.80 
0.51-1.26 
Up to 
5yrs 
 
1.20 
1.11-1.30 
0.96 
0.83-1.10 
1.24 
1.08-1.41 
1.00 
0.84-1.19 
1.07 
0.94-1.22 
0.94 
0.83-1.07 
1.36 
1.12-1.65 
1.29 
1.06-1.57 
1.27 
1.09-1.49 
1.15 
0.99-1.34 
0.91 
0.68-1.22 
0.88 
0.66-1.17 
Up to 
10yrs 
 
1.26 
1.18-1.35 
1.08 
1.01-1.15 
1.50 
1.35-1.67 
1.25 
1.12-1.39 
1.20 
1.08-1.34 
1.02 
0.92-1.13 
1.55 
1.32-1.82 
1.28 
1.09-1.51 
1.30 
1.15-1.46 
1.12 
1.00-1.27 
1.12 
0.89-1.40 
0.97 
0.77-1.22 
CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; MI = myocardial infarction 
Model 1: Age at diagnosis of gout, gender, gout*gender interaction, BMI, ever/never smoking and alcohol exposure, Charlson co-morbidity index 
Model 2: Model 1 plus preindex history of hypertension, hyperlipidaemia, chronic kidney disease, prescription of aspirin or statins 
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All CHD: Results of the unadjusted analyses showed both male and female 
participants with gout were at increased risk of all CHD events with the greatest 
excess risk in women.  After adjustment in model 1 these risks persisted, although 
attenuated, but the trend differed between genders.  In men, although there was 
an increased risk of all CHD after one and five years of follow-up, there was not 
after two years.  After adjustment in model 2, men were only at increased risk of a 
cardiovascular event after 10 years of follow-up and women after two and ten 
years of follow-up.   
Angina: Men were at increased risk of angina after one, five and 10 years, and 
women after two, five and 10 years in the unadjusted analysis. After adjustment in 
model 1, risks were attenuated but persisted at two, five and 10 years in women, 
and one and 10 years in men.  After adjustment in model 2, risks were again 
attenuated but women were at increased risk of vascular event after five and 10 
years of follow-up but men were not at any time point.   
MI: Men were at increased risk of MI after five and 10 years of follow-up in the 
unadjusted analyses, after adjustment in model 1 these risks were slightly 
attenuated but persisted, but there was no increased risk of MI in men after 
adjustment in model 2.  There was no statistically significant increased risk of MI in 
women at any time point in either the unadjusted or adjusted analysis. 
Tables 6.11 and 6.12 show the results comparing gout and non-gout participants 
risk of developing all cerebrovascular events, TIA or CVA limited to one year, two 
years, five years and ten years after index date, with and without adjusting for 
potential confounders. 
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Table 6.11: Unadjusted HRs comparing gout and non-gout participants risk of developing all cerebrovascular events, TIA or CVA within a specified time 
following index date 
 
Follow up 
time 
All CVD TIA CVA 
No of 
events 
Men Women No of 
events 
Men Women No of 
events 
Men Women 
HR 
95%CI 
HR 
95%CI 
HR 
95% CI 
HR 
95% CI 
HR 
95% CI 
HR 
95% CI 
Up to 1yr 647 1.01 
0.78-1.30 
1.34 
1.00-1.78 
233 1.13 
0.75-1.71 
1.49 
0.95-2.34 
310 0.88 
0.60-1.29 
1.32 
0.87-2.00 
Up to 2yrs 1170 0.99 
0.82-1.19 
1.48 
1.20-1.83 
443 0.94 
0.69-1.28 
1.50 
1.07-2.10 
555 0.96 
0.73-1.26 
1.49 
1.10-2.03 
Up to 5yrs 1569 1.12 
1.00-1.27 
1.17 
1.00-1.37 
1064 1.17 
0.97-1.41 
1.26 
1.00-1.59 
1356 1.06 
0.89-1.25 
1.30 
1.06-1.59 
Up to 10yrs 4007 1.11 
0.97-1.26 
1.39 
1.18-1.65 
1725 1.25 
1.09-1.45 
1.57 
1.30-1.89 
2368 1.12 
0.98-1.27 
1.67 
1.43-1.95 
All cerebrovascular disease (CVD) includes all incident TIA, CVA and all other codes relating to incident cerebrovascular disease 
CVA = cerebrovascular accident; CVD = cerebrovascular disease; CI = confidence interval; HR = hazard ratio; TIA = transient ischaemic 
attack 
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Table 6.12: Adjusted HRs comparing risk of incident cerebrovascular events, TIA and CVA within a specified time following index date 
 
Follow 
up time 
 
All CVD TIA CVA 
Men  Women Men Women Men Women 
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR  
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
Up to 
1yr 
 
0.99 
0.76-1.27 
0.94 
0.72-1.22 
1.35 
1.01-1.80 
1.22 
0.90-1.64 
1.11 
0.73-1.68 
1.02 
0.67-1.54 
1.50 
0.96-2.36 
1.26 
0.78-2.05 
0.83 
0.57-1.22 
1.05 
0.81-1.36 
1.30 
0.86-1.98 
1.19 
0.78-1.82 
Up to 
2yrs 
 
0.96 
0.80-1.16 
0.86 
0.71-1.04 
1.46 
1.18-1.80 
1.39 
1.13-1.71 
0.91 
0.67-1.24 
0.79 
0.57-1.08 
1.46 
1.04-2.06 
1.43 
1.02-2.01 
0.93 
0.71-1.22 
0.84 
0.63-1.10 
1.46 
1.07-2.00 
1.45 
1.06-1.98 
Up to 
5yrs 
 
1.07 
0.95-1.21 
0.93 
0.83-1.06 
1.13 
0.96-1.32 
1.08 
0.92-1.26 
1.11 
0.92-1.34 
0.95 
0.78-1.15 
1.22 
0.96-1.54 
1.17 
0.93-1.49 
1.01 
0.85-1.20 
0.88 
0.74-1.05 
1.23 
1.00-1.51 
1.17 
0.95-1.43 
Up to 
10yrs 
 
1.11 
0.97-1.26 
0.95 
0.83-1.09 
1.35 
1.14-1.60 
1.17 
0.99-1.38 
1.22 
1.05-1.41 
1.02 
0.88-1.18 
1.50 
1.24-1.81 
1.26 
1.05-1.53 
1.08 
0.95-1.23 
0.93 
0.81-1.06 
1.58 
1.35-1.84 
1.34 
1.15-1.57 
CVA = cerebrovascular accident; CVD = cerebrovascular disease; CI = confidence interval; HR = hazard ratio; TIA = transient ischaemic attack 
Model 1: Age at diagnosis of gout, gender, gout*gender interaction, BMI, ever/never smoking and alcohol exposure, Charlson co-morbidity index 
Model 2: Model 1 plus preindex history of hypertension, hyperlipidaemia, chronic kidney disease, prescription of aspirin or statins 
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All CVD: There was no increased risk of all cerebrovascular events in men in 
unadjusted analyses or adjusted analysis.  Female participants with gout had an 
excess risk of all cerebrovascular events at two and ten years post-diagnosis of 
gout, but not at one and five years post-diagnosis.  Excess risk was greatest at 
two years post-diagnosis in women, with an almost 50% increase in risk compared 
to female participants without gout. After adjustment in model 1, risks remained 
similar and were increased after one, two and 10 years of follow-up.  After 
adjustment in model 2, only risk after two years of follow-up persisted.    
TIA: Increased risk of TIA was only found after ten years follow-up male 
participants with gout in unadjusted analysis, and after adjustment in model 1, with 
no increased risk persisting after adjustment for the covariates in model 2.  
Women were found to be at increased risk of TIA when follow-up was limited to 
two and ten years in the unadjusted analysis, and this risk remained significant but 
attenuated after adjustment in both models 1 and 2. Risk of TIA was greatest 
when follow-up was limited to two years of follow-up.   
No increased risk of CVA was found in male participants with gout, compared to 
those without in the unadjusted or adjusted analysis, whilst women with gout were 
found to have an increased risk of incident CVA at two, five and ten years after 
diagnosis of gout.  This excess risk persists at both time points after adjustment for 
model 1 and 2, with risk remaining similar after adjustment in both models at the 
two year time point.   Table 6.13 shows the results comparing gout and non-gout 
participants risk of incident peripheral vascular disease limited to one year, two 
years, five years and ten years after index date, with and without adjusting for 
potential confounders. 
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Table 6.13: HRs comparing risk of incident PVD within a specified time following index date 
 
Follow up time No. of 
events 
Unadjusted Model 1 Model 2  
Men Women Men Women Men Women 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
HR 
95%CI 
Up to 1yr 191 1.44 
1.00-2.08 
3.06 
1.58-5.92 
1.45 
1.00-2.11 
2.96 
1.52-5.75 
1.33 
0.92-1.93 
2.63 
1.35-5.13 
Up to 2yrs 368 1.40 
1.07-1.83 
2.17 
1.39-3.37 
1.37 
1.05-1.80 
2.12 
1.36-3.33 
1.25 
0.95-1.64 
1.96 
1.24-3.09 
Up to 5yrs 815 1.37 
1.13-1.66 
1.98 
1.49-2.62 
1.33 
1.10-1.62 
1.79 
1.34-2.40 
1.20 
0.99-1.46 
1.69 
1.26-2.25 
UP to 10yrs 1300 1.39 
1.19-1.62 
2.35 
1.87-2.94 
1.35 
1.16-1.58 
2.17 
1.73-2.73 
1.18 
1.01-1.38 
1.88 
1.50-2.38 
CI = confidence interval; HR = hazard ratio 
Model 1: Age at diagnosis of gout, gender, gout*gender interaction, BMI, ever/never smoking and alcohol exposure, Charlson co-morbidity index 
Model 2: Model 1 plus preindex history of hypertension, hyperlipidaemia, chronic kidney disease, prescription of aspirin or statins 
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Peripheral vascular disease  
The excess risk of PVD was the highest of all risks identified.  Men were at 
increased risk of PVD after two, five and ten years in the unadjusted analysis and 
after adjustment for the covariates in model 1, risk only persists after 10 years of 
follow-up in model 2.  Women are at increased risk of PVD at all time points in 
unadjusted and after adjustment in model 1 and 2.  Women are at greater risk than 
men, and risk is greatest after one year of follow-up. 
 
The assumption of proportional hazards was tested using Schoenfeld residuals.  
Where this assumption was not satisfied, suggesting that risk associated with 
some or all covariates within the model did not remain constant over time, these 
covariates were re-entered into the model as time-covariates, allowing the 
assumption of proportional hazards to be satisfied for that particular vascular event 
of interest.  The time-varying covariates entered into each model are shown in 
table 6.14 below. 
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Table 6.14: Time-varying covariates entered into each Cox Regression model by follow up time 
Years 
post-
diagnosis 
of gout 
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1 year  M1    Angina         
 M2    Angina     Angina     
2 years M1    All CVD         
 M2    All vasc 
 All CVD 
    All vasc 
 All CHD 
    All vasc 
5years M1  All vasc 
 All CHD 
 Angina 
 All CVD 
  All CVD 
 CVA 
 All vasc 
 All CHD 
 Angina 
 All CVD 
 CVA 
      
 M2    All vasc 
 All CVD 
 CVA 
  All CVD 
 CVA 
  All vasc 
 All CHD 
 Angina 
  All CHD 
 All CVD 
 Angina  All vasc 
 All CHD 
 Angina 
 All CVD 
 TIA 
 CVA 
Model 1 (M1) covariates = gender, gout*gender interaction, baseline age, BMI, ever/never smoking and alcohol exposure, Charlson co-morbidity index score 
Model 2 (M2) covariates = Model 1 plus baseline history of hypertension, hyperlipidaemia, chronic kidney disease, prescription of aspirin or statins 
BMI = body mass index; CHD = cardiovascular disease; CVA = cerebrovascular accident; CVD = cerebrovascular disease; HLD = hyperlipidaemia; HTN = 
hypertension  
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6.4.4  Multilevel discrete time event history analysis 
This section reports the results of the discrete time event history analysis 
(MDtEHA).  The follow-up time for each participant was divided into one-year time 
windows, starting from the index date, and ending at the vascular event, or the first 
of death, transfer away from the practice contributing the record, or censoring at 
ten years.  The exposure status for each covariate within each of these one-year 
windows was determined by searching each participant’s electronic health record 
(EHR). The results are presented in tables 6.15 and 6.16 as adjusted odds ratio of 
any participant (gout or no-gout) experiencing a vascular event associated with the 
covariates of interest.   
Table 6.15:  Odds ratio of all vascular events  
 
 
Odds of vascular event reduced with each successive year following diagnosis of 
gout, from OR 0.89 (0.86-0.92) in the second year following baseline (as year 1 
was the referent value) to OR 0.11 (0.10-0.12) in the tenth year.  These are the 
Covariate Odds ratio 95% CI p for significance  
Gout (in men) 1.37 1.34-1.42 <0.01 
Gout (in women*) 1.56 1.50-1.63 <0.01 
Age  1.03 1.03-1.03 <0.01 
Gender 0.79 0.77-0.80 <0.01 
Gout*Gender 
Interaction 
1.13 1.08-1.20 <0.01 
*Due to the significant gout*gender interaction the effect of gout in women on risk 
of vascular event was estimated using the lincom option 
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odds for all participants of experiencing an incident vascular event in each year, 
assuming that they have not experienced the event of interest prior to this, thus 
both those with  and without gout have an odds ratio of vascular event of 0.89 in 
year 2 compared with year 1.   It should also be considered that this is censored 
data, and thus participants (gout or non-gout) can only continue to be at risk of an 
event provided that they have not been censored in the previous window. It is 
likely that both a healthy survivor effect (whereby those at greatest risk of vascular 
event experience the event earlier leaving only those at least risk of vascular event 
“at risk” in later time windows) and the removal of those who have already been 
censored from the “at risk” population in successive years will reduce risk in all 
participants, and does not necessarily contribute anything to the discussion of the 
association between gout and risk of vascular event.  For this reason these values 
will not be reported in models results of MDtEHA that follow. 
 
The Hosmer & Lemeshow test of goodness-of-fit p <0.01, indicates a significant 
difference between observed and expected number of events predicted by this 
model.  This implies there are additional important predictors not included in this 
model, justifying further multivariable analysis, reported in table 6.16.   
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Table 6.16:  Odds ratio of all vascular events according to exposure to all covariates during follow-
up 
 
Hosmer & Lemeshow test of goodness-of-fit p=0.33, indicates a reasonable model 
fit for the multivariable model. 
 
There was a significant interaction between gout and gender as in the continuous 
model, and both women with gout and men with gout were more likely to 
experience an incident vascular event, and the effect of gout on likelihood of 
vascular event was greater in women.    
 
Covariate Odds ratio 95% CI p for significance  
Gout (in men) 1.16 1.12-1.21 <0.01 
Gout (in women*) 1.25 1.19-1.32 <0.01 
Male gender 0.79 0.77-0.81 <0.01 
Gout*Gender Interaction 1.08 1.02-1.14 <0.01 
Age in 1-yr window 1.03 1.03-1.03 <0.01 
Incident hyperlipidaemia 1.13 1.09-1.18 <0.01 
Incident CKD 0.66 0.61-0.72 <0.01 
Charlson Score 1.22 1.20-1.23 <0.01 
Blood pressure ( Normal (≤150/90) referent) 
High (>150/90) 1.11 1.04-1.19 <0.01 
Not recorded 0.71 0.67-0.76 <0.01 
Body mass index (≤25 referent) 
>25 1.09 1.02-1.16 0.01 
Not recorded 0.59 0.56-0.62 <0.01 
Prescription of aspirin 2.61 2.53-2.69 <0.01 
Prescription of statins 1.48 1.41-1.56 <0.01 
*Due to the significant gout*gender interaction the effect of gout in women on risk of 
vascular event was estimated using the lincom option; CKD = chronic kidney disease 
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Increased odds of experiencing a vascular event was predicted by increasing age, 
high blood pressure measurement in that year, raised BMI measurement in that 
year (BMI >25), hyperlipidaemia, increasing Charlson co-morbidity score, and 
prescription of statins and aspirin.   
 
Reduced odds of experiencing a vascular event was predicted by male gender, 
renal disease and in those patients who did not have the blood pressure or BMI 
measured in that year.   
6.5 Strengths and limitations of this study 
The strengths and limitations of this analysis will be discussed alongside those of 
the sub-group analysis in chapter 7, as the main strengths and weaknesses are 
similar.  
6.6  Summary 
These results showed gout patients are at increased risk of all vascular events.  
This risk was highest in women, who are at increased risk of all vascular events: 
including all cardiovascular events, angina, CVA, TIA and PVD, whereas men are 
at increased risk of all vascular events, all cardiovascular events and PVD after 
adjustment for traditional vascular risk factors.  A gender difference in the time at 
which risk of various vascular diseases is greatest was also identified and possible 
mechanisms discussed. MDtEHA was used to investigate population risk factors 
which influence the probability of experiencing a vascular event.  These included 
gout in both men and women, and raised blood pressure and BMI, whilst male 
participants and those with CKD were less likely to experience a vascular event.   
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However, the factors which influence probability of incident vascular event in 
patients with gout remain unclear, and these will be investigated in further in 
Chapter 7. 
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Chapter 7:  Gout group only analysis: methods and 
results 
7.1  Overview 
Having presented evidence of an association between gout and vascular disease 
in sections 3.8 and 6.4, and the risk factors which influence the risk of 
experiencing a first vascular event across all participants (gout and non-gout) in 
section 6.4.4, this chapter will investigate the factors which influence the risk of 
vascular event specifically in patients with gout, focussing especially in the role of 
uric acid and treatment for hyperuricaemia as discussed in section 2.5.   
7.2  Gout-specific risk factors and risk of vascular event 
In order to try to understand why some patients with gout experience a vascular 
event whilst others do not, a subgroup analysis of the gout patients was 
undertaken.  
The influence of the known vascular risk factors included in the multivariable 
analysis of the cohort study discussed above on the risk of experiencing a 
vascular event were investigated, but additional gout-specific characteristics were 
also investigated.  These were: 
 Allopurinol prescription (the most commonly used urate lowering therapy): 
yes/no 
 Hyperuricaemia (defined as SUA > 360 micromol/litre) within the 6 months 
before and after diagnosis of gout, and during follow-up (using an average 
value generated for each participant between baseline and vascular event 
or censoring): yes/no/missing  
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 Frequency of consultation for gout between diagnosis of gout and event of 
interest or censoring (divided into quartiles), as a proxy for gout severity  
 Total consultations prior to event of interest or censoring (divided into 
quartiles), as a proxy for consulting behaviour 
 
7.2.1  Statistical methods 
Logistic regression uses either continuous (e.g. weight in kilograms) or categorical 
predictor variables (e.g. body mass index 17-20, 21-25, 26+) to predict the odds of 
a binary (e.g. presence or absence of a vascular event) or ordinal (e.g. mild, 
moderate or severe disease) outcome variable, in this case the odds of a 
participant with gout experiencing an incident vascular event using a combination 
of predictor variables specific to patients with gout.   
The odds predicted using logistic regression can be considered to be the 
probability of the participant experiencing a vascular event divided by the 
probability of not experiencing a vascular event.  This probability will always fall 
between 0 and 1, resulting in an easier interpretation of results.  This probability 
also takes into account the threshold effect, whereby the collective effect of a 
group of variables on an individual’s risk of an outcome is low until a particular 
threshold is reached, after which risk rises rapidly, remaining around 1 once the 
level of those collective variables is high enough.  The S-shaped curve of the 
logistic function used to predict outcome from variables in this model (rather than 
the straight line used in linear regression) represents this threshold effect well.  
(Kleinbaum & Klein, 2010) The natural logarithm of the odds is then taken to allow 
“transformation” of the binary outcome to become continuous, and the log-odds 
are then fitted against the predictor variables using linear regression.  The inverse 
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value of the predicted value of the log-odds is then taken, and this becomes the 
odds ratio of experiencing the event of interest based upon the predictors entered 
into the model.  (Kleinbaum & Klein, 2010)  
The covariates entered into the model were the known vascular risk factors 
included in the main cohort study analysis above, a binary indicator for ever/never 
having been prescribed allopurinol, a categorical variable for yes/no/missing 
hyperuricaemia in the 6 months before and after diagnosis of gout, and between 
diagnosis and date of vascular event or censoring, and a categorical variable for 
frequency of consultations.  Frequency of consultations (for gout and total 
consultations) was categorised into quartiles (with the lowest quartile as the 
referent category) as the numbers of consultations varied significantly and so to 
include this as inclusion as a continuous variable would have yielded an odds ratio 
per unit increase in number of consultations that was too small to be of practical 
value.   
 
Goodness-of-fit of the model (i.e. how well the model predicts the outcome 
variable from the predictors) was assessed using the Hosmer & Lemeshow test of 
model fit. This test compares observed with expected frequency of outcomes 
using a Pearson chi-squared test. The observed and predicted frequency should 
match closely, and the closer the match, the better the model fit, indicated by a 
non-significant p value associated with the chi squared test. (Hosmer et al, 2013)  
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7.3  Medication and risk of vascular event 
Other factors which may increase or reduce risk of vascular event include 
prescription medication.  Exposure to certain medications, such as anti-platelet 
(e.g. aspirin) and cholesterol-lowering (e.g. HMG Co-A Reductase inhibitors 
“statins”) medications, may confer protection against vascular disease, 
(Antithrombotic Trialists' Collaboration, 1994; Antithrombotic Trialists' 
Collaboration, 2002; Naci et al, 2013) whereas exposure to others, such as non-
steroidal anti-inflammatory drugs, may increase risk of vascular events. (Bhala et 
al, 2013)  
Multilevel discrete time event history analysis (MDtEHA) was used to explore the 
effect of medications used to treat both acute and chronic gout, and to treat co-
morbidities which may predispose to vascular disease (e.g. hypertension, 
hyperlipidaemia) or in primary prevention of vascular disease (e.g. antiplatelet 
medications) on likelihood of incident vascular event in patients with gout.   
Medications of interest were: 
 Treatments for acute gout 
- Colchicine 
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
 
 Treatments for chronic gout 
- Allopurinol 
- Uricosurics e.g. probenecid 
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 Anti-hypertensives 
- Angiotensin-converting enzyme (ACE) inhibitors 
- Angiotensin II receptor antagonists (AII) 
- Beta-adrenergic receptor antagonists 
- Calcium channel antagonists 
- Centrally acting antihypertensives 
- Diuretics 
- Renin inhibitors 
- Vasodilators 
 Anti-platelet medications 
- Aspirin 
- Clopidogrel 
- Dipyridamole 
 
 Lipid-lowering medications 
- Hydroxymethylglutaryl-CoA reductase (HMG-CoA) inhibitors 
- Fibrates 
- Cholesterol-absorption inhibitors 
The rationale for these choices is described below. 
 
7.3.1 Treatments for acute gout 
Treatments for acute gout are aimed at reducing the MSU-crystal associated 
inflammation which results in the painful synovitis which separates clinical gout 
from asymptomatic hyperuricaemia.  Since this inflammation has been implicated 
in the link between gout and vascular disease, it would seem reasonable to 
examine the effect of treatments used to reduce inflammation on the risk of 
vascular disease in patients with gout. 
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Colchicine 
As described in Chapter 1, colchicine is a commonly prescribed treatment for 
acute gout that works by inhibiting neutrophil motility and activity.  Since activated 
neutrophils have been identified in atherosclerotic plaques in patients with 
unstable coronary disease, it has been suggested that inhibition of these activated 
neutrophils using colchicine may reduce risk of vascular events.  Existing literature 
has examined the effect of colchicine on risk of vascular events in patients with 
existing vascular disease, demonstrating effective secondary prevention of 
cardiovascular events in those with existing stable coronary disease. (Nidorf et al, 
2013) The effect of colchicine on the risk of cardiovascular disease in patients with 
gout has also been explored, but the primary outcome for the majority of patients 
included in this study is limited to myocardial infarction, and the available evidence 
is conflicting.  Grimaldi-Bensouda et al, 2013, found no effect on risk of MI 
associated with use of colchicine, whereas Crittenden et al, 2012, reported 
decreased prevalence of myocardial infarction in patients with gout treated with 
colchicine, but did not examine other vascular outcomes.  (Crittenden et al, 2012; 
Grimaldi-Bensouda et al, 2014)  Thus the effect of colchicine on vascular 
outcomes in patients with gout merits further investigation. 
 
NSAIDs 
NSAIDs are commonly used treatments for acute gout, and yet use of NSAIDs has 
been associated with increased risk of vascular event.  (Bhala et al, 2013) A meta-
analysis of 754 trials reported use of either selective COX-2 inhibitors or diclofenac 
to increase risk of vascular death by half, risk of major vascular event by a third, 
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and risk of major coronary event by almost two thirds.  Ibuprofen was shown to 
double the risk of major coronary events, and all NSAIDs to double the risk of 
heart failure. (Bhala et al, 2013) In light of the association of both NSAIDs and 
gout with increased risk of vascular event, the relationship of prescription NSAID 
use in gout patients with their risk of incident vascular disease merits further 
examination, as there is little existing literature, although NSAIDs purchased over-
the-counter cannot be accounted for and needs to be considered as a potential 
limitation which may affect the results. 
7.3.2 Treatments for chronic gout 
Since hyperuricaemia has been established as a risk factor for both cardiovascular 
and cerebrovascular disease it would seem likely that reduction of serum uric acid 
(SUA) level using urate lowering therapy would also impact on the risk of 
cardiovascular and cerebrovascular events. (Kim et al, 2009; Kim et al, 2010)  
Drugs in common usage at the time the study data was collected included 
xanthine oxidase inhibitors (e.g. allopurinol) and uricosurics (e.g. probenecid).  
Febuxostat (an alternative xanthine oxidase inhibitor) was not approved for use 
until 2008, and so would not have been in use during our study period (incident 
diagnosis of gout between 1987 and 1999, with a maximum of 10 years follow-up), 
and was therefore not included in this investigation. 
 
Allopurinol 
Allopurinol is the most commonly used urate lowering therapy prescribed for the 
treatment of chronic gout. (Annemans et al, 2008; Soriano et al, 2011) Evidence 
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supports various cardiovascular benefits conferred by allopurinol in non-gout 
patients, including reduction in blood pressure, (Agarwal et al, 2013) and  left 
ventricular mass in patients with left ventricular hypertrophy and diabetes or 
ischaemic heart disease, (Rekhraj et al, 2013; Szwejkowski et al, 2013) and an 
increase in exercise tolerance in patients with chronic stable angina. (Noman et al, 
2010)  However, little is known of the effect of allopurinol on vascular risk in 
patients with gout. 
 
Uricosurics 
There is little evidence investigating the effect of uricosurics on vascular risk in 
either gout or non-gout patients, but it would not be unreasonable to consider the 
impact of  other forms of urate lowering therapy on vascular risk in addition to 
xanthine oxidase inhibitors.  Since uricosurics lower serum urate levels using a 
different mechanism to xanthine oxidase inhibitors, by blocking renal tubular 
reabsorption of uric acid thus increasing renal excretion of urate, examination of 
the prescription of uricosurics on risk of vascular disease in gout may suggest 
whether any effect of urate-lowering therapy on vascular disease relates directly to 
the reduction in serum urate levels, or to the mechanism by which that urate 
lowering therapy works. 
7.3.3 Medications used to treat cardiovascular risk factors 
In patients at risk of vascular disease several groups of medications are typically 
used to try to reduce that risk, either as primary prevention before the disease is 
manifest, or secondary prevention to prevent further progression of disease.  
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These medicines are usually those which treat co-morbidities which predispose to 
vascular disease (e.g. hyperlipidaemia or hypertension) or target some of the 
mechanisms which underlie the pathogenesis of vascular disease (e.g. anti-
platelet medications).  These are discussed below. 
  
Anti-platelet medication 
Since platelets are known to play an important role in the pathogenesis of 
coronary artery diseases, anti-platelet medications have become commonplace in 
both the primary and secondary prevention of vascular disease. (Clappers et al, 
2007) Currently available anti-platelet medication used in the prophylaxis of 
various forms of vascular disease includes aspirin, clopidogrel and dipyridamole.   
Each acts on a different part of the thrombotic pathway, and for this reason may 
also be used in combination, particularly in cerebrovascular disease or post-MI.  
(Jones et al, 2013; National Collaborating Centre for Chronic Conditions, 2008a)  
 
Aspirin has been shown to reduce risk of serious vascular events (non-fatal MI, 
non-fatal stroke, or vascular death), arterial occlusion and venous 
thromboembolism among patients at high risk.  (Antithrombotic Trialists' 
Collaboration, 1994; Antithrombotic Trialists' Collaboration, 2002) It does this 
primarily through actions which are anti-inflammatory, protect from oxidative 
stress, enhance fibrinolysis, and suppress plasma coagulation and platelet-
dependent inhibition of thrombin production.  (Mehta, 2002; Patrono, 1994)  
 
Salicylates are also known to exert a uricosuric effect in high doses. However, in 
low doses such as those commonly used for cardiovascular protection, aspirin is 
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thought to increase levels of urate by reducing renal excretion. (Caspi et al, 2000) 
Thus the effect of aspirin on risk of vascular disease in gout may be conflicting in 
that it may have an anti-platelet effect, but also increase uric acid.  
 
Other anti-platelet drugs used to reduce risk of vascular diseases include 
clopidogrel which is used in the prophylaxis of coronary artery disease, and 
dipyridamole which is used in the prophylaxis of cerebrovascular disease.  Due to 
the increased cost when compared with aspirin, clopidogrel and dipyridamole are 
less frequently used in mono-therapy.   
 
Cholesterol-lowering medications  
Hypercholesterolaemia is a common comorbidity in patients with gout and is 
reported to be present in approximately 45% of gout patients. (Annemans et al, 
2008; Riedel et al, 2004)  The cholesterol-lowering class of drugs include statins, 
fibrates and ezetimibe.  Statins and fibrates reduce lipid levels by inhibiting the 
body’s production of cholesterol and triglycerides by the liver, whilst ezetimibe 
inhibits intestinal absorption of dietary cholesterol.   
 
Given the association between hyperlipidaemia and atherosclerotic vascular 
disease, and the reduction in all-cause mortality, cardiovascular mortality and 
major coronary events attributed to these drugs, it would seem reasonable to 
investigate their effect on risk of vascular disease in patients with gout. (Naci et al, 
2013)  
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Anti-hypertensives 
Aside from the effect of controlling hypertension on vascular risk, use of 
antihypertensives may influence risk of vascular disease through the more direct 
action of some on levels of SUA. 
 
ACE inhibitors (particularly enalapril and captopril), angiotensin II receptor 
antagonists (particularly losartan), calcium channel blockers such as verapamil, 
and beta-blockers (particularly timolol) are also known to have a uricosuric action.  
(Spieker et al, 2002)  
 
Thus, the inclusion of all classes of anti-hypertensive drugs in this investigation of 
their effect on risk of vascular disease in gout patients may provide a helpful 
comparison between the effect of those thought to be uricosuric, and those that 
are not. 
 
Diuretics are a particular class of antihypertensive known to have a long standing 
association with gout as chronic diuretic therapy is known to predispose to 
hyperuricaemia.  A number of mechanisms have been proposed to explain this, 
including increased uric acid reabsorption resulting from reduction in circulating 
volume and direct effects on the urate transporters in the proximal tubule, and 
competitive inhibition of organic anion transporter (OAT) 4 by diuretics increasing 
urate reabsorption has also been shown. (Hagos et al, 2007; Hueskes et al., 2012) 
Some diuretics have also been shown to reduce uric acid excretion. (El‐Sheikh et 
al, 2008)  
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Since the main therapeutic indications for diuretics are the treatment of fluid 
retention associated with cardiovascular diseases such as heart failure and 
hypertension, it may be that the effect of diuretics is to reduce risk of vascular 
disease in patients with gout through reducing risk factors such as hypertension.  
However, since diuretics predispose to hyperuricaemia, and hyperuricaemia is 
known to predispose to vascular disease, (Kim et al, 2009; Kim et al, 2010) it may 
be that diuretics increase risk of vascular disease in patients with gout by reducing 
urate excretion and driving up SUA levels. 
7.3.4  Calculation of dosage 
Medications of interest were identified from each participant’s electronic health 
records (EHR) using codes returned by a browser provided by the CPRD.  Each 
code uniquely identified a particular strength of tablet, and this could be combined 
with the quantity of tablets supplied and duration of prescription, or the number of 
tablets the patient was directed to take per day, to identify not only the presence or 
absence of a prescription for that medication in each year-long time window, but to 
calculate the prescribed dosage.   
For the purpose of analysis, dosage of treatment was converted into defined daily 
dose (DDD).  This is a validated measure of drug consumption maintained and 
administered by the World Health Organisation (WHO), and is defined as the 
assumed average maintenance dose per day for a drug used for its main 
indication in adults. (http://www.whocc.no/ddd/definition_and_general_considera/, 
last accessed 19th June 2014)  The DDD of each drug is considered to be 
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functionally equivalent to that of any other drug used for a similar purpose, and 
thus can be used to compare drugs within and across pharmacological groups, 
facilitating our comparison of the effect of groups of drugs (treatments for acute 
and chronic gout and cardioprotective medications) on risk of vascular disease.  
 
It is calculated by multiplying the dose of the drug prescribed by the quantity given 
and dividing this by the DDD value assigned to that particular drug.  Total dose of 
drugs (reported as DDDs) prescribed in each year-long time window were 
calculated for each participant, and then divided by 365 to give an average DDD 
dose per day.  This average was then categorised into quartiles based on the use 
by pharmacological group.     
 
Since allopurinol, once prescribed, is likely to remain a lifelong prescription in the 
absence of adverse events or intolerance, it is usually added to the patients repeat 
prescription.  This allows the patient to request an allopurinol prescription without 
needing a repeat consultation.  However, repeat prescriptions are only usually 
issued if they have been requested by, or on behalf of, the patient.  Since 
allopurinol has limited indications, patients are only likely to continue to request 
repeat issues if they are actually taking the tablets.  Therefore, non-compliance 
can be identified by periods where allopurinol is not issued following initiation.  The 
number of prescriptions for allopurinol issued following initiation throughout 
remaining follow-up may provide supporting evidence of compliance or non-
compliance in this sample.  The effect on risk of incident vascular event of either 
compliance or non-compliance with allopurinol, as well as the dose prescribed, in 
each time window was examined using MDtEHA.  Since comparison within or 
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between other pharmacological groups was not required, dosage was divided into 
<300mg, =300mg (the most commonly prescribed fixed dosage) or >300mg per 
day, instead of using DDDs.  Compliance with allopurinol was measured using 
medication possession ratio (MPR). (Sclar et al, 1991) This is the number of days 
of medication supplied within a set time interval divided by the number of days in 
the specified time interval and was calculated for each year long time window.   
Known vascular risk factors which may influence the relationship between 
medications and risk of incident vascular event were identified from the patient’s 
electronic record, in each one year time window, using codes identified from the 
CPRD browser.  The rationale for selection of these criteria is described in detail in 
section 5.4.   
Analysis was conducted using SPSS Statistics version 20.0 (SPSS Inc, IBM Corp; 
2012 ) and Stata statistical software release 12 (StataCorp: College Station, TX, 
2011) 
7.4  Results  
This section will report the results of the investigation of factors influencing the 
odds of a vascular event in patients with gout.  The frequency and percentage of 
gout participants (n= 8386) who have ever been prescribed urate lowering therapy 
(allopurinol), have recorded hyperuricaemia at first diagnosis of gout, 
hyperuricaemia over follow-up (using the mean of any recorded urate 
measurements between diagnosis of gout and event of interest or censoring), and 
the distribution of the number of consultations for gout following diagnosis (as a 
proxy for severity), and total number of consultations (as a proxy for consulting 
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behaviour) will be presented.  This will be followed by the results of the analysis of 
the influence of these risk factors on odds of an incident vascular event in patients 
with gout. 
7.4.1 Gout case participants and gout-specific exposures 
This section reports the frequency and percentage of gout participants who have 
the aforementioned gout-specific exposures. 
Mean age at diagnosis with gout was 66.6 years (SD 10.8). 3527 (42%) 
participants were prescribed allopurinol prior to having a vascular event, with 
median time to prescription of allopurinol from diagnosis of gout being 10 months 
(interquartile range 5-54 months).  Mean age at first prescription of allopurinol was 
72.4 years.  The most frequently prescribed dosage of allopurinol prescribed was 
300mg (63.8%) with only (36.2%) prescribed a dosage other than 300mg and (1%) 
prescribed more than 300mg)   
Routine measurement of SUA was not common practice. Only 46% (n=3871) of 
participants had any measurement of serum urate between 6 months prior to their 
diagnosis of gout and the end of their complete follow up.   Less than 40% 
(n=1206) of the participants who were prescribed allopurinol as urate lowering 
therapy had a recorded measurement of SUA within the 6 months before or after 
commencing this treatment.  The frequency and percentage of gout participants 
who have the exposures of interest are summarised in table 7.1 below. 
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Table 7.1 Frequency and percentage of gout-specific exposures  
 
Gout specific exposures Frequency (n=8386) 
(%) 
 
Record of urate lowering therapy (allopurinol) prescription 
Yes 3527 (42.1) 
No 4859 (57.9) 
 
Abnormal presenting urate level (≥360 micromol/L) 
Yes 1296 (15.5) 
No 299(3.6) 
Missing 6791(81.0) 
 
Abnormal mean urate level (≥360 micromol/L) 
Yes 2883 (34.4) 
No 981(11.7) 
Missing 4522 (53.9) 
 
No of consultations for gout 
1 6653 (79.3) 
2 1378 (16.4) 
3 322 (3.8) 
4+ 33 (0.4) 
 
7.4.2 Association of gout-specific exposures with subsequent vascular disease in 
gout cases 
This section reports the association between gout-specific exposures and odds of 
experiencing an incident vascular event in gout patients.  
Table 7.2 presents the odds of a vascular event according to gout-specific 
exposure, and shows that gout participants exposed to allopurinol were more likely 
to experience all vascular and cardiovascular events, whilst those consulting more 
frequently for gout were less likely to experience a vascular event. 
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Gout participants who did not have serum urate recorded at diagnosis of gout, or 
over their follow-up (until vascular event or censoring) were also more likely to 
experience vascular events, highlighting the role of surveillance in patients with 
gout in the management of vascular risk.
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Table 7.2 Associations between gout-specific exposures and vascular event
 All vascular* All CHD* Angina* MI* All CVD* TIA* CVA* PVD* 
Ever/Never exposure to allopurinol prior to vascular event (Referent value: never exposed)  
Ever exposed to 
Allopurinol  
1.15 
1.06-1.26 
1.27 
1.14-1.42 
1.43 
1.21-1.69 
1.13 
0.92-1.39 
1.00 
0.86-1.17 
1.09 
0.87-1.36 
0.96 
0.79-1.16 
1.15 
0.91-1.47 
Number of gout consultations (quartiles)  (Referent value: quartile1) 
2 0.89 
0.80-1.00 
0.89 
0.78-1.02 
0.80 
0.65-0.99 
0.90 
0.70-1.15 
0.94 
0.78-1.13 
0.93 
0.71-1.21 
0.94 
0.75-1.18 
0.78 
0.58-1.05 
3 0.78 
0.68-0.89 
0.85 
0.72-1.00 
0.71 
0.55-0.92 
0.73 
0.54-1.00 
0.64 
0.50-0.82 
0.56 
0.39-0.82 
0.61 
0.44-0.83 
0.56 
0.38-0.83 
4 0.62 
0.55-0.69 
0.63 
0.54-0.72 
0.42 
0.34-0.53 
0.57 
0.43-0.74 
0.61 
0.50-0.74 
0.55 
0.41-0.74 
0.59 
0.46-0.77 
0.48 
0.35-0.65 
Total number of consultations (quartiles) (Referent value: quartile 1) 
2 1.03 
0.84-1.27 
1.00 
0.76-1.32 
1.36 
0.81-2.29 
1.05 
0.69-1.60 
1.06 
0.74-1.51 
0.88 
0.47-1.65 
1.15 
0.75-1.77 
2.26 
1.00-5.10 
3 1.06 
0.87-1.28 
1.07 
0.83-1.38 
1.60 
0.98-2.59 
0.80 
0.54-1.20 
1.19 
0.86-1.65 
1.54 
0.89-2.66 
1.02 
0.68-1.53 
2.55 
1.17-5.55 
4 1.35 
1.13-1.62 
1.47 
1.16-1.88 
2.88 
1.81-4.57 
0.83 
0.56-1.21 
1.29 
0.94-1.77 
1.84 
1.09-3.12 
0.99 
0.67-1.46 
3.67 
1.72-7.83 
Presenting hyperuricaemia (≥360 micromol/L) (Referent value: no) 
Yes 1.28 
1.00-1.63 
1.24 
0.91-1.69 
1.50 
0.92-2.46 
1.57 
0.84-2.91 
1.78 
1.11-2.87 
1.53 
0.77-3.02 
1.85 
1.02-3.34 
1.01 
0.56-1.80 
Missing 1.29 
1.02-1.62 
1.21 
0.91-1.61 
1.42 
0.89-2.24 
1.52 
0.85-2.71 
1.76 
1.12-2.74 
1.68 
0.89-3.17 
1.61 
0.92-2.80 
0.93 
0.55-1.58 
Mean urate level hyperuricaemic (≥360 micromol/L) (Referent value: no) 
Yes 1.30 
1.08-1.56 
1.28 
1.02-1.61 
0.95 
0.64-1.40 
1.17 
0.68-2.02 
1.27 
0.96-1.69 
1.10 
0.75-1.63 
1.30 
0.82-2.06 
0.93 
0.58-1.48 
Missing 1.36 
1.13-1.64 
1.31 
1.05-1.65 
0.61 
0.40-0.92 
1.13 
0.65-1.97 
1.36 
1.02-1.80 
1.02 
0.69-1.50 
1.93 
1.23-3.02 
0.94 
0.60-1.48 
Hosmer & 
Lemeshow p 
0.36 0.16 0.87 0.11 0.62 0.56 0.54 0.68 
* Odds ratio (95% Confidence intervals) are presented 
CHD = coronary heart disease; CVA = cerebrovascular accident; CVD = cerebrovascular disease; PVD = peripheral vascular disease; TIA = transient ischaemic attack 
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7.4.3 Association between odds of experiencing a vascular event and exposure to 
medications used to treat acute and chronic gout 
This section will present the results of the multilevel discrete-time event history 
analysis (MDtEHA) investigating how changing exposure to medications used to 
treat acute and chronic gout affect the odds of an incident vascular event.  As 
previously discussed, the covariates of interest were measured in each year-long 
follow-up window from diagnosis of gout.  The results presented are the odds of 
incident vascular event in all gout patients associated with exposure to each 
particular covariate following diagnosis of gout.  Table 7.3 shows the odds ratio of 
experiencing an incident vascular event in patients with gout who are exposed to 
medications used to treat acute and chronic gout, in comparison with those who 
are not. 
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Table 7.3 Daily dose of treatments for gout and odds of all vascular events
 NSAIDs (n=5458) Colchicine (n=850) Allopurinol (n=3527) Uricosurics (n=159) 
Number of events  1587 198 806 23 
Covariate Odds 
ratio 
95% CI Odds 
ratio 
95%CI Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Average dose of drug (DDD) per day (quartiles) (reference category: no exposure) 
1 1.18 1.08-1.28 1.11 0.80-1.55 0.99 0.87-1.14 3.68 1.82-7.44 
2 1.07 0.96-1.18 0.91 0.62-1.35 1.00 0.86-1.16 2.48 0.88-6.99 
3 1.31 1.18-1.46 1.15 0.79-1.69 1.10 0.92-1.31 1.96 0.56-6.91 
4 1.35 1.17-1.55 0.84 0.43-1.65 1.07 0.87-1.33 3.98 1.12-14.12 
Age in 1-yr window 1.03 1.02-1.04 1.03 1.02-1.04 1.03 1.02-1.04 1.03 1.02-1.04 
Male gender 0.84 0.74-0.96 0.85 0.75-0.96 0.85 0.75-0.96 0.84 0.75-0.96 
Incident hyperlipidaemia 1.18 0.99-1.41 1.18 0.99-1.41 1.18 0.99-1.41 1.18 0.99-1.41 
Incident CKD 0.78 0.58-1.04 0.77 0.58-1.02 0.76 0.57-1.01 0.75 0.57-1.00 
Charlson Score 1.20 1.14-1.26 1.19 1.14-1.25 1.20 1.14-1.26 1.19 1.14-1.25 
Blood pressure ( Normal (≤150/90) referent)      
High (>150/90) 1.29 1.19-1.40 1.30 1.20-1.40 1.29 1.20-1.40 1.29 1.20-1.40 
Not recorded 0.79 0.73-0.86 0.79 0.73-0.85 0.79 0.73-0.86 0.79 0.73-0.85 
Body mass index (≤25 referent)      
>25 0.92 0.77-1.09 0.93 0.79-1.10 0.93 0.78-1.10 0.93 0.79-1.11 
Not recorded 0.75 0.64-0.86 0.75 0.65-0.87 0.75 0.65-0.87 0.75 0.65-0.88 
p for significance of test 
of goodness of fit* 
0.07 0.07 0.07 0.07 
CI= confidence interval; DDD= defined daily dose; CKD = chronic kidney disease 
*Used Hosmer & Lemeshow test for model fit where non-significant test indicates model approximates the data i.e. good model fit 
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As described in section 4.6.2, the discrete-time event history model has the 
advantage that covariates measured following diagnosis of gout can be included in 
the model (e.g. incidence of new co-morbidities, giving up smoking or prescription 
of new medication), as opposed to be measured at baseline as in Cox proportional 
hazards (CPH) regression.  This results in an overall estimate of the odds of 
experiencing an incident vascular event in all gout patients associated with each 
covariate but taking into account changes in risk factors over the course of follow-
up, rather than simply those present at baseline as in the Cox regression.  The 
results presented in table 7.3 show the odds of experiencing an incident vascular 
event associated with each covariate across all gout patients.  
An incident vascular event was found to be more likely in patients who had been 
exposed to prescribed NSAIDS with a trend in risk associated with increased 
exposure, and in those who were in the lowest and highest strata of exposure to 
uricosurics, although the numbers exposed to uricosurics was small.  Likelihood of 
experiencing a first vascular event was no different in patients who had been 
exposed to colchicine or allopurinol than those who had not.   
In addition, odds of experiencing a first vascular event was also increased by 
increasing age and Charlson score and a high blood pressure measurement 
recorded in that year. 
In contrast, male patients, those with incident chronic kidney disease, and those in 
whom there was no recorded measurement of blood pressure or BMI in that year 
were less likely to experience a first vascular event.  
Given that risk of vascular disease was unaffected by exposure to allopurinol at 
any dose strata, this relationship was explored further. Table 7.4 presents the 
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results where the influence of medication possession ratio (the proportion of each 
year long time window the patient had a prescription for allopurinol issued, and 
considered a proxy for compliance with allopurinol treatment) and mean daily 
dosage of allopurinol in milligrams (not defined daily doses as in table 7.3 as no 
comparison with other medication groups was planned for these results) per year-
long time window were included as covariates to explore their influence on the risk 
of experiencing an incident vascular event. 
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Table 7.4 Dose and duration of allopurinol therapy in risk of all vascular events  
 
 
Participants taking ≤300mg of allopurinol (300mg fixed dose being the most 
common way to prescribed allopurinol in primary care) were more likely to 
experience a first vascular event than those who had never taken allopurinol, but 
those taking >300mg were not, although only 36.2% of the study population were 
prescribed a dose other than 300mg, and of those only 1% were prescribed a 
dose greater than 300mg per day. 
Increasing medication possession ratio (the proportion of each year-long time 
window that the patient has a prescription for allopurinol) was found to reduce the 
risk of experiencing an incident vascular event.   
Covariate Odds ratio 95% CI p for significance 
MPR 0.55 0.42-0.72 <0.01 
Mean allopurinol dosage in each year (referent no allopurinol) 
<300 1.44 1.13-1.85 <0.01 
300 1.57 1.23-2.01 <0.01 
>300 1.38 0.61-3.11 0.43 
Male gender 0.96 0.86-1.07 0.47 
Age in 1-yr window 1.02 1.01-1.02 <0.01 
Incident 
hyperlipidaemia 
0.67 0.56-0.80 <0.01 
Incident CKD 0.33 0.26-0.43 <0.01 
Charlson Score 1.54 1.48 -1.61 <0.01 
Blood pressure (Normal (≤150/90) referent) 
High (>150/90) 1.52 1.37-1.69 <0.01 
Not recorded  0.75 0.67-0.85 <0.01 
Body mass index (≤25 referent) 
>25 0.84 0.69-1.02 0.08 
Not recorded 0.74 0.62-0.88 <0.01 
Prescription of aspirin 5.46 4.90-6.09 <0.01 
Prescription of statins 1.61 1.38-1.89 <0.01 
CI= confidence interval; CKD = chronic kidney disease; MPR=medication 
possession ratio 
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7.4.4 Association between exposure to medications used to treat vascular risk 
factors and risk of incident vascular event in patients with gout. 
This section presents the results of the MDtEHA investigating how changing use of 
medications used to treat vascular risk factors affect the risk of experiencing an 
incident vascular event in patients with gout.   
As before, the covariates of interest measured in each year following diagnosis of 
gout were used to estimate odds ratio of experiencing an incident vascular event 
in all gout patients associated with each particular covariate.  The results 
presented are the likelihood of any gout patient experiencing an incident vascular 
event where that covariate is present (presence compared with absence, a one 
unit increase in value or progression between categories in categorical variables).  
Table 7.5 shows the odd ratios in gout patients of experiencing an incident 
vascular event associated with exposure to medications used to reduce vascular 
risk. 
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Table 7.5: Daily dose of drugs used to treat vascular risk factors and odds of all vascular events 
 Anti-hypertensives (n=5563) Anti-platelet drugs (n=1979) Lipid-lowering (n=1376) 
Number of events 1987 1002 483 
Covariate Odds ratio 95% CI Odds ratio 95%CI Odds ratio 95% CI 
Average dose of drug (DDD) per day (quartiles) (referent not exposed) 
1st quartile 1.57 1.40-1.76 2.98 2.60-3.41 2.20 1.83-2.63 
2nd quartile 1.61 1.41-1.84 2.40 2.08-2.77 1.49 1.19-1.88 
3rd quartile 1.57 1.37-1.81 1.97 1.58-2.45 1.34 1.03-1.74 
4th quartile 1.45 1.24-1.69 1.98 1.65-2.38 1.00 0.73-1.36 
Age in 1-yr window 1.03 1.02-1.03 1.03 1.02-1.03 1.03 1.02-1.04 
Male gender 0.80 0.70-0.90 0.86 0.76-0.98 0.85 0.75-0.96 
Incident hyperlipidaemia 1.14 0.96-1.36 1.12 0.94-1.34 1.00 0.82-1.22 
Incident CKD 0.72 0.54-0.96 0.77 0.58-1.03 0.75 0.56-1.00 
Charlson Score 1.17 1.12-1.23 1.16 1.10-1.22 1.18 1.12-1.24 
Blood pressure ( Normal (≤150/90) referent)    
High (>150/90) 1.24 1.15-1.35 1.30 1.20-1.41 1.29 1.19-1.40 
Not recorded 0.89 0.82-0.96 0.83 0.77-0.91 0.80 0.74-0.87 
Body mass index (≤25 referent)    
>25 0.89 0.75-1.06 0.92 0.78-1.10 0.92 0.78-1.09 
Not recorded 0.72 0.62-0.83 0.76 0.65-0.88 0.76 0.66-0.88 
p for significance of test of 
goodness of fit* 
0.08 0.09 0.08 
CI = confidence interval; DDD= defined daily dose; CKD = chronic kidney disease all stages (defined using Read codes found in 
appendix 2); Hyperlipidaemia defined using Read codes found in appendix 2 
*Used Hosmer & Lemeshow test for model fit where non-significant test indicates model approximates the data i.e. good model fit 
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The results presented in table 7.5 show that gout patients who had been exposed 
to any of the three classes of medications used to treat vascular risk factors 
investigated were more likely to experience an incident vascular event than those 
that had not.  The odds ratios were attenuated by increased exposure within all 
three classes of drugs, suggesting that those exposed to higher doses were less 
likely to have a first vascular event, and gout patients who were in the highest 
strata of exposure to lipid-lowering medications had no increased risk of 
experiencing a first vascular event.  Other variables in the model influenced odds 
of vascular events in a similar way to that presented in section 7.4.3. 
7.5 Limitations and strengths of this study 
This section will discuss the limitations and strengths of this cohort study and the 
level of generalisability that results from these.  
7.5.1 Limitations  
Data Source 
The use of data from routinely collected primary care EHR is accepted as a cost-
effective way to undertake epidemiological studies of large patient populations 
across a broad population spread. (Jordan et al, 2006)  The CPRD is the largest 
database of primary care EHR in the world, containing anonymised data for 
approximately 5.5% of the population of England and Wales. This data set was 
formally known as the General Practice Research Database (GPRD). Currently 
over 650 general practices contribute nationally representative data with over 5 
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million active patients. (www.cprd.com/intro.asp last accessed 14/06/2014)  
Practices must meet rigorous standards for data quality prior to inclusion and the 
high validity of diagnosis in the CPRD has been reported by two systematic 
reviews.  (Herrett et al, 2010; Khan et al, 2010a)  
Datasets such as the primary care EHR used for retrospective cohort studies are 
not collected for the express purpose of answering a particular research question, 
resulting in the inability to specify the particular variables of interest about which 
information is collected.  Thus, levels of missing data for some of the variables of 
particular interest in this study, especially BMI, levels of serum urate, and 
exposure to smoking and alcohol, within the dataset were higher than would have 
been liked. In addition, it was felt that this data was not likely to be missing at 
random and as such the assumptions required for use of multiple imputation would 
not be satisfied. (Taylor et al, 2013) Some variables which may have a bearing on 
the relationships examined, such as family history of heart disease and physical 
activity, could not be included in the analysis due to poor levels of recording.  
Similarly, whilst matching by general practice is an accepted method of accounting 
for socio-demographic differences, there may be considerable socio-demographic 
variation within a practice area that may influence this relationship, and no 
individual level data was available, meaning that any potential effect could neither 
be accounted for in the analysis, nor explored any further.   
Confounding by Indication 
Confounding by indication, also known as confounding by severity of disease, 
results from the effect of prognostic factors on treatment decisions and produces a 
biased estimate of the treatment’s effect on the outcome of interest.  The most 
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obvious example of this is that those participants with the most severe disease are 
most likely to receive treatment, but are also more likely to experience 
complications or poorer outcomes.  This can result in treatment’s looking harmful, 
when in fact they are not, simply because those who receive them are more likely 
to experience the outcome of interest for reasons unrelated to the treatment itself.  
Differences between participants in the likelihood of receiving treatments can be 
difficult to account for, and this must be highlighted as a major limitation to the 
examination of the effect of treatments on vascular risk in the gout-exposed group.  
Propensity scoring is one technique that could be used to address confounding by 
indication in future studies, using measures of relevant prognostic factors to model 
the likelihood of a participant receiving the treatment of interest.  (Rosenbaum & 
Rubin, 1983)  Since the accuracy of the propensity score is dependent upon the 
information used to specify it, large numbers of variables are often needed as 
predictors, not only confounders but also all other variables thought likely to 
influence likelihood of receiving treatment.    
The propensity score can be entered into a regression model as a covariate, or 
can be used to match participants who do and do not receive the treatment but 
who have the same propensity score, (have similar prognostic factors and 
likelihood of receiving the treatment whether in fact they actually receive it).  This 
allows the effect of treatments on the outcome of interest to be compared between 
those who do and do not receive treatment but are similar in other respects.   
In this study, each participant has multiple exposure intervals, during which they 
either received a treatment or did not, and using a binary outcome variable to 
reflect this, propensity scores could be calculated using parameter estimates from 
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a mixed-effects logistic regression analyses, which include a random subject effect 
to account for the multiple observations within each subject. (Umbrello et al, 2012)  
However there is evidence to suggest that propensity scoring does not perform 
well in the presence of missing data, since assumptions about the nature and 
ignorability of the missing data will need to be made.  (Hill, 2004)  As mentioned in 
section 7.5.1 missing data is a limitation of this study.  A number of techniques for 
estimating propensity scores in the presence of missing data have been 
suggested including complete case analysis (Little & Rubin, 1987) and multiple 
imputation. (D’Agostino et al, 2000)  Complete case analysis uses only 
participants with complete data, excluding those where there are missing data.  
This makes the assumption that those participants removed are a random sample 
of the whole dataset with respect to the covariates, and also reduces the size of 
the study sample.  (Hill, 2004) The most frequently applied approach is that of 
multiple imputation, whereby missing values are replaced by “draws” from a 
predictive distribution, allowing analysis of a complete dataset. (Rubin, 1987)  
However, multiple imputation also requires that the assumption that the data is 
missing at random be satisfied, which as described in section 7.5.1 was not felt to 
be the case in this study.   
Nevalainen et al, 2009, proposed a two-fold fully conditional specification algorithm 
to impute missing data in longitudinal data. It imputes missing values at a given 
time point, conditional on information at the same time point and immediately 
adjacent time points. The application of this procedure to similar data has been 
outlined in Welch et al, 2014, however since the estimation of treatment effects in 
the gout-exposed patients formed only a small part of this thesis it was not applied 
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here due to the constraints of time.  Future investigations could incorporate this 
approach to impute missing data allowing the estimation of propensity scores to 
account for differences between subjects who received treatments, and those who 
did not, and minimise the effect of confounding by indication. 
Study design 
A further limitation of this work is the nature of the study itself.  To take into 
account differences between exposed and unexposed groups, multiple 
adjustments on risk factors for vascular events have been performed.  However, 
even if the main risk factors have been taken into account, residual confounding 
effects cannot be ruled out.  Moreover, as an epidemiological study design, 
although an association can be demonstrated, causation cannot be inferred. 
Gout participant identification 
This study used diagnostic codes Read codes attached to episodes of care 
recorded within the electronic primary care medical record as the definition of gout.  
Recording of these codes is based upon primary care diagnosis, usually made on 
clinical grounds, without aspiration and examination of synovial fluid for the 
presence of MSU crystals.  This introduces the potential for misclassification bias, 
although previous studies indicate reasonable validity of gout diagnosis in primary 
care, (Roddy et al, 2007; Roddy et al, 2010) and previous studies undertaken in 
the CPRD have selected gout cases using a primary care diagnosis. (Mikuls et al, 
2005a; Mikuls et al, 2005b)  
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Coding of events 
It follows therefore, that the use of Read codes to identify outcomes of interest, 
may also risk misclassification bias.  Particularly in cardiovascular disease, 
terminology used to describe events has changed over time, and thus coding 
behaviours of GPs may also have changed over time. Whilst every effort has been 
made to use the most specific codes, terms such as Acute Coronary Syndrome 
could describe either MI or unstable angina, and common use of more generalised 
codes for cerebrovascular disease potentially adds to the risk of misclassification.  
However, validity of coding has been shown to be high in the CPRD (Khan et al, 
2010; Herrett et al, 2010) 
7.5.2 Study Strengths  
This study has a number of strengths compared with existing literature.  This is the 
largest study to examine the association of gout with incident vascular disease in 
primary care patients to date.  Furthermore, it is the first study to examine risk of 
incident peripheral vascular disease in primary care gout patients.  
The use of a large number of well-validated primary care EHR means the study is 
generalisable to the wider population of gout patients. Validity of cardiovascular 
disease diagnoses in CPRD was assessed by a recent systematic review, which 
reported a positive predictive value of diagnosis of myocardial infarction coded in 
CPRD of over 80%, and comparable reliability of coding for ischaemic heart 
disease to other primary care databases. (Khan et al, 2010a) The exclusion of 
patients with a prior history of vascular events reduced both surveillance bias and 
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the additional risk conferred by a vascular history, allowing the contribution of gout 
itself to be more accurately investigated.  
In addition, matching patients by age, gender and GP practice reduces the risk of 
socio-demographic confounding, whilst the adjustment for potential explanatory 
covariates in two models, allows more accurate examination of contribution of 
particular risk factors, and removes the element of surveillance bias associated 
with disease monitoring for other chronic conditions such as hypertension and 
diabetes. 
7.6 Summary 
This section has described and reported the sub-group analysis of the 
retrospective cohort study investigating the effect of risk factors in gout patients 
who experience vascular events and those who do not, using techniques of logistic 
regression and multilevel discrete-time event history analysis.  This investigation 
found that poor surveillance of SUA was associated with increased risk of 
experiencing a first vascular event, whilst frequent consultation for gout reduced 
this risk, highlighting the role of surveillance in reduction of vascular risk in gout 
patients.  
Gout patients who were exposed to prescribed NSAIDs and uricosurics, as well as 
drugs used to treat vascular risk factors were more likely to experience a first 
vascular event, a difference in the result of exposure to these medications to that 
which might be expected, suggesting mechanisms that underlie this additional risk 
in patients with gout are different to those in the general population.  Exposure to 
allopurinol did not influence the risk of experiencing a vascular event. However, 
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the effect of cumulative exposure to these medications (including prior to diagnosis 
of gout), and the time since most recent prescription for these medicines, on the 
risk of experiencing a first vascular event remains unclear.  This will be 
investigated in subsequent chapters.
      
252 
         
   
Chapter 8: Nested case-control study examining the 
association between drug exposures and risk of vascular 
event in the gout group 
8.1 Overview 
Chapter 7 identified an increased risk of incident vascular event in gout patients 
exposed to medications used in the treatment of gout and the treatment of 
vascular risk factors, following their diagnosis of gout. This chapter will describe 
the use of a nested case-control study to further investigate the effect of both 
cumulative exposure (including prior to the diagnosis of gout), and time since most 
recent prescription of these medications on the risk of an incident vascular event in 
patients with gout to test the hypothesis that the effect of exposure to these groups 
of medications on the risk of vascular event differs according to cumulative 
exposure and time since most recent exposure. Choice of study design, the 
methodology of selecting cases and controls and identifying exposures and the 
statistical analyses chosen will be presented, followed the results and potential 
implications of these findings. 
8.2 Background 
This section will describe the rationale for undertaking the study and choice of 
study design. 
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8.2.1 Rationale 
Whilst it is clear from the retrospective cohort study that gout is an independent 
risk factor for vascular disease, it remains unclear why some gout patients suffer 
vascular events, whilst others do not.  Exposures to certain medications such as 
aspirin and statins may confer protection against vascular disease, (Antithrombotic 
Trialists' Collaboration, 1994; Antithrombotic Trialists' Collaboration, 2002; Naci et 
al, 2013) whereas exposure to others, such as non-steroidal anti-inflammatory 
drugs, may increase risk of vascular events.  (Bhala et al, 2013)  The results of the 
multilevel discrete-time event history analysis presented in chapter 7 suggest that 
contemporaneous exposure to medications used to treat both acute and chronic 
gout, and those used to treat vascular risk factors (e.g. hypertension and 
hyperlipidaemia) or the mechanisms underlying vascular risk (e.g. anti-platelet 
medications) following diagnosis of gout does not seem to reduce the risk of an 
incident vascular event as might be expected.  The reasons for this are unclear, as 
is the influence of cumulative exposure to these medications (including prior to 
diagnosis of gout) on the risk of a vascular event, and time since most recent 
prescription for the drug.    
The clarification of these relationships will inform clinical decision making, since if 
patients currently taking the medications of interest (particularly urate-lowering 
therapy and medications used to treat vascular risk factors) are less likely to 
experience a vascular event than those who have previously taken, but 
discontinued them, this would provide justification for indefinite prescribing and 
encourage patient compliance.  However, if there are other medications of interest 
(particularly NSAIDs) whereby cumulative exposure might increase the risk of an 
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incident vascular event, then this might justify recommendations to prefer 
colchicine over NSAIDs in the treatment of, and prophylaxis against, acute flares 
of gout whilst initiating urate-lowering therapy in those at high vascular risk, or in 
those who have previously had high cumulative exposure to NSAIDs.   
Therefore a nested case-control study was used to examine these relationships, 
which will then be compared with the results presented in chapter 7 to identify 
differences between cumulative exposures and those which follow diagnosis of 
gout. 
8.2.2 Choice of study design 
As discussed in chapter 4, the case-control design identifies patients with a 
particular outcome of interest, matches them to controls who have not experienced 
that outcome of interest, and looks retrospectively at particular exposures to 
determine whether these exposures influence the risk of experiencing the outcome 
of interest.  This is in contrast to the cohort study where patients are selected 
based upon their exposure to a particular disease and followed until they do or do 
not develop an outcome of interest.  The retrospective cohort study presented in 
chapters 5, 6 and 7 compared risk of vascular events in those with gout to those 
without gout and identified gout as an independent risk factor for vascular disease, 
and the subgroup analyses presented in chapter 7 investigate which factors 
following the diagnosis of gout may predispose some gout patients to experience 
vascular events whilst others do not. These findings suggest that the mechanism 
underlying excess vascular risk in patients with gout differs from that in the general 
population, and that exposure to medications that should make experiencing a 
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vascular event less likely including urate lowering therapy, anti-inflammatories and 
medications to treat vascular risk factors, following diagnosis of gout, do not 
attenuate this risk as expected.   
 
The case-control design was chosen in order to allow comparison of cumulative 
exposure to medications of interest (including prior to diagnosis of gout), and most 
recent prescription for these drugs in patients with gout who experienced a first 
vascular event of interest, with those who did not.   Use of a nested case-control 
design allowed comparison of groups of gout patients based on outcome of 
interest (vascular event), whilst matching by age, gender and general practice to 
reduce potential confounding.  It allows a more accurate comparison of the 
predictors of vascular event in those who experience a vascular event compared 
with those who do not, rather than the contribution of each covariate to overall 
vascular risk across all participants.  It also facilitates investigation of a number of 
exposures simultaneously.   
8.3 Matching of cases and controls 
This section describes the identification and matching of cases and controls for the 
nested case-control analysis from within the cohort. 
8.3.1 Eligibility for inclusion  
Since the study design is a nested case-control study, where the case and control 
population are selected from the existing cohort study population, all gout patients 
from the retrospective cohort study described above were eligible for inclusion. 
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8.3.2 Case definition 
Cases were defined as those gout patients from the cohort who had experienced 
any type of vascular event during the follow-up period.  The codes used to identify 
vascular events of interest are shown in Appendix 2 
8.3.3 Control selection 
Controls were defined as those gout patients from the cohort who had not 
experienced any type of vascular event during the follow-up period.  Patients who 
had experienced a vascular event (cases) were eligible to act as controls in the 
period of their follow-up prior to their event, providing that the time of interest was 
after their diagnosis of gout and that this part of their follow-up was included in the 
original study data. (Lubin & Gail, 1984; Robins et al, 1986)  
8.3.4 Matching of cases and controls 
All gout patients who had experienced a vascular event during the original cohort 
study follow-up were matched to at least one control gout patient who had not 
experienced a vascular event.  They were matched using the same matching 
variables described in section 4.4.2 (year of birth, gender and registered general 
practice) to minimise confounding (as described in section 4.4.2).  In addition 
controls were also required to be alive at the time their matched case experienced 
the vascular event, having survived event free until that point.   
      
257 
         
   
8.4 Exposures of interest 
Exposures of interest included any drugs which may influence the likelihood of 
vascular events. Those chosen included drugs used in the treatment of acute and 
chronic gout (colchicine, NSAIDs, allopurinol and uricosurics) and drugs used to 
treat vascular risk factors or mechanisms underlying vascular risk in the anti-
platelet, lipid-lowering and anti-hypertensive groups (shown in Table 8.1).  The 
reasons for their inclusion were similar to those presented in section 7.3. 
Table 8.1 Medications of interest  
 
Anti-platelet Lipid-lowering Anti-hypertensives 
Aspirin HMG CoA reductase 
inhibitors (“statins”) 
ACE inhibitors (e.g. ramipril) 
 
 
Clopidogrel 
 
Fibrates (e.g. 
fenofibrate) 
 
A II receptor antagonists (e.g. 
candesartan) 
 
Dipyridamole 
 
Selective cholesterol 
uptake inhibitors (e.g. 
ezetimibe) 
 
α-adrenergic receptor antagonists 
(e.g. doxazosin) but excluding 
those only used for benign 
prostatic hypertrophy (e.g. 
tamsulosin) 
   
β-adrenergic receptor antagonists 
(e.g. atenolol) 
   
Calcium channel receptor 
antagonists (e.g. amlodipine) 
   
Centrally acting anti-hypertensives 
(e.g. methyldopa) 
  Diuretics (e.g. 
bendroflumethiazide) 
   
Vasodilator anti-hypertensives 
(e.g. hydralazine) 
HMG CoA = 3-hydroxy-3-methylglutaryl-coenzyme A; ACE = angiotensin-
converting enzyme; A II = angiotensin II 
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Exposures were identified within the electronic health record (EHR) using codes 
returned by the CPRD browser.  These were then used to examine the effect of 
cumulative exposure to each group of drugs and the temporal relationship of these 
exposures to vascular event. 
8.4.1 Cumulative exposure to medication 
Cumulative exposure to medications of interest was investigated in order to more 
accurately establish predictors of vascular risk in patients with gout by comparing 
exposures in those who had a vascular event with those who did not.  Given that 
in the results presented in sections 7.4.3 and 7.4.4, exposures following diagnosis 
of gout did not all influence the risk of experiencing a vascular event in a way that 
would be expected, and that the exposures investigated were measured per year 
following diagnosis of gout, rather than cumulatively, it seems reasonable to 
extend the investigation of exposures to include cumulative exposure since 
duration of therapy may be an important factor in their influence on vascular risk. 
This lends clinical utility to the estimate of risk associated with the exposure, since 
demonstrating that duration of therapy is important may justify earlier initiation of 
these drugs, or even multi-drug primary prevention strategies in patients with gout, 
whereas demonstration of lack of influence on vascular risk in patients with gout 
may prompt investigation of other strategies by which to manage vascular risk in 
gout. 
 
Cumulative exposure to medications was assessed by calculating prescribed 
dosage and duration of exposure which was then converted to the defined daily 
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dosage (as described in section 7.3.4) and summed to give a cumulative exposure 
until a vascular event was experienced or until dummy date equivalent to the date 
of vascular event experienced by the case to which they were matched for 
controls.  Exposure to each group of drugs was then categorised into above and 
below median exposure (with no exposure as the referent category) as the 
cumulative levels of exposure varied significantly and so to include this as a 
continuous variable would have yielded an odds ratio per unit increase in DDD that 
was too small to be of practical value.   
8.4.2 Time since most recent prescription for medications of interest and odds of 
vascular event 
The previous investigation presented in sections 7.4.3 and 7.4.4 allowed exposure 
to medications of interest to vary year by year, however any difference in risk of 
vascular event between those currently using, having recently used or having used 
the drugs in the past could not be assessed.  The clinical rationale for investigating 
the risk of experiencing a vascular event according to most recent use of the drug 
is to start to understand patterns in how drugs influence vascular risk, for example, 
if exposure to a particular medication within two years but not five years reduced 
odds of a vascular event then this provides evidence that benefit of these drugs is 
lost if they are stopped, providing justification for indefinite prescribing, and 
encouraging improved patient compliance.    
 
Temporal relationship of the prescription of particular drugs with vascular event 
was ascertained by categorising into four mutually exclusive time windows: most 
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recent exposure within two years of date of vascular event/matched date for 
controls, between two and five years and more than five years from date of 
vascular event or matched date for controls, and those who had never been 
exposed (no recorded use at any time prior to date of vascular event) which 
became the referent category.  
Due to the small numbers of participants in each group, when investigating 
combinations of drugs, exposure was classified into ever exposed compared with 
never exposed (prior to the date of vascular event). 
8.5 Explanatory covariates 
As discussed in section 2.4.2, many factors contribute to an individual’s likelihood 
of developing vascular disease.  In considering the role played by exposures of 
interest in the likelihood of subsequent vascular disease following a diagnosis of 
gout, these other factors which may influence this relationship must be accounted 
for.  Those considered important in this study will be discussed here. 
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8.5.1 Adjustment for explanatory covariates 
In order to account for the role that other factors play in the risk of developing 
vascular disease after a diagnosis of gout, similar potential confounders to those 
described in section 5.4 were introduced into the analysis.  These were:  
 age at diagnosis of gout  
 dichotomised values for being over-weight (BMI ≥ 25kg/m2 yes/no/missing) 
 ever/never/missing exposure to smoking or alcohol  
 Charlson Co-morbidity Index score  
 hypertension  
 renal disease (defined as chronic kidney disease or acute/chronic renal 
failure)  
 hyperlipidaemia  
8.6 Statistical analysis 
Descriptive statistics were used to describe the baseline characteristics of the 
sample including patient demographics and presence of co-morbidities.  Odds 
ratio and 95% confidence intervals of vascular event associated with current, 
recent and past exposure to each group of drugs as well as cumulative exposure 
above and below the median exposure to that group of drugs were calculated 
using conditional logistic regression.  All analysis was conducted using Stata 
statistical software release 12 (StataCorp: College Station, TX, 2011). 
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8.7 Results 
8.7.1 Number of cases and controls 
In the original cohort study, 2409 gout patients experienced a vascular event.  Of 
these, 437 had at least one exact matched control for year of birth, gender and 
registered general practice who did not experience a vascular event during the 
follow-up period in question.  Thus, the final patient population included 437 cases 
(gout patients who had experienced a vascular event) and 437 controls (gout 
patients who had not experienced a vascular event); a total of 874 patients. 
8.7.2 Description of the study population 
The majority of patients included were male (79.9% n=698), and as cases and 
controls were matched on gender so the proportion of males and females in each 
group was similar.  Year of birth was also a matching variable and so mean age at 
diagnosis of gout in the study population overall was 65.1 years (SD 9.1), and 
mean age at event/dummy date was 70.3 years (SD 8.9). Both were similar in 
those who experienced a vascular event and their matched controls. Mean 
duration of exposure to gout was also similar, 5.3 years (SD 3.4) at event/dummy 
date for cases and 4.9 years (SD 2.8) for controls.  Table 8.2 shows the frequency 
and percentage of vascular risk factors in cases and controls. 
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Table 8.2 Frequency and percentage of vascular risk factors in cases and controls  
 
Vascular risk factor  Cases Controls p for significance 
of difference * 
N (%) N (%) 
Pre index 
hypertension 
187 (42.8%) 152 (34.8%) <0.01 
Pre index 
hyperlipidaemia 
33 (7.6%) 23 (5.3%) 0.04 
Pre index diabetes 14(3.2%) 9 (2.1%) 0.17 
Pre index renal 
disease 
7 (1.6%) 4 (0.9%) 0.41 
BMI >25 kg/m2 291 (66.6%) 269 (61.6%) 0.10 
History of alcohol 
consumption 
354 (81.0%) 364 (83.3%) 0.07 
Current/former 
smoker 
137 (31.4%) 115 (26.3%) <0.01 
BMI=body mass index;  
* statistical significance assessed using Chi-squared test 
 
From table 8.2, it can be seen that the prevalence of hypertension, 
hyperlipidaemia, diabetes, renal disease, being overweight and smoking was 
slightly higher at diagnosis of gout in those who went on to experience a vascular 
event than those who did not, although this difference was only statistically 
significant for hypertension, hyperlipidaemia and smoking exposure.  History of 
alcohol consumption was more prevalent in those who did not experience a 
vascular event, although this difference was not statistically significant. 
Of the 437 gout patients who experienced a vascular event, the frequency and 
percentage of types of incident vascular event experienced are shown in table 8.3.  
The majority n=250 (57.2%) experienced cardiovascular events. 
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Table 8.3:  Frequency and percentage of types of incident vascular event experienced 
 
 N % of all first vascular 
events 
All vascular events 437 100 
All cardiovascular events 
(not including those coded 
as angina or MI) 
250 
(130) 
57.2 
(29.7) 
Angina 71 16.2 
MI 49 4.3 
All cerebrovascular 
events 
(not including those coded 
as TIA or CVA) 
160 
(74) 
36.6 
(16.9) 
CVA 45 10.3 
TIA 41 9.4 
PVD 27 6.2 
MI = myocardial infarction; CVA = cerebrovascular accident; TIA= transient 
ischaemic attack; PVD = peripheral vascular disease 
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8.7.3 Frequency and percentage of prescriptions for drugs of interest in cases and 
controls  
Tables 8.4a and 8.4b demonstrate the distribution of prescriptions for the drugs of 
interest in relation to the event or dummy date for cases and controls.  Those used 
to treat gout are shown in table 8.4a, and drugs used to treat vascular risk factors 
are shown in 8.4b.  The drugs included to treat vascular risk factors are described 
in section 7.3.3. 
 
The number of patients prescribed uricosuric medications was too small to allow 
further meaningful analysis, and so no further results are presented relating to this 
class of drugs. 
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Table 8.4a:  Distribution of prescriptions for drugs used to treat gout  
 
Date of most recent 
prescription in relation 
to vascular 
event/dummy date 
Allopurinol 
N (%) 
Uricosurics 
N (%) 
Colchicine 
N (%) 
NSAIDs 
N (%) 
Cases Controls Cases Controls Cases Controls Cases Controls 
0-2 years 123  
(28.1) 
112  
(25.6) 
3  
(0.7) 
1  
(0.2) 
30  
(6.9) 
17  
(3.9) 
282 (64.5) 269 (61.6) 
2-5 years 13  
(3.0) 
19  
(4.3) 
2  
(0.5) 
0 12  
(2.7) 
15  
(3.4) 
86  (19.7) 94  (21.5) 
More than 5 years 11 
(2.5) 
11  
(2.5) 
2  
(0.5) 
0 17  
(3.9) 
5  
(1.1) 
45  
(10.3) 
51  (11.7) 
Never 290 (66.4) 295 (67.5) 430 (98.3) 436  
(99.8) 
353 (86.5) 400 (91.5) 24  
(5.5) 
23  
(5.3) 
Total 437 437 437 437 437 437 437 437 
NSAIDs = Non-steroidal anti-inflammatory drugs 
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Table 8.4b:  Distribution of prescriptions for drugs used to treat vascular risk factors 
 
Date of most recent 
prescription in relation to 
vascular event/dummy date 
Antiplatelet 
N (%) 
Lipid-lowering 
N (%) 
Antihypertensives 
N (%) 
Cases Controls Cases Controls Cases Controls 
0-2 years 244 (55.8) 57 (13.0) 130 (29.7) 32 (7.3) 361 (82.6) 234 (53.5) 
2-5 years 6 (1.4) 4 (0.9) 4 (0.9) 1 (0.2) 11 (2.5) 23 (3.0) 
More than 5 years 2 (0.5) 9 (2.1) 1 (0.2) 1 (0.2) 3 (0.7) 20 (2.3) 
Never 180 (42.3) 367 (84.0) 302 (69.1) 402 (92.2) 62 (14.2) 180 (41.2) 
Total 437 437 437 437 437 437 
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8.7.4 Results of conditional logistic regression 
This section will describe the results of the conditional logistic regression, 
examining the relationship between prescription of drugs of interest and likelihood 
of incident vascular disease in patients with gout. 
8.7.4.1 Univariate analysis 
The odds ratio of experiencing a vascular event in patients with gout when having 
been exposed to the drug of interest within 2 years, 2-5 years and more than 5 
years previously, compared to never having been exposed to the drug is shown 
below. Table 8.5a shows the odds ratios and 95% confidence intervals for 
prescription of drugs used to treat gout, and table 8.5b shows the odds ratios and 
95% confidence intervals for prescription of drugs used to treat vascular risk 
factors. 
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Table 8.5a: Risk of vascular event associated with drugs used to treat gout 
 
Most recent prescription 
in relation to 
event/dummy date 
Odds Ratio (95% CI) 
Allopurinol Colchicine NSAIDs 
Reference value: Never exposed 
 0-2 years 1.12 
(0.90-1.40) 
1.85 
(1.19-2.89) 
1.01 
(0.65-1.55) 
2-5 years 0.71 
(0.43-1.18) 
0.83 
(0.46-1.52) 
0.87 
(0.55-1.38) 
More than 5 years ago 1.02 
(0.56-1.84) 
3.37 
(1.67-6.83) 
0.83 
(0.49-1.40) 
CI = confidence interval; NSAIDs = non-steroidal anti-inflammatory drugs 
 
Table 8.5a shows that exposure to allopurinol or NSAIDs does not influence the 
risk of experiencing a vascular event.  In contrast, exposure to colchicine within 
two years and more than 5 years from vascular event made a vascular event more 
likely, with greater odds in those who were most recently prescribed colchicine 
more than 5 years before the vascular event.  
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Table 8.5b: Risk of vascular event associated with drugs used to treat vascular risk factors 
 
Most recent prescription 
in relation to 
event/dummy date 
Odds Ratio (95% CI) 
Antiplatelet Lipid-lowering Anti-
hypertensives 
Referent value: never exposed 
0-2 years 9.51 
(6.98-12.94) 
7.67 
(5.26-11.17) 
4.27 
(3.32-5.48) 
2-5 years 2.34 
(0.76-7.18) 
7.98 
(1.14-55.65) 
2.24 
(1.13-4.46) 
More than 5 years 0.22 
(0.04-1.29) 
2.77 
(0.72-10.66) 
1.11 
(0.40-3.09) 
CI = confidence interval 
 
Table 8.5b shows that exposure to anti-hypertensives, anti-platelet and lipid-
lowering medications within 2 years made a vascular event more likely.  
Additionally, exposure to lipid-lowering and anti-hypertensive medications within 2-
5 years also made vascular event more likely, although whilst the risk of 
experiencing an event increased with time since most recent prescription for lipid-
lowering medications, it did reduce but remain increased with time since exposure 
to anti-hypertensive medications. 
 
The odds of vascular event according to cumulative exposure to each group of 
drugs above and below the median are shown below.  Table 8.6a shows the odds 
ratio and 95% confidence intervals associated with exposure to drugs used to treat 
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gout, and table 8.6b shows the odds ratio and 95% confidence intervals 
associated with exposure to drugs used to treat vascular risk factors.  
 
Table 8.6a: Cumulative exposure to drugs used to treat gout and relationship to odds of vascular 
event 
 
Cumulative 
exposure 
Allopurinol 
Odds Ratio  
(95%CI) 
Colchicine 
Odds Ratio  
(95%CI) 
NSAIDs 
Odds Ratio  
(95%CI) 
Referent value: Never exposed 
Below median 1.16 
(0.83-1.64) 
1.38 
(0.77-2.48) 
0.71 
(0.46-1.11) 
Above median 0.90 
(0.62-1.31) 
1.66 
(0.88-3.12) 
0.50 
(0.31-0.80) 
CI = Confidence interval; NSAIDs = Non-steroidal anti-inflammatory drugs 
 
Table 8.6a shows that the risk of a vascular event is unaffected by level of 
cumulative exposure to allopurinol and colchicine.  Above median exposure to 
NSAIDs is shown to reduce risk of a vascular event. 
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Table 8.6b: Cumulative exposure to drugs used to treat vascular risk factors and relationship to 
odds of vascular event 
 
Cumulative 
exposure 
Antiplatelet 
Odds Ratio  
(95%CI) 
Lipid-lowering 
Odds Ratio  
(95%CI) 
Antihypertensives 
Odds Ratio  
(95%CI) 
Referent value: Never exposed 
Below median 2.12 
(1.57-2.88) 
3.63 
(2.63-5.01) 
1.97 
(1.30-2.98) 
Above median 2.85 
(1.97-4.13) 
4.02 
(2.73-5.93) 
1.65 
(1.03-2.64) 
CI = Confidence interval 
 
Table 8.6b shows that participants exposed to anti-platelet, lipid-lowering and anti-
hypertensive medications are more likely to experience a vascular event, with 
those who had above median exposure to anti-platelet and lipid-lowering 
medications more likely to experience a vascular event than those with below 
median exposure.  In contrast, those with above median exposure to anti-
hypertensives were less likely to experience a vascular event than those with 
below median exposure, but still more likely than those who were unexposed.  
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8.7.4.2 Multivariable analysis 
The odds ratio of experiencing a vascular event in patients with gout who are 
prescribed drugs of interest compared to those who are not, after adjustment for 
age at diagnosis of gout, gender, history of hypertension, hyperlipidaemia, renal 
disease, Charlson co-morbidity score, overweight (BMI>25kg/m2 yes/no), 
ever/never exposure to smoking or alcohol, are presented in tables 8.7a and 8.7b 
below.  Table 8.7a presents the odds ratio and 95% confidence intervals 
associated with exposure to drugs used to treat gout, and table 8.7b presents the 
odds ratio and 95% confidence intervals associated with exposure to drugs used 
to treat vascular risk factors. 
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Table 8.7a:  Multivariable analysis – drugs used to treat gout 
 
 Odds Ratio (95% CI) 
Allopurinol Colchicine NSAIDs 
Most recent prescription in relation to event/dummy date (referent: never exposed) 
0-2 years 0.99 
(0.68-1.45) 
1.25 
(0.73-2.14) 
1.69 
(0.90-3.16) 
2-5 years 0.57 
(0.31-1.03) 
0.61 
(0.33-1.13) 
1.20 
(0.64-2.26) 
More than 5 years 0.64 
(0.32-1.28) 
3.12 
(1.47-6.65) 
1.03 
(0.54-1.95) 
Cumulative exposure DDD: Referent value: never exposed 
Below median 1.28 
(0.90-1.82) 
1.72 
(0.94-3.14) 
0.67 
(0.42-1.06) 
Above median 0.95 
(0.63-1.43) 
2.00 
(1.09-3.70) 
0.44 
(0.27-0.74) 
Age at diagnosis of gout 0.93 
(0.88-0.99) 
0.92 
(0.87-0.98) 
0.91 
(0.86-0.97) 
Overweight (BMI >25kg/m2): Referent value: no 
Yes 1.17 
(0.91-1.49) 
1.17 
(0.91-1.50) 
1.15 
(0.89-1.47) 
Missing 0.76 
(0.50-1.15) 
0.85 
(0.55-1.30) 
0.73 
(0.48-1.11) 
Ever exposure to alcohol: Referent value: no exposure 
Yes 0.67 
(0.48-0.93) 
0.69 
(0.50-0.96) 
0.70 
(0.51-0.98) 
Missing 0.77 
(0.47-1.28) 
0.78 
(0.46-1.31) 
0.83 
(0.50-1.36) 
Ever exposed to smoking: Referent value: no exposure 
Yes 1.20 
(0.95-1.52) 
1.18 
(0.94-1.49) 
1.23 
(0.97-1.56) 
Missing 0.79 
(0.60-1.07) 
0.76 
(0.56-1.02) 
0.80 
(0.60-1.08) 
Charlson co-morbidity 
score 
1.25 
(1.09-1.43) 
1.28 
(1.14-1.45) 
1.26 
(1.10-1.45) 
Hypertension 1.40 
(1.13-1.74) 
1.42 
(1.14-1.76) 
1.40 
(1.13-1.73) 
Hyperlipidaemia 1.38 
(0.91-2.08) 
1.56 
(1.03-2.37) 
1.35 
(0.90-2.01) 
Renal disease 1.03 
(0.38-2.77) 
1.02 
(0.36-2.87) 
0.98 
(0.35-2.74) 
CI = confidence interval; DDD = defined daily dosage; NSAIDs = non-steroidal 
anti-inflammatory drugs 
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Table 8.7a shows that in the multivariable model, exposure to allopurinol does not 
influence the risk of experiencing a vascular event, most recent exposure more 
than 5 years previously and above median exposure to colchicine made a vascular 
event more likely whilst above median exposure to NSAIDs reduced the odds of a 
vascular event.  Presence of hypertension and increasing Charlson co-morbidity 
score increased odds of a vascular event, whereas increasing age at diagnosis of 
gout and exposure to alcohol made a vascular event less likely. 
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Table 8.7b:  Multivariable analysis – drugs used to treat vascular risk factors 
 
 Odds Ratio (95% CI) 
Antiplatelet Lipid-lowering Antihypertensives 
Most recent prescription in relation to event/dummy date (referent: never exposed) 
0-2 years 4.86 
(3.20-7.37) 
2.91 
(1.85-4.59) 
3.37 
(2.36-4.81) 
2-5 years 1.62 
(0.55-4.79) 
3.09 
(0.30-31.56) 
1.50 
(0.74-3.03) 
More than 5 years 0.18 
(0.03-1.15) 
0.45 
(0.13-1.63) 
0.96 
(0.33-2.81) 
Cumulative exposure DDD: Referent value: never exposed 
Below median 2.20 
(1.59-3.03) 
3.63 
(2.55-5.18) 
1.94 
(1.27-2.95) 
Above median 3.14 
(2.12-4.66) 
4.55 
(2.96-7.00) 
1.63 
(1.01-2.65) 
Age at diagnosis of gout 1.48 
(1.17-1.87) 
0.90 
(0.84-0.96) 
0.93 
(0.88-0.98) 
Overweight (BMI >25kg/m2):Referent value: no  
Yes 1.14 
(0.83-1.56) 
1.04 
(0.78-1.38) 
0.95 
(0.72-1.24) 
Missing 0.72 
(0.42-1.23) 
1.08 
(0.68-1.73) 
0.57 
(0.37-0.88) 
Ever exposure to alcohol: Referent value: no exposure 
Yes 0.76 
(0.48-1.21) 
0.68 
(0.46-1.00) 
0.59 
(0.41-0.84) 
Missing 0.85 
(0.39-1.86) 
0.92 
(0.54-1.58) 
0.80 
(0.45-1.40) 
Ever exposed to smoking: Referent value: no exposure 
Yes 1.28 
(0.96-1.71) 
1.23 
(0.94-1.61) 
1.15 
(0.90-1.48) 
Missing 0.94 
(0.64-1.37) 
0.75 
(0.54-1.05) 
0.80 
(0.45-1.40) 
Charlson co-morbidity 
score 
1.48 
(1.17-1.87) 
1.32 
(1.16-1.51) 
1.26 
(1.11-1.44) 
Hypertension 1.15 
(0.89-1.49) 
1.25 
(1.00-1.57) 
N/A 
Hyperlipidaemia 1.81 
(1.03-3.19) 
N/A 1.27 
(0.81-1.97) 
Renal disease 1.33 
(0.26-6.88) 
0.59 
(0.20-1.74) 
0.60 
(0.23-1.61) 
CI = confidence interval; DDD = defined daily dosage; NSAIDs = non-steroidal 
anti-inflammatory drugs 
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Table 8.7b shows patients exposed to anti-platelet, anti-hypertensive and lipid-
lowering medications within two years are more likely to experience a vascular 
event in the multivariable model.  Odds of experiencing a vascular event was 
increased with both above and below median exposures to all three classes of 
drugs, with risk greater in those with above median exposure to anti-platelet and 
lipid-lowering medications.  In contrast, those with above median exposure to anti-
hypertensives were less likely to experience a vascular event than those with 
below median exposure, but still more likely than those who were unexposed. 
Table 8.8a reports the odds ratio of experiencing a vascular event given exposure 
to combinations of medications without adjustment for other vascular risk factors, 
table 8.8b reports the odds ratio of experiencing a vascular event given exposure 
to combinations of medications used to treat vascular events in the full 
multivariable model.  Table 8.8c reports the odds ratio of experiencing a vascular 
event given exposure to combinations of medications used to treat vascular events 
and allopurinol in the multivariable model.   
These tables show that even in combination, exposure to the medications used to 
treat vascular risk factors does not reduce the risk of experiencing an incident 
vascular event.  However, those participants exposed to allopurinol were less 
likely to experience an incident vascular event if that exposure was also in the 
presence of combinations of:  
 anti-hypertensives and anti-platelet  drugs 
 anti-platelet and lipid-lowering drugs  
 anti-hypertensive, anti-platelet and lipid-lowering 
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Table 8.8a Odds ratio of experiencing a vascular event following exposure to combinations of medications 
 
Combination of 
medications 
(ever compared 
with never 
exposure) 
Anti-hypertensive + 
anti-platelet 
Anti-hypertensive + 
lipid-lowering 
Anti-platelet + lipid-
lowering 
Anti-hypertensive + 
anti-platelet + lipid-
lowering 
Anti-hypertensive + 
anti-platelet + lipid-
lowering + 
allopurinol 
OR(95% CI) OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
Anti-hypertensives 1.74  
(1.41-2.14) 
1.97  
(1.61-2.42) 
 1.72  
(1.39-2.12) 
1.77  
(1.43-2.18) 
Anti-platelet 3.50  
(2.52-4.86) 
 3.09  
(2.24-4.26) 
2.82  
(2.05-3.88) 
3.02  
(2.18-4.20) 
Lipid-lowering  5.66  
(3.76-8.52) 
4.30  
(2.82-6.57) 
4.21  
(2.76-6.41) 
4.34  
(2.87-6.57) 
Allopurinol     0.75  
(0.63-0.88) 
Hosmer & 
Lemeshow p for 
goodness of fit 
0.20 0.17 0.23 0.26 0.27 
CI = confidence interval; OR = odds ratio 
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Table 8.8b Odds ratio of experiencing a vascular event following exposure to combinations of medications used to treat vascular risk factors in a 
multivariable model 
Combination of medications 
(Ever compared to never 
exposure) 
Anti-hypertensive + anti-platelet Anti-hypertensive + lipid-
lowering 
Anti-platelet + lipid-lowering Anti-hypertensive + anti-platelet 
+ lipid-lowering 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Anti-hypertensives 1.70 (1.37-2.10) 1.95 (1.58-2.40)  1.70 (1.36-2.11) 
Anti-platelet 3.58 (2.55-5.01)  3.10 (2.22-4.32) 2.87 (2.06-3.99) 
Lipid-lowering  5.79 (3.81-8.81) 4.33 (2.75-6.82) 4.34 (2.78-6.79) 
Overweight (BMI >25kg/m
2
):Referent value: no 
Yes 1.11 (0.86-1.43) 1.10 (0.84-1.45) 1.09 (0.83-1.43) 1.08 (0.82-1.41) 
Missing 0.56 (0.36-0.87) 0.73 (0.48-1.13) 0.67 (0.42-1.06) 0.62 (0.39-0.97) 
Ever exposure to alcohol: Referent value: no exposure 
Yes 0.73 (0.50-1.07) 0.65 (0.46-0.92) 0.73 (0.50-1.07) 0.67 (0.46-0.99) 
Missing 0.71 (0.38-1.31) 0.73 (0.42-1.24) 0.72 (0.40-1.31) 0.69 (0.39-1.24) 
Ever exposure to smoking: Referent value: no exposure 
Yes 1.25 (0.95-1.63) 1.11 (0.86-1.44) 1.24 (0.93-1.65) 1.21 (0.90-1.62) 
Missing 0.98 (0.73-1.33) 0.98 (0.72-1.33) 1.02 (0.74-1.41) 0.97 (0.70-1.36) 
Charlson 1.20 (1.04-1.38) 1.25 (1.10-1.42) 1.30 (1.14-1.49) 1.29 (1.12-1.47) 
Hypertension   1.21 (0.95-1.52)  
Hyperlipidaemia 1.15 (0.67-1.96)    
Renal disease 1.19 (0.32-4.46) 0.60 (0.22-1.60) 0.76 (0.26-2.28) 0.65 (0.20-2.09) 
Hosmer & Lemeshow p for 
goodness of fit 
0.22 0.19 0.26 0.28 
CI = confidence interval; OR = odds ratio 
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Table 8.8c Odds ratio of experiencing a vascular event following exposure to combinations of medications used to treat vascular risk factors and allopurinol 
in a multivariable model 
 
Combination of medications 
(Ever compared with never 
exposure) 
Anti-hypertensive + anti-
platelet + allopurinol 
Anti-hypertensive + lipid-
lowering + allopurinol 
Anti-platelet + lipid-lowering 
+ allopurinol 
Anti-hypertensive + anti-
platelet + lipid-lowering + 
allopurinol 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Anti-hypertensives 1.73 (1.40-2.15) 1.98 (1.61-2.44)  1.69 (1.36-2.10) 
Anti-platelet 3.77 (2.67-5.30)  3.29 (2.36-4.61) 3.11 (2.24-4.31) 
Lipid-lowering  5.88 (3.87-8.94) 4.42 (2.82-6.92) 4.33 (2.83-6.60) 
Allopurinol 0.78 (0.66-0.91) 0.87 (0.74-1.02) 0.76 (0.64-0.90) 0.73 (0.63-0.89) 
Overweight (BMI >25kg/m
2
):Referent value: no 
Yes 1.13 (0.87-1.46) 1.12 (0.86-1.47) 1.13 (0.86-1.49) 1.12 (0.85-1.47) 
Missing 0.54 (0.34-0.86) 0.73 (0.47-1.13) 0.67 (0.41-1.08) 0.61 (0.37-0.99) 
Ever exposure to alcohol: Referent value: no exposure 
Yes 0.75 (0.51-1.10) 0.65 (0.46-0.93) 0.76 (0.51-1.13) 0.72 (0.49-1.07) 
Missing 0.74 (0.39-1.39) 0.74 (0.43-1.27) 0.75 (0.40-1.39) 0.71 (0.38-1.31) 
Ever exposure to smoking: Referent value: no exposure 
Yes 1.26 (0.96-1.66) 1.12 (0.87-1.44) 1.27 (0.95-1.70) 1.22 (0.91-1.64) 
Missing 0.99 (0.73-1.33) 0.98 (0.72-1.33) 1.04 (0.75-1.43) 1.04 (0.76-1.44) 
Charlson 1.19 (1.03-1.37) 1.25 (1.10-1.41) 1.29 (1.13-1.48) 1.25 (1.10-1.43) 
Hypertension   1.21 (0.95-1.52)  
Hyperlipidaemia 1.18 (0.68-2.04)    
Renal disease 1.38 (0.36-5.21) 0.64 (0.24-1.70) 0.90 (0.30-2.67) 0.81 (0.26-2.55) 
Hosmer & Lemeshow p for 
goodness of fit 
0.23 0.19 0.27 0.29 
CI = confidence interval; OR = odds ratio 
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Table 8.8c shows that, in contrast to the results presented in table 8.7a where it 
was shown that exposure to allopurinol alone does not influence risk of 
experiencing an incident vascular event, in the presence of all the combinations of 
medications used to treat vascular risk factors (except the combination of anti-
hypertensive medications with lipid-lowering medications) those who had ever 
been exposed to allopurinol were less likely to experience an incident vascular 
event than those who had never been.  This suggests that there may be a role for 
combination therapy in the prevention of vascular events in gout patients, using 
both treatments for vascular risk factors and allopurinol. 
8.8 Strengths and limitations of this study 
8.8.1 Strengths 
This study has several strengths.  It uses a matched design to reduce the 
influence of socio-economic confounders that may bias the estimate of effect size, 
and uses a multivariable model to investigate the effect of other potential 
confounders on the relationships of interest between exposures to medications 
and odds of incident vascular event.   
The use of primary care EHR means that reliable data on prescribed medications 
was available for a long period of time, preceding the diagnosis of gout (or 
matched index date for controls) where the cohort study time begins.  This allows 
assessment of cumulative exposure to these drugs in order to compare these 
findings with those from the multilevel discrete-time event history analysis 
(MDtEHA) whereby exposure was measured per one year of follow-up and did not 
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include any exposure prior to the study.  Furthermore the use of DDD in 
calculating exposure allowed direct comparison of the effect of different groups of 
medications on odds of vascular event, which is not otherwise possible.  This is 
the first study to examine the effect of exposure to these medications on risk of all 
vascular events in patients with gout, and to use DDD in order to facilitate inter-
group comparison.    This study is also the first to investigate the temporal 
relationship of the most recent prescription for the medications of interest to odds 
of first vascular event.  This is also the first study to quantify the effect of time 
since last prescription of the drugs of interest on the risk of a vascular event, which 
is important since it informs clinical decisions about the optimum prescribing 
patterns for each individual drugs to reduce vascular risk, and also the peaks and 
troughs of risk relating to these prescriptions identifying key points at which to 
target surveillance for vascular events. 
8.8.2 Limitations 
This study was not without its limitations and these are described below 
Data source 
The limitations of conducting epidemiological research using primary care EHR 
such as those used in this study has previously been discussed in section 7.5.1 
however one added limitation of this particular study was that it was a nested 
case-control study where cases and controls could only be selected from an 
existing sample population.  This limited the number of cases and controls 
available for inclusion, although in case-control studies additional efficiency is not 
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necessarily added by increased numbers of cases and controls,  since if matching 
variables are related to exposures of interest, then the frequency of exposures in 
controls can be distorted towards that of the cases, introducing selection bias. 
(Rothman & Greenland, 1998)  
Study design 
The case-control design is susceptible to information bias, which is systematic 
inaccuracy in the estimate of effect size resulting from differences in the type of 
data collected, or the methods of data collection within the study.  This can also be 
present in studies using EHR if the records of those who have the outcome of 
interest are searched more thoroughly for the exposures of interest.  Although 
every attempt was made to avoid this by searching the records of cases and 
controls using the same lists of codes to identify medications, the possibility of this 
cannot be completely eliminated. 
Furthermore, the requirement for matching on age, gender and registered general 
practice to adjust for socio-economic confounders, and the nesting of the case-
control study within the existing cohort population limited the number of potential 
participants for inclusion, and resulted in a ratio of 1:1 matching, which for reasons 
described in section 4.4.2 may reduce the power of the study to detect a true 
association.  However, matching within case-control studies can also introduce 
selection bias if the matching criteria are related to the exposure, since the 
purpose of using controls is to estimate the distribution of the exposure in the 
source population and if controls are matched to cases on a factor correlated with 
the exposure then the frequency of exposure in the controls may be distorted 
towards that of the cases.  This selection bias behaves like confounding and may 
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influence the effect estimate, usually towards the null, although this bias can be 
minimised by controlling for the matching variables in the analysis, as was the 
case in this study.  (Rothman & Greenland, 1998)  
Confounding by indication 
As mention in section 7.5.1 confounding by indication is a potential problem in all 
observational studies, including those of a case-control design, resulting from the 
effect of prognostic factors on treatment decisions and producing a biased 
estimate of the treatment’s effect on the outcome of interest.  It is possible that 
participants in this study with the most severe disease are also those most likely to 
receive treatment, but also more likely to experience complications or poorer 
outcomes.  The results whereby treatments look harmful, when in fact they are 
not, may simply reflect treatments being offered to those with the poorest 
prognosis and not as a result of the treatment itself.  
Identification of exposures 
Exposure to medications and covariates of interest was determined using lists of 
codes identified from the browser supplied by the CPRD.  Whilst every effort was 
made to ensure that these lists were as comprehensive as possible, including 
attempting to identify validated lists of codes from existing literature, and in the 
absence of these by searching each chapter of the CPRD code browser relating to 
the organ system of interest individually to ensure that only the most specific and 
appropriate codes were included, it is possible that they were not exhaustive, 
introducing the possibility of an inaccurate estimate of effect size.  Furthermore, as 
in the cohort study identification of the covariates of interest, e.g. hypertension rely 
on the accurate and consistent coding of these conditions in the EHR by GPs, 
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which although is thought to have high validity in the CPRD, cannot be 
guaranteed.  However this is unlikely to differ between cases and controls groups 
and therefore is not likely to explain the study findings. 
In addition, the EHR includes only prescribed medications. In the case of several 
NSAIDs (e.g. ibuprofen or diclofenac) and aspirin these medications are available 
to purchase over the counter, and therefore cumulative exposure to these drugs 
may have been underestimated, although this would be similar for those who 
experienced an event of interest and those who did not.    
Exposure to some of the drugs of interest, particularly uricosurics and colchicine 
was rare, and the smaller numbers may not have been enough to detect any 
influence on odds of experiencing a first vascular event.   
8.9 Summary 
This chapter has presented a nested case-control study and the effect of exposure 
to medications used to treat gout and vascular risk factors on likelihood of first 
vascular event.   
Exposure to allopurinol at any time relative to vascular event, or in any cumulative 
amount did not influence likelihood of vascular event.  Participants who were 
exposed to colchicine more than 5 years ago were more likely to experience a 
vascular event as were those with above median cumulative exposure.  In 
contrast, those with above average exposure to NSAIDs were less likely to 
experience a vascular event than those who were not exposed.   
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Participants who had been exposed to anti-platelet, anti-hypertensive and lipid-
lowering medications within 2 years were more likely to experience a vascular 
event, odds of experiencing a vascular event increased with above median 
exposure to anti-platelet and lipid-lowering medications compared with below 
median or no exposure.  In contrast, those with above median exposure were less 
likely to experience a vascular event compared with those with below median 
exposure, but was increased compared with those with no exposure.   
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Chapter 9:  Discussion 
9.1 Overview 
This chapter will discuss the findings of the cohort study and their potential 
implications for clinical practice 
9.2 Association of gout and vascular disease 
This study provides evidence that gout is an independent risk factor for all vascular 
events, all cardiovascular events and incident peripheral vascular disease in men, 
and all vascular events with the exception of MI and all cerebrovascular events in 
female gout patients, in this cohort of primary care gout patients over the age of 
50.  The trend in the magnitude of this risk was found to be greater in women and 
increased over time.   
The precise mechanism underlying the association between gout and vascular 
disease reported in this study remains unclear, but although risk is attenuated after 
accounting for the full range of traditional risk factors (age, gender, gout*gender 
interaction, smoking and alcohol exposure, BMI, Charlson co-morbidity score, 
history of hypertension, hyperlipidaemia, renal disease, exposure to prescription of 
aspirin or statins), excess risk of all vascular events, all cardiovascular events and 
PVD persists in both genders, and excess risk of angina, CVA and TIA also 
persists in women.    
The results of this study highlight many differences in the associations between 
gout and different types of vascular disease.  These include differences in strength 
and significance of the associations between different types of vascular disease, 
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and effects of gender and risk of vascular disease over time.  These will be 
discussed in the context of existing literature. 
9.2.1 Association of gout and cardiovascular disease 
Previous studies examining this association have been conflicting; however, this 
may arise from the heterogeneity of ascertainment of gout, geographical location, 
study population (health professionals, patients managed in primary and 
secondary care) and study sample size and gender distribution used.  This study 
aimed to estimate the excess risk of vascular disease in a typical gout patient, 
which in the UK is managed in primary care, includes both men and women and is 
over the age of 50 at diagnosis of gout.  Patients with a prior history of vascular 
disease were excluded in order to minimise the effect of surveillance bias on the 
estimate of risk. To our knowledge this is the largest study undertaken in primary 
care to examine this association to date.   
Investigating these associations in primary care, where the majority of gout 
patients are managed, is important since many of the large prospective studies 
examining these associations (such as the Framingham study, (Abbott et al, 1988) 
Multiple Risk Factor Intervention Trial (MR-FIT), (Krishnan et al, 2008) and the 
Health Professionals Follow-up Study, (Choi & Curhan, 2007)) either recruit from 
secondary care, more specialised populations such as health professionals, or 
have other more restrictive recruitment criteria which limits their generalisability.   
Previous studies examining the association between gout and cardiovascular 
disease have been conflicting; after adjustment for vascular risk factors results 
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from the Framingham study reported an increased incidence of CHD and angina in 
men but not women, although the number of women in their gout population was 
small (n=19/111 17%). (Abbott et al, 1988)   Furthermore, the Framingham study 
design required participants to attend biennially for cardiovascular assessment, 
which despite facilitating accurate determination of risk factors, potentially 
introduced surveillance bias if awareness of these risk factors prompted patients to 
modify their lifestyle in order to mitigate against the onset of vascular disease. 
However, both a prospective study using a population of male health professionals 
from the US, and a primary care case-control study using gout patients of both 
genders from the Netherlands reported no increased incidence of CHD.  (Gelber et 
al, 1997; Janssens et al, 2003)  
Studies of the association between gout and MI produce similar conflicting reports 
with the findings of two studies in agreement with the results of this study; 
Krishnan et al, 2006, reporting an increased incidence of non-fatal and all MI in a 
male study population and Choi and Curhan,  2007, reporting an increased risk of 
non-fatal MI in men. (Choi & Curhan, 2007; Krishnan et al, 2006)  Increased risk of 
non-fatal and all MI, (Kuo et al, 2013) and increased risk of all MI, (Seminog & 
Goldacre, 2013) have both been reported in samples of mixed gender, but the 
results are adjusted for, but not presented by, gender making direct comparison 
with these findings difficult.  However, DeVera et al, 2010, reported an increased 
incidence of non-fatal and all MI in women but not men in a retrospective cohort 
study in Canada, whilst Abbott et al, 1988, report no association between gout and 
MI in either gender.  (Abbott et al, 1988; De Vera et al, 2010)  DeVera et al, 2010, 
used a similar sized population of gout patients to our sample (9642), however 
their participants were recruited from an older age (over 65 years) and included 
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those managed in primary and secondary care.  (De Vera et al, 2010)  This may 
introduce the potential for confounding by disease severity since patients 
managed in secondary care represent the more severe end of the disease 
spectrum and are more likely to be at risk of complications of gout including 
vascular events. Furthermore the excess risk identified in this study may be 
explained by a number of lifestyle factors such as smoking, alcohol and BMI which 
they were unable to account for in their analyses, meaning that despite their 
known influence on vascular risk, the contribution of these risk factors to the 
estimate of risk in this study remained unmeasured.  (De Vera et al, 2010) The 
results of this study suggest the excess risk of vascular disease in gout patients, 
although perhaps not of the same magnitude, is similar to that seen in other 
inflammatory arthritides, such as RA, with the greatest risk conferred in patients 
with established disease. (Aviña‐Zubieta et al, 2008)  Mechanisms such as 
accelerated atherosclerosis and auto-immune inflammatory pathways involving 
TNF-alpha, IL-1 and IL-6 are thought to be responsible for increased 
cardiovascular risk in other inflammatory arthritides, (Soltész et al, 2011) and  are 
equally applicable in gout following activation of the inflammasome in response to 
MSU crystals, (Jin et al, 2012) with evidence of persistent inflammation between 
acute attacks. (Pascual et al, 1999; Roddy et al, 2013) In addition to this, 
hyperuricaemia has been shown to increase cardiovascular risk through 
endothelial dysfunction, renovascular disease, hypertension and direct pro-
inflammatory effects on vascular cells. (Jin et al, 2012; Soltész et al, 2011) This 
mechanism will be discussed in more detail in section 9.3. 
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9.2.2 Gout and cerebrovascular disease 
An increased risk of all cerebrovascular events, TIA and CVA was found in 
women, and increased risk of TIA found in men with gout after adjustment for the 
covariates in model 1.  After adjustment for the wider range of covariates in model 
2, the risk remained but was attenuated in women with gout and was not seen in 
men.  The association between gout and incident cerebrovascular disease has not 
been extensively researched, and thus there is little existing literature with which to 
compare these results.  A recently published paper reported an increased risk of 
subsequent stroke following gout requiring hospital admission in patients with no 
previous history of stroke.  They report a rate ratio for all strokes of 1.71(1.68-
1.75), ischaemic stroke 1.68 (1.64-1.73), haemorrhagic stroke 1.69 (1.61-1.77) 
and stroke of unspecified type of 2.00 (1.95-2.06).  The associations were stronger 
in younger age groups and also stronger in women than men.  (Seminog & 
Goldacre, 2013) However, the sample of gout patients used required hospital 
admission for their gout, which is not representative of the wider population of 
patients with gout, and introduces confounding by gout disease severity.  
Furthermore, no attempt was made to account for traditional vascular risk factors 
which are likely to have an important bearing on this relationship. 
Teng et al, 2012, investigated mortality from fatal stroke in patients with gout, but 
no statistically significant associations were found in either gender, which would 
support the findings in male but not female participants of this study.  (Teng et al, 
2012)  
These findings suggest that traditional vascular risk factors may be responsible for 
these increased risks in men, but that there are alternative factors influencing 
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these relationships in women.  These will be discussed in more detail in section 
9.5. 
9.2.3 Gout and peripheral vascular disease 
The association with peripheral vascular disease in both genders is also 
particularly strong.   This supports the findings of the single study to have 
previously investigated this relationship. (Baker et al, 2007) Few studies have also 
linked hyperuricaemia with PVD. (Langlois et al, 2003; Shankar et al, 2008; Tseng, 
2004; Vigna et al, 1992)  This association may result from common risk factors 
shared by gout and PVD, such as hypertension and metabolic syndrome. 
(Shammas, 2007) It has also been suggested that tissue damage caused by 
hypoxia resulting from peripheral arterial disease leads to adenine nucleotide 
breakdown and increased production of uric acid. (Langlois et al, 2003)   
9.3  Mechanisms underlying differing risk of vascular disease by site 
This is the first study to date to examine associations with all three of these forms 
of vascular disease simultaneously allowing direct comparison.  Having discussed 
the associations between gout and different forms of vascular disease in the 
context of existing literature, the reasons for the differences between these 
associations will now be discussed.   
Major risk factors for cardiovascular disease are also considered risk factors for 
cerebrovascular diseases and peripheral vascular disease.  However, it has been 
reported that some risk factors are more strongly associated with particular forms 
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of vascular disease, for example hypertension is the most significant risk factor for  
cerebrovascular disease, (O'Donnell et al, 2010) hyperlipidaemia for coronary 
heart disease and smoking and diabetes for PVD.  (Fowkes et al, 2013) Data from 
the Framingham study were used to develop individual calculators, which used 
combinations of the risk factors most strongly associated with each type of 
vascular disease to estimate a patient’s risk of coronary heart disease, stroke and 
PVD.  (Murabito et al, 1997; Wilson et al, 1998; Wolf et al, 1991) These were later 
used to create a calculator of overall cardiovascular risk, although the authors 
acknowledge that this overall risk model does not perform as well as the individual 
calculators in estimating risk of particular diseases.  (D'Agostino et al, 2008)   
It is possible that excess risk associated with gout differs between vascular 
diseases at different sites because either hyperuricaemia, or the pro-inflammatory 
cytokines released in response to the presence of MSU crystals, preferentially 
predispose to cardiovascular and peripheral vascular disease as opposed to 
cerebrovascular disease, or interact more potently with other risk factors involved 
in cardio- or peripheral vascular disease pathogenesis rather than cerebrovascular 
disease.  
The reasons for the importance of particular vascular risk factors in the distribution 
of atherosclerosis across different vascular beds, e.g. plaques of the carotid 
endothelium rather than those of the coronary arteries, remain unclear.  Some of 
the answers may lie in the mechanisms by which atherosclerosis predisposes to 
vascular disease, and the interaction of uric acid and the pro-inflammatory 
cytokines released as part of an MSU-induced inflammatory pathway.  These 
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mechanisms include both decreased endothelium-dependent vasomotion and 
plaque deposition, and these will be discussed in turn.   
As described in section 2.4.1 oxidative stress plays an important role in 
endothelium-dependent vasodilation, through reduction in the bioavailability and 
action of nitric oxide on vascular smooth muscle cells, and inhibition of platelet 
aggregation and expression of adhesion molecules,  (Pennathur & Heinecke, 
2007) resulting in a  proatherogenic state. (Landmesser et al, 2006) The 
involvement of uric acid in this pathway is complex, since whilst uric acid is known 
to be an anti-oxidant, soluble uric acid can also react to form oxidants, increase 
lipid oxidation, upregulate the renin-angiotensin system and induce endothelial 
dysfunction through proinflammatory and proliferative effects on vascular smooth 
muscle cells.  (Kanellis & Kang, 2005)  
The relationship between the action of xanthine oxidase, hyperuricaemia and other 
contributors to vascular risk are presented in figure 9.1 below. 
Figure 9.1 Role of hyperuricaemia in vascular risk 
 
Source: (Anker et al, 2003) 
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Insulin resistance (IR) and cell death increase purine levels and thus stimulate 
increased action of xanthine oxidase (XO), which results in increased levels of uric 
acid but also production of free radicals which in turn promote release of 
inflammatory cytokines.  Tissue hypoxia also stimulates increased action of XO, 
release of inflammatory cytokines and further perpetuation of vascular dysfunction.  
(Anker et al, 2003) The contribution of the action of XO and uric acid therefore 
seems to be most directly linked to endothelial dysfunction which would suggest 
that gout should predispose to forms of vascular disease where endothelial 
dysfunction is most important in its pathogenesis or manifests clinical symptoms 
early in its course prior to plaque deposition.  This same theory has been applied 
to explain the relationship between smoking and vascular disease, as it is known 
that smoking predisposes to vascular disease by its systemic pro-thrombotic 
effect, and smoking is a stronger risk factor in cardiovascular and peripheral 
vascular disease, than cerebrovascular disease.  It may be that this pro-thrombotic 
effect is more important than plaque formation in the development and progression 
of cardiovascular and peripheral vascular diseases, but plaque rupture and 
thrombosis are most strongly associated with acute events such as CVA and MI, 
rather than stable angina or peripheral vascular disease and so the relationship is 
likely to be more complex. Endothelial dysfunction is common to the pathogenesis 
of all types and stages of vascular disease, and it seems likely that the pro-
thrombotic effect of smoking interacts to accelerate the progression of 
atherosclerotic disease.  This may also be the case with hyperuricaemia and gout 
whereby the increased action of XO combined with the high levels of circulating 
pro-inflammatory cytokines accelerate progression from endothelial dysfunction to 
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plaque deposition and instability through their cumulative contribution to oxidative 
stress.   
Whilst it is possible that different risk factors predispose to plaque deposition 
compared to endothelial dysfunction, it is also possible that the relative importance 
of these two mechanisms may differ between vascular beds.   For example, if 
atherogenesis is more important than endothelial dysfunction in the pathogenesis 
of coronary artery disease, then it is likely that factors which strongly predispose to 
atherogenesis are more likely to predispose to coronary artery disease.   Selzer et 
al, 2004, showed that in women with systemic lupus erythematosus (SLE), 
traditional vascular risks and raised CRP predisposed more to atherogenesis, 
whereas whilst these factors also contributed to decreased arterial compliance, 
some SLE-specific characteristics such as low white cell count and high C3 levels 
also played an important role in increased vascular stiffness. (Selzer et al, 2004) It 
may be that a similar interaction between hyperuricaemia, and or pro-inflammatory 
cytokines released as part of MSU-driven inflammation, and traditional vascular 
risk factors such as hyperlipidaemia may predispose particularly to deposition in 
the coronary arteries and peripheral arteries rather than the carotid endothelium. 
Perhaps the biggest risk factor for coronary heart disease is dyslipidaemia, a 
common co-morbidity in patients with gout. (Annemans et al, 2008) A recent 
review suggested that the relationship between lipids and cardiovascular disease 
is different in patients with rheumatoid arthritis, as presence of a proinflammatory 
state as a result of this condition reduces total cholesterol as well as HDL and LDL 
cholesterol levels in these patients, and that anti-inflammatory therapies increase 
these levels to varying degrees.  In addition, the resulting increase in lipid levels is 
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not associated with an increased number of cardiovascular events, and disease-
modifying drugs used to treat RA, such as methotrexate, have been associated 
with a reduction in cardiovascular death and incidence of MI in patients with RA. 
(Gonzalez-Gay & Gonzalez-Juanatey, 2014; Steiner & Urowitz, 2009) This would 
support the relationship between disease activity and risk of vascular disease in 
inflammatory conditions, and would seem an area of interest for future research in 
gout.   
The interaction of uric acid with low-density lipoprotein (LDL) can be pro-oxidant or 
anti-oxidant in a similar way to the role of uric acid in oxidative stress, with the 
direction of the effect dependent upon the oxidative state of the LDL.  In the 
presence of un-oxidised LDL, uric acid will act as an antioxidant.  However, in the 
presence of oxidised LDL, uric acid becomes a pro-oxidant, a transformation that 
is poorly understood.  (Krishnan, 2010)  Oxidised LDL is known to be an important 
predictor of atherosclerosis, mediating endothelial injury. (Ishigaki et al, 2009) 
Binding of LDL to the endothelium is thought to be part of the initiation of 
atherosclerosis, and expression of LDL binding molecules in the plaque 
potentiates its development, where these LDLs can be modified or aggregated.  
These modified LDLs chronically stimulate an inflammatory response, inducing the 
release of chemoattractants and adhesion molecules by the endothelium and 
vascular smooth muscle cells.  (Bentzon et al, 2014) Patients with gout have been 
shown to have high levels of antibodies to oxidised LDL, and that the 
concentration of these antibodies was related to LDL particle size and HDL levels. 
(Jiang et al, 2014) Levels of oxidised LDL are positively correlated with levels of 
pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and high sensitivity CRP, a marker 
of inflammation produced by the liver in response to IL-6, further suggesting that 
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MSU-induced inflammation in gout may be associated with increased levels of 
oxidised-LDL.  (Jiang et al, 2014) Levels of oxidised LDL were not found to be 
correlated with serum uric acid levels, (Jiang et al, 2014) again supporting the 
hypothesis that as for RA, (Zhang et al, 2014) it is gout disease activity rather than 
cumulative exposure to hyperuricaemia or dyslipidaemia that is the more important 
factor in predisposition to atherosclerosis, which is itself considered an 
inflammatory condition.  (Hansson, 2009) Evidence is emerging to support the link 
between total body urate load and risk of CHD, with presence of tophi shown to be 
associated with significant excess risk of cardiovascular mortality even after 
adjustment for baseline serum urate levels. (Perez-Ruiz et al, 2014)  
The metabolic syndrome, described in section 2.5.2 is also a common co-
morbidity in gout, and represents a cluster of vascular risk factors.  It has been 
reported to be an important factor in the pathogenesis of cardiovascular disease in 
rheumatoid arthritis, (Gremese & Ferraccioli, 2011) resulting from the expression 
of adipokines by adipocytes and immune cells, which form an important link 
between inflammation and metabolism underpinning insulin resistance, further 
impairing endothelial function.   (Deng & Scherer, 2010)  
Gremese & Ferraccioli, 2011, argue that as post-mortem evidence from RA 
patients demonstrates the presence of more inflammation and unstable plaques in 
the arterial media, but less atherosclerosis than in age and gender matched 
controls dying from cardiovascular causes, with similar overall numbers of lesions 
and grades of stenosis, the mechanisms underlying cardiovascular mortality differ 
in RA patients.  (Gremese & Ferraccioli, 2011) This would seem to support the 
importance of plaque instability and thus the role of thrombi in the association 
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between vascular disease and inflammatory arthritis, and perhaps the argument 
that the difference in risk of cardiovascular and peripheral vascular disease, and 
cerebrovascular disease in patients with gout relates to the relative importance of 
endothelial dysfunction, plaque deposition and thrombus formation in each of 
these conditions.   
However, if this were the full explanation, one would expect to see a statistically 
significant increase in risk of MI which this study did not find in women, and only 
found in men after adjustment for the less extensive range of covariates in model 
1. This may be explained by an increased risk of unheralded fatal MI which we 
were unable to identify since cause of death was not available in this dataset.  
Similar mechanisms have been reported in RA patients, in that they are thought to 
be at increased risk of silent MI and sudden death, compared with symptomatic 
angina, (Gabriel, 2008; Maradit‐Kremers et al, 2005) and thus incident disease 
may go unrecognised in primary care which could also be the case in gout.   
It is also possible the differences in risk between sites of vascular disease may not 
relate to a difference in underlying pathophysiology, but simply to the more reliable 
identification and general coding of incident cardiovascular disease compared with 
cerebrovascular disease.   
9.4 Differences over follow-up time 
The results of the cohort study when the follow-up time is limited to one, two and 
five years exposes differences not only in the strength and significance of 
associations between gout and different vascular diseases, but also how these 
risks vary over time.   
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In the unadjusted analysis, the general trend is one of increasing relative risk over 
time for all vascular events, and all cardiovascular events, and is similar for both 
genders.  However, after adjustment for the full range of vascular risk factors this 
trend changes with risk of cerebrovascular disease (all CVD, CVA and TIA) and 
PVD greater in the short term (up to one or two years) in women, whilst risk of all 
CHD and angina was greater in the longer term (up to five or ten years).  In men 
only risk of all CHD and PVD persisted and both were greater in the longer term. 
The trend in incidence of vascular diseases in patients with gout over time has not 
previously been reported.  However, the findings of increased risk of all 
cerebrovascular disease, CVA, TIA and PVD in women being greatest within one 
to two years of diagnosis of gout, whilst risk of cardiovascular disease is greatest 
five to ten years after diagnosis supports the theory that the mechanism underlying 
risk of vascular disease in gout may be different than those without an 
inflammatory condition and may also differ between vascular disease at different 
sites.  The difference in risk of PVD over time between men and women, with 
women being at greatest risk immediately following diagnosis of gout and men at 
greatest risk in the longer term, also suggests different mechanisms underlying the 
same vascular disease between genders.  These gender differences will be 
discussed in more detail in section 9.5. 
The trend in increasing risk over time of the other vascular outcomes measured 
could be explained in a number of ways.  It may be the result of cumulative 
exposure to vascular risk factors (such as duration of gout or duration of 
hyperuricaemia), the importance of plaque deposition later in the atherosclerotic 
process in the pathogenesis of these conditions, may represent participants with 
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smaller initial inflammatory burden, or simply reflect the effective use of treatments 
for gout leading to a reduction in cardiovascular risk. Further research is required 
to elucidate the contributions made by these differing potential explanations, 
although this is likely to be multi-factorial.  The non-linear increase in the vascular 
outcomes which did demonstrate increased risk over time would support the 
multifactorial nature of this relationship.  The observed decrease in risk in men 
between one and two years, and in women between two and five years following 
diagnosis of gout, followed by a similar or continued increase in risk thereafter, 
was consistent in all vascular events and all cardiovascular events.    This pattern 
would seem to suggest a “threshold effect” whereby cumulative exposures to risk 
factors must reach a critical mass, or combine in a particular way, before the 
threshold at which increased risk of a particular event is reached.  This threshold 
effect underpins the use of an S-shaped curve in logistic regression models used 
to predict risk, and suggests that the effect of a particular covariate on an 
individual’s risk of a particular outcome is minimal for low levels of the covariate 
until a particular threshold is reached. The risk then rises rapidly and remains high 
once the level of the covariate gets large enough.  (Kleinbaum & Klein, 2010)  A 
similar “threshold effect” has been previously described in the effect of lipoproteins 
on mortality in the general population, whereby mortality in cardiovascular disease 
was not linearly related, and only increased in those participants with the highest 
quintile of serum cholesterol measurements. (Goldbourt et al, 1985)  
9.5 Gender specific associations 
Research into the epidemiology of gout in women remains relatively scarce; 
however our findings of increased risk of vascular disease in females are 
      
302 
         
   
consistent with those of two previous studies that included female participants.  
(De Vera et al, 2010; Teng et al, 2012) 
The reasons for this increased risk remain unclear, but may result from prolonged 
exposure to hyperuricaemia prior to the onset of clinical gout since women have 
been observed to have lower mean serum urate levels and an older mean age at 
onset of gout when compared to men, (Chen et al, 2012; Harrold et al, 2006) and 
women have also been shown to be at a lower risk of developing gout at a given 
level of hyperuricaemia then men with a comparable level serum urate. (Bhole et 
al, 2010)   Since the incidence of gout is higher in post-menopausal women, it has 
been suggested that oestrogen is an important influence, by means of an effect on 
renal excretion of urate. (Bhole et al, 2010; Hak et al, 2010) Following the 
menopause, not only do levels of oestrogen reduce, but the incidence of 
abdominal obesity and associated hyperinsulinaemia increase, further impairing 
the renal excretion of urate and increasing the inflammatory effect on the vascular 
endothelium.  (Bhole et al, 2010) It has been suggested that the same metabolic 
factors considered to be traditional vascular risk factors play a more important role 
in women than men, (Chen et al, 2012) not simply resulting from an increased 
incidence, but perhaps reflecting a stronger multiplicative effect between 
hyperuricaemia and metabolic vascular risk factors resulting in a higher propensity 
of women to hyperuricaemia-induced microvascular damage. (Cipolli et al, 2012)  
It is possible that in women, the sudden influx of pro-inflammatory cytokines 
associated with the incidence of MSU crystal-induced inflammatory arthritis which 
defines gout, following asymptomatic hyperuricaemia, either results in a 
pathogenic interaction with other vascular risk factors to accelerate the progress of 
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disease from incidence of endothelial dysfunction to symptomatic vascular event.  
Alternatively this sudden increase in pro-inflammatory cytokines may predispose 
to plaque destabilisation and thrombosis in existing asymptomatic disease.  It is 
also possible that since endothelial dysfunction is known to be an early feature of 
vascular disease, (Bentzon et al, 2014) that this mechanism plays a more 
important role in the pathogenesis of these conditions in women than plaque 
formation.        
A more complex relationship between hyperuricaemia and vascular risk factors in 
women than in men is one possible explanation for the gender differences in the 
findings of this study, however it is also possible that less aggressive screening 
for, and management of, both gout and vascular risk factors in female patients in 
primary care is responsible for the gender difference in these associations.  It has 
been shown that in RA patients, delay in diagnosis of RA is likely to be longer in 
women, (Lard et al, 2001) and that men with RA are more likely to receive 
comprehensive cardiovascular assessment than women. (Monk et al, 2013) 
Further research is required in order to elucidate the nature and importance of 
these relationships in patients with gout. 
9.6 Strength of association 
The HR for development of vascular disease in this study is lower than that 
reported for other inflammatory diseases, although a variety of different estimates 
of risk and outcome measures are used.  This makes direct comparison of the 
findings difficult since odds ratios cannot be directly compared with standardised 
incidence ratios, and measurement of cardiovascular outcomes which include 
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stroke may yield differing estimates of risk than those which specifically measure 
coronary heart disease or MI.   
Patients with rheumatoid arthritis have been reported to have increased risk of 
incident CVD (RR 1.48 95%CI 1.36-1.62), MI (RR 1.68 95%CI 1.40-2.03), CVA 
(RR 1.41 95%CI 1.14-1.74) and heart failure (RR 1.87 95%CI 1.47-2.39) in a 
meta-analysis of observational studies. (Avina-Zubieta et al, 2012)  The magnitude 
of increased risk found in women with gout in this study is not dissimilar to that 
conferred by RA where practice has already been altered to identify and manage 
the risk of cardiovascular disease.  (Peters et al, 2010)  
SLE has also been associated with an increased risk of incident cardiovascular 
events with estimates of between a two and three fold increase in risk compared to 
the general population (RR 2.66 (95%CI 2.16-3.16)), (Magder & Petri, 2012) (HR 
2.26 (95%CI 1.45-3.52)). (Hak et al, 2009)  However, despite the smaller 
magnitude of the risk of incident CVD conferred by gout compared to SLE, the 
majority of SLE patients (and participants included in research studies 
investigating its relationship with cardiovascular disease) are female, which would 
support this study’s findings of increased risk in women. (Wade & Major, 2011)  
The increased risk of vascular disease associated with other inflammatory 
conditions is likely to suggest a common pathway linking inflammatory disease 
and vascular risk.  However, the smaller magnitude of increase in risk in gout 
compared to RA and SLE, for example, may reflect the earlier mean age of onset 
of both RA and SLE, and thus the effect of prolonged exposure to inflammatory 
cytokines thought to responsible for the additional risk. 
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Increased risk of stroke has been associated with ankylosing spondylitis, PMR, RA 
and SLE. (Zoller et al, 2012) This would support the findings of increased risk of 
stroke in the female participants in this study, although due to the use of 
generalised codes for recording cerebrovascular events, it was not possible to 
differentiate haemorrhagic from ischaemic stroke in this study.  Despite their many 
shared risk factors, the findings may have been different had it been possible to 
investigate them separately in this study.   
The magnitude of the increased risk of cerebrovascular events is greater in these 
other inflammatory conditions and it is possible that this is explained by the 
younger mean age of onset of conditions such as SLE, AS and RA when 
compared with gout, which results in a longer duration of exposure to systemic 
inflammation, thus increasing risk of cerebrovascular disease. 
An increased prevalence of PVD has also been shown in patients with SLE, 
(Erdozain et al, 2014; June & Scalzi, 2013)  
9.7 Multilevel Discrete Time Event History Analysis 
To date, this approach has not been used to estimate the effect of changing 
covariates during follow-up, on the risk of vascular disease in patients with gout. 
Similar to the continuous survival analysis model, this discrete-time model also 
demonstrates a significant interaction between gout and gender in the effect on 
the risk of an incident vascular event, and the direction of the association between 
gout and risk of vascular events, for both genders, is also similar.  
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Other risk factors that were associated with the risk of an incident vascular event 
were prescription of aspirin and statins, obesity and raised blood pressure 
measurement, all of which made an incident vascular event more likely across all 
participants (gout and no gout).  Male participants and those with CKD (both with 
and without gout) were less likely to experience a first vascular event, and this is in 
keeping with evidence that gout is protective against vascular mortality in patients 
with CKD. (Kok et al, 2012)  This relationship may reflect surveillance bias 
introduced following increased vigilance for vascular risk factors following a 
diagnosis of gout or CKD.  However, given that both gout and renal disease 
individually increase vascular risk, (Foley et al, 1998) the mechanism underlying 
this observation requires further investigation.  Similarly, patients who did not have 
a measurement of BMI or blood pressure were less likely to have a vascular event 
than those who had a normal measurement, suggesting that GPs are successfully 
identifying and measuring risk factors in those at greatest risk.  However, there 
may also be an element of confounding by disease severity, since those with more 
severe disease are more likely to develop complications such as vascular disease, 
but are also more likely to have risk factors measured. 
9.8 Gout-specific exposures and risk of vascular disease 
Incident vascular events were more likely in patients with gout in whom there was 
poor surveillance of SUA, whilst those who consulted frequently for gout were less 
likely to have a first vascular event, highlighting the role of surveillance in reduction 
of vascular risk in gout patients.   
Gout patients exposed to allopurinol were more likely to experience all vascular 
events, all cardiovascular events and angina, but not MI or cerebrovascular or 
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PVD.   This finding is supported by a recent cohort study which demonstrated an 
increase in risk of vascular events in patients with gout with no prior history of 
vascular disease, of a similar magnitude to that reported here, although they were 
unable to adjust for some important confounding factors (e.g. BMI) in their 
analysis. (Kok et al, 2014) However, the findings of this study and that of Kok et al, 
2014, contrast with the evidence reporting reduction in risk of cardiovascular 
events conferred by gout treatment with allopurinol using a “treat-to-target” 
approach, and aiming for suppression of urate below 360 micromol/litre. (Joo et al, 
2014; Wei et al, 2011)  They also contrast with evidence supporting cardiovascular 
benefit of allopurinol on blood pressure, left ventricular hypertrophy and exercise 
tolerance in chronic stable angina in non-gout patients. (Agarwal et al, 2013; 
Noman et al, 2010; Rekhraj et al, 2013; Szwejkowski et al, 2013)  This may 
suggest that there are gout-specific factors which contribute to vascular risk that 
allopurinol is unable to mitigate against.  This will be discussed in more detail in 
section 9.9.1 
Those without a measurement of serum urate recorded within the 6 months before 
or after diagnosis of gout were more likely to experience a first vascular event, (all 
vascular events and all cerebrovascular events) whilst those with recorded 
hyperuricaemia (SUA >360micromol/litre) during the same time period were not.  
This suggests that surveillance of urate levels in general practice plays a role in 
reducing risk of vascular disease, even where urate lowering therapy is not 
prescribed.  This may result from selection bias, whereby those patients likely to 
request urate monitoring are most engaged with reduction in the severity of their 
disease and therefore less likely to have a vascular event, or those GPs least 
likely to request urate monitoring are less aware of the role of hyperuricaemia and 
      
308 
         
   
gout in vascular risk.  Little is known of influences on GP monitoring urate levels 
and understanding of the vascular sequelae of gout.  
Those gout patients consulting their GP more frequently (for any reason) were 
more likely to experience a first vascular event, perhaps reflecting the increased 
risk of vascular disease also found associated with increasing Charlson score.  
Conversely, patients who consulted their GP more frequently for gout were less 
likely to experience a first vascular event, and yet if frequency of consultation for 
gout is considered a proxy for severity, one might expect repeated consultation to 
predict increased risk of a vascular event. One explanation could be that more 
frequent consultation for gout increases likelihood of initiation of ULT which, 
although not demonstrated in this study may, when used optimally, contribute to a 
reduction of vascular risk.  It is also possible that this finding is simply a reflection 
of the effect of surveillance bias, whereby repeated consultation provides more 
scope for opportunistic intervention regarding vascular risk factors.  Alternatively, it 
may be that those who consult for their gout are less likely to have a vascular 
event than those who do not resulting from sub-optimal self-management of 
inflammation associated with flares using over-the-counter NSAIDs or other 
analgesia, rather than prescribed NSAIDs or colchicine.  Little is known of the 
characteristics of gout patients who self-manage and the difference in long term 
health outcomes from those who are managed by their GP. 
9.9 Medications and risk of vascular disease 
Given the increased risk of experiencing an incident vascular event associated 
with gout identified by this study and the findings that exposure to allopurinol made 
a vascular event more likely, this section will discuss the investigation of the effect 
      
309 
         
   
of medications used to treat gout and vascular risk factors, such as hypertension, 
on odds of a vascular event.  Two separate approaches were used to investigate 
this association; multilevel discrete-time event history analysis to investigate the 
contemporaneous association between changing risk factors and medications 
following diagnosis of gout and a nested case-control study to investigate the 
association between cumulative exposure to and time since most recent 
prescription for medications of interest. 
9.9.1 Drugs used in the management of gout 
Allopurinol 
The findings of this study did not support a reduction in the risk of vascular disease 
associated with the use of urate-lowering drugs, despite the increased risk of 
vascular disease in patients with gout identified in chapters 3 and 6, the evidence 
that hyperuricaemia is also a risk factor for vascular disease suggesting that it 
would be reasonable to expect that urate-lowering therapy would confer some 
protective benefit in those gout patients it is prescribed for, and as discussed in 
section 7.3.2  various cardiovascular benefits conferred by allopurinol in non-gout 
patients have been demonstrated. However, less than half of the gout group was 
prescribed allopurinol.   
Exposure to allopurinol at any time, or in any cumulative amount did not predict 
any change in odds of an incident vascular event compared to those who were 
never exposed, nor did vascular risk differ with time since last exposure to 
allopurinol, i.e. those having taken allopurinol within 2 years are not more or less 
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likely to experience a vascular event than those who not received a prescription for 
allopurinol for more than 5 years.   
The findings of this study are in line with those of a recent case-control study 
investigating the effect of allopurinol on risk of MI, which also found that allopurinol 
did not significantly influence this risk. (Grimaldi-Bensouda et al, 2014) Since 
allopurinol is the most commonly used urate-lowering therapy, (Annemans et al, 
2008; Cea Soriano et al, 2011) it would seem that this lack of effect of allopurinol 
on vascular risk merits further investigation. 
There are several explanations for the finding that allopurinol use does not 
influence the risk of vascular disease.  The first is that since the mechanism of 
action of allopurinol is to inhibit xanthine oxidase reducing both serum urate levels 
and oxidative stress, prescribed dosage (which can vary by individual) must be 
titrated in order to adequately and consistently inhibit xanthine oxidase.  Therefore 
prescribing behaviour and adequate allopurinol dosing may be an important 
contributory factor.  
National and international guidance recommends a titration regime for allopurinol, 
starting at 100mg and increasing dose according to the effect on serum urate 
levels when measured regularly, to attain suppression of urate below a target level 
of 360mmol/l. (Jordan et al, 2007; Zhang et al, 2006a) It has been reported that 
titration of allopurinol in this way can reduce incidence of cardiovascular co-
morbidities. (Joo et al, 2014) However, evidence would suggest that GPs are 
much more likely to prescribe a fixed dose of 300mg, with reports of as few as 2-
4% of patients receiving a dose greater than 300mg, and less than 50% of patients 
on urate therapy achieving a serum urate of less than 360mmol/L. (Annemans et 
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al, 2008; Wei et al, 2011) Similarly, studies have found regular measurement of 
serum urate is rare with reports of any serum urate testing in less than 10% of 
patients. (Annemans et al, 2008) This was also seen in this study and due to lack 
of urate data, no significant conclusions can be drawn about the effectiveness of 
allopurinol prescribed in lowering urate levels.  It may be that allopurinol dose may 
be more important than duration of therapy in conferring cardiovascular benefit, 
since data shows gout patients taking higher doses of allopurinol (≥300mg) are 
more likely to have adequately suppressed levels of SUA, and have lower 
cardiovascular risk than those on lower doses (≤100mg). (Wei et al, 2011) In 
addition it is “high dose” allopurinol that has been shown to reduce cardiovascular 
risk in non-gout groups, with at least two of the studies using doses of ≥600mg, 
(Erdogan et al, 2012; Noman et al, 2010) which were only prescribed for 1% of this 
study population, although this is in line with estimates from other studies.  
(Annemans et al, 2008)  The use of cumulative exposure in this study, the product 
of dosage and duration of therapy, allowed comparison of the effect of a higher 
dose for a shorter time with lower doses for a longer time.  This has not previously 
been investigated in patients with gout, although it has been examined in patients 
with congestive heart failure (CHF), (Struthers et al, 2002) which suggested that 
whilst long-term low-dose (<300mg) allopurinol was harmful to cardiovascular 
outcomes, long-term high-dose (>300mg) allopurinol was associated with reduced 
cardiovascular risk in patients with CHF.  (Struthers et al, 2002) This study does 
not suggest that there is a difference between low dose allopurinol taken for a 
short time (lowest exposure) and high dose allopurinol taken for a longer period 
(highest exposure) in patients with gout implying that it is not cumulative exposure 
to allopurinol but rather the degree to which the action of XO or oxidative stress is 
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inhibited in each individual by the dose of allopurinol they receive that determines 
the effect on vascular risk.   
Given evidence of ongoing suboptimal prescribing of allopurinol, (Kuo et al, 2014; 
Roddy et al, 2007) the findings of this study demonstrating that exposure to 
allopurinol does not influence odds of incident vascular disease may simply reflect 
inadequate suppression of xanthine oxidase resulting from inadequate dose 
titration.  However, even in the highest quartiles of daily dose of allopurinol risk of 
vascular disease was unaffected suggesting that other factors may also be 
important.   
Further to the theory that suboptimal prescribing of allopurinol may contribute to 
the lack of effect of urate lowering therapy on risk of vascular disease, there may 
be patient factors, such as co-morbidity or polypharmacy which predict allopurinol 
prescribing behaviour which, once identified, may be used to change practice.   
For example, the BNF carries a caution limiting prescription of allopurinol to 
100mg or below in the presence of renal impairment, and thus it may be expected 
that presence of renal disease may reduce likelihood of receiving a prescription for 
allopurinol. (Joint Formulary Committee, 2013) However, little is known of factors 
influencing allopurinol prescription in primary care. 
In addition, even in patients for whom allopurinol is prescribed in line with 
accepted best practice, measures of prescribing behaviour cannot take into 
account compliance of patients with prescribed medication.  In other words, the 
lack of effect of allopurinol on likelihood of incident vascular disease may simply 
be due to the patient not taking the drug as prescribed.  There is evidence to 
support this suggestion, with recent literature reporting that adherence and 
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persistence with urate lowering therapy is poor in patients with gout. (De Vera et 
al, 2014; Kuo et al, 2014)  The findings presented in table 7.4, report increased 
medication possession ratio (i.e. the amount of days in a set period in which 
patients have a prescription for allopurinol) reduced the odds of experiencing a 
vascular event, suggesting a relationship between compliance with allopurinol and 
vascular risk.   
It is also possible that these findings may simply reflect confounding by indication 
whereby patients with most severe gout are more likely to be prescribed 
allopurinol, and are more likely to be at greater risk of complications such as 
vascular disease than those with less severe gout.  Where confounding by 
indication is present, the estimate of risk does not accurately reflect the effect of 
allopurinol on risk of vascular event, since it cannot account for differences in 
severity between the two groups.   
Uricosurics 
Patients in the lowest and highest quartiles of exposure to uricosurics were more 
likely to experience an incident vascular event.  Their odds of a vascular event 
were almost four times that of those not exposed to uricosurics, more than that in 
any of the other classes of drugs investigated.  
There is limited evidence that probenecid is positively inotropic, increasing 
myocardial contractility.  (Koch et al, 2013) Other inotropes such as dopamine and 
dobutamine have been associated with arrhythmias, myocardial infarction and 
increased mortality in patients with decompensated heart failure, (Felker & 
O’Connor, 2001) and it could be reasonably suspected that a similar mechanism 
underlies the increased odds of vascular events in this group.   
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An alternative explanation for this finding may be confounding by indication, 
whereby similar to those prescribed allopurinol, prescription of uricosurics results 
from more severe gout and potentially increased risk of vascular disease.  
There has been little investigation of the role of uricosurics in reducing vascular 
risk in gout or non-gout populations, as their role in the management of 
hyperuricaemia and gout has been largely superseded by that of xanthine oxidase 
inhibitors.    
Furthermore, these findings must be interpreted with caution due to the small 
numbers of patients prescribed uricosurics within this study population. 
Colchicine 
Gout patients who had been prescribed colchicine more than 5 years ago were 
more likely to experience a vascular event, although there was no 
contemporaneous association between exposure to colchicine and increased odds 
of a vascular event identified in either the multilevel discrete time event history 
analysis, or the nested case-control study.  Above median cumulative exposure to 
colchicine also made an incident vascular event more likely.    
Existing literature has examined the effect of colchicine on risk of vascular events 
in patients with existing vascular disease, demonstrating effective secondary 
prevention of cardiovascular events in those with existing stable coronary disease. 
(Nidorf et al, 2013) The effect of colchicine on risk of cardiovascular disease in 
patients with gout has also been explored, but the primary outcome for the 
majority of studies is limited to myocardial infarction, and results are conflicting.  
Grimaldi-Bensouda et al, 2013, found no effect on risk of MI associated with use of 
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colchicine, which supports the findings of this study, whereas Crittenden et al, 
2012, reported decreased prevalence of myocardial infarction in patients with gout, 
but did not examine other vascular outcomes.  (Crittenden et al, 2012; Grimaldi-
Bensouda et al, 2014) 
The explanation for these findings may lie in the reasons underlying cumulative 
exposure to colchicine; those with below median cumulative exposure to 
colchicine may either be patients who had infrequent attacks for which they sought 
treatment and therefore a lower inflammatory burden contributing to their risk of a 
vascular event, whereas those with above median cumulative exposure may have 
had frequent flares treated with colchicine, or have been prescribed it for 
prophylaxis against acute flares during initiation of ULT, both of which may 
indicate more severe gout which is more likely to be associated with complications 
such as vascular disease.   
However, similar to the findings for allopurinol, higher cumulative use of colchicine 
did not make an incident vascular event less likely which would suggest multiple 
contributory factors to increased vascular risk unlikely to be completely mitigated 
by one drug. 
NSAIDs 
Time since exposure to NSAIDs did not influence odds of experiencing a vascular 
event.  However, the findings related to cumulative exposure to NSAIDs differed; 
the MDtEHA examining the cumulative exposure within each year-long window 
following diagnosis of gout reported increased odds of a vascular event associated 
with increased exposure, in line with current evidence in the general population, 
(Bhala et al, 2013) but the case-control study showed that those with above 
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median cumulative exposure to NSAIDs were less likely to experience a vascular 
event that those not exposed to NSAIDs.   There is no existing literature on 
cardiovascular risk in patients with gout treated with NSAIDs with which to 
compare our findings, but in light of the individual associations of both NSAIDs and 
gout with increased risk of subsequent vascular event, further research is required 
to explore this. 
This difference may arise from the time period over which the cumulative exposure 
is calculated, since it is cumulative exposure measured in the case-control study 
whilst only exposure per year-long time window is considered in the cohort study.  
Perhaps the difference is the result of surveillance bias whereby those who are 
prescribed the highest amounts of NSAIDs are those who consult most often, 
thereby presenting increased opportunity for health surveillance and optimisation 
preventing poorer vascular outcomes.  Furthermore, since NSAIDs such as 
ibuprofen and diclofenac are available to buy over the counter those with the 
lowest exposures may simply be those who choose not to consult, allowing less 
opportunistic screening for or management of vascular risk factors.   
This relationship may also result from confounding by indication whereby higher 
doses of NSAIDs are only prescribed to those with the lowest co-morbidity and the 
lowest risk of vascular event.  Since renal disease is a relative contraindication to 
use of NSAIDs, those with least exposure to NSAIDs may well represent those 
with renal disease which itself is predisposes to vascular disease.   The 
association of greater cumulative exposure to NSAIDs with reduced odds of 
vascular event may also relate to the use of NSAIDs as prophylaxis against acute 
attacks during the initiation of ULT or may reflect surveillance bias whereby 
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patients consulting GPs with frequent acute attacks or for titration of ULT also 
provide more opportunity for identification and management of vascular risk.  
However, this was not the case for colchicine, where those with above median 
cumulative exposure to colchicine had increased odds of vascular event. 
9.9.2 Drugs used to treat vascular risk factors 
Antihypertensives 
Gout patients who had been prescribed anti-hypertensives had higher odds of 
experiencing an incident vascular event than those who had not, and those with 
above median exposure to anti-hypertensives were more likely to experience a 
vascular event than those unexposed, but this risk was less than in those who had 
below median exposure.  It seems therefore that increased exposure to anti-
hypertensives can attenuate some of the excess risk, but not all.   
Recent evidence has highlighted the increased prevalence of gout in those with 
uncontrolled hypertension and at least one additional cardiovascular risk factor, 
with prevalence increasing with the addition of each additional risk factor.  
(Juraschek et al, 2013a) The prevalence ratio of gout in those with uncontrolled 
blood pressure (BP) and two additional cardiovascular risk factors compared to 
those without cardiovascular risk factors was reported to be 4.5 (95%CI 3.1-6.3), 
suggesting that patients with gout and hypertension are already at high vascular 
risk.  (Juraschek et al, 2013a) It is likely that the addition of increased risk from 
hyperuricaemia and MSU crystal-induced inflammation combined with 
hypertension does further increase vascular risk, and that these results, whereby 
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those prescribed anti-hypertensives had increased odds of experiencing a 
vascular event simply reflects cumulative vascular risk, rather than there being a 
genuine association between the drugs themselves and vascular risk.   
However, an alternative explanation may be that it is those that have poorly 
controlled blood pressure despite anti-hypertensive medications, or who have 
additional risk factors which both reduce the threshold for prescription of anti-
hypertensives and increase vascular risk (e.g. diabetes or renal disease) who 
remain more likely to experience a first vascular event even in the presence of 
prescribed antihypertensives. 
The role of hypertension in the pathogenesis of vascular disease is well 
acknowledged if still not completely clear.  It has been suggested that 
hypertension predisposes to vascular disease as a result of damage to both the 
arterial structure and function resulting from increased arterial pressure, as well as 
interactions with dyslipidaemia.  (Chobanian, 2002; Hollander, 1976) This 
sustained increased pressure is thought to stimulate production of endothelial 
adherence molecules and cytokines, increase adherence of reactive white blood 
cells and promote their penetration into the intima, increase proliferation of 
vascular smooth muscle and connective tissue, and reduce endothelial 
vasodilatation whilst promoting vasoconstriction. (Chobanian, 2002; Lembo et al, 
1998) Gout and MSU-crystal induced inflammation share a number of these 
mechanisms responsible for a pro-atherogenic state in common with hypertension, 
and since hypertension is common co-morbidity in gout, (Annemans et al, 2008) it 
is not difficult to understand why patients with gout and hypertension are at 
increased risk of vascular disease.  These results suggest that risk of experiencing 
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a vascular event reduces with increasing exposure to anti-hypertensives, although 
this risk cannot be completely attenuated, and this would support evidence that 
medications used as anti-hypertensives, particular those which act on the renin-
angiotensin system (RAS) are able to positively influence the structural changes 
contributing to formation of atherosclerosis, most notably reversing endothelial 
dysfunction thereby slowing or reducing progression to renal and cardiovascular 
damage. (Ruilope et al, 2007) It has also been suggested that synergistic action 
between drugs which target the RAS and HMG Co-A Reductase inhibitors can 
improve both endothelial function and insulin sensitivity in patients with Type II 
diabetes suggesting that perhaps a combined approach to management of 
cardiovascular risk should be adopted in those at high risk.  (Lee et al, 2014) 
However, the effect of this approach is yet to be reported in either the general 
population or those with inflammatory conditions.   
This study demonstrates that although management of hypertension is important 
in reducing cardiovascular risk, exposure to these medications alone is not 
sufficient. The effect of early and optimum treatment of hypertension in order to 
increase cumulative exposure and minimise vascular damage resulting from 
uncontrolled hypertension in patients with gout warrants further investigation.  
Antiplatelet medications 
Gout patients who had been prescribed antiplatelet medications were more likely 
to experience an incident vascular event than those who had not, but their usage 
does not seem to reduce that risk in either the cohort or case-control study.  The 
case-control study reports that participants who were most recently exposed to 
anti-platelet medications within 2 years were more likely to experience a vascular 
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event than unexposed participants, but most recent exposure outside of that time 
period did not make a vascular event more likely.  Furthermore those participants 
with above median exposure were more likely to experience a vascular event than 
the unexposed, and this risk was greater than in those with below median 
exposure.  It is possible that these findings simply reflect the appropriate 
prescription of anti-platelet medications for those at greatest risk of a vascular 
event since   platelets play an important role in the pathogenesis of vascular 
disease, and thus anti-platelet drugs play an important role in the reduction of risk 
of vascular events through a variety of mechanisms.   
Aspirin is the most commonly used and reduces platelet aggregation, oxidative 
stress, plasma coagulation and platelet-dependent inhibition of thrombin 
production, also contributing to the vascular protective effect.  (Mehta, 2002; 
Patrono, 1994) Clopidogrel binds irreversibly to the receptors on the surface of 
platelets which are activated by the presence of pro-aggregatory substances, 
preventing activation of receptors which are required for strong platelet 
aggregation. (Clappers et al, 2007) Dipyridamole blocks cellular uptake of 
adenosine, increasing levels of free plasma adenosine converted to cAMP, which 
in increased levels within the platelet inhibits aggregation. (Behan & Storey, 2004)  
However, thrombosis is only one component underlying the pathophysiology of 
vascular disease, with oxidative stress and atherosclerosis also contributing.  
Therefore, however effective anti-platelet drugs may be at attenuating the risk 
associated with the thrombotic component, there are other contributory factors 
which these drugs may not mitigate against.    
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Whilst in high doses aspirin is known to have a uricosuric effect, in lower doses 
used for cardiovascular protection, aspirin is thought to increase serum levels of 
urate by reducing renal excretion.  (Caspi et al, 2000)  Thus, it seems that 
exposure to aspirin may simply be a proxy marker for gout patients at high risk of 
vascular event, or alternatively, it may actually increase levels of hyperuricaemia 
thus increasing the vascular risk conferred, rather than reducing it.   
There is currently no evidence examining the relationship between anti-platelet 
drugs, gout and vascular disease, but these findings may suggest that usual 
strategies for primary prevention of vascular disease can mitigate some of the 
excess risk associated with gout but not eliminate it.   
Lipid-lowering medications  
Statins have been shown to reduce all-cause mortality, cardiovascular mortality 
and major coronary events in the general population.  (Naci et al, 2013)   In this 
population, gout patients who had been prescribed lipid-lowering medication, 
which included fibrates and ezetimibe in addition to statins, were more likely to 
experience a first vascular event, although this likelihood reduced with increasing 
exposure with those taking the highest quartile of daily dose of lipid-lowering drugs 
having no increased risk of a vascular event, in the cohort study.  The case-control 
study also demonstrates that patients with above median exposure to lipid-
lowering drugs, although more likely to have a vascular event than those who were 
unexposed, were less likely to experience a vascular event than in those with 
below median exposure.  This supports the importance of lipids in vascular risk in 
patients with gout, by predisposing to oxidative stress, endothelial dysfunction and 
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plaque deposition; together with effects on cytokine levels including IL-1, IL-6 and 
TNF. (Jiang et al, 2014)  
This may also reflect appropriate prescription of lipid-lowering medications for 
those at greatest risk of vascular event.  However, in contrast to the results of this 
study in patients with gout, in the general population lipid-lowering drugs have 
been shown to successfully reduce risk of vascular event.  (Naci et al, 2013) This 
would imply that there is some other contributory or potentiating factor which 
makes lipid-lowering drugs less effective in patients with gout.  In other 
inflammatory rheumatological conditions it has been suggested that this factor is 
chronic inflammation which interacts directly and indirectly with both traditional and 
novel vascular risk factors.  (Choy & Sattar, 2009) It has been shown that 
treatment of rheumatoid arthritis can improve pro-atherogenic lipid abnormalities 
without the use of lipid-lowering medications.   (Steiner & Urowitz, 2009) This 
would imply that cardiovascular risk associated with hyperlipidaemia in treated RA 
patients should be similarly reduced by the use of lipid-lowering medications to 
that in the general population. 
This has not been investigated in patients with gout, but it is possible that a similar 
interaction between chronic inflammation in untreated or suboptimally managed 
gout and lipid structure and function exists, altering not only the ratio of 
cardioprotective HDL to pro-atherogenic LDL, but also changing the structure of 
these lipids and modifying their function by further impairing the cardioprotective 
effect of the remaining HDL, and potentiating the pro-atherogenic effects of LDL 
through oxidation.  (Choy & Sattar, 2009) This may explain the temporal 
relationship of use of lipid-lowering medication and risk of vascular event, since 
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only most recent exposure within two years was found to be associated with 
increased odds of a first vascular event, whilst most recent exposure outside of 
two years (those who might be expected to be at greatest risk since lipid-lowering 
medication had been indicated and initiated but discontinued) was not associated 
with increased odds of a vascular event.  If lipid profiles in patients with gout follow 
a similar pattern to those in RA then vascular risk due to hyperlipidaemia can be 
attenuated using lipid-lowering medications in those patients with adequate 
suppression of the inflammatory component, but not whilst inflammation persists.  
This chronic inflammation is likely to render the majority of patients with gout, not 
simply those in this study, at risk from pro-atherogenic lipid profiles against which 
lipid-lowering medications are ineffective given that management of gout is often 
suboptimal, (Cottrell et al, 2013; Kuo et al, 2014; Mikuls et al, 2005a; Roddy et al, 
2007) and that even where ULT is offered persistence with it is poor. (De Vera et 
al, 2014; Kuo et al, 2014)  
An alternative explanation is that use of HMG Co-A reductase inhibitors (“statins”) 
has been associated with insulin resistance and increased risk of diabetes, both of 
which further increase vascular risk, (Lee et al, 2014) and are known to commonly 
co-exist in patients with gout, (Annemans et al, 2008) and it may be that patients 
with gout are particularly susceptible to these cumulative risks.   
Whatever the explanation, the findings of this study suggest that use of lipid-
lowering medications alone does not attenuate cardiovascular risk in patients with 
gout, and that further investigation of both the effect of chronic inflammation in 
gout on lipid profile, as well as the effect of optimum treatment of gout on 
cardiovascular outcomes is warranted.   
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9.9.3 Drug combinations 
Similar to the results discussed in 9.9.2 whereby drugs used to treat 
cardiovascular risk factors do not, in isolation, completely eliminate vascular risk, 
combinations of these medications do not reduce the odds of experiencing a 
vascular event.  However, in the presence of all the combinations examined, with 
the exception of anti-hypertensives with lipid-lowering medications, those 
participants exposed to allopurinol were less likely to experience an incident 
vascular event, whereas allopurinol in isolation did not reduce odds of a vascular 
event.  It is likely that this finding reflects a synergistic effect between allopurinol 
and the medications used to reduce vascular risk factors.  There is a growing body 
of evidence that combinations of medications which include aspirin, anti-
hypertensives and statins taken as individual tablets, or in fixed-dose combination 
poly-pills, reduce relative risk of cardiovascular disease by 50-60% in high risk 
individuals, with this reduction increasing to 70-80% where lifestyle interventions 
are also optimised.  (Yusuf et al, 2014)  Given the evidence that allopurinol also 
has substantial cardiovascular benefits, particularly its effect on oxidative stress 
and endothelial dysfunction as discussed in section 9.9.1, it seems reasonable 
that the addition of allopurinol to these combinations should reduce the risk of a 
vascular event.   
Although this particular investigation is limited by small sample size and the 
comparison between ever and never exposure to these drugs, these novel findings 
justify further and more detailed investigation of the principle of combination 
therapy in the management of gout and associated vascular risk.  In other 
conditions which have been linked with increased risk of vascular disease, for 
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example diabetes, this approach has already been adopted into clinical practice.  
Patients with diabetes are automatically considered for the initiation of the 
medications used to treat vascular risk factors that were investigated in this study 
at diagnosis, with lower blood pressure targets and a lower threshold for 
commencing primary prevention of vascular disease. (National Collaborating 
Centre for Chronic Conditions, 2008b) The results of this study suggest that further 
investigation of the effect of early initiation of similar primary prevention strategies 
in combination with allopurinol following diagnosis of gout is warranted. 
9.10 Clinical implications of these findings 
Medications used to treat vascular risk factors do not reduce the risk of 
experiencing an incident vascular event in patients with gout as might be 
expected, or has been demonstrated in the general population.  (Antithrombotic 
Trialists' Collaboration, 2002; Naci et al, 2013)  This would suggest that alternative 
strategies should be investigated.   It is possible that prescription of these 
medications results in patients feeling “protected” from vascular risk and thus not 
controlling lifestyle factors e.g. BMI or dietary intake of cholesterol as strictly as 
they might have, further increasing vascular risk.  However, the results presented 
in table 8.8c whereby in the presence of medications used to treat vascular risk 
factors participants exposed to allopurinol are less likely to experience a vascular 
event, suggest that a combination approach to the management of vascular risk, 
which uses allopurinol in addition to the medications traditionally used to treat 
vascular risk factors should be considered in gout patients.  Further research is 
needed to investigate the efficacy of such an approach. 
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Use of allopurinol alone in this study does not make an incident vascular event any 
more or less likely.  As previously discussed, the pattern of prescribing of 
allopurinol in this study is sub-optimal with the most commonly prescribed dose of 
being 300mg and only 1% prescribed a dose in excess of 300mg.  This sub-
optimal use of allopurinol is no different to no use of allopurinol in terms of its 
effect on vascular risk, suggesting that current prescribing behaviours need to 
change. 
Finally, since above median exposure to colchicine made a vascular event more 
likely, whilst above median exposure to NSAIDs made a vascular event less likely, 
the results of this study would suggest that NSAIDs should be preferentially 
considered for management of acute flares, and particularly as prophylaxis during 
initiation of urate-lowering therapy, in those at high vascular risk, although further 
research is required to investigate this in the absence of any head-to-head trials 
between NSAIDs and colchicine in the management of gout. 
9.11 Summary 
This chapter has discussed gout as an independent risk factor for incident 
vascular disease, particularly peripheral vascular disease.  Female gout patients 
were at greatest risk, despite being the minority of gout patients, perhaps reflecting 
the importance of post-menopausal oestrogen deficiency in impairing renal 
excretion of urate, or less effective identification and management of both gout 
and vascular disease in women.  The strongest association found was between 
gout and cardiovascular and peripheral vascular disease, both of which are most 
strongly associated with atherosclerosis, however evidence examining vascular 
risk in other inflammatory arthritides has indicated that plaque instability and 
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decreased arterial compliance are most strongly implicated in the pathogenesis of 
increased vascular risk in these conditions.  The interaction between uric acid, pro-
inflammatory cytokines and LDL-cholesterol in gout patients potentiating first 
endothelial dysfunction, followed by accelerated atherosclerosis and plaque 
instability was highlighted as the most likely mechanism underlying this 
association in gout patients.  This multifactorial aetiology is supported by the 
inability of any of the drugs used to treat gout or vascular risk factors investigated 
to reduce the risk of an incident vascular event when used in isolation.  However, 
in the presence of combinations of medications used to treat vascular risk factors, 
exposure to allopurinol reduced odds of a vascular event.  More research is 
required to elucidate the exact nature of these relationships and the mechanisms 
underlying them.
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Chapter 10: Contribution of this work 
10.1 Overview 
This chapter will summarise the importance and original findings highlighted in this 
thesis. The implications of this research for clinical practice will be discussed and 
further research questions identified as a result of this investigation will be 
presented.   
10.2 Gout and risk of vascular disease 
This is the first study to date to examine associations with all three of these forms 
of vascular disease simultaneously allowing direct comparison, and thus 
identifying a difference in risk between vascular beds, and between genders.  The 
results of the main retrospective cohort analysis described in chapters 5 to 7 
highlighted that   
Men with gout were at increased risk of all vascular events, all cardiovascular 
events and PVD  
Women with gout were at increased risk of all vascular events, all 
cardiovascular events, angina, TIA, CVA and PVD  
To demonstrate the effect of these findings on existing knowledge of the incidence 
of coronary heart disease in patients with gout, these results were added to the 
meta-analysis of existing studies examining this relationship presented in Chapter 
3.  Both studies included in the previous meta-analysis used a male only gout 
population and since the results of this study are presented by gender (due to a 
significant gout*gender interaction) the results for all CHD events for men were 
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pooled.  The study effect sizes and weights are presented in Table 10.1 and Table 
10.2 and the Forest plots shown in Figure 10.1 and 10.2 below.  
Table 10.1 Study effect sizes and weights in meta-analysis of crude results of studies examining 
the association between gout and incident coronary heart disease 
 
Study Hazard Ratio 95% CI % Weight 
Abbott et al, 1988 1.60 1.10-2.20 13.07 
Gelber et al, 1997 0.85 0.40-1.81 3.05 
Clarson et al, 2014 1.36 1.27-1.45 83.88 
D + L pooled effect 
size 
1.37 1.20-1.57 100.00 
CI= confidence interval; D+L= DerSimonian and Laird 
 
I2 = 14.2% which reflects no significant heterogeneity, and Cochran’s Q test 
yielded p=0.31 also suggesting no significant heterogeneity. 
Table 10.2 Study effect sizes and weights in meta-analysis of adjusted results of studies examining 
the association between gout and incident coronary heart disease 
 
I2 = 61.6% which reflects significant heterogeneity, but Cochran’s Q test yielded 
p=0.07 suggesting no significant heterogeneity. 
Study Hazard Ratio 95% CI % Weight 
Abbott et al, 1988 1.60 1.10-2.50 32.43 
Gelber et al, 1997 0.59 0.24-1.46 12.36 
Clarson et al, 2014 1.08 1.01-1.15 55.22 
D + L pooled effect 
size 
1.14 0.80-1.63 100.00 
CI= confidence interval; D+L= DerSimonian and Laird 
      
 
         
   
3
3
0
 
Figure 10.1 Meta-analysis of crude incidence of CHD updated to include the findings of this study 
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Figure 10.2 Meta-analysis of adjusted incidence of CHD updated to include the findings of this study 
NOTE: Weights are from random effects analysis 
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This study is the largest of the three to examine this relationship and alters the 
pooled estimate of risk of incident coronary heart disease in both crude and 
adjusted findings, and reduces the degree of between study heterogeneity.  The 
pooled estimate of the crude incidence of CHD becomes statistically significant, 
whereas previously it was not, and demonstrates an increased risk of 
approximately 30% in patients with gout compared to those without.  Although the 
pooled estimate of the adjusted risk did increase, it remained statistically non-
significant, however, it should be noted that incidence of all CHD was only one 
outcome measured by this study, and the results presented estimating risk of 
cerebrovascular and peripheral vascular disease continue to point to an 
association between gout and vascular risk, even after adjustment for traditional 
vascular risk factors.  
Major risk factors for vascular disease at one site e.g. coronary arteries had been 
thought to be equal risk factors at other vascular sites e.g. carotid and peripheral 
arteries, but this study demonstrates that gout predisposes most strongly to PVD, 
followed by CHD both of which are contributed to most strongly by atherosclerosis 
rather than thrombosis which is known to be preferentially associated with MI and 
CVA.  It seems likely that the inflammation associated with gout interacts both 
directly and indirectly with other vascular risk factors to predispose most strongly 
to atherosclerotic vascular disease (cardiovascular and PVD) rather than to that 
where thrombus formation is the dominant causative factor (MI and stroke), 
although excess risk of stroke was found in women with gout after adjustment for 
multiple potential confounders.    
By examining the risk of experiencing a first vascular event up to one, two, five 
and ten years following diagnosis of gout, excess risk of MI in men, and all 
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cerebrovascular events, CVA, TIA and PVD in women was found to be greatest in 
the first one or two years following diagnosis of gout, whereas excess risk of 
cardiovascular outcomes and PVD in men increases over time.  The relationship 
of time following diagnosis of gout to excess vascular risk in patients with gout has 
not previously been reported.  Furthermore the change in risk when follow-up is 
limited to one, two, five and ten years was not linear, with a reduction in excess 
risk in men between one and two years, and in women between two and five 
years, suggesting a “threshold effect” of contributory factors on the risk of 
experiencing a first vascular event.     
Use of multilevel discrete-time event history analysis allows the effect of changes 
in these covariates during follow-up on overall odds of vascular event, in all 
participants to be investigated, and has not been used to investigate the 
relationship between gout and risk of vascular event.  The use of this technique 
confirmed that men (gout and non-gout) were less likely to experience a vascular 
event than women.  Participants (gout and non-gout) with CKD also had reduced 
odds of a vascular event. Exposure to gout, as well as raised blood pressure, 
obesity and prescription of aspirin and statins increased odds of an incident 
vascular event in both genders.   
This is also the first study to investigate factors specific to gout patients which 
influence the risk of a vascular event, including prescription of allopurinol (found to 
predict increased likelihood of all vascular events, all cardiovascular events and 
angina), measurement of SUA (not having a record of SUA measurement 
predicted increased risk of a vascular event), number of GP consultations for any 
reason (as an indicator of consulting behaviour) and Charlson co-morbidity score 
(both of which increased likelihood of a vascular event as their values increased) 
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and number of consultations for gout (as a proxy for disease severity) which was 
found to reduce likelihood of all vascular events suggesting that disease 
surveillance may be important in helping to mitigate this risk.    
The final original contribution of this research to the understanding of the 
relationship between gout and vascular disease is the investigation of the effect of 
drugs used to treat both acute and chronic gout and medications used to treat 
vascular risk factors on this association.  Exposure to these drugs was calculated 
using DDD which allows comparison of the effect of different levels of exposure 
between groups of drugs.  Cumulative exposure to each group of drugs per year 
following diagnosis of gout was calculated and analysed using MDtEHA (again a 
novel use of this technique). The advantage of using this technique was that it 
allowed exposure to change year by year and therefore the effect of dynamic 
exposure to medications such as those only likely to be taken occasionally (e.g. 
colchicine) to be estimated.  The influence of cumulative exposure to the same 
groups of drugs was also investigated using a nested case-control design, which 
additionally examined the relationship between time since most recent prescription 
for these drugs and vascular event.  This identified that taking allopurinol did not 
affect likelihood of a first vascular event, and above median exposure to colchicine 
made a vascular event more likely, whilst above median exposure to NSAIDs 
made a vascular event less likely, suggesting NSAIDs may be preferable in 
managing acute flares and as prophylaxis during initiation of urate-lowering 
therapy in patients at high vascular risk.  Use of all medications used to treat 
vascular risk factors within 2 years made a first vascular event more likely, 
suggesting that current strategies used to manage CV risk reduction in the general 
population (which are mainly targeted at traditional CV risk factors such as 
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hypertension) are not sufficiently effective in patients with gout, perhaps reflecting 
the role of non-traditional risk factors such as inflammation and urate in the 
pathogenesis of vascular risk in gout.  However of particular importance are the 
findings that in the presence of the drugs used to treat vascular risk factors, 
patients exposed to allopurinol were less likely to experience a vascular event.  
This suggests that perhaps a combination approach to the management of gout, 
and associated vascular risk, similar to that in diabetes, should be adopted, and 
that allopurinol should be considered an essential part of that risk reduction 
strategy. 
The addition of the findings using different the different study methods have some 
important implications for clinical practice and these will now be discussed. 
10.3 Implications for clinical practice 
Evidence suggests that the burden of gout is rising, (Kuo et al, 2014; Robinson et 
al, 2013; Roddy & Doherty, 2010) and thus, at the population level, even a small 
increase in vascular risk will give rise to a substantial number of new vascular 
events.  The results of this study demonstrate that although the absolute risk of 
vascular events per 1000 person years, even in the general population, is low, in 
women with gout the number of peripheral vascular events is more than doubled, 
and the total number of other cardiovascular (including angina but not MI) and 
cerebrovascular events (including CVA and TIA) are increased by half. The 
findings of this study suggest a need for important changes to clinical practice. 
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10.3.1 Screening for and identifying vascular diseases 
There is evidence that cardiovascular in gout patients often goes unrecognised 
and under-treated in primary care. (Roddy et al, 2010) Only a quarter of people 
consulting with acute gout have screening for cardiovascular risk factors within the 
subsequent month, despite both national and international guidance 
recommending this. (Jordan et al, 2007; Khanna et al, 2012a; Zhang et al, 2006a)  
However, this study reports for the first time that in women, risk of cerebrovascular 
events and PVD is greatest in the two years following diagnosis of gout, 
suggesting that prompt intervention to reduce this risk should follow diagnosis of 
gout.  The threshold effect in risk identified between one and two years in men and 
two and five years provides justification for regular and routine screening for 
vascular risk factors in patients with gout.   
Furthermore, both gout and vascular disease have historically been considered 
diseases of men.  However, these findings quite clearly show that this is not the 
case with the most notable increased risk of vascular disease in women, and thus, 
even in that minority of patients who are screened for vascular risk factors, those 
chosen may not be those most at risk.  For this reason, both attitudes and practice 
must change with this new perspective on vascular risk to address both gout-
specific and traditional vascular risk factors as a matter of priority in women with 
gout.     
The association between gout and PVD reported in this study is a novel finding, 
and is the strongest of those identified.  There is evidence which reports that 44% 
of patients screened for PVD had PVD without evidence of cardiovascular 
disease, (Hirsch et al, 2001) suggesting that this manifestation of systemic 
      
337 
 
 
atherosclerosis may not have been detected by routine practice in primary care, 
even by those adhering to current guidance.  This highlights the need to consider 
screening for PVD in patients with a diagnosis of gout, not currently recognised as 
part of best practice, in addition to measuring traditional vascular risk factors.   
Furthermore, recent evidence has highlighted the increased prevalence of gout in 
those with uncontrolled hypertension and at least one additional cardiovascular 
risk factor, with prevalence increasing with each additional risk factor.  Prevalence 
ratio of gout in those with uncontrolled BP and two additional CV risk factors 
compared to those without CV risk factors was reported to be 4.5 (95%CI 3.1-6.3). 
(Juraschek et al, 2013a) This suggests that patients with gout, particularly women, 
should be included in “at risk” groups when public health measures aimed at 
reducing cardiovascular disease at a population level are being planned and 
resourced since treating cardiovascular disease costs the healthcare system in the 
UK approximately £8.6billion in 2009.  (Townsend et al, 2012) Secondary care 
costs accounted for 64% of these costs, whilst primary care only 13%.  If, by 
optimal identification and management of gout-specific and traditional vascular risk 
factors in patients with gout in primary care, it was possible to reduce the 
requirement for, and associated costs of, secondary care, then there are clearly 
financial gains to be made for the health economy, in addition to improved 
outcomes for patients.     
10.3.2 Management of vascular risk factors in patients with gout 
The results of this study point to disease activity and consequent inflammatory 
burden as important risks in gout that current vascular risk management strategies 
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are ineffective against.  Therefore the management of vascular risk in patients with 
gout must include effective management of gout itself, similar to the approach 
taken in RA where it has been shown that optimum control of RA disease activity 
can correct pro-atherogenic lipid profiles associated with disease activity. (Steiner 
& Urowitz, 2009) Thus a change in practice to adopt a more aggressive approach 
to the use of medications, including newer agents, may be justified, with not only a 
lower threshold for initiation of medication, but consistent titration to achieve 
complete xanthine oxidase (XO) inhibition in order to reduce symptomatic burden 
of gout, associated inflammation and also its contribution to vascular risk through 
oxidative stress.    
Traditional approaches to the reduction of cardiovascular risk appear less effective 
in patients with gout in this study than in the general population.  Current guidance 
on primary prevention of cardiovascular disease has been amended to explicitly 
state that existing cardiovascular risk calculators do not perform accurately in 
estimating risk in patients with inflammatory disorders such as SLE and RA.  This 
has led to the inclusion of RA as a risk factor in the QRISK2 cardiovascular risk 
calculator, (Hippisley-Cox et al, 2008) although the estimate of risk used in the risk 
equation is specific to RA and cannot necessarily be used to accurately estimate 
risk in other inflammatory conditions such as gout.   This is important since primary 
prevention usually takes the form of treatment of traditional vascular risk factors 
such as hyperlipidaemia, but patients with high inflammatory burden and low LDL 
have been shown to have poorer survival than those with high LDL and low 
inflammatory burden, whilst currently unlikely to receive any primary prevention 
measures.  Thus there will be a proportion of patients with inflammatory 
conditions, including gout, who are at unrecognised and untreated increased risk 
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of incident vascular disease, and a further proportion of patients with inflammatory 
conditions who are identified to be at increased risk of vascular disease using 
traditional measures, but in whom that risk is grossly underestimated.  If this is not 
accounted for in tools widely used to estimate vascular risk and inform treatment 
decisions, clinicians will be unable to effectively estimate vascular risk in patients 
with inflammatory conditions, where a reduced threshold at which medications 
used to treat vascular risk factors should be initiated, or initiation as part of the 
routine management of inflammatory conditions following diagnosis may be of 
benefit.   
In contrast, the findings whereby use of these medications within 2 years 
increased likelihood of vascular event compared with never having taken these 
medications may form the basis of an argument for discontinuing these drugs in 
some – however, it may also suggest that GPs are appropriately treating vascular 
risk factors in those most at risk without the ability to completely offset this risk.   
Perhaps the most important clinical implication of this study is that whilst in 
isolation, exposure to any of these medications did not reduce risk of vascular 
event, in the presence of medications used to treat vascular risk factors, those 
patients exposed to allopurinol are less likely to experience a vascular event. This 
is the first evidence to support a combination approach to the management of gout 
and associated vascular risk, similar to that adopted in diabetes, where allopurinol 
plays an essential role in synergistically reducing vascular risk in patients with 
gout. 
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10.3.3 Treatment of gout 
Current evidence suggests that the clinical management of gout in primary care is 
suboptimal, (Kuo et al, 2014; Mikuls et al, 2005a; Roddy et al, 2007) and the 
burden of the condition is not to be underestimated with approximately 1 in 40 
people in the UK, and over 8 million people in the US affected. (Kuo et al, 2014; 
Zhu et al, 2011) Only the minority of these receive ULT, and of those that do very 
few achieve adequate suppression of urate levels.  (Annemans et al, 2008; Kuo et 
al, 2014) Prescribing of the higher doses of allopurinol that have been associated 
with cardiovascular benefit is extremely rare, (Annemans et al, 2008) and this was 
also the case in this study cohort, similarly measurement of serum urate was also 
infrequent suggesting that a treat-to-target approach to the titration of ULT was not 
in use, and in this study cohort not having serum urate recorded following 
diagnosis of gout predicted increased odds of vascular disease.  Dosing of ULT 
required to achieve complete inhibition of XO and adequate suppression of SUA 
varies from one individual to another and the common practice of using fixed 
doses of allopurinol ≤300mg, (Annemans et al, 2008; Cottrell et al, 2013) is 
unlikely to be helpful in mitigating vascular risk.  This is supported by the findings 
in this study that all levels of cumulative exposure to, and current use of allopurinol 
did not reduce odds of vascular event compared with no exposure to allopurinol 
within this cohort where indicators of optimal prescribing (regular measurement of 
serum urate to inform titration and prescription of doses in excess of 300mg) are 
only present in a small minority.  As it has been demonstrated in patients with RA 
that a more aggressive management of the condition can reduce vascular risk, a 
similar aggressive approach to the management of gout by earlier initiation and 
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active titration to achieve target urate levels may be justified with the aim of 
reducing both symptomatic and vascular burden.   
10.4 Future research questions 
In reviewing the existing literature surrounding the relationship between gout and 
vascular disease it has become obvious that whilst much has been written about 
this association, there is actually a paucity of studies investigating it.  Furthermore, 
the mechanisms underpinning this relationship are the subject of much discussion, 
but little research.  The specific research questions identified that should be 
considered important for future patient care are described below. 
10.4.1 Basic science research 
The literature discussing the mechanisms underlying the pathophysiology of 
vascular risk at different sites has been presented in previous chapters, but most 
of this evidence comes from research into other inflammatory conditions, or 
extrapolation of hypotheses tested in the general population.  There is little 
investigation of the mechanism responsible for excess vascular risk in gout, 
particularly gout in women.  Of particular interest is the lipid profile in patients with 
gout, since reduction in HDL, LDL and total cholesterol in patients with RA has 
been demonstrated, increasing vascular risk.  Whether patients with gout have a 
similarly abnormal lipid profile is not yet known, and particularly relevant to 
improving care of gout patients as it has been shown that in RA this abnormal lipid 
profile can be corrected by optimal control of the RA itself, without lipid-lowering 
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medication, and establishing the influence of optimal control of gout on lipid profile 
in gout patients may inform future guidelines on the management of gout. 
It is likely that elucidating the interaction and relative importance of novel risk 
factors in gout in the pathogenesis of different forms, and at different stages of 
vascular disease may significantly inform clinical practice in optimally managing 
these risks, as it has in RA.    
10.4.2 Epidemiological research 
Prior to this study there had only been two previous investigations of the incidence 
of cardiovascular disease in patients with gout, and one study each of the 
incidence of cerebrovascular and peripheral vascular disease.  Whilst the results 
of this study can be considered generalisable to a UK primary care population, 
further investigation of the incidence of cerebrovascular disease and peripheral 
vascular disease is warranted, and comparison between populations (e.g. New 
Zealand and Asia) would be valuable.  It has previously been assumed that the 
risk of vascular disease increases over time, but there is little evidence to support 
this suggestion, and the findings of this study suggest that risk of some vascular 
outcomes are greatest in the first one or two years following diagnosis of gout 
particularly in women.  If this is the case in other gout populations, this would 
support more aggressive management of gout, and routine primary prevention of 
vascular risk, required from diagnosis.   
There is also much important epidemiological work required to elucidate how to 
manage this excess risk of vascular diseases most effectively in patients with gout, 
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since the findings of this study suggest that traditional methods are not wholly 
effective.  Studies which are able to include serum urate levels or disease severity 
as covariates are scarce, and as such little is understood of the impact of optimal 
gout management on vascular risk. 
Until the mechanisms by which patients with gout are at increased risk of vascular 
disease are further elucidated, clinicians will remain unable to optimally mitigate 
this risk. It is only by understanding the most important risk factors underpinning 
this association that an effective treatment strategy can be devised, without which 
gout patients will continue to experience potentially preventable health outcomes.   
10.5 Peer-reviewed publications from this thesis 
Two peer-reviewed publications have been published reporting the findings 
described in this thesis.  These are:  
Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen 
CD. Increased cardiovascular mortality associated with gout: a systematic review 
and meta-analysis.  European Journal of Preventive Cardiology. 2013:  doi: 
10.1177/2047487313514895 Published Online First 26 November 2013 
Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD.  Increased 
risk of vascular disease associated with gout: a retrospective cohort study in the 
UK Clinical Practice Research Datalink.  Annals of the Rheumatic Diseases. 2014: 
doi: 10.1136/annrheumdis-2014-205252  Published Online First 27 Aug 2014 
Copies can be found in Appendix 3. 
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10.6 Summary 
This section has discussed the findings of the retrospective matched-cohort study 
examining the association between gout and cardiovascular, cerebrovascular and 
peripheral vascular disease, in a cohort of primary care patients over the age of 
50, with no prior history of vascular disease.  Women are at greatest risk of 
vascular disease with the exception of MI, and all cerebrovascular events, and risk 
of peripheral vascular disease is greater than that of cardiovascular or 
cerebrovascular disease.  Risk of peripheral vascular disease and cerebrovascular 
disease in women and angina in men is greatest in the one or two years following 
diagnosis of gout.   
Reasons for these differences may include stronger predisposition to vascular 
disease at different sites associated with particular risk factors, or differences in 
the importance of endothelial dysfunction, plaque deposition and thrombosis in 
vascular disease at different sites and the risk factors which predispose to these.  
Inflammation and oxidative stress resulting from disease activity and inflammatory 
burden are likely to play a major role in excess risk of vascular disease in gout, in 
addition to the contribution of hyperuricaemia, and it is these gout-specific vascular 
risk factors which are difficult to mitigate against using traditional methods of 
vascular risk reduction.   
Exposure to medications used to treat chronic gout, and colchicine do not alter the 
odds of vascular event, except with exposure to NSAIDs, where above median 
NSAID exposure made a vascular event less likely. Exposure to drugs used to 
mitigate against cardiovascular risk such as anti-hypertensives, anti-platelets and 
lipid-lowering drugs, was also associated with increased odds of vascular event, 
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although increasing dose exposure reduced odds in all three classes of drugs.  
Perhaps the most important finding is that whilst in isolation none of the drugs 
investigated (with the exception of the highest cumulative exposure to NSAIDs) 
made a vascular event less likely, however, in the presence of drugs used to treat 
vascular risk factors those participants exposed to allopurinol were less likely to 
experience a vascular event suggesting a role for combination therapy in 
managing gout and associated vascular risk.  
In summary, the increased risk of vascular disease in gout is a complex 
multifactorial phenomenon that is still not well understood, and further research is 
required to find reliable ways to identify those patients with gout most likely to 
experience a vascular event and effective management strategies by which to 
reduce these risks. 
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Appendix 1 – Search Strategies 
Cardiovascular 
Medline Results Embase Results CINAHL Results 
Exp MYOCARDIAL ISCHEMIA/ 325758 Exp ISCHEMIC HEART 
DISEASE/ 
369641 Exp MYOCARDIAL 
ISCHEMIA/ 
39627 
Exp CARDIOVASCULAR 
DISEASES/ 
1689301 Exp CORONARY ARTERY 
DISEASE/ 
175968 Exp CORONARY 
DISEASE/ 
21619 
Exp CORONARY DISEASE/ 167710 Exp CARDIOVASCULAR 
DISEASE/ 
2361569 Exp CARDIOVASCULAR 
DISEASES/ 
197801 
(Heart and disease*).ti,ab 168855 (heart and disease*).ti,ab 199057 (heart and disease*).ti,ab 19806 
(Coronary and disease*).ti,ab 119885 (coronary and disease*).ti,ab 142892 (coronary and 
disease*).ti,ab 
13405 
Chd.ti,ab 14100 Chd.ti,ab 17373 Chd.ti,ab 2295 
Cardiovascular.ti,ab 222865 Cardiovascular.ti,ab 267075 Cardiovascular.ti,ab 29567 
Angina.ti,ab 41023 Angina.ti,ab 47472 Angina.ti,ab 3061 
Cvd.ti,ab 11723 Cvd.ti,ab 14529 Cvd.ti,ab 2279 
Exp MYOCARDIAL 
INFARCTION/ 
134432 Exp HEART INFARCTION/ 209176 Exp MYOCARDIAL 
INFARCTION/ 
19063 
(myocardial and infarction).ti,ab 117481 (Myocardial and infarction).ti,ab 137618 (myocardial and 
infarction).ti,ab 
12581 
Exp ATHEROSCLEROSIS/ 14946 Exp CORONARY ARTERY 
ATHEROSCLEROSIS/ 
14258 ATHEROSCLEROSIS/ 
(doesn’t explode) 
990 
Atherosclero*.ti,ab 92930 Atherosclero*.ti,ab 108554 Atherosclero*.ti,ab 5922 
(Heart and attack).ti,ab 7192 (Heart and attack*).ti,ab 8560 (heart and attack).ti,ab 1485 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
or 9 or 10 or 11 or 12 or 13 or 14 
1857949 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
or 9 or 10 or 11 or 12 or 13 or 14 
2490265 1 or 2 or 3 or 4 or 5 or 6 or 
7 or 8 or 9 or 10 or 11 or 
12 or 13 or 14 
216197 
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Cerebrovascular 
Medline Results Embase Results CINAHL Results 
Exp CEREBROVASCULAR 
DISORDERS/ 
241225 Exp CEREBROVASCULAR 
DISORDERS/ 
340121 Exp 
CEREBROVASCULAR 
DISORDERS/ 
42315 
(Stroke* or poststroke* or 
CVA*).ti,ab 
121867 (Stroke* or poststroke* or 
CVA*).ti,ab 
151706 (Stroke* or poststroke* or 
CVA*).ti,ab 
27578 
(cerebrovascular* or cerebral 
vascular).ti,ab 
24900 (cerebrovascular* or cerebral 
vascular).ti,ab 
29451 (cerebrovascular* or 
cerebral vascular).ti,ab 
4281 
(cerebral or cerebellar or 
brainstem or vertebrobasilar or 
brain).ti,ab 
791101 (cerebral or cerebellar or 
brainstem or vertebrobasil* or 
brain).ti,ab 
867926 (cerebral or cerebellar or 
brainstem or vertebrobasil* 
or brain).ti,ab 
39990 
(Infarct* or isch?emi* or 
thrombo* or apoplexy or 
emboli*).ti,ab 
626489 (Infarct* or isch?emi* or 
thrombo* or apoplexy or 
emboli*).ti,ab 
726532 (Infarct* or isch?emi* or 
thrombo* or apoplexy or 
emboli*).ti,ab 
34599 
4 AND 5 85549 4 AND 5 102629 4 AND 5 4198 
(cerebral or intracerebral or 
intracranial or brain or brainstem 
or cerebellar or 
vertebrobasilar).ti,ab 
836500 (cerebral or intracerebral or 
intracranial or brain or brainstem 
or cerebellar or 
vertebrobasil*).ti,ab 
918036 (cerebral or intracerebral 
or intracranial or brain or 
brainstem or cerebellar or 
vertebrobasil*).ti,ab 
42750 
(haemorrhage* or hemorrhag* 
or haematoma or hematoma or 
bleed*).ti,ab 
177576 (haemorrhage* or hemorrhag* or 
haematoma or hematoma or 
bleed*).ti,ab 
308530 (haemorrhage* or 
hemorrhag* or haematoma 
or hematoma or 
bleed*).ti,ab 
17842 
7 AND 8 43218 7 AND 8 55090 7 AND 8 3634 
(cerebrovascular ADJ 
accident).ti,ab 
2690 (cerebrovascular ADJ 
accident).ti,ab 
3299 (cerebrovascular ADJ 
accident).ti,ab 
508 
1 or 2 or 3 or 6 or 7 or 9 or 10 1010830 1 or 2 or 3 or 6 or 7 or 9 or 10 1150055 1 or 2 or 3 or 6 or 7 or 9 or 
10 
83059 
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Peripheral Vascular Disease 
Medline Results Embase Results CINAHL Results 
Exp PERIPHERAL VASCULAR 
DISEASES/ 
40877 Exp PERIPHERAL VASCULAR 
DISEASE/ 
1034100 Exp PERIPHERAL 
VASCULAR DISEASES/ 
5529 
Exp ARTERIOSCLEROSIS 114921 Exp ARTERIOSCLEROSIS/ 155158 Exp 
ARTERIOSCLEROSIS/ 
10800 
INTERMITTENT 
CLAUDICATION/ (doesn’t exp) 
6450 Exp INTERMITTENT 
CLAUDICATION/ 
7217 INTERMITTENT 
CLAUDICATION/ 
586 
((peripheral ADJ vascular*) or 
atherosclerosis or 
arteriosclerosis or PVD or PAOD 
or PAD).ti,ab 
104353 ((peripheral ADJ vascular*) or 
atherosclerosis or 
arteriosclerosis or PVD or PAOD 
or PAD).ti,ab 
120121 ((peripheral ADJ 
vascular*) or 
atherosclerosis or 
arteriosclerosis or PVD or 
PAOD or PAD).ti,ab 
6988 
(arter* ADJ occlus*) 25696 (arter* ADJ occlus*) 29352 (arter* ADJ occlus*) 1618 
(periph* ADJ arter*) 13340 (periph* ADJ arter*) 15856 (periph* ADJ arter*) 1462 
(obstruct* ADJ arter*) 469 (obstruct* ADJ arter*) 497 (obstruct* ADJ arter*) 177 
(claudica*) 7214 (claudica*) 8271 (claudica*) 634 
(limb* ADJ isch?emi*) 4276 (limb* ADJ isch?emi*) 5224 (limb* ADJ isch?emi*) 54 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 
8 or 9 
241458 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
or 9 
1079153 1 or 2 or 3 or 4 or 5 or 6 or 
7 or 8 or 9 
21563 
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Gout  
Medline Results Embase Results CINAHL Results 
Exp GOUT/  8890 Exp GOUT/ (nothing below) 12085 GOUT/ (doesn’t explode) 997 
Gout*.ti,ab 8343 Gout*.ti,ab 9158 Gout*.ti,ab 762 
OR 11228 OR 13858 OR 1139 
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Outcomes 
Medline Results Embase Results CINAHL Results 
Exp INCIDENCE/ 147723 Exp INCIDENCE/ 207401 INCIDENCE/ (doesn’t exp) 16622 
Inciden*.ti,ab 499443 Inciden*.ti,ab 559518 Inciden*.ti,ab 48420 
Exp PREVALENCE/ 152963 Exp PREVALENCE/ 277261 PREVALENCE/ (doesn’t 
explode) 
21503 
Prevalen*.ti,ab 359636 Prevalen*.ti,ab 413497 Prevalen*.ti,ab 47943 
Exp MORTALITY/ 240944 Exp MORTALITY/ 477207 Exp MORTALITY/ 25261 
Mortality.ti,ab 374929 Mortality.ti,ab 430657 Mortality.ti,ab 43611 
Exp MORBIDITY/ 305558 Exp MORBIDITY/ 152262 Exp MORBIDITY/ 39336 
Morbid*.ti,ab 216898 Morbid*.ti,ab 258219 Morbid*.ti,ab 25152 
OR 1442828 OR 1709643 OR 165606 
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Totals  
Medline Results Embase Results CINAHL Results 
Cardiovascular AND gout 
AND outcomes 
491 Cardiovascular AND gout AND 
outcomes 
1251 Cardiovascular AND gout 
AND outcomes  
34 
  Limit HUMAN 1102   
Cerebrovascular and 
outcomes 
93 Cerebrovascular AND gout AND 
outcomes 
219 Cerebrovascular AND 
gout AND outcomes 
5 
Peripheral vascular AND gout 
AND outcomes 
77 Peripheral vascular AND gout AND 
outcomes 
 Peripheral vascular AND 
gout AND outcomes 
8 
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Appendix 2 – Read codes used to identify conditions of 
interest 
Codes used to identify hypertension  
 
CPRD 
Medcode 
Read 
code 
Read term 
204 G2...00 Hypertensive disease 
351 G20..11 High blood pressure 
799 G20..00 Essential hypertension 
1894 G201.00 Benign essential hypertension 
2666 14A2.00 H/O: hypertension 
3425 662O.00 On treatment for hypertension 
3712 G20z.11 Hypertension NOS 
4344 9N03.00 Seen in hypertension clinic 
4372 G202.00 Systolic hypertension 
4444 662..12 Hypertension monitoring 
4668 G22..00 Hypertensive renal disease 
5215 9OI..00 Hypertension monitoring admin. 
5513 8HT5.00 Referral to hypertension clinic 
7057 G2z..00 Hypertensive disease NOS 
7329 G24..00 Secondary hypertension 
8732 G2...11 BP - hypertensive disease 
8857 G21z011 Cardiomegaly - hypertensive 
10818 G20z.00 Essential hypertension NOS 
10961 9h31.00 Excepted from hypertension qual indicators: 
Patient unsuit 
10976 9h32.00 Excepted from hypertension qual indicators: 
Informed dissent 
12680 8CR4.00 Hypertension clinical management plan 
12948 662H.00 Hypertension treatm.stopped 
13186 662P.00 Hypertension monitoring 
13188 662G.00 Hypertensive treatm.changed 
15106 G22z.00 Hypertensive renal disease NOS 
15377 G200.00 Malignant essential hypertension 
16059 G24z.00 Secondary hypertension NOS 
16173 G21zz00 Hypertensive heart disease NOS 
16292 G21..00 Hypertensive heart disease 
16565 6627 Good hypertension control 
18482 662c.00 Hypertension six month review 
18590 662b.00 Moderate hypertension control 
18765 G2y..00 Other specified hypertensive disease 
19070 662d.00 Hypertension annual review 
21826 662F.00 Hypertension treatm. started 
21837 G232.00 Hypertensive heart&renal dis wth (congestive) 
heart failure 
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22333 8I3N.00 Hypertension treatment refused 
24127 9OIA.11 Hypertension monitored 
25371 G241000 Secondary benign renovascular hypertension 
27511 6628 Poor hypertension control 
27525 9OI..11 Hypertension clinic admin. 
27634 9N1y200 Seen in hypertension clinic 
28874 9OI8.00 Hypertens.monitor phone invite 
29310 G22z.11 Renal hypertension 
30776 6629 Hypertension:follow-up default 
31117 9OI4.00 Hypertens.monitor.1st letter 
31127 9OI5.00 Hypertens.monitor 2nd letter 
31175 9OI6.00 Hypertens.monitor 3rd letter 
31341 G24z100 Hypertension secondary to drug 
31387 G24z000 Secondary renovascular hypertension NOS 
31464 G21z.00 Hypertensive heart disease NOS 
31755 G240.00 Secondary malignant hypertension 
32423 G222.00 Hypertensive renal disease with renal failure 
34744 G244.00 Hypertension secondary to endocrine disorders 
36305 9OIA.00 Hypertension monitor.chck done 
39649 G220.00 Malignant hypertensive renal disease 
41634 9OI7.00 Hypertens.monitor verbal inv. 
42229 G24zz00 Secondary hypertension NOS 
43220 9OI2.00 Refuses hypertension monitor. 
43935 G221.00 Benign hypertensive renal disease 
45149 9OI1.00 Attends hypertension monitor. 
50157 G210.00 Malignant hypertensive heart disease 
51635 G241z00 Secondary benign hypertension NOS 
52127 G211100 Benign hypertensive heart disease with CCF 
52427 G211.00 Benign hypertensive heart disease 
57288 G241.00 Secondary benign hypertension 
57987 G234.00 Hyperten heart&renal dis+both(congestv)heart 
and renal fail 
59383 G240000 Secondary malignant renovascular hypertension 
69753 Gyu2.00 [X]Hypertensive diseases 
73293 G240z00 Secondary malignant hypertension NOS 
83473 G203.00 Diastolic hypertension 
95334 G210000 Malignant hypertensive heart disease without 
CCF 
97533 Gyu2100 [X]Hypertension secondary to other renal 
disorders 
98230 67H8.00 Lifestyle advice regarding hypertension 
99259 662q.00 Trial reduction of antihypertensive therapy 
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Codes used to identify hyperlipidaemia 
CPRD 
Medcode 
Read 
code 
Read term 
339 C320.00 Pure hypercholesterolaemia 
340 9N0I.00 Seen in lipid clinic 
637 C324.00 Hyperlipidaemia NOS 
1173 C321.00 Pure hyperglyceridaemia 
2091 9N0J.00 Seen in cholesterol clinic 
2493 44P3.00 Serum cholesterol raised 
3386 C320000 Familial hypercholesterolaemia 
3484 C320.11 Familial hypercholesterolaemia 
5791 C322.00 Mixed hyperlipidaemia 
7447 C320z00 Pure hypercholesterolaemia NOS 
9936 66X..00 Lipid disorder monitoring 
10780 8B6A.00 Statin prophylaxis 
10783 8BAG.00 Cholesterol reduction programme 
10813 8I3C.00 Statin declined 
10899 8BAG200 Cholesterol reduction program - declined 
11529 8I76.00 Statin not tolerated 
12111 8BL1.00 Patient on maximal tolerated lipid lowering 
therapy 
12439 C321000 Hypertriglyceridaemia 
12569 ZV65317 [V]Dietary surveillance in 
hypercholesterolaemia 
13657 8HT1.00 Referral to lipid clinic 
16085 1442 H/O: raised blood lipids 
16306 C325.00 Lipoprotein deficiencies 
16937 8B28.00 Lipid lowering therapy 
26019 C320200 Hyperlipidaemia, group A 
30335 9N4K.00 DNA - Did not attend cholesterol clinic 
32244 8BG2.00 Lipid lowering therapy indicated 
33694 ZC2CJ00 Dietary advice for hyperlipidaemia 
34224 C320300 Low-density-lipoprotein-type (LDL) 
hyperlipoproteinaemia 
34825 C320100 Hyperbetalipoproteinaemia 
35720 44P4.00 Serum cholesterol very high 
36806 9Oc..00 Lipid disorder monitoring administration 
39147 8BAG000 Cholesterol reduction programme - invited 
39699 C325000 High density lipoid deficiency 
39849 8I3J.00 Lipid lowering therapy declined 
51023 8BAG100 Cholesterol reduction program - attended 
52992 C322.11 Fredrickson type IIb lipidaemia 
53091 C320y00 Other specified pure hypercholesterolaemia 
54499 C321.11 Fredrickson type IV lipidaemia 
55855 C320.12 Fredrickson type IIa lipidaemia 
59095 C320.13 Low density lipoproteinaemia 
59564 C322.12 Fredrickson type III lipidaemia 
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66240 Cyu8D00 [X]Other hyperlipidaemia 
69881 C323.12 Fredrickson type I lipaemia 
71157 C327z00 Lipidoses NOS 
71747 8CR3.00 Hyperlipidaemia clinical management plan 
95952 C328.00 Dyslipidaemia 
97166 9Oc0.00 Attends lipid disorder monitoring 
97989 C320500 Familial defective apolipoprotein B-100 
99032 9Oc3.00 Lipid disorder monitoring second letter 
99456 C321.12 Very low density lipoprotinaemia 
      
412 
 
 
Codes used to identify chronic kidney disease 
CPRD 
Medcode 
Read 
code 
Read term 
350 K06..00 Renal failure unspecified 
512 K05..00 Chronic renal failure 
6712 K050.00 End stage renal failure 
6774 14D..11 H/O: kidney disease 
6842 K060.11 Impaired renal function 
8330 K0D..00 End-stage renal disease 
8919 K08..00 Impaired renal function disorder 
9959 14D..12 H/O: renal disease 
11787 K060.00 Renal impairment 
12479 1Z13.00 Chronic kidney disease stage 4 
12566 1Z12.00 Chronic kidney disease stage 3 
12585 1Z14.00 Chronic kidney disease stage 5 
12586 1Z11.00 Chronic kidney disease stage 2 
12720 1Z1..00 Chronic renal impairment 
19473 66i..00 Chronic kidney disease monitoring 
25980 K08z.00 Impaired renal function disorder NOS 
26001 4519 Deteriorating renal function 
29013 1Z10.00 Chronic kidney disease stage 1 
30735 6AA..00 Chronic kidney disease annual review 
30739 9Ot0.00 Chronic kidney disease monitoring first letter 
31549 7L1A.00 Compensation for renal failure 
32423 G222.00 Hypertensive renal disease with renal failure 
39840 K08y.00 Other impaired renal function disorder 
41013 K08y300 Renal function impairment with growth failure 
46626 9hE..00 Exception reporting: chronic kidney disease 
quality indicato 
47342 Q48y000 Congenital renal failure 
50804 K08yz00 Other impaired renal function disorder NOS 
53852 K05..12 End stage renal failure 
53940 Kyu2100 [X]Other chronic renal failure 
61930 Kyu2.00 [X]Renal failure 
64636 7L1Az00 Compensation for renal failure NOS 
69679 9Ot4.00 Chronic kidney disease monitoring telephone 
invite 
71271 9Ot..00 Chronic kidney disease monitoring 
administration 
72962 9Ot1.00 Chronic kidney disease monitoring second letter 
72964 9Ot2.00 Chronic kidney disease monitoring third letter 
88494 9Ot3.00 Chronic kidney disease monitoring verbal invite 
94789 1Z17.00 Chronic kidney disease stage 1 with proteinuria 
94793 1Z1B.00 Chronic kidney disease stage 3 with proteinuria 
94965 1Z15.00 Chronic kidney disease stage 3A 
95121 1Z1A.00 Chronic kidney disease stage 2 without 
proteinuria 
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95122 1Z1H.00 Chronic kidney disease stage 4 with proteinuria 
95123 1Z1C.00 Chronic kidney disease stage 3 without 
proteinuria 
95145 1Z1B.11 CKD stage 3 with proteinuria 
95146 1Z19.00 Chronic kidney disease stage 2 with proteinuria 
95175 1Z1E.00 Chronic kidney disease stage 3A without 
proteinuria 
95176 1Z1E.11 CKD stage 3A without proteinuria 
95177 1Z1G.00 Chronic kidney disease stage 3B without 
proteinuria 
95178 1Z1F.00 Chronic kidney disease stage 3B with proteinuria 
95179 1Z16.00 Chronic kidney disease stage 3B 
95180 1Z1F.11 CKD stage 3B with proteinuria 
95188 1Z1C.11 CKD stage 3 without proteinuria 
95405 1Z1L.00 Chronic kidney disease stage 5 without 
proteinuria 
95406 1Z1J.00 Chronic kidney disease stage 4 without 
proteinuria 
95408 1Z1D.00 Chronic kidney disease stage 3A with proteinuria 
95422 9Ni9.00 Did not attend chronic kidney disease monitoring 
clinic 
95508 1Z1K.00 Chronic kidney disease stage 5 with proteinuria 
95571 1Z1D.11 CKD stage 3A with proteinuria 
95572 1Z18.00 Chronic kidney disease stage 1 without 
proteinuria 
97587 1Z1J.11 CKD stage 4 without proteinuria 
97683 1Z1L.11 CKD stage 5 without proteinuria 
97978 1Z1A.11 CKD stage 2 without proteinuria 
97979 1Z19.11 CKD stage 2 with proteinuria 
97980 1Z17.11 CKD stage 1 with proteinuria 
99160 1Z1K.11 CKD stage 5 with proteinuria 
99312 1Z1H.11 CKD stage 4 with proteinuria 
 
 
 
 
 
 
 
 
 
      
414 
 
 
 
Codes used to identify diabetes mellitus 
CPRD 
Medcode 
Read 
code 
Readterm 
506 C100112 Non-insulin dependent diabetes mellitus 
608 66A2.00 Follow-up diabetic assessment 
711 C10..00 Diabetes mellitus 
758 C10F.00 Type 2 diabetes mellitus 
1038 C100011 Insulin dependent diabetes mellitus 
1407 C10FJ00 Insulin treated Type 2 diabetes mellitus 
1549 C10E.00 Type 1 diabetes mellitus 
1647 C108.00 Insulin dependent diabetes mellitus 
1682 C101.00 Diabetes mellitus with ketoacidosis 
1684 66A4.00 Diabetic on oral treatment 
2378 66AJ.00 Diabetic - poor control 
2379 9N1Q.00 Seen in diabetic clinic 
2475 C104.11 Diabetic nephropathy 
2478 66AJ100 Brittle diabetes 
3550 66A..00 Diabetic monitoring 
4513 C109.00 Non-insulin dependent diabetes mellitus 
5884 C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
6125 66AS.00 Diabetic annual review 
6430 9NM0.00 Attending diabetes clinic 
6509 C108700 Insulin dependent diabetes mellitus with retinopathy 
6791 C108800 Insulin dependant diabetes mellitus - poor control 
6813 1434.00 H/O: diabetes mellitus 
7059 8H2J.00 Admit diabetic emergency 
7563 66A3.00 Diabetic on diet only 
7777 8H4F.00 Referral to diabetologist 
7795 C106.12 Diabetes mellitus with neuropathy 
8306 8H7f.00 Referral to diabetes nurse 
8403 C109700 Non-insulin dependant diabetes mellitus - poor 
control 
8414 8CA4100 Pt advised re diabetic diet 
8836 66AR.00 Diabetes management plan given 
8842 66A5.00 Diabetic on insulin 
9013 66AJ.11 Unstable diabetes 
9897 9OL..00 Diabetes monitoring admin. 
10098 C10yy00 Other specified diabetes mellitus with other spec 
comps 
10418 C10ED00 Type 1 diabetes mellitus with nephropathy 
10692 C10EM00 Type 1 diabetes mellitus with ketoacidosis 
10824 9N1i.00 Seen in diabetic foot clinic 
10977 66Ac.00 Diabetic peripheral neuropathy screening 
11041 9h41.00 Excepted from diabetes qual indicators: Patient 
unsuitable 
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11047 66AH000 Conversion to insulin 
11094 9NND.00 Under care of diabetic foot screener 
11348 9h42.00 Excepted from diabetes quality indicators: Informed 
dissent 
11471 8B3l.00 Diabetes medication review 
11551 C10B.00 Diabetes mellitus induced by steroids 
11677 8H7r.00 Refer to diabetic foot screener 
11848 C314.11 Renal diabetes 
11930 9NN9.00 Under care of diabetes specialist nurse 
12030 9OL6.00 Diabetes monitoring 3rd letter 
12213 8BL2.00 Patient on maximal tolerated therapy for diabetes 
12225 8H7C.00 Refer, diabetic liaison nurse 
12262 8I3X.00 Diabetic retinopathy screening refused 
12307 66AU.00 Diabetes care by hospital only 
12455 C10E.11 Type I diabetes mellitus 
12507 9N2i.00 Seen by diabetic liaison nurse 
12640 C10FC00 Type 2 diabetes mellitus with nephropathy 
12675 66AQ.00 Diabetes: shared care programme 
12736 C10F500 Type 2 diabetes mellitus with gangrene 
13071 66AI.00 Diabetic - good control 
13078 13AC.00 Diabetic weight reducing diet 
13191 9OL..11 Diabetes clinic administration 
13192 9OLA.00 Diabetes monitor. check done 
13194 9OL4.00 Diabetes monitoring 1st letter 
13195 9OL5.00 Diabetes monitoring 2nd letter 
13196 66AD.00 Fundoscopy - diabetic check 
13197 9OL1.00 Attends diabetes monitoring 
13279 C104y00 Other specified diabetes mellitus with renal 
complications 
13597 42W1.00 Hb. A1C < 7% - good control 
13604 42W3.00 Hb. A1C > 10% - bad control 
14049 42WZ.00 Hb. A1C - diabetic control NOS 
14050 42c..00 HbA1 - diabetic control 
14803 C100100 Diabetes mellitus, adult onset, no mention of 
complication 
14889 C100111 Maturity onset diabetes 
15690 C103.00 Diabetes mellitus with ketoacidotic coma 
16230 C106.00 Diabetes mellitus with neurological manifestation 
16490 66AH.00 Diabetic treatment changed 
16491 C106.13 Diabetes mellitus with polyneuropathy 
16502 C104.00 Diabetes mellitus with renal manifestation 
17236 14P3.00 H/O: insulin therapy 
17262 C109600 Non-insulin-dependent diabetes mellitus with 
retinopathy 
17545 C108F11 Type I diabetes mellitus with diabetic cataract 
17858 C108.12 Type 1 diabetes mellitus 
17859 C109.12 Type 2 diabetes mellitus 
17869 66AL.00 Diabetic-uncooperative patient 
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17886 66AM.00 Diabetic - follow-up default 
18143 C109G11 Type II diabetes mellitus with arthropathy 
18167 66AT.00 Annual diabetic blood test 
18209 C109012 Type 2 diabetes mellitus with renal complications 
18219 C109.13 Type II diabetes mellitus 
18230 C108J12 Type 1 diabetes mellitus with neuropathic 
arthropathy 
18264 C109J12 Insulin treated Type II diabetes mellitus 
18278 C109J00 Insulin treated Type 2 diabetes mellitus 
18311 68A7.00 Diabetic retinopathy screening 
18387 C10E700 Type 1 diabetes mellitus with retinopathy 
18390 C10FM00 Type 2 diabetes mellitus with persistent 
microalbuminuria 
18425 C10FB00 Type 2 diabetes mellitus with polyneuropathy 
18496 C10F600 Type 2 diabetes mellitus with retinopathy 
18505 C108.11 IDDM-Insulin dependent diabetes mellitus 
18642 C10EH00 Type 1 diabetes mellitus with arthropathy 
18662 8HBH.00 Diabetic retinopathy 6 month review 
18683 C10E500 Type 1 diabetes mellitus with ulcer 
18766 212H.00 Diabetes resolved 
18777 C10F000 Type 2 diabetes mellitus with renal complications 
18824 8I3W.00 Diabetic foot examination declined 
19381 8HTk.00 Referral to diabetic eye clinic 
19739 68A9.00 Diabetic retinopathy screening offered 
20900 9OLA.11 Diabetes monitored 
21482 C102.00 Diabetes mellitus with hyperosmolar coma 
21983 C108012 Type 1 diabetes mellitus with renal complications 
22023 66AJz00 Diabetic - poor control NOS 
22130 9OL3.00 Diabetes monitoring default 
22487 C10N.00 Secondary diabetes mellitus 
22573 C106z00 Diabetes mellitus NOS with neurological 
manifestation 
22823 66Ab.00 Diabetic foot examination 
22871 C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
22884 C10F.11 Type II diabetes mellitus 
24363 8A13.00 Diabetic stabilisation 
24423 C108.13 Type I diabetes mellitus 
24458 C109711 Type II diabetes mellitus - poor control 
24490 C100000 Diabetes mellitus, juvenile type, no mention of 
complication 
24693 C109G00 Non-insulin dependent diabetes mellitus with 
arthropathy 
24694 C108B00 Insulin dependent diabetes mellitus with 
mononeuropathy 
24836 C109C12 Type 2 diabetes mellitus with nephropathy 
25591 C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
25627 C10F700 Type 2 diabetes mellitus - poor control 
25636 66Aa.00 Diabetic diet - poor compliance 
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26054 C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
26603 9OL2.00 Refuses diabetes monitoring 
26604 66AY.00 Diabetic diet - good compliance 
26605 9OLB.00 Attended diabetes structured education programme 
26855 C108400 Unstable insulin dependant diabetes mellitus 
28574 9h4..00 Exception reporting: diabetes quality indicators 
28622 2126300 Diabetes resolved 
28769 66AV.00 Diabetic on insulin and oral treatment 
28856 8CP2.00 Transition of diabetes care options discussed 
28873 66Ai.00 Diabetic 6 month review 
29041 66AN.00 Date diabetic treatment start 
29979 C109900 Non-insulin-dependent diabetes mellitus without 
complication 
30294 C10EL00 Type 1 diabetes mellitus with persistent 
microalbuminuria 
30323 C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
30648 9N4p.00 Did not attend diabetic retinopathy clinic 
31141 9OL8.00 Diabetes monitor.phone invite 
31240 9OL7.00 Diabetes monitor.verbal invite 
31241 9OLZ.00 Diabetes monitoring admin.NOS 
31310 C108900 Insulin dependant diabetes maturity onset 
32403 C107.11 Diabetes mellitus with gangrene 
32556 C107.12 Diabetes with gangrene 
32619 66Af.00 Patient diabetes education review 
32627 C10FN00 Type 2 diabetes mellitus with ketoacidosis 
33254 C105.00 Diabetes mellitus with ophthalmic manifestation 
33343 C10y.00 Diabetes mellitus with other specified manifestation 
33807 C107200 Diabetes mellitus, adult with gangrene 
34268 C10F200 Type 2 diabetes mellitus with neurological 
complications 
34283 C105z00 Diabetes mellitus NOS with ophthalmic 
manifestation 
34450 C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes 
mellitus 
34528 3882.00 Diabetes well being questionnaire 
34541 8HVU.00 Private referral to diabetologist 
34912 C109400 Non-insulin dependent diabetes mellitus with ulcer 
35105 C104100 Diabetes mellitus, adult onset, with renal 
manifestation 
35107 C104z00 Diabetes mellitis with nephropathy NOS 
35288 C10E800 Type 1 diabetes mellitus - poor control 
35383 9OLD.00 Diabetic patient unsuitable for digital retinal 
photography 
35385 C10FH00 Type 2 diabetes mellitus with neuropathic 
arthropathy 
35399 C107.00 Diabetes mellitus with peripheral circulatory disorder 
36633 C109K00 Hyperosmolar non-ketotic state in type 2 diabetes 
mellitus 
36695 C10D.00 Diabetes mellitus autosomal dominant type 2 
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37648 C109J11 Insulin treated non-insulin dependent diabetes 
mellitus 
37806 C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
38103 9N0m.00 Seen in diabetic nurse consultant clinic 
38129 9N0o.00 Seen in community diabetic specialist nurse clinic 
38130 ZRB6.00 Diabetes wellbeing questionnaire 
38161 C108711 Type I diabetes mellitus with retinopathy 
38617 C101y00 Other specified diabetes mellitus with ketoacidosis 
38986 C100.00 Diabetes mellitus with no mention of complication 
39070 C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
39317 C106100 Diabetes mellitus, adult onset, + neurological 
manifestation 
39809 C108J00 Insulin dependent diab mell with neuropathic 
arthropathy 
40023 C102000 Diabetes mellitus, juvenile type, with hyperosmolar 
coma 
40401 C109500 Non-insulin dependent diabetes mellitus with 
gangrene 
40682 C10E900 Type 1 diabetes mellitus maturity onset 
40837 C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
40962 C109H00 Non-insulin dependent d m with neuropathic 
arthropathy 
41049 C108712 Type 1 diabetes mellitus with retinopathy 
41389 C105100 Diabetes mellitus, adult onset, + ophthalmic 
manifestation 
41686 Cyu2000 [X]Other specified diabetes mellitus 
41716 C108C00 Insulin dependent diabetes mellitus with 
polyneuropathy 
42505 C101z00 Diabetes mellitus NOS with ketoacidosis 
42567 C103000 Diabetes mellitus, juvenile type, with ketoacidotic 
coma 
42729 C108E11 Type I diabetes mellitus with hypoglycaemic coma 
42762 C109612 Type 2 diabetes mellitus with retinopathy 
42831 C10E200 Type 1 diabetes mellitus with neurological 
complications 
43139 C102100 Diabetes mellitus, adult onset, with hyperosmolar 
coma 
43227 C10F311 Type II diabetes mellitus with multiple complications 
43453 C10C.00 Diabetes mellitus autosomal dominant 
43785 C109D00 Non-insulin dependent diabetes mellitus with 
hypoglyca coma 
43857 C10M.00 Lipoatrophic diabetes mellitus 
43921 C10E400 Unstable type 1 diabetes mellitus 
43951 66AK.00 Diabetic - cooperative patient 
44260 C108F00 Insulin dependent diabetes mellitus with diabetic 
cataract 
44312 9M10.00 Informed dissent for diabetes national audit 
44440 C108E00 Insulin dependent diabetes mellitus with 
hypoglycaemic coma 
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44443 C108500 Insulin dependent diabetes mellitus with ulcer 
44779 C109E12 Type 2 diabetes mellitus with diabetic cataract 
44982 C10FE00 Type 2 diabetes mellitus with diabetic cataract 
45276 C10E312 Insulin dependent diabetes mellitus with multiple 
complicat 
45467 C109B00 Non-insulin dependent diabetes mellitus with 
polyneuropathy 
45491 C10z.00 Diabetes mellitus with unspecified complication 
45913 C109712 Type 2 diabetes mellitus - poor control 
45914 C108812 Type 1 diabetes mellitus - poor control 
45919 C109212 Type 2 diabetes mellitus with neurological 
complications 
46150 C109512 Type 2 diabetes mellitus with gangrene 
46290 C108y00 Other specified diabetes mellitus with multiple 
comps 
46301 C10EC00 Type 1 diabetes mellitus with polyneuropathy 
46521 9N2d.00 Seen by diabetologist 
46624 C10C.11 Maturity onset diabetes in youth 
46850 C108811 Type I diabetes mellitus - poor control 
46917 C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
46963 C108000 Insulin-dependent diabetes mellitus with renal 
complications 
47011 8Hj0.00 Referral to diabetes structured education 
programme 
47032 8CS0.00 Diabetes care plan agreed 
47315 C10F711 Type II diabetes mellitus - poor control 
47321 C10F100 Type 2 diabetes mellitus with ophthalmic 
complications 
47341 8A12.00 Diabetic crisis monitoring 
47370 8HLE.00 Diabetology D.V. done 
47377 C105y00 Other specified diabetes mellitus with ophthalmic 
complicatn 
47409 C109B11 Type II diabetes mellitus with polyneuropathy 
47582 C10E000 Type 1 diabetes mellitus with renal complications 
47649 C10E100 Type 1 diabetes mellitus with ophthalmic 
complications 
47650 C10E300 Type 1 diabetes mellitus with multiple complications 
47816 C109H11 Type II diabetes mellitus with neuropathic 
arthropathy 
47954 C10F900 Type 2 diabetes mellitus without complication 
48192 C109E11 Type II diabetes mellitus with diabetic cataract 
49074 C10F400 Type 2 diabetes mellitus with ulcer 
49146 C108211 Type I diabetes mellitus with neurological 
complications 
49276 C108100 Insulin-dependent diabetes mellitus with ophthalmic 
comps 
49554 C10EF00 Type 1 diabetes mellitus with diabetic cataract 
49655 C10F611 Type II diabetes mellitus with retinopathy 
49869 C109G12 Type 2 diabetes mellitus with arthropathy 
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49884 6761.00 Diabetic pre-pregnancy counselling 
49949 C10E411 Unstable type I diabetes mellitus 
50175 66AW.00 Diabetic foot risk assessment 
50225 C109011 Type II diabetes mellitus with renal complications 
50429 C109100 Non-insulin-dependent diabetes mellitus with 
ophthalm comps 
50527 C10FB11 Type II diabetes mellitus with polyneuropathy 
50813 C109A11 Type II diabetes mellitus with mononeuropathy 
50972 C100z00 Diabetes mellitus NOS with no mention of 
complication 
51261 C10E.12 Insulin dependent diabetes mellitus 
51697 C10G.00 Secondary pancreatic diabetes mellitus 
51756 C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
51957 C108511 Type I diabetes mellitus with ulcer 
52104 C108300 Insulin dependent diabetes mellitus with multiple 
complicatn 
52212 Cyu2.00 [X]Diabetes mellitus 
52236 C10A.00 Malnutrition-related diabetes mellitus 
52237 9360.00 Patient held diabetic record issued 
52283 C108200 Insulin-dependent diabetes mellitus with neurological 
comps 
52303 C109000 Non-insulin-dependent diabetes mellitus with renal 
comps 
53200 C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
53238 66AG.00 Diabetic drug side effects 
53392 C10F911 Type II diabetes mellitus without complication 
54008 C10EJ00 Type 1 diabetes mellitus with neuropathic 
arthropathy 
54212 C109F00 Non-insulin-dependent d m with peripheral 
angiopath 
54600 C10E412 Unstable insulin dependent diabetes mellitus 
54601 9NN8.00 Under care of diabetologist 
54846 9OL9.00 Diabetes monitoring deleted 
54856 C101100 Diabetes mellitus, adult onset, with ketoacidosis 
54899 C109F11 Type II diabetes mellitus with peripheral angiopathy 
55075 C109411 Type II diabetes mellitus with ulcer 
55239 C10EQ00 Type 1 diabetes mellitus with gastroparesis 
55842 C109200 Non-insulin-dependent diabetes mellitus with neuro 
comps 
56268 C109D11 Type II diabetes mellitus with hypoglycaemic coma 
56448 C108A00 Insulin-dependent diabetes without complication 
56803 C107400 NIDDM with peripheral circulatory disorder 
57278 C10F011 Type II diabetes mellitus with renal complications 
57723 8HHy.00 Referral to diabetic register 
58604 C109611 Type II diabetes mellitus with retinopathy 
59253 C10FG00 Type 2 diabetes mellitus with arthropathy 
59288 C103y00 Other specified diabetes mellitus with coma 
59365 C109C00 Non-insulin dependent diabetes mellitus with 
nephropathy 
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59725 C109111 Type II diabetes mellitus with ophthalmic 
complications 
59903 C106.11 Diabetic amyotrophy 
59991 C10D.11 Maturity onset diabetes in youth type 2 
60107 C108411 Unstable type I diabetes mellitus 
60208 C108J11 Type I diabetes mellitus with neuropathic arthropathy 
60499 C108600 Insulin dependent diabetes mellitus with gangrene 
60699 C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
60796 C10FL11 Type II diabetes mellitus with persistent proteinuria 
61021 68AB.00 Diabetic digital retinopathy screening offered 
61071 C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
61122 C10H.00 Diabetes mellitus induced by non-steroid drugs 
61344 C108011 Type I diabetes mellitus with renal complications 
61470 66Al.00 Diabetic monitoring - higher risk albumin excretion 
61523 C106y00 Other specified diabetes mellitus with neurological 
comps 
61557 8HKE.00 Diabetology D.V. requested 
61670 889A.00 Diab mellit insulin-glucose infus acute myocardial 
infarct 
61829 C108212 Type 1 diabetes mellitus with neurological 
complications 
62107 C109511 Type II diabetes mellitus with gangrene 
62146 C109300 Non-insulin-dependent diabetes mellitus with 
multiple comps 
62209 C10EM11 Type I diabetes mellitus with ketoacidosis 
62352 C108H11 Type I diabetes mellitus with arthropathy 
62613 C10EA11 Type I diabetes mellitus without complication 
62674 C10FA00 Type 2 diabetes mellitus with mononeuropathy 
63017 C108911 Type I diabetes mellitus maturity onset 
63357 C107100 Diabetes mellitus, adult, + peripheral circulatory 
disorder 
63371 C10y100 Diabetes mellitus, adult, + other specified 
manifestation 
63412 8CR2.00 Diabetes clinical management plan 
63690 C10FR00 Type 2 diabetes mellitus with gastroparesis 
63762 C10z100 Diabetes mellitus, adult onset, + unspecified 
complication 
64142 8Hl1.00 Referral for diabetic retinopathy screening 
64283 C10zy00 Other specified diabetes mellitus with unspecified 
comps 
64357 C10zz00 Diabetes mellitus NOS with unspecified complication 
64446 C108G00 Insulin dependent diab mell with peripheral 
angiopathy 
64449 C108z00 Unspecified diabetes mellitus with multiple 
complications 
64571 C109C11 Type II diabetes mellitus with nephropathy 
64668 C10FJ11 Insulin treated Type II diabetes mellitus 
65025 C107z00 Diabetes mellitus NOS with peripheral circulatory 
disorder 
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65062 C103z00 Diabetes mellitus NOS with ketoacidotic coma 
65267 C10F300 Type 2 diabetes mellitus with multiple complications 
65616 C108H00 Insulin dependent diabetes mellitus with arthropathy 
65704 C109412 Type 2 diabetes mellitus with ulcer 
66145 C10EN11 Type I diabetes mellitus with ketoacidotic coma 
66274 66Ah.00 Insulin needles changed for each injection 
66475 66Ak.00 Diabetic monitoring - lower risk albumin excretion 
66675 C10A000 Malnutrition-related diabetes mellitus with coma 
66872 C108D11 Type I diabetes mellitus with nephropathy 
66965 C109H12 Type 2 diabetes mellitus with neuropathic 
arthropathy 
67212 C10H000 DM induced by non-steroid drugs without 
complication 
67853 C106000 Diabetes mellitus, juvenile, + neurological 
manifestation 
67905 C109211 Type II diabetes mellitus with neurological 
complications 
68105 C10EB00 Type 1 diabetes mellitus with mononeuropathy 
68390 C108512 Type 1 diabetes mellitus with ulcer 
68546 ZRB4.00 Diabetes clinic satisfaction questionnaire 
68792 C10z000 Diabetes mellitus, juvenile type, + unspecified 
complication 
68843 C103100 Diabetes mellitus, adult onset, with ketoacidotic 
coma 
69124 C107300 IDDM with peripheral circulatory disorder 
69152 66Aj.00 Insulin needles changed less than once a day 
69163 8HTi.00 Referral to multidisciplinary diabetic clinic 
69278 C109E00 Non-insulin depend diabetes mellitus with diabetic 
cataract 
69676 C10EA00 Type 1 diabetes mellitus without complication 
69748 C105000 Diabetes mellitus, juvenile type, + ophthalmic 
manifestation 
69993 C10E600 Type 1 diabetes mellitus with gangrene 
70316 C109112 Type 2 diabetes mellitus with ophthalmic 
complications 
70448 C107000 Diabetes mellitus, juvenile +peripheral circulatory 
disorder 
70766 C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
70821 C10yz00 Diabetes mellitus NOS with other specified 
manifestation 
72320 C109A00 Non-insulin dependent diabetes mellitus with 
mononeuropathy 
72333 8HME.00 Listed for Diabetology admissn 
72345 C102z00 Diabetes mellitus NOS with hyperosmolar coma 
72702 C10E812 Insulin dependent diabetes mellitus - poor control 
82474 8Hl4.00 Referral to community diabetes specialist nurse 
83485 66Am.00 Insulin dose changed 
83532 66Ao.00 Diabetes type 2 review 
85660 66An.00 Diabetes type 1 review 
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85991 C10FM11 Type II diabetes mellitus with persistent 
microalbuminuria 
90301 66Ag.00 Insulin needles changed daily 
91646 C10F411 Type II diabetes mellitus with ulcer 
91942 C10E311 Type I diabetes mellitus with multiple complications 
91943 C10EC11 Type I diabetes mellitus with polyneuropathy 
93390 9OLH.00 Attended DAFNE diabetes structured education 
programme 
93468 C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
93491 9OLJ.00 DAFNE diabetes structured education programme 
completed 
93529 9OLK.00 DESMOND diabetes structured education 
programme completed 
93530 9OLE.00 Attended DESMOND structured programme 
93631 9OLL.00 XPERT diabetes structured education programme 
completed 
93657 8Hj4.00 Referral to DESMOND diabetes structured 
education programme 
93704 8Hj3.00 Referral to DAFNE diabetes structured education 
programme 
93727 C10FE11 Type II diabetes mellitus with diabetic cataract 
93854 9OLM.00 Diabetes structured education programme declined 
93870 8Hj5.00 Referral to XPERT diabetes structured education 
programme 
93875 C10E712 Insulin dependent diabetes mellitus with retinopathy 
93878 C10E511 Type I diabetes mellitus with ulcer 
93922 C104000 Diabetes mellitus, juvenile type, with renal 
manifestation 
94011 9OLG.00 Attended XPERT diabetes structured education 
programme 
94186 9OLF.00 Diabetes structured education programme 
completed 
94330 8H4e.00 Referral to diabetes special interest general 
practitioner 
94383 C10N000 Secondary diabetes mellitus without complication 
94699 ZRB5.00 Diabetes treatment satisfaction questionnaire 
94955 9NiE.00 Did not attend XPERT diabetes structured education 
programme 
94956 8I84.00 Did not complete XPERT diabetes structured 
education program 
95093 8I83.00 Did not complete DESMOND diabetes structured 
educat program 
95094 8I81.00 Did not complete diabetes structured education 
programme 
95159 9NiD.00 Did not attend DESMOND diabetes structured 
education program 
95343 C10E711 Type I diabetes mellitus with retinopathy 
95539 C10FS00 Maternally inherited diabetes mellitus 
95553 9NiA.00 Did not attend diabetes structured education 
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programme 
95636 C10ER00 Latent autoimmune diabetes mellitus in adult 
95813 9N1o.00 Seen in multidisciplinary diabetic clinic 
95992 C108A11 Type I diabetes mellitus without complication 
95994 66Aq.00 Diabetic foot screen 
96010 66Ap.00 Insulin treatment initiated 
96235 C10E911 Type I diabetes mellitus maturity onset 
96506 C10G000 Secondary pancreatic diabetes mellitus without 
complication 
97281 9Nl4.00 Seen by general practitioner special interest in 
diabetes 
97446 C108912 Type 1 diabetes mellitus maturity onset 
97474 C108412 Unstable type 1 diabetes mellitus 
97809 8I82.00 Did not complete DAFNE diabetes structured 
education program 
97849 C10E912 Insulin dependent diabetes maturity onset 
97894 C10EP11 Type I diabetes mellitus with exudative maculopathy 
98071 C10E112 Insulin-dependent diabetes mellitus with ophthalmic 
comps 
98392 C10C.12 Maturity onset diabetes in youth type 1 
98616 C10F211 Type II diabetes mellitus with neurological 
complications 
98704 C10E512 Insulin dependent diabetes mellitus with ulcer 
98723 C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
98954 3883.00 Diabetes treatment satisfaction questionnaire 
99231 C108B11 Type I diabetes mellitus with mononeuropathy 
99311 C10E111 Type I diabetes mellitus with ophthalmic 
complications 
99716 C10EE12 Insulin dependent diabetes mellitus with 
hypoglycaemic coma 
99719 C10EA12 Insulin-dependent diabetes without complication 
100292 Cyu2300 [X]Unspecified diabetes mellitus with renal 
complications 
100347 C10A500 Malnutritn-relat diabetes melitus wth periph circul 
complctn 
      
425 
 
 
Codes used to identify all cardiovascular events 
CPRD 
Medcode 
Read code Read term 
240 G3...00 Ischaemic heart disease 
1344 G340.12 Coronary artery disease 
1490 G5z..00 Heart disease NOS 
1628 3213100 Exercise ECG abnormal 
1655 G340.11 Triple vessel disease of the heart 
1676 G3z..00 Ischaemic heart disease NOS 
1792 G3...13 IHD - Ischaemic heart disease 
1811 G5yz.00 Other heart disease NOS 
2491 G30..12 Coronary thrombosis 
3997 1J6..00 Suspected heart disease 
3999 G340000 Single coronary vessel disease 
5254 G340100 Double coronary vessel disease 
5413 G340.00 Coronary atherosclerosis 
7320 G343.00 Ischaemic cardiomyopathy 
8246 322..00 ECG: myocardial ischaemia 
8568 G37..00 Cardiac syndrome X 
9276 G31y000 Acute coronary insufficiency 
9413 G31y.00 Other acute and subacute ischaemic heart 
disease 
13571 G30..16 Thrombosis - coronary 
15661 G310.11 Dressler's syndrome 
15754 G34z.00 Other chronic ischaemic heart disease NOS 
17133 G30A.00 Mural thrombosis 
18134 182A.00 Chest pain on exertion 
18889 G34z000 Asymptomatic coronary heart disease 
20416 G3...12 Atherosclerotic heart disease 
21844 G31y300 Transient myocardial ischaemia 
22383 G3y..00 Other specified ischaemic heart disease 
23078 G34y100 Chronic myocardial ischaemia 
24540 G34y000 Chronic coronary insufficiency 
24683 G5y1.00 Myocardial degeneration 
24783 G3...11 Arteriosclerotic heart disease 
26965 32F2.00 ECG: T wave abnormal 
26966 32E3.00 ECG: S-T elevation 
26967 32F4.00 ECG: T wave inverted 
26973 3222 ECG:shows myocardial ischaemia 
27951 G31..00 Other acute and subacute ischaemic heart 
disease 
27977 G31yz00 Other acute and subacute ischaemic heart 
disease NOS 
28138 G34..00 Other chronic ischaemic heart disease 
29421 G344.00 Silent myocardial ischaemia 
30171 G5...00 Other forms of heart disease 
32450 G33z400 Ischaemic chest pain 
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34633 G34y.00 Other specified chronic ischaemic heart 
disease 
35287 322Z.00 ECG: myocardial ischaemia NOS 
35713 G34yz00 Other specified chronic ischaemic heart 
disease NOS 
36193 G5y..00 Other specified heart disease 
36523 G311.00 Preinfarction syndrome 
36609 G342.00 Atherosclerotic cardiovascular disease 
39449 G312.00 Coronary thrombosis not resulting in 
myocardial infarction 
39655 G311.12 Impending infarction 
39693 G31y200 Subendocardial ischaemia 
41179 G5yyz00 Other ill-defined heart disease NOS 
42104 32E4.00 ECG: S-T depression 
47637 Gyu3300 [X]Other forms of chronic ischaemic heart 
disease 
52517 Gyu3.00 [X]Ischaemic heart diseases 
54251 G311z00 Preinfarction syndrome NOS 
56621 G5y2.00 Cardiovascular arteriosclerosis unspecified 
57334 G557300 Gouty tophi of heart 
59687 G5yy.00 Other ill-defined heart disease 
68401 Gyu3200 [X]Other forms of acute ischaemic heart 
disease 
95550 8H2V.00 Admit ischaemic heart disease emergency 
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Codes used to identify angina 
CPRD 
Medcode 
Read 
code 
Read term 
1414 G33z300 Angina on effort 
1430 G33..00 Angina pectoris 
1431 G311.13 Unstable angina 
4656 G311.11 Crescendo angina 
7347 G311100 Unstable angina 
7696 G33z200 Syncope anginosa 
9555 G33z500 Post infarct angina 
11048 G331.11 Variant angina pectoris 
11983 G311500 Acute coronary syndrome 
12804 G33z700 Stable angina 
12986 G331.00 Prinzmetal's angina 
17307 G311200 Angina at rest 
18118 G311400 Worsening angina 
18125 G330000 Nocturnal angina 
19655 G311.14 Angina at rest 
19827 3213111 Positive exercise ECG test 
20095 G330.00 Angina decubitus 
25842 G33z.00 Angina pectoris NOS 
26863 G33z600 New onset angina 
28554 G33zz00 Angina pectoris NOS 
29902 G330z00 Angina decubitus NOS 
34328 G311300 Refractory angina 
36854 G332.00 Coronary artery spasm 
39546 Gyu3000 [X]Other forms of angina 
pectoris 
54535 G33z100 Stenocardia 
66388 G33z000 Status anginosus 
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Codes used to identify myocardial infarction 
CPRD 
Medcode 
Read code Read term 
241 G30..00 Acute myocardial infarction 
1204 G30..14 Heart attack 
1677 G30..15 MI - acute myocardial infarction 
1678 G308.00 Inferior myocardial infarction NOS 
3704 G307.00 Acute subendocardial infarction 
5387 G301.00 Other specified anterior myocardial infarction 
7783 323..00 ECG: myocardial infarction 
8935 G302.00 Acute inferolateral infarction 
9507 G307000 Acute non-Q wave infarction 
10562 G307100 Acute non-ST segment elevation myocardial 
infarction 
12139 G300.00 Acute anterolateral infarction 
12229 G30X000 Acute ST segment elevation myocardial infarction 
13566 G30..11 Attack - heart 
14658 G30z.00 Acute myocardial infarction NOS 
14897 G301z00 Anterior myocardial infarction NOS 
14898 G305.00 Lateral myocardial infarction NOS 
17689 G30..17 Silent myocardial infarction 
17872 G301100 Acute anteroseptal infarction 
18842 G35..00 Subsequent myocardial infarction 
23579 G310.00 Postmyocardial infarction syndrome 
23708 G361.00 Atrial septal defect/curr comp folow acut 
myocardal infarct 
23892 G304.00 Posterior myocardial infarction NOS 
24126 G360.00 Haemopericardium/current comp folow acut 
myocard infarct 
26972 3234 ECG:posterior/inferior infarct 
26975 3233 ECG: antero-septal infarct. 
28736 G30y000 Acute atrial infarction 
29553 G366.00 Thrombosis atrium,auric append&vent/curr comp 
foll acute MI 
29643 G303.00 Acute inferoposterior infarction 
29758 G30X.00 Acute transmural myocardial infarction of 
unspecif site 
30330 G309.00 Acute Q-wave infarct 
30421 G30..13 Cardiac rupture following myocardial infarction 
(MI) 
32272 G38..00 Postoperative myocardial infarction 
32854 G30B.00 Acute posterolateral myocardial infarction 
34803 G30y.00 Other acute myocardial infarction 
36423 G36..00 Certain current complication follow acute 
myocardial infarct 
37657 G362.00 Ventric septal defect/curr comp fol acut 
myocardal infarctn 
      
429 
 
 
38609 G351.00 Subsequent myocardial infarction of inferior wall 
40429 G301000 Acute anteroapical infarction 
40996 7929111 Percut translum coronary thrombolytic therapy- 
streptokinase 
41221 G30y200 Acute septal infarction 
41835 G384.00 Postoperative subendocardial myocardial 
infarction 
45809 G350.00 Subsequent myocardial infarction of anterior wall 
46017 G30yz00 Other acute myocardial infarction NOS 
46112 G380.00 Postoperative transmural myocardial infarction 
anterior wall 
46166 G35X.00 Subsequent myocardial infarction of unspecified 
site 
46276 G381.00 Postoperative transmural myocardial infarction 
inferior wall 
52705 3236 ECG: lateral infarction 
55401 3235 ECG: subendocardial infarct 
59032 323Z.00 ECG: myocardial infarct NOS 
59189 G363.00 Ruptur cardiac wall w'out haemopericard/cur 
comp fol ac MI 
59940 G364.00 Ruptur chordae tendinae/curr comp fol acute 
myocard infarct 
62626 G30y100 Acute papillary muscle infarction 
63467 G306.00 True posterior myocardial infarction 
68357 G31y100 Microinfarction of heart 
68748 G38z.00 Postoperative myocardial infarction, unspecified 
69474 G365.00 Rupture papillary muscle/curr comp fol acute 
myocard infarct 
72562 G353.00 Subsequent myocardial infarction of other sites 
96838 Gyu3400 [X]Acute transmural myocardial infarction of 
unspecif site 
97001 44p2.00 Cardiac troponin positive 
99991 Gyu3600 [X]Subsequent myocardial infarction of 
unspecified site 
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Codes used to identify all cerebrovascular disease 
CPRD 
Medcode 
Read code Read term 
1786 G60..00 Subarachnoid haemorrhage 
2156 G631.11 Stenosis, carotid artery 
2417 G65..13 Vertebro-basilar insufficiency 
2418 G6...00 Cerebrovascular disease 
2652 G634.00 Carotid artery stenosis 
3535 G61z.00 Intracerebral haemorrhage NOS 
3979 G672.00 Hypertensive encephalopathy 
4152 G631.12 Thrombosis, carotid artery 
4240 G631.00 Carotid artery occlusion 
4273 G621.00 Subdural haemorrhage - nontraumatic 
5051 G61..00 Intracerebral haemorrhage 
5184 G670.11 Precerebral atherosclerosis 
5185 G64z111 Lateral medullary syndrome 
5268 G650.11 Insufficiency - basilar artery 
7912 G614.00 Pontine haemorrhage 
8837 G64..00 Cerebral arterial occlusion 
9696 G604.00 Subarachnoid haemorrhage from posterior 
communicating artery 
9843 G755000 Cranial arteritis 
10062 G6z..00 Cerebrovascular disease NOS 
10189 G674000 Cerebral amyloid angiopathy 
10794 G656.00 Vertebrobasilar insufficiency 
11171 G670.00 Cerebral atherosclerosis 
12555 G671z00 Generalised ischaemic cerebrovascular disease 
NOS 
12634 G673200 Carotid artery dissection 
13564 G613.00 Cerebellar haemorrhage 
13577 G67..00 Other cerebrovascular disease 
15019 G641.00 Cerebral embolism 
16507 G65z100 Intermittent cerebral ischaemia 
16517 G640.00 Cerebral thrombosis 
17326 G60X.00 Subarachnoid haemorrh from intracranial artery, 
unspecif 
17734 G622.00 Subdural haematoma - nontraumatic 
18689 G660.00 Middle cerebral artery syndrome 
18912 G623.00 Subdural haemorrhage NOS 
19201 G61X100 Right sided intracerebral haemorrhage, unspecified 
19260 G662.00 Posterior cerebral artery syndrome 
19280 G661.00 Anterior cerebral artery syndrome 
19412 G602.00 Subarachnoid haemorrhage from middle cerebral 
artery 
20284 G62z.00 Intracranial haemorrhage NOS 
21118 G651000 Vertebro-basilar artery syndrome 
22018 G673000 Dissection of cerebral arteries, nonruptured 
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22400 G674.00 Cerebral arteritis 
22677 G70y011 Carotid artery disease 
23361 G68..00 Late effects of cerebrovascular disease 
23465 G652.00 Subclavian steal syndrome 
23580 G60z.00 Subarachnoid haemorrhage NOS 
23942 G650.00 Basilar artery syndrome 
24385 G671100 Chronic cerebral ischaemia 
28314 G61X000 Left sided intracerebral haemorrhage, unspecified 
29939 G600.00 Ruptured berry aneurysm 
30045 G616.00 External capsule haemorrhage 
30202 G617.00 Intracerebral haemorrhage, intraventricular 
31060 G61X.00 Intracerebral haemorrhage in hemisphere, 
unspecified 
31595 G610.00 Cortical haemorrhage 
31704 G677.00 Occlusion/stenosis cerebral arts not result cerebral 
infarct 
31805 G62..00 Other and unspecified intracranial haemorrhage 
31876 G72y000 Aneurysm of common carotid art 
32447 G630.00 Basilar artery occlusion 
33377 G651.00 Vertebral artery syndrome 
33499 G665.00 Pure motor lacunar syndrome 
34117 G67y.00 Other cerebrovascular disease OS 
34758 G641.11 Cerebral embolus 
35059 G673100 Carotico-cavernous sinus fistula 
36178 G620.00 Extradural haemorrhage - nontraumatic 
36390 G72y200 Aneurysm of internal carotid artery 
37199 G70y000 Carotid artery atherosclerosis 
37493 G67z.00 Other cerebrovascular disease NOS 
37947 G676.00 Nonpyogenic venous sinus thrombosis 
40053 G671.00 Generalised ischaemic cerebrovascular disease 
NOS 
40338 G611.00 Internal capsule haemorrhage 
40847 G632.00 Vertebral artery occlusion 
41910 G605.00 Subarachnoid haemorrhage from basilar artery 
42331 G603.00 Subarachnoid haemorrhage from anterior 
communicating artery 
43451 G682.00 Sequelae of other nontraumatic intracranial 
haemorrhage 
44740 G680.00 Sequelae of subarachnoid haemorrhage 
44765 G653.00 Carotid artery syndrome hemispheric 
45781 G63..00 Precerebral arterial occlusion 
46316 G612.00 Basal nucleus haemorrhage 
47642 G64z100 Wallenberg syndrome 
48149 G681.00 Sequelae of intracerebral haemorrhage 
50594 G654.00 Multiple and bilateral precerebral artery syndromes 
50678 G72y100 Aneurysm of external carotid artery 
51138 G68W.00 Sequelae/other + unspecified cerebrovascular 
diseases 
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51311 G6y..00 Other specified cerebrovascular disease 
51326 G63y.00 Other precerebral artery occlusion 
51759 G677000 Occlusion and stenosis of middle cerebral artery 
51767 G666.00 Pure sensory lacunar syndrome 
54744 F11x200 Cerebral degeneration due to cerebrovascular 
disease 
55247 G65z000 Impending cerebral ischaemia 
55602 G677300 Occlusion and stenosis of cerebellar arteries 
56007 G601.00 Subarachnoid haemorrhage from carotid siphon and 
bifurcation 
57315 G618.00 Intracerebral haemorrhage, multiple localized 
57527 G677100 Occlusion and stenosis of anterior cerebral artery 
60692 G606.00 Subarachnoid haemorrhage from vertebral artery 
62342 G615.00 Bulbar haemorrhage 
63830 G63..12 Stenosis of precerebral arteries 
65770 G677200 Occlusion and stenosis of posterior cerebral artery 
70536 G671000 Acute cerebrovascular insufficiency NOS 
71274 G677400 Occlusion+stenosis of multiple and bilat cerebral 
arteries 
71585 G63z.00 Precerebral artery occlusion NOS 
73901 Gyu6.00 [X]Cerebrovascular diseases 
90572 Gyu6500 [X]Occlusion and stenosis of other precerebral 
arteries 
92036 Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
96630 Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, 
unspecified 
97122 G673300 Vertebral artery dissection 
98188 G679.00 Small vessel cerebrovascular disease 
98642 G633.00 Multiple and bilateral precerebral arterial occlusion 
99367 Gyu6A00 [X]Other cerebrovascular disorders in diseases CE 
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Codes used to identify cerebrovascular accident (stroke) 
CPRD 
Medcode 
Read code Read term 
569 G64..12 Infarction - cerebral 
1298 G66..11 CVA unspecified 
1469 G66..00 Stroke and cerebrovascular accident unspecified 
3149 G64z.00 Cerebral infarction NOS 
5363 G64..11 CVA - cerebral artery occlusion 
5602 G64z.12 Cerebellar infarction 
6116 G66..13 CVA - Cerebrovascular accident unspecified 
6155 G64..13 Stroke due to cerebral arterial occlusion 
6228 G68X.00 Sequelae of stroke,not specfd as h'morrhage or 
infarction 
6253 G66..12 Stroke unspecified 
6960 G61..11 CVA - cerebrovascular accid due to intracerebral 
haemorrhage 
7780 G667.00 Left sided CVA 
8443 G663.00 Brain stem stroke syndrome 
9985 G64z200 Left sided cerebral infarction 
10504 G64z300 Right sided cerebral infarction 
12833 G668.00 Right sided CVA 
15252 G64z.11 Brainstem infarction NOS 
16956 G669.00 Cerebral palsy, not congenital or infantile, acute 
17322 G664.00 Cerebellar stroke syndrome 
18604 G61..12 Stroke due to intracerebral haemorrhage 
23671 G63y000 Cerebral infarct due to thrombosis of precerebral 
arteries 
24446 G63y100 Cerebral infarction due to embolism of precerebral 
arteries 
25615 G64z000 Brainstem infarction 
26424 G64z400 Infarction of basal ganglia 
27975 G641000 Cerebral infarction due to embolism of cerebral 
arteries 
33543 G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl 
artrs 
36717 G640000 Cerebral infarction due to thrombosis of cerebral 
arteries 
39344 G676000 Cereb infarct due cerebral venous thrombosis, 
nonpyogenic 
39403 G683.00 Sequelae of cerebral infarction 
40758 G6W..00 Cereb infarct due unsp occlus/stenos precerebr artrs 
53745 Gyu6400 [X]Other cerebral infarction 
57495 G63..11 Infarction - precerebral 
91627 Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl 
artrs 
94482 Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr 
arteries 
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Codes used to identify transient ischaemic attack 
CPRD 
Medcode 
Read 
code 
Read term 
504 G65..00 Transient cerebral ischaemia 
1433 G65..12 Transient ischaemic attack 
1895 G65z.00 Transient cerebral ischaemia NOS 
6489 G655.00 Transient global amnesia 
15788 G65zz00 Transient cerebral ischaemia NOS 
19354 G65y.00 Other transient cerebral ischaemia 
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Codes used to identify peripheral vascular disease 
CPRD 
Medcode 
Read 
code 
Read term 
1517 G73z000 Intermittent claudication 
1826 G73..12 Ischaemia of legs 
2760 G73zz00 Peripheral vascular disease NOS 
3530 G73z.00 Peripheral vascular disease NOS 
4325 G73yz00 Other specified peripheral vascular disease NOS 
5414 G732000 Gangrene of toe 
5702 G73..11 Peripheral ischaemic vascular disease 
5943 G73..00 Other peripheral vascular disease 
6827 G73..13 Peripheral ischaemia 
9099 7A47.00 Other emergency bypass of femoral artery or 
popliteal artery 
9204 G732.00 Peripheral gangrene 
11766 7A47.16 Other emergency bypass of femoral artery 
12735 G732100 Gangrene of foot 
14797 G702.00 Extremity artery atheroma 
16148 SP12.00 Peripheral vascular complications of care 
16260 G702z00 Extremity artery atheroma NOS 
16284 G701.00 Renal artery atherosclerosis 
23871 G73y100 Peripheral angiopathic disease EC NOS 
38907 G73y.00 Other specified peripheral vascular disease 
43648 7A41211 Emergency femoro-femoral prosthetic cross over 
graft 
43651 7A47000 Emerg bypass femoral art by fem/pop art anast c 
prosth NEC 
44250 7A41000 Emerg bypass iliac art by iliac/femoral art 
anastomosis NEC 
48939 7A47C00 Emerg bypass femoral artery by fem/fem art 
anastomosis NEC 
52342 7A47200 Emerg bypass femoral art by fem/pop a anast c 
vein graft NEC 
60693 7A47300 Emerg bypass pop art by pop/pop art anast c vein 
graft NEC 
62775 7A47B00 Emerg bypass pop art by pop/peron art anast c vein 
graft NEC 
63238 7A47.13 Other emergency bypass of deep femoral artery 
65692 7A47y00 Other emergency bypass of femoral or popliteal 
artery OS 
66820 7A47400 Emerg bypass femoral art by fem/tib art anast c 
prosth NEC 
66879 7A47700 Emerg bypass pop art by pop/tib art anast c vein 
graft NEC 
66917 7A41600 Emerg bypass leg artery by aorta/com fem art 
anastomosis NEC 
67818 7A47100 Emerg bypass popliteal art by pop/pop art anast c 
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prosth NEC 
68141 7A41400 Emerg bypass comm iliac art by aorta/com iliac art 
anast NEC 
68320 7A47z00 Other emergency bypass of femoral or popliteal 
artery NOS 
70922 7A47D00 Emerg bypass popliteal artery by pop/fem art 
anastomosis NEC 
72448 7A41200 Emerg bypass iliac artery by femoral/femoral art 
anast NEC 
72491 7A47.11 Other emerg bypass femoral or popliteal art by 
anastomosis 
73961 Gyu7400 [X]Other specified peripheral vascular diseases 
96255 7A47600 Emerg bypass femoral art by fem/tib a anast c vein 
graft NEC 
97606 7A47.15 Other emergency bypass of superficial femoral 
artery 
98174 G733.00 Ischaemic foot 
99676 7A47800 Emerg bypass femoral art by fem/peron art anast c 
prosth NEC 
100113 7A47.12 Other emergency bypass of common femoral artery 
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Increased cardiovascular mortality
associated with gout: a systematic
review and meta-analysis
LE Clarson1, P Chandratre1, SL Hider1, J Belcher1,
C Heneghan2, E Roddy1 and CD Mallen1
Abstract
Background: Hyperuricaemia, the biochemical precursor to gout, has been shown to be an independent risk factor for
mortality from cardiovascular disease (CVD), although studies examining the clinical phenomenon of gout and risk of
CVD mortality report conflicting results. This study aimed to produce a pooled estimate of risk of mortality from
cardiovascular disease in patients with gout.
Design: Systematic review and meta-analysis.
Methods: Electronic bibliographic databases were searched from inception to November 2012, with results reviewed by
two independent reviewers. Studies were included if they reported data on CVD mortality in adults with gout who were
free of CVD at time of entry into the study. Pooled hazard ratios (HRs) for this association were calculated both
unadjusted and adjusted for traditional vascular risk factors.
Results: Six papers, including 223,448 patients, were eligible for inclusion (all (CVD) mortality n¼ 4, coronary heart
disease (CHD) mortality n¼ 3, and myocardial infarction mortality n¼ 3). Gout was associated with an excess risk of
CVD mortality (unadjusted HR 1.51 (95% confidence interval, CI, 1.17–1.84)) and CHD mortality (unadjusted HR 1.59,
95% CI 1.25–1.94)). After adjusting for traditional vascular risk factors, the pooled HR for both CVD mortality (HR 1.29,
95% CI 1.14–1.44) and CHD mortality (HR 1.42, 95% CI 1.22–1.63) remained statistically significant, but none of the
studies reported a significant association with myocardial infarction.
Conclusions: Gout increases the risk of mortality from CVD and CHD, but not myocardial infarction, independently of
vascular risk factors.
Keywords
Cardiovascular disease, coronary heart disease, gout, mortality, myocardial infarction
Received 30 August 2013; accepted 9 November 2013
Introduction
Gout is the most common form of inﬂammatory arth-
ritis and is estimated to aﬀect 1.4% of the population in
the UK and Germany and 4% in the USA.1,2 In recent
literature, both hyperuricaemia (the biochemical pre-
cursor to gout) and other inﬂammatory arthritides
have been shown to be independent risk factors for
mortality from cardiovascular disease (CVD).3–6
Several mechanisms for these associations have been
suggested, including immobility resulting from joint
pain and the additional cardiovascular risk conferred
by medications (such as nonsteroidal anti-inﬂammatory
drugs) used to manage these conditions.7 Latterly, it
has been suggested that systemic inﬂammation leads
to atherogenesis via endothelial dysfunction, decreased
arterial compliance, impaired blood ﬂow, and thus
a proatherogenic state.8 Therefore patients with
gout may be at increased vascular risk due to both
hyperuricaemia and crystal-induced inﬂammation,
1Keele University, Keele, UK
2Oxford University, Oxford, UK
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Keele University, Keele, Staffordshire, ST5 5BG, UK.
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! The European Society of
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DOI: 10.1177/2047487313514895
ejpc.sagepub.com
now recognized to persist even in the asymptomatic
intercritical period.9
However, the precise nature of the relationship
remains unclear since gout and CVD share many
common risk factors, such as hypertension and
obesity,10 introducing a potential source of
confounding.
Epidemiological studies examining the relationship
between gout and mortality from CVD have, to date,
reported conﬂicting ﬁndings even where they are under-
taken in similar populations and geographical
areas.11,12 Although one systematic review has been
published, no attempt was made to pool the data
described.13
For this reason, a systematic review and meta-ana-
lysis was undertaken to pool estimates of risk from
existing studies in order to examine the relationship
between gout and mortality from CVD.
Methods
Data sources and searches
Four electronic databases (MEDLINE, EMBASE,
CINAHL, and The Cochrane Library) were searched
from their inception until 17 November 2012, for stu-
dies of the association between gout and cardiovascular
mortality. Search terms describing gout (both free-text
and using database speciﬁc indexing trees) were com-
bined using the Boolean operator ‘AND’ with terms
describing the outcome of cardiovascular mortality. A
full list of search terms is available as an online supple-
ment. Reference lists of relevant reports and review art-
icles were screened to identify additional sources of
data.
Study selection
Studies were eligible for inclusion if they were of a trial
or epidemiological design (cohort, cross-sectional),
included adults aged 18 and over, and examined the
association of interest in a cohort of patients free
from vascular disease at diagnosis of gout. Case–
control studies were not included due to the likelihood
of sampling and recall bias associated with this design.
No geographical or language restrictions were imposed.
Two authors (LC, PC) independently screened all of
the titles and abstracts, after which, for those con-
sidered potentially relevant, full-text articles were
independently reviewed to determine eligibility for
inclusion. A third reviewer (SH) was identiﬁed in case
of disagreement or uncertainty. Studies reporting dif-
ferent deﬁnitions of cardiovascular mortality were
grouped according to these deﬁnitions for analysis.
All studies reported mortality coded according to the
International Classiﬁcation of Disease 9th or 10th revi-
sion, with comparisons suggesting both revisions iden-
tify a similar prevalence of medical conditions.14
Studies were included if they reported mortality from
any of: any CVD (ICD-9 codes 390–459, ICD-10 codes
I00–I99), coronary heart disease (CHD: including myo-
cardial infarction, MI; ICD-9 codes 410–414, ICD-10
codes I20–I25), or speciﬁcally MI (ICD-9 code 414,
ICD-10 codes I21–I22).
Data extraction and quality assessment
Data extraction and quality assessment was undertaken
by two reviewers independently (LC, PC), using a spe-
ciﬁcally designed data extraction form. Methodological
quality assessment criteria were based upon the
Newcastle–Ottawa scale.15 This consists of three com-
ponents; selection of study group, quality of adjustment
for confounding, and ascertainment of the outcome of
interest in the cohorts (maximum score of nine). Two
additional outcome criteria were added, assessing the
appropriateness of statistical methods and the separ-
ation of patients with gout from those with asymptom-
atic hyperuricaemia. Authors were contacted for
additional information where necessary. Higher meth-
odological quality is indicated by a higher score.
Data synthesis and analysis
Pooled estimates of hazard ratios (HRs) were calcu-
lated using the DerSimonian and Laird random-eﬀects
model,16 for mortality from any CVD or CHD. This
technique weights individual studies according to
sample size and variance, giving a pooled estimate
and 95% conﬁdence interval. A random eﬀects model
was chosen due to the number of papers included and
the likelihood of heterogeneity across study popula-
tions. I2 was used to calculate heterogeneity between
studies, estimating the percentage of variability in
results attributed to between-study diﬀerences.17
Statistical analysis was performed using STATA IC
12. Publication bias was assessed using funnel plots.
Begg’s rank correlation test and Egger’s linear regres-
sion test were used to detect any asymmetry in the
funnel plot that may be due to publication bias.18,19
Results
Description of the studies
The initial search identiﬁed 1293 potentially relevant
papers. After title and abstract screening, 1192 papers
were excluded either because they did not examine the
association of interest or were editorial or discursive
articles. The remaining 101 papers were reviewed in
336 European Journal of Preventive Cardiology 22(3)
full text, and of these 95 were excluded (Figure 1). Six
studies reporting outcomes for 223,448 patients were
included: 149,532 men and 73,916 women. Four studies
reported on mortality from any CVD,11,12,20,21
three reported on mortality from CHD,11,12,20 and
three reported on mortality from MI.11,22,23 Two stu-
dies were conducted in Asia20,21 and four in the USA or
Canada.11,12,22,23 Numbers of participants ranged from
910512 to 57,852.23 Three studies included male-only
study populations.11,12,22 Follow up ranged from 56
months20 to 17 years.12 The characteristics of the
included studies are described in Table 1.
Scores for methodological quality of studies, where
the maximum score was 11, ranged from nine11,12
to 11,21 indicating a high level of methodological qual-
ity in all included studies.
Gout and mortality from any CVD
The pooled estimate of unadjusted HR for mortality
due to any CVD based on four studies was 1.51 (95%
CI 1.17–1.84) (comparing patients with gout to those
without gout).11,12,20,21 A signiﬁcant degree of study
heterogeneity was noted (I2¼ 66.8%, p¼ 0.029).
Based on the same four studies, after adjustment for
vascular risk factors, the pooled multivariate HR for
mortality due to any CVD was 1.29 (95% CI 1.13–
1.44), with no statistically signiﬁcant heterogeneity
(I2¼ 0%, p¼ 0.541) (Figure 2). The individual vascular
risk factors adjusted for in each study are shown in
Table 1. Examining the eﬀect of gender on overall
CVD mortality, two studies included only men,11,12
and whilst one study included both men and women,
so a separate analysis by gender was not undertaken.20
One study reported risk of CVD mortality by gender,
but did not ﬁnd increased risk in either gender (men:
HR 1.10, 95% CI 0.82–1.46; women: HR 1.51, 95% CI
1.00–2.30).21
Gout and mortality from CHD
The pooled estimate of unadjusted HR for mortality
due to CHD based on three studies was 1.59 (95% CI
1.25–1.94) (comparing patients with gout to those
Figure 1: 
1293 articles identified 
101 reviewed in full text 
6 papers included reporting on 
mortality from: 
Any cardiovascular disease (4) 
Coronary heart disease (3) 
Myocardial infarction (3) 
Excluded (95): 
No outcome of interest (51) 
Not trial (14) 
No gout group (9) 
No control groups (11) 
Inadequate methodological 
data (5) 
Not available in full text (5) 
Excluded based on 
title/abstract (1192) 
Figure 1. Selection of studies included in the review.
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without gout).11,12,21 Moderate heterogeneity was
noted (I2¼ 55%, p¼ 0.108). Based on the same three
studies, after adjustment for vascular risk factors, the
pooled multivariate HR for mortality due to CHD was
1.42 (95% CI 1.22–1.63), with no statistically signiﬁcant
heterogeneity (I2¼ 0%, p¼ 0.660) (Figure 3). Two of
these studies used a solely male population.11,12 In the
remaining study, an increased risk of mortality from
CHD was reported in women, HR 1.81, 95% CI
1.07–3.05), but not men, HR 1.16, 95% CI 0.81–1.67).21
Gout and mortality from MI
Three studies report on the association between gout
and mortality from MI. However, these studies were
unsuitable for meta-analysis due to signiﬁcant hetero-
geneity in the statistical analysis undertaken and out-
comes reported, and thus are described.
One study, from the USA, reported no increased risk
of fatal MI in 1123 men with gout compared to 11,743
age-matched male controls (odds ratio, OR, 0.96, 95%
CI 0.66–1.44).22 However, another paper reporting
results from this same study using a smaller population
of 655 men with gout compared to 8450 without did
report an excess risk of mortality from MI in gout
patients (HR 1.46, 95% CI 1.03–2.06).12 A further
study from Canada reported an excess risk of mortality
from MI in a mixed population of 9642 gout patients
compared to 48210 controls, but reported an increased
mortality risk only for women with gout (n¼ 3890)
(HR 1.57, 95% CI 1.18–2.09), but not men (HR 1.19,
95% CI 0.96–1.49).23 After adjustment for vascular risk
factors, none of the studies report a statistically signiﬁ-
cant excess risk of mortality from MI in gout patients
of either gender.
Publication bias assessment
No evidence of publication bias was seen for either any
CVD mortality (Begg’s tests: crude p¼ 0.149, multi-
variate p¼ 0.734; Egger’s tests: crude p¼ 0.06, multi-
variate p¼ 0.442) or CHD mortality (Begg’s tests:
crude p¼ 0.296, multivariate p¼ 0.296; Egger’s tests:
crude p¼ 0.164, multivariate p¼ 0.197).
Discussion
This systematic review and meta-analysis found a sig-
niﬁcant association between gout and mortality from
any CVD and CHD. It does not support an association
between gout and mortality from MI based upon cur-
rent evidence.
Our results are consistent with a previous systematic
review of four studies,13 which concluded that gout is
an independent risk factor for cardiovascular mortality.T
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NOTE: Weights are from random effects analysis
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Figure 2. Meta-analysis of adjusted findings of studies reporting mortality from any cardiovascular disease.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.660)
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Figure 3. Meta-analysis of adjusted findings of studies reporting mortality from coronary heart disease.
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Three of the studies included in that review were
included in this meta-analysis;11,12,20 however, one
was excluded24 as the study population consisted of
renal dialysis and transplantation patients, and was
not felt to be broadly representative of, or comparable
with, the wider gout population, and impaired renal
function is itself acknowledged to increase risk of car-
diovascular mortality.25,26 One more recent study was
included in our review.21 Our systematic review builds
on the previously published work by conducting the
ﬁrst meta-analysis determining the excess risk of car-
diovascular mortality associated with gout.
The precise relationship between gout and CVD
remains unclear. The persistence of excess risk of car-
diovascular and CHD mortality associated with gout in
the pooled multivariate analysis, even after adjustment
for traditional vascular risk factors, would suggest
there are other important factors which inﬂuence this
relationship. It is possible that this association is an
indirect one, and simply an extension of the increased
risk of CVD conferred by hyperuricaemia.3 This occurs
through a mechanism of ampliﬁed oxidation of
lipids and induction of cellular oxidative stress which
contributes to endothelial dysfunction, resulting in
decreased arterial compliance, impaired blood ﬂow,
and a proatherogenic state.27 However, since few stu-
dies include data on uric acid levels, we are unable to
explore this further. Studies have also demonstrated
renovascular disease, renal injury, and hypertension
can result from this hyperuricaemic-mediated endothe-
lial dysfunction,28 further contributing to cardiovascu-
lar risk. Uric acid is also thought to have direct
proinﬂammatory eﬀects on vascular cells,29,30 with evi-
dence that reduction of uric acid levels reduces cardio-
vascular risk.31 Allopurinol, the most commonly used
urate-lowering therapy, has been shown to improve
endothelial dysfunction,32,33 blood pressure,32,34
and exercise tolerance in patients with chronic stable
angina.35
However, given that other inﬂammatory arthritides,
such as rheumatoid arthritis and ankylosing spondyl-
itis, not associated with hyperuricaemia also confer
increased cardiovascular risk,4,5 it would seem likely
that the relationship is more complex. Common path-
ways of accelerated atherosclerosis resulting from endo-
thelial dysfunction and impaired arterial compliance, as
well as autoimmune inﬂammatory mechanisms invol-
ving proinﬂammatory cytokines such as tumour necro-
sis factor a and interleukins 1 and 6, by which
inﬂammatory arthritides increase cardiovascular risk,
have been suggested, and inﬂammatory activity is felt
to be the major risk factor for the development of sub-
sequent vascular disease.36 Monosodium urate crystals
deposited in gout have been shown to strongly induce
inﬂammation in humans, through direct neutrophil
activation and activation of the NALP3 inﬂammasome
resulting in the release of similar proinﬂammatory cyto-
kines, during an acute attack.28 There is growing evi-
dence that this inﬂammation persists between attacks,37
with recent ultrasound studies demonstrating the pres-
ence of inﬂammation and synovitis in the intercritical
period.9,38 This recent literature has conﬁrmed that
gout should be considered a chronic inﬂammatory
joint disease, and therefore, the possibility that persist-
ent inﬂammation is one mechanism for increased
burden of vascular disease in both gout and rheumatoid
arthritis. The eﬀect of inﬂammation on CVD has
prompted the European League Against Rheumatism
(EULAR) to publish recommendations for cardiovas-
cular screening and management in both rheumatoid
arthritis and gout patients,39,40 including an aggressive
approach to managing both risk factors and inﬂamma-
tory burden.
However, the reasons for the absence of a similar
association with mortality from MI remain unclear.
This diﬀerence may reﬂect the presence of alternative
underlying factors in the pathogenesis of MI when
compared with other forms of CHD. Evidence suggests
that coronary artery morphology is the most important
factor diﬀerentiating patients who experience angina,
compared to those with MI.41 It may also reﬂect mis-
classiﬁcation bias where, in the absence of post-mortem
examination, cause of death is recorded as CHD or
CVD rather than speciﬁcally MI. It may also result
from surveillance bias, whereby diagnosis of gout and
subsequent monitoring lead to increased likelihood of
detection and management of CHD, and better educa-
tion of patients about the need for prompt medical
attention at the onset of symptoms to prevent progres-
sion to MI. However, it may simply be that further
studies are required to investigate this particular
relationship.
The limitations of our review include the small
number of papers available for inclusion. However,
each of these studies uses a large study population
and, combined, the number of patients included in
this meta-analysis exceeds 220,000. Moreover, by
undertaking the meta-analysis in a stepwise fashion,
pooling the studies one-by-one in chronological order,
the pooled HR was not signiﬁcantly altered from the
HR reported in the ﬁrst paper (published in 2007) after
the addition of any of the later papers.
Despite a comprehensive search strategy, the possi-
bility remains that some relevant articles may not have
been identiﬁed. Similarly, papers with negative ﬁndings
are less likely to be published, although there was no
signiﬁcant indication of publication bias from Begg’s
and Egger’s tests. However, it must be acknowledged
that Begg’s and Egger’s tests have low power to detect
biases where study numbers are small.42
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There was some heterogeneity between papers in the
deﬁnitions of gout cases and the vascular risk factors
included in the multivariate analyses, and unmeasured
confounding must be considered given the observa-
tional nature of the included studies. Misclassiﬁcation
bias may also occur where studies relied upon diagnos-
tic codes or death certiﬁcates to deﬁne outcomes.
The strengths of our review are that only large
cohort studies are included, with participants being
free of CVD at baseline. Data extraction and thorough
methodological quality assessment was undertaken by
two reviewers independently. Crude and multivariate
data were pooled separately and potential sources of
heterogeneity examined. Finally, no evidence of publi-
cation bias was found in our review.
In conclusion, whilst observational studies cannot
demonstrate causation, this meta-analysis of large,
high-quality cohort studies strongly supports gout as
an independent risk factor for mortality from CVD
and CHD. Current evidence does not support such an
association with MI. The clinical implications of this
review are the need to promote identiﬁcation and man-
agement of cardiovascular risk factors in patients with
gout, but also to identify and optimally manage gout in
patients at risk of CVD. Further research will be
required to establish whether the optimal management
of gout, or the aggressive management of cardiovascu-
lar risk factors reduces negative outcomes for these
patients.
Funding
This work was supported by the National School of Primary
Care Research (grant number 88) and an Arthritis Research
UK Clinician Scientist Award to CDM.
Conflict of interest
The authors declare that there is no conﬂict of interest.
References
1. Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK
and Germany: prevalence, comorbidities and management
in general practice 2000–2005. Ann Rheum Dis 2008; 67:
960–966.
2. Zhu Y, Pandya BJ and Choi HK. Prevalence of gout and
hyperuricemia in the US general population: the National
Health and Nutrition Examination Survey 2007–2008.
Arthritis Rheum 2011; 63: 3136–3141.
3. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and
coronary heart disease: a systematic review and meta-ana-
lysis. Arthritis Care Res 2010; 62: 170–180.
4. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of
cardiovascular mortality in patients with rheumatoid arth-
ritis: a meta-analysis of observational studies. Arthritis
Rheum 2008; 59: 1690–1697.
5. Szabo SM, Levy AR, Rao SR, et al. Increased risk of
cardiovascular and cerebrovascular diseases in individ-
uals with ankylosing spondylitis: a population-based
study. Arthritis Rheum 2011; 63: 3294–3304.
6. Gladman DD, Ang M, Su L, et al. Cardiovascular mor-
bidity in psoriatic arthritis. Ann Rheum Dis 2009; 68:
1131–1135.
7. McGettigan P and Henry D. Cardiovascular risk with
non-steroidal anti-inflammatory drugs: systematic
review of population-based controlled observational stu-
dies. PLoS Med 2011; 8: e1001098.
8. Brook RD, Yalavarthi S, Myles JD, et al. Determinants
of vascular function in patients with chronic gout. J Clin
Hypertens (Greenwich) 2011; 13: 178–188.
9. Roddy E, Menon A, Hall A, et al. Polyarticular sono-
graphic assessment of gout: a hospital-based cross-
sectional study. Joint Bone Spine 80: 295–300.
10. Choi HK, Atkinson K, Karlson EW, et al. Obesity,
weight change, hypertension, diuretic use and risk of
gout in men: the health professionals follow-up study.
Arch Intern Med 2005; 165: 742–748.
11. Choi HK and Curhan G. Independent impact of gout on
mortality and risk of coronary heart disease. Circulation
2007; 116: 894–900.
12. Krishnan E, Svendsen K, Neaton JD, et al; MRFIT
Research Group. Long-term cardiovascular mortality
among middle-aged men with gout. Arch Intern Med
2008; 168: 1104–1110.
13. Lottmann K, Chen X and Schadlich PK. Association
between gout and all-cause as well as cardiovascular mor-
tality: a systematic review. Curr Rheumatol Rep 2012; 14:
195–203.
14. Quan H, Sundararajan V, Halfon P, et al. Coding algo-
rithms for defining comorbidities in ICD-9-CM and ICD-
10 administrative data. Med Care 2005; 43: 1130–1139.
15. Wells G, Shea A, O’Connell D, et al. The Newcastle–
Ottawa Scale (NOS) for assessing the quality of nonran-
domised studies in meta-analyses. Ottawa: Ottawa
Hospital Research Institute. Available at: www.ohri.ca/
programs/clinical_epidemiology/oxford.htm (2008, con-
sulted February 2013).
16. DerSimonian R and Laird N. Meta-analysis in clinical
trials. Control Clin Trials 1986; 7: 177–188.
17. Higgins JP and Thompson SG. Quantifying heterogen-
eity in a meta-analysis. Stat Med 2002; 21: 1539–1558.
18. Begg CB and Mazumdar M. Operating characteristics of
a rank correlation test for publication bias. Biometrics
1994; 50: 1088–1101.
19. Egger M, Smith GD, Schneider M, et al. Bias in meta-
analysis detected by a simple graphical test. Br Med J
1997; 315: 629–634.
20. Kuo CF, See LC, Luo SF, et al. Gout: an independent
risk factor for all-cause and cardiovascular mortality.
Rheumatology 2010; 49: 141–146.
21. Teng GG, Ang LW, Saag KG, et al. Mortality due to
coronary heart disease and kidney disease among middle-
aged and elderly men and women with gout in the
Singapore Chinese Health Study. Ann Rheum Dis 2012;
71: 924–928.
342 European Journal of Preventive Cardiology 22(3)
22. Krishnan E, Baker JF, Furst DE, et al. Gout and the risk
of acute myocardial infarction. Arthritis Rheum 2006; 54:
2688–2696.
23. DeVera MA, Rahman MM, Bhole V, et al. Independent
impact of gout on the risk of acute myocardial infarction
among elderly women: a population-based study. Ann
Rheum Dis 2010; 69: 1162–1164.
24. Cohen SD, Kimmel PL, Neff R, et al. Association of
incident gout and mortality in dialysis patients. J Am
Soc Nephrol 2008; 19: 2204–2210.
25. Mahmoodi BK, Matsushita K, Woodward M, et al;
Chronic Kidney Disease Prognosis Consortium.
Associations of kidney disease measures with mortality
and end-stage renal disease in individuals with and with-
out hypertension: a meta-analysis. Lancet 2012; 380:
1649–1661.
26. Gaita D, Mihaescu A and Schiller A. Of heart and
kidney: a complicated love story. Eur J Prev Cardiol
2012; Epub ahead of print.
27. Ceriello A and Motz E. Is oxidative stress the pathogenic
mechanism underlying insulin resistance, diabetes, and
cardiovascular disease? The common soil hypothesis
revisited. Arterioscler Thromb Vasc Biol 2004; 24:
816–823.
28. Jin M, Yang F, Yang I, et al. Uric acid, Hyperuricemia
and vascular diseases. Front Biosci 2012; 17: 656–669.
29. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates
monocyte chemoattractant protein-1 production in vas-
cular smooth muscle cells via mitogen-activated protein
kinase and cyclooxygenase-2. Hypertension 2003; 41:
1287–1293.
30. Kang DH, Park SK, Lee IK, et al. Uric acid-induced
C-reactive protein expression: implication on cell prolif-
eration and nitric oxide production of human vascular
cells. J Am Soc Nephrol 2005; 16: 3553–3562.
31. Hoieggen A, Alderman MH, Kjeldsen SE, et al; LIFE
Study Group. The impact of serum uric acid on cardio-
vascular outcomes in the LIFE study. Kidney Int 2004;
65: 1041–1049.
32. Kanbay M, Huddam B, Azak A, et al. A randomized
study of allopurinol on endothelial function and esti-
mated glomular filtration rate in asymptomatic hyperur-
icemia subjects with normal renal function. Clin J Am Soc
Nephrol 2011; 6: 1887–1894.
33. Melendez-Ramirez G, Perez-Mendez O, Lopez-Osorio C,
et al. Effect of the treatment with allopurinol on the
endothelial function in patients with hyperuricemia.
Endocr Res 2012; 37: 1–6.
34. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treat-
ment of hyperuricemia with allopurinol on blood pres-
sure, creatinine clearance, and proteinuria in patients
with normal renal functions. Int Urol Nephrol 2007; 39:
1227–1233.
35. Noman A, Ang DS, Ogston S, et al. Effect of high-dose
allopurinol on exercise in patients with chronic stable
angina: a randomised, placebo controlled crossover
trial. Lancet 2010; 375: 2161–2167.
36. Solte´sz P, Kerekes G, De´r H, et al. Comparative assess-
ment of vascular function in autoimmune rheumatic dis-
eases: considerations of prevention and treatment.
Autoimmun Rev 2011; 10: 416–425.
37. Pascual E. Persistence of monosodium urate crystals and
low-grade inflammation in the synovial fluid of patients
with untreated gout. Arthritis Rheum 1991; 34: 141–145.
38. Filippucci E, Scire` CA, Delle Sedie A, et al. Ultrasound
imaging for the rheumatologist. XXV. Sonographic
assessment of the knee in patients with gout and calcium
pyrophosphate deposition disease. Clin Exp Rheumatol
2010; 28: 2–5.
39. Peters MJ, Symmons DP, McCarey D, et al. EULAR
evidence-based recommendations for cardiovascular risk
management in patients with rheumatoid arthritis and
other forms of inflammatory arthritis. Ann Rheum Dis
2010; 69: 325–323.
40. Zhang W, Doherty M, Bardin T, et al. EULAR Standing
Committee for International Clinical Studies Including
Therapeutics. EULAR evidence based recommendations
for gout. Part II: Management. Report of a task force of
the EULAR Standing Committee for International
Clinical Studies Including Therapeutics (ESCISIT). Ann
Rheum Dis 2006; 65: 1312–1324.
41. Ambrose JA, Winters SL, Arora RR, et al. Coronary
angiographic morphology in myocardial infarction: a
link between the pathogenesis of unstable angina and
myocardial infarction. J Am Coll Cardiol 1985; 6:
1233–1238.
42. Sterne JAC, Gavaghan D and Egger M. Publication and
related bias in meta-analysis: power of statistical tests and
prevalence in literature. J Clin Epidemiol 2000; 53:
1119–1129.
Clarson et al. 343
EXTENDED REPORT
Increased risk of vascular disease associated with
gout: a retrospective, matched cohort study in
the UK Clinical Practice Research Datalink
Lorna E Clarson,1 Samantha L Hider,1 John Belcher,1 Carl Heneghan,2
Edward Roddy,1 Christian D Mallen1
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2014-205252).
1Research Institute for Primary
Care & Health Sciences, Keele
University, Keele, Staffordshire,
UK
2Department of Primary Care
Health Sciences, Oxford
University, Oxford, UK
Correspondence to
Dr Lorna Clarson, Research
Institute for Primary Care &
Health Sciences, Keele
University, Keele, Staffordshire
ST5 5BG, UK;
l.clarson@keele.ac.uk
Received 17 January 2014
Revised 1 August 2014
Accepted 2 August 2014
To cite: Clarson LE,
Hider SL, Belcher J, et al.
Ann Rheum Dis Published
Online First: [please include
Day Month Year]
doi:10.1136/annrheumdis-
2014-205252
ABSTRACT
Objectives To determine whether gout increases risk of
incident coronary heart disease (CHD), cerebrovascular
(CVD) and peripheral vascular disease (PVD) in a large
cohort of primary care patients with gout, since there have
been no such large studies in primary care.
Methods A retrospective cohort study was performed
using data from the Clinical Practice Research Datalink
(CPRD). Risk of incident CHD, CVD and PVD was
compared in 8386 patients with an incident diagnosis of
gout, and 39 766 age, sex and registered general practice-
matched controls, all aged over 50 years and with no prior
vascular history, in the 10 years following incidence of
gout, or matched index date (baseline). Multivariable Cox
Regression was used to estimate HRs and covariates
included sex and baseline measures of age, Body Mass
Index, smoking, alcohol consumption, Charlson
comorbidity index, history of hypertension, hyperlipidaemia,
chronic kidney disease, statin use and aspirin use.
Results Multivariable analysis showed men were at
increased risk of any vascular event (HRs (95% CIs)) HR
1.06 (1.01 to 1.12), any CHD HR 1.08 (1.01 to 1.15) and
PVD HR 1.18 (1.01 to 1.38), while women were at
increased risk of any vascular event, HR 1.25 (1.15 to
1.35), any CHD HR 1.25 (1.12 to 1.39), and PVD 1.89
(1.50 to 2.38)) but not any CVD.
Conclusions In this cohort of over 50s with gout, female
patients with gout were at greatest risk of incident vascular
events, even after adjustment for vascular risk factors,
despite a higher prevalence of both gout and vascular
disease in men. Further research is required to establish the
reason for this sex difference.
INTRODUCTION
Gout is the most prevalent inﬂammatory arthritis,
affecting an estimated 2.5% of the population in
the UK,1 and 3.9% in North America.2 It is asso-
ciated with elevated levels of serum uric acid (SUA)
and deposition of monosodium urate crystals in
tissues and joints, leading to excruciating painful
attacks of peripheral joint synovitis which, in the
UK, are largely managed in primary care by general
practitioners (GP) who refer on for specialised care
only if necessary.
Hyperuricaemia, the biochemical precursor to
gout, has been linked with an increased incidence
of, and mortality from, both CHD and stroke.3 4
Although gout is traditionally thought of as an
intermittent inﬂammatory condition, recent ultra-
sound studies have identiﬁed persistent subclinical
inﬂammation in the intercritical period between
acute attacks.5 It has been hypothesised that the
combination of persistent inﬂammation and hyper-
uricaemia may potentiate or synergise CHD devel-
opment.6 Deposition of urate crystal material in
vessel walls has been proposed to cause neutrophil
and platelet activation and release of inﬂammatory
mediators that promote cardiovascular damage.7–9
Epidemiological studies examining the relationship
between gout and CHD report conﬂicting ﬁndings,
with a signiﬁcant association reported by some,10–13
but not others,14–16 and investigations of risk of cere-
brovascular disease (CVD) or peripheral vascular
disease (PVD) in patients with gout comparatively
fewer.16–18 Consequently, the risk intrinsic to gout
itself, compared to that from hyperuricaemia or vas-
cular risk factors, such as hypertension and obesity
commonly found in patients with gout, remains
unclear. Additionally, many of these studies have been
conducted in secondary care populations, who may
be characterised by more severe disease, rather than
primary care where the majority of patients with gout
are managed.19
The use of data from routinely collected primary
care records is accepted as a cost-effective way to
undertake epidemiological studies of large patient
populations across a broad population spread.20 The
UK Clinical Practice Research Datalink (CPRD) is the
largest database of electronic primary care health
records (EHR) in the world, and has previously been
used in the study of the association of inﬂammatory
conditions and vascular disease,21 22 as well as in the
epidemiology of gout.1 23
We sought to investigate the association between
gout and incident CHD, CVD and PVD in a large
sample of the UK general practice population.
METHODS
Clinical practice research datalink
The UK CPRD contains data for approximately 9%
of the UK population. Currently, 650 general prac-
tices contribute high-quality data with over 5.5
million active patients,24 thought to be broadly rep-
resentative of the general UK population,24 25 and
high validity of diagnosis in the CPRD has been
reported.26 27
Participant identiﬁcation
Patients consulting in primary care between 1987
and 1999, with an incident diagnosis of gout, were
identiﬁed. Potential control subjects with no history
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of gout were stratiﬁed by general practice, year of birth and sex,
and up to ﬁve were randomly selected from the appropriate
stratum for each patient with gout. Baseline for patients with
gout was considered to be the ﬁrst entry of a diagnostic code
for gout in their EHR, and for patients without gout the date of
diagnosis of gout in their matched gout patient. Pre-baseline
EHRs were searched for codes relating to prescriptions for col-
chicine or urate-lowering therapy, and where these were present,
the patient record was individually examined to determine
whether a prior diagnosis of gout was probable, and subsequent
inclusion or exclusion.
Participants in both cohorts were required to be aged over 50
years at baseline, since vascular events themselves are rare under
the age of 50 years, and are often inﬂuenced by other under-
lying factors which may be difﬁcult to account for. Patients with
a previous history of vascular disease were excluded in order to
minimise the surveillance bias associated with follow-up for a
previous event, and remove the contribution of additional risk
conferred by a previous event.
Outcome measures
Outcomes of interest were time to ﬁrst recording of CHD, CVD
and PVD within the patient’s EHR. Events of interest were
angina, myocardial infarction (MI) and any CHD (including
angina, MI and all less speciﬁc codes describing incident coron-
ary heart disease), stroke/cerebrovascular accident (CVA), transi-
ent ischaemic attack (TIA) and any CVD (including TIA, CVA
and all less speciﬁc codes describing incident cerebrovascular
events) and PVD (considered to be any narrowing of arteries
distal to the arch of the aorta and identiﬁed in the EHR using
codes associated with symptoms at incidence of disease, eg,
intermittent claudication, or asymptomatic identiﬁcation by
screening in high-risk populations, eg, diabetics). The term ‘any
vascular event’ was used to describe overall risk of developing
any of these outcomes of interest. Due to the nature of the
coding, we were not able to separate ischaemic from haemor-
rhagic cerebrovascular events, and for this reason they were con-
sidered together. A list of Read Codes used is available on
request. Participants were followed from baseline until they
experienced an event of interest, or in those who remained
event-free, until the occurrence of death, transfer away from the
practice contributing their records to the CPRD, last collection
of records from the practice by the CPRD, or 10 years from
baseline, whichever was the earliest.
Vascular risk factors
Potential explanatory covariates were chosen by consensus
between GPs and rheumatologists, to represent traditional risk
factors for vascular diseases, well described in the literature, and
used in previous studies of vascular disease.10–12 14 Baseline
data on presence of hypertension, hyperlipidaemia, chronic
kidney disease, Body Mass Index (BMI), ever/never exposure to
alcohol, smoking, statins and aspirin were identiﬁed for all parti-
cipants from their EHR using relevant Read Codes. Smoking
and alcohol data were entered as categorical variables, (ever/
never exposure or missing) in order to minimise the effect that
missing data in the recording of these covariates would have on
the size of the dataset available for analysis. Charlson
Co-morbidity Index28 at baseline was also calculated using a
technique described by Khan et al.29 This index is calculated
based upon the presence or absence of 19 weighted comorbid
conditions, including history of diabetes which was, therefore,
not separately included in the multivariate analysis. Physical
activity and family history of vascular disease were not included
in the multivariable analysis due to high levels of missing data,
and hyperuricaemia could not be included since SUA is not rou-
tinely measured in non-gout patients in the UK.
Statistical analysis
Descriptive statistics were used to describe the baseline demo-
graphics of the sample. Cox proportional hazard modelling was
used to produce both unadjusted and adjusted HRs, estimating
the excess risk of the various forms of vascular disease, asso-
ciated with gout,30 using robust SEs to adjust for any clustering
induced by matching.31 The validity of the proportional hazards
assumption was tested using Schoenfeld residuals and Stata’s
own diagnostic test. Where this assumption was violated, sug-
gesting the risk associated with potential explanatory covariates
may vary over time, the relevant variables were reintroduced
into the model as time-varying covariates.32
Baseline age, BMI, smoking and alcohol exposure and
Charlson comorbidity index, along with sex and gout×sex
interaction were introduced into the ﬁrst model for analysis
(Model 1), in order to minimise surveillance bias and represent
a typical patient with gout presenting to a GP for the ﬁrst time.
Additionally, the second model also included baseline history of
hypertension, hyperlipidaemia, chronic kidney disease and
exposure to prescription statins and aspirin.
The association with vascular events was investigated by sex
subset. The interaction between gout and sex was tested, with
signiﬁcance assessed using the Wald test, since robust SEs were
used. Stratiﬁed effect sizes were calculated in order to clarify sex
differences, using the STATA LINCOM command to calculate
the appropriate linear combinations from the model containing
the interaction. This has the added advantage of using all the
data rather than ﬁtting separate models for sex.33 Data were
analysed using Stata statistical software release 12 (StataCorp:
College Station, TX, 2011).
This study protocol received approval from the Independent
Scientiﬁc Advisory Committee for the Medicines and
Healthcare products Regulatory Agency Database Research (ref-
erence number 10_109)
RESULTS
A total of 8386 patients with gout were age, sex and practice-
matched to 39 766 participants without gout. Mean age at diag-
nosis for patients with gout was 66.3 years (SD 10.8), and 69.4%
were male. Patients with gout had an increased prevalence of all
risk factors of interest at baseline, with the exception of diabetes
mellitus, when compared with non-gout patients (table 1).
The proportional hazards assumption for gout exposure was
met for all types of vascular events. The time-varying covariates
entered for each outcome are available in the online
supplementary table S1.
A statistically signiﬁcant interaction between gout and sex was
found, and for this reason, the results are presented by sex. The
details of the interaction in the gout effect between men and
women are available in the online supplementary table S2.
Totally, 11 266 vascular events occurred during the follow-up
(table 2). Absolute risk of any vascular event per 1000 person
years in men with gout was 43.63 (41.55 to 45.77) compared
to 33.70 (32.86 to 34.55) in men without gout, corresponding
to a crude HR of 1.29 (1.22 to 1.36), and in women with gout
it was 51.89 (48.32 to 55.64) compared to 33.41 (32.15 to
34.71), corresponding to a HR of 1.56 (1.44 to 1.69). The
most marked increase was in risk of PVD in women, where
absolute risk more than doubled, from 3.05 (2.68 to 3.46) to
7.09 (5.81 to 8.55) events per 1000 person-years in women
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with gout, corresponding to an unadjusted HR of 2.35 (1.87 to
2.94). There was a statistically signiﬁcant increased risk of all
vascular outcomes for women with gout, with the exception of
MI, and for men with gout except any CVD and CVA (table 2).
In both sexes, previously identiﬁed risks remained signiﬁcant,
but were attenuated after adjustment for the vascular risk factors
included in model 1 (table 3).
After adjustment for the extended range of covariates
included in model 2, a clear sex difference emerged. Gout was
an independent risk factor for any vascular event, any CHD and
PVD, but not for any of the other vascular outcomes of interest
for men. However, gout remained an independent risk factor
for all types of vascular diseases in women except MI and any
CVD (table 3) and, additionally, the magnitude of risk of all
outcomes was found to be greater in women.
DISCUSSION
This study provides evidence that patients of both sexes with
gout are at increased risk of any vascular events, any CHD and
PVD even after adjustment for traditional vascular risk factors,
but the magnitude of this risk is greater in women. Additionally,
female gout patients are at increased risk of angina, TIA and
CVA, but male patients with gout are not.
While our recent meta-analysis demonstrated an increased
risk of mortality from cardiovascular causes,34 meta-analysis of
risk of incident cardiovascular disease in gout has not been
undertaken to date. Previous studies examining the association
between gout and incident CHD have been conﬂicting; adjusted
results from the Framingham study reported an increased inci-
dence of CHD and angina in men but not women, but both a
prospective study on male health professionals from the USA
and a primary care case-control study using patients of both
sexes with gout from The Netherlands, reported no increased
incidence of CHD.10 14 15 Studies of the association between
gout and MI produce similar conﬂicting reports. Krishnan
et al,11 report an increased incidence of non-fatal and all MI in
a male cohort nested in a controlled trial examining the efﬁcacy
of coronary risk reduction in men at high risk of vascular
disease, DeVera et al,35 report an increased incidence of non-
fatal and all MI in women, but not men in a retrospective
cohort study in Canada, and no association between gout and
MI in either sex reported by Abbott et al, 1988.10
The contradictory nature of current evidence may arise from
signiﬁcant heterogeneity of study design, and ascertainment of
Table 1 Participant demographics at baseline
Gout Non-gout p For significance
Participants, n 8386 39 766
Age at diagnosis, years 66.3 (±10.8) 66.2 (±10.7) 0.99
Male, % 69.4 69.2 0.70
Ever smoker (missing), % 28.3 (23.1) 26.2 (31.2) <0.01
Ever drinker (missing), % 73.5 (13.8) 64.4 (21.2) <0.01
BMI >25 kg/m2 (missing),% 59.7 (18.3) 43.6 (25.0) <0.01
Hypertension, % 36.0 17.3 <0.01
Hyperlipidaemia, % 5.7 3.2 <0.01
Diabetes, % 4.2 4.4 0.33
Chronic kidney disease, % 1.4 0.2 <0.01
Ever statin use, % 34.3 25.6 <0.01
Ever aspirin use, % 42.7 33.4 <0.01
BMI, Body Mass Index
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gout, choice of potential explanatory covariates and study popu-
lations used, all of which (with the exception of one35) are of
smaller size than that used here, and some of which are specia-
lised (e.g. health professionals),12 14 or solely male.11 12 14
The ﬁndings of increased risk of vascular disease in females
are consistent with those of two previous studies.16 35 The
reasons for this increased risk remain unclear, but prolonged
exposure to hyperuricaemia prior to the onset of clinical gout
may play a role, since women have been observed to have an
older mean age at onset of gout, lower mean SUA levels, and
reduced risk of incident gout compared with men with a com-
parable level of hyperuricaemia.36–38 This prolonged exposure
may be lengthened further if clinicians are less vigilant for gout
in women, potentially delaying diagnosis and increasing crystal
and inﬂammatory burden. Incidence of gout is higher in post-
menopausal women,39 suggesting that oestrogen is an important
inﬂuence, both on renal urate handling, and also on the
increased incidence of abdominal obesity and associated hyper-
insulinaemia after menopause which further impairs renal excre-
tion of urate.38 A stronger multiplicative effect between
hyperuricaemia and metabolic vascular risk factors resulting in a
higher propensity of women to hyperuricaemia-induced micro-
vascular damage has also been suggested.40 However, there may
simply be less aggressive management of vascular risk factors or
gout itself in female primary care patients. Although there was a
statistically signiﬁcant difference between the proportions of
male and female patients with gout prescribed allopurinol (43%
vs 39%, p<0.01 for difference) in our sample, a difference of
this magnitude is unlikely to fully explain the sex differences
seen, and further research is required in order to elucidate the
nature of this relationship.
The increased incidence of PVD found in patients of both
sexes with gout is also in line with the only other study to have
examined this relationship.17 This association may result from
common risk factors shared by gout and PVD, such as hyperten-
sion, and chronic kidney disease,41 but further research is
needed to investigate this.
Our ﬁndings have several important implications for clinical
practice. First, current evidence suggests that the clinical man-
agement of gout in primary care is suboptimal,1 42 despite
approximately 1 in 40 people in the UK, and over 8 million
people in the USA currently affected.1 2 Thus, even a small
increase in vascular risk will give rise to a substantial number of
new vascular events. Since there is evidence that cardiovascular
disease in patients with gout often goes unrecognised and
undertreated in primary care, with only a quarter of people con-
sulting with acute gout screened for cardiovascular risk factors
within the subsequent month,43 despite both national and inter-
national guidance recommending this,44–46 the results of this
study suggest a substantial need to change practice. Second,
both gout and vascular disease have historically been considered
diseases of men, and so even in that minority of patients who
are screened for vascular risk factors, those chosen may not be
those most at risk, and since this study highlights the most
serious consequences for women, perhaps more attention
should be paid to prompt and reliable diagnosis of gout, fol-
lowed by optimal management in female patients, including
serious consideration of vascular risk reduction.
Third, screening for PVD in patients with gout is not currently
recommended as part of best practice. The increased risk of inci-
dent PVD was present in both sexes, and was the strongest of
those we identiﬁed. There is evidence that 44% of patients
screened for PVD had PVD without evidence of CHD,47 suggest-
ing that this may not have been detected by routine practice in
primary care, even by those adhering to current guidance on car-
diovascular screening in gout, and suggesting the need for a
change in recommendations to include screening for PVD.
This study has a number of strengths compared with existing
literature. The use of a large number of well-validated primary
care EHR means the study is generalisable to the wider popula-
tion of patients with gout. Additionally, matching patients by
age, sex and GP practice reduces the risk of sociodemographic
confounding. Moreover, the exclusion of patients with a prior
history of vascular events reduces both surveillance bias and the
additional risk conferred by a vascular history, allowing the con-
tribution of gout itself to be more accurately investigated.
The limitations of this study include possible misclassiﬁcation
bias from the use of diagnostic codes to deﬁne either gout,
based upon primary care diagnosis usually made on clinical
grounds, or CHD/CVD outcomes of interest, where termin-
ology may have changed over time or generalised codes may
have been used. Previous studies indicate reasonable validity of
gout diagnosis in primary care.42 43 and other studies under-
taken in the CPRD have selected gout cases using a primary
care diagnosis.1 23 48 Similarly, a recent review of validity of
diagnoses in CPRD reported a positive predictive value of diag-
nosis of MI coded in CPRD of over 80%, with comparable reli-
ability of coding for ischaemic heart disease to other primary
care databases,26 although literature on identiﬁcation of vascular
diseases in EHR databases is sparse.
Table 3 Adjusted risk of vascular disease by sex
Outcome
Model 1 Model 2
HR men
(95% CI)
HR women
(95% CI) p For sex interaction
HR men
(95% CI)
HR women
(95% CI) p For sex interaction
Any vascular 1.22 (1.16 to 1.29) 1.45 (1.34 to 1.57) <0.001 1.06 (1.01 to 1.12) 1.25 (1.15 to 1.35) <0.001
Any CHD 1.26 (1.18 to 1.35) 1.50 (1.35 to 1.67) 0.005 1.08 (1.01 to 1.15) 1.25 (1.12 to 1.39) 0.024
Angina 1.20 (1.08 to 1.34) 1.55 (1.32 to 1.82) 0.010 1.02 (0.92 to 1.13) 1.28 (1.09 to 1.51) 0.003
MI 1.30 (1.15 to 1.46) 1.12 (0.89 to 1.40) 0.254 1.12 (1.00 to 1.27) 0.97 (0.77 to 1.22) 0.263
Any CVD 1.11 (0.97 to 1.26) 1.35 (1.14 to 1.60) 0.068 0.95 (0.83 to 1.09) 1.17 (0.99 to 1.38) 0.058
TIA 1.22 (1.05 to 1.41) 1.50 (1.24 to 1.81) 0.085 1.02 (0.88 to 1.18) 1.26 (1.05 to 1.53) 0.796
CVA 1.08 (0.95 to 1.23) 1.58 (1.35 to 1.84) <0.001 0.93 (0.81 to 1.06) 1.34 (1.15 to 1.57) <0.001
PVD 1.35 (1.16 to 1.58) 2.17 (1.73 to 2.73) <0.001 1.18 (1.01 to 1.38) 1.89 (1.50 to 2.38) 0.04
Model 1 covariates: sex, gout×sex interaction, baseline age, Body Mass Index >25 kg/m2, ever/never smoking, ever/never alcohol consumption, Charlson Comorbidity Score.
Model 2 covariates include Model 1 and baseline history of hypertension, hyperlipidaemia, chronic kidney disease, ever/never statin use, ever/never aspirin use.
CHD, coronary heart disease; CVA, cerebrovascular attack; CVD, cerebrovascular disease; MI, myocardial infarction; PVD, peripheral vascular disease; TIA, transient ischaemic attack.
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While multiple adjustments on risk factors for vascular events
have been performed to take into account differences between
exposed and unexposed groups, we cannot rule out residual
confounding effects. Similarly, while matching by registered
general practice is an accepted method of accounting for socio-
demographic differences, there may be considerable sociodemo-
graphic variation within a practice area that may inﬂuence this
relationship. Furthermore, we were unable to adjust for hyperur-
icaemia (since SUA is not routinely measured in patients without
gout in the UK) and family history of vascular disease and levels
of physical activity in our analysis (due to poor levels of record-
ing), which may have some bearing on this relationship.
However, some degree of the effect of the variables we were
unable to account for is likely to be reﬂected in the other risk
factors included, for example, physical activity and BMI.
In conclusion, this study suggests an association between gout
and subsequent CHD and PVD in both sexes, independent of
traditional vascular risk factors. These risks are greatest in
women, and a particularly strong association between gout and
incident PVD in both sexes was found. Further work is required
to establish the effect of optimum management of both vascular
risk factors and gout itself on the long-term health of gout
patients, clarify the nature of the relationship between gout and
PVD, and the mechanism by which women are at greatest risk.
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